CA2459562C - Synthetic heparin pentasaccharides - Google Patents
Synthetic heparin pentasaccharides Download PDFInfo
- Publication number
- CA2459562C CA2459562C CA2459562A CA2459562A CA2459562C CA 2459562 C CA2459562 C CA 2459562C CA 2459562 A CA2459562 A CA 2459562A CA 2459562 A CA2459562 A CA 2459562A CA 2459562 C CA2459562 C CA 2459562C
- Authority
- CA
- Canada
- Prior art keywords
- group
- mpm
- sop
- groups
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
- C07H15/10—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/18—Acyclic radicals, substituted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
- C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/02—Acyclic radicals
- C07H7/033—Uronic acids
Abstract
Preparation of synthetic monosaccharides, disaccharides, trisaccharides, tetrasaccharides and pentasaccharides for use in the preparation of synthetic heparinoids.
Description
TITLE
Synthetic Heparin Pentasaccharides Field of the Invention This invention is directed to intermediates, and processes for the chemical synthesis of AT-III binding heparin or heparinoid, pentasaccharides.
Background Art Vascular thrombosis is a cardiovascular disease indicated by the partial or total occlusion of a blood vessel by a clot containing blood cells and fibrin.
In arteries, it results predominantly from platelet activation and leads to heart attack, angina or stroke, whereas venous thrombosis results in inflammation and pulmonary emboli. The coagulation of blood is the result of a cascade of events employing various enzymes collectively known as activated blood-coagulation factors. Heparin, a powerful anticoagulant has been used since the late 1930's in the treatment of thrombosis. In its original implementation, tolerance problems were noted and so reduced dosage was suggested to reduce bleeding and improve efficacy. In the early 1970's, clinical trials did indeed indicate acceptable tolerance was obtainable whilst still preserving antithrombotic activity. Unfractioned heparin (UFH) is primarily used as an anticoagulant for both therapeutic and surgical indications, and is usually derived from either bovine lung or porcine mucosa. Amongst the modern uses of unfractioned heparin are the management of unstable angina, an adjunct to chemotherapy and anti-inflammatory treatment, and as a modulation agent for growth factors and treatment of haemodynamic disorders.
In the late 1980's, the development of low molecular weight heparins (LMWHs) led to improvements in antithrombotic therapy. LMWHs are derived from UFH by such processes as; chemical degradation, enzymatic deOolymerisation and y-radiation cleavage. This class of heparins has recently been used for treatment of trauma related thrombosis. Of particular interest is the fact that their relative effects on platelets are minimal compared to
Synthetic Heparin Pentasaccharides Field of the Invention This invention is directed to intermediates, and processes for the chemical synthesis of AT-III binding heparin or heparinoid, pentasaccharides.
Background Art Vascular thrombosis is a cardiovascular disease indicated by the partial or total occlusion of a blood vessel by a clot containing blood cells and fibrin.
In arteries, it results predominantly from platelet activation and leads to heart attack, angina or stroke, whereas venous thrombosis results in inflammation and pulmonary emboli. The coagulation of blood is the result of a cascade of events employing various enzymes collectively known as activated blood-coagulation factors. Heparin, a powerful anticoagulant has been used since the late 1930's in the treatment of thrombosis. In its original implementation, tolerance problems were noted and so reduced dosage was suggested to reduce bleeding and improve efficacy. In the early 1970's, clinical trials did indeed indicate acceptable tolerance was obtainable whilst still preserving antithrombotic activity. Unfractioned heparin (UFH) is primarily used as an anticoagulant for both therapeutic and surgical indications, and is usually derived from either bovine lung or porcine mucosa. Amongst the modern uses of unfractioned heparin are the management of unstable angina, an adjunct to chemotherapy and anti-inflammatory treatment, and as a modulation agent for growth factors and treatment of haemodynamic disorders.
In the late 1980's, the development of low molecular weight heparins (LMWHs) led to improvements in antithrombotic therapy. LMWHs are derived from UFH by such processes as; chemical degradation, enzymatic deOolymerisation and y-radiation cleavage. This class of heparins has recently been used for treatment of trauma related thrombosis. Of particular interest is the fact that their relative effects on platelets are minimal compared to
2 heparin, providing an immediate advantage when treating platelet compromised patients. The degree of depolymerisation of UFH can be controlled to obtain LMWH of different lengths. Dosage requirements for the treatment of deep vein thrombosis (DVT) are significantly reduced when employing LMWH as opposed to UFH, although in general the efficacy of both therapeutics seems to be comparable. In addition, LMWH can be effective as an alternative therapeutic for patients who have developed a sensitivity to UFH. Unfortunately, there has recently been a great deal of concern in the use of LMWH due to the perceived potential for cross-species viral contamination as a result of the animal source of the parent UFH.
One way of avoiding the possibility of cross-species contamination, is to prepare heparins by chemical synthesis. This method would also provide the opportunity to develop second generation heparins or heparinoids, that can be tailored to target particular biological events in the blood coagulation cascade.
An investigation to determine the critical structural motif required for an important binding event in a coagulation cascade involving heparin, dates back to the 1970's. Some structural features of heparin were defined, but the binding domains of interest remained essentially undefined. Research conducted by Lindahl and co-workers1 and separately by Choay and co-workers2 eventually led to the determination that a pentasaccharide sequence constituted the critical binding domain for the pro-anticoagulant cofactor, antithrombin III (AT-Ill). After determination of the critical heparin sugar sequence, complete chemical syntheses were embarked upon to further prove the theories. Complete syntheses of the pentasaccharide binding domain were completed at similar times by Sinay and co-workers3 and by Van Boeckel and co-workers4.Significant difficulties were encountered during both these reported syntheses. The synthesis by Van Boeckel and co-workers provided a method on reasonable scale (156mg's of final product) and with improved yields compared to the Sinay synthesis, but still only provided an overall yield of 0.22%, (compared with 0.053% for the Sinay synthesis). One particular problem encountered during the final deprotection, was the intermolecular reaction of the hemiacetal (the reducing end functionality of the sugar), which
One way of avoiding the possibility of cross-species contamination, is to prepare heparins by chemical synthesis. This method would also provide the opportunity to develop second generation heparins or heparinoids, that can be tailored to target particular biological events in the blood coagulation cascade.
An investigation to determine the critical structural motif required for an important binding event in a coagulation cascade involving heparin, dates back to the 1970's. Some structural features of heparin were defined, but the binding domains of interest remained essentially undefined. Research conducted by Lindahl and co-workers1 and separately by Choay and co-workers2 eventually led to the determination that a pentasaccharide sequence constituted the critical binding domain for the pro-anticoagulant cofactor, antithrombin III (AT-Ill). After determination of the critical heparin sugar sequence, complete chemical syntheses were embarked upon to further prove the theories. Complete syntheses of the pentasaccharide binding domain were completed at similar times by Sinay and co-workers3 and by Van Boeckel and co-workers4.Significant difficulties were encountered during both these reported syntheses. The synthesis by Van Boeckel and co-workers provided a method on reasonable scale (156mg's of final product) and with improved yields compared to the Sinay synthesis, but still only provided an overall yield of 0.22%, (compared with 0.053% for the Sinay synthesis). One particular problem encountered during the final deprotection, was the intermolecular reaction of the hemiacetal (the reducing end functionality of the sugar), which
3 led to the formation dimers and trimers. To reduce the likelihood of this occuring, an a-methyl glycoside of the pentasaccharide was synthesised. The structures of interest are represented in Figure 1, wherein I represents the hemiacetal form, and II represents the a-methylglycoside form.
0S0j"
boc ,0 o OH HO _ 03SNH o OH
COO- 0 bo3S0 -03SNH a \rõ....r HNR R=SO; OH
HO H
I
..Z..._...0OH OSOi HNSO-3 ¨ OSO;.
D E
F G
H
II
Figure I
As mentioned, studies have determined that the significant biological event in preventing thrombosis is the binding of a pentasaccharide sequence5 of heparin, to heparin cofactor antithrombin Ill (AT-Ill). As well as pentasaccharide I, the important derivative II has also been prepared by total synthesis6. Compound II has recently completed phase III clinical trials for the treatment of deep-vein thrombosis. The following patents display some relevance to the present invention. Patent US 4,401,662 claims composition of matter on the pentasaccharide AT-III binding sequence of heparin as does US 4,496,550. Patents EP 0,084,999 and US 4,818,816 detail synthetic methodologies towards pentasaccharide I, and derivative II.
"
0S0j"
boc ,0 o OH HO _ 03SNH o OH
COO- 0 bo3S0 -03SNH a \rõ....r HNR R=SO; OH
HO H
I
..Z..._...0OH OSOi HNSO-3 ¨ OSO;.
D E
F G
H
II
Figure I
As mentioned, studies have determined that the significant biological event in preventing thrombosis is the binding of a pentasaccharide sequence5 of heparin, to heparin cofactor antithrombin Ill (AT-Ill). As well as pentasaccharide I, the important derivative II has also been prepared by total synthesis6. Compound II has recently completed phase III clinical trials for the treatment of deep-vein thrombosis. The following patents display some relevance to the present invention. Patent US 4,401,662 claims composition of matter on the pentasaccharide AT-III binding sequence of heparin as does US 4,496,550. Patents EP 0,084,999 and US 4,818,816 detail synthetic methodologies towards pentasaccharide I, and derivative II.
"
4 Object of the Invention It is an object of the invention to provide a synthetic preparation for heparin pentasaccharides, and intermediates thereof, and to novel intermediates for heparin pentasaccharides, and to novel heparin pentasaccharides.
The present invention provides composition of matter of intermediates, and a process for the synthesis, of AT-Ill binding heparins and heparinoids.
What this entails is a stepwise synthetic process employing monosaccharide building blocks.
The nature of the AT-III binding pentasaccharide is such, that under cursory analysis of the individual monomeric units constituting the pentasaccharide, we note that each is distinct from the others. Secondly, we can see that there is an alternating stereospecificity in regard to the glycosidic linkages (Fig. 2).
a-linked 13-linked a-linked 13-linked 0HOS03- I coo_ 1, OSOi I, OSOi L.(\,.. OHD 0 0S0-3 COOP
HO C B A
1 HNS03- i OH 1 HNS0-3 1 0S03 1 NHS03 Glucosamine Glucuronic add Glucosamine lduronic add Glycosides and hemi-2-N-sulphated and 2-N-sulphated, 2-0-sulphated acetal of Glucosamine, 6-0-sulphated 3-0-sulphated and both 2-N-sulphated and 6-0-sulphated 6-0-sulphated Fig. 2 In a synthesis, the difference evident in each block requires that each individual monomer used in the synthesis will need a different protecting group pattern. In light of this, it is essential in the synthesis of the above pentasaccharide that a protecting group strategy is carefully conceived. As can be seen, the pentasaccharide displays 0-sulphation, N-sulphation, there are free hydroxyl groups, and there are stereospecific glycosidic linkages.
The present invention provides composition of matter of intermediates, and a process for the synthesis, of AT-Ill binding heparins and heparinoids.
What this entails is a stepwise synthetic process employing monosaccharide building blocks.
The nature of the AT-III binding pentasaccharide is such, that under cursory analysis of the individual monomeric units constituting the pentasaccharide, we note that each is distinct from the others. Secondly, we can see that there is an alternating stereospecificity in regard to the glycosidic linkages (Fig. 2).
a-linked 13-linked a-linked 13-linked 0HOS03- I coo_ 1, OSOi I, OSOi L.(\,.. OHD 0 0S0-3 COOP
HO C B A
1 HNS03- i OH 1 HNS0-3 1 0S03 1 NHS03 Glucosamine Glucuronic add Glucosamine lduronic add Glycosides and hemi-2-N-sulphated and 2-N-sulphated, 2-0-sulphated acetal of Glucosamine, 6-0-sulphated 3-0-sulphated and both 2-N-sulphated and 6-0-sulphated 6-0-sulphated Fig. 2 In a synthesis, the difference evident in each block requires that each individual monomer used in the synthesis will need a different protecting group pattern. In light of this, it is essential in the synthesis of the above pentasaccharide that a protecting group strategy is carefully conceived. As can be seen, the pentasaccharide displays 0-sulphation, N-sulphation, there are free hydroxyl groups, and there are stereospecific glycosidic linkages.
5 Therefore, a protection strategy is required such that (1) sulphation can be effected at the required sites, whilst leaving some hydroxyl groups unsulphated (nob that due to the chemical lability of N- and 0-sulphates, sulphation needs to be effected late in the synthesis), (2) a protection strategy is required that assists in effecting the appropriate glycosidic linkage and (3) a protection strategy is required that enables the correct (in terms of regio-and stereoisomerism) glycosidic linkages to be formed. a-Glycosidic linkages are typically generated by the use of what are known as non-participating protecting groups, whilst 0-linkages are effected by participating protecting groups. Some N- and 0-participating and non-participating protecting groups are known to the art (the art being considered carbohydrate chemistry). It is also well known to the art that the kind of protecting groups employed can effect the reactivity of the building block. The culmination of these requirements are demonstrated in the exemplary building block in Fig. 3 below, which displays the kind of characteristics required to effect the synthesis of heparin oligosaccharides.
R31--2 (34 oR Cl ' x Fig. 3, Exemplary Building Block C
In exemplary building block C, X is a leaving group suitable of reacting with another monomer or acceptor, to form an interglycosidic linkage; R.1 is a non-participating amino protecting group so as to effect an a-linkage upon activation of X followed by coupling to an appropriate acceptor; R2 and R4 can be similarly protected to allow for eventual 0-sulphation, whilst R3 is required to be differentially protected so as to allow the formation of an acceptor hydroxyl group to couple this block to the next in the chain. The building blocks in Fig. 4 exemplify the kind of derivatised monosaccharides required to effect the synthesis of heparin AT-III binding pentasaccharides.
R31--2 (34 oR Cl ' x Fig. 3, Exemplary Building Block C
In exemplary building block C, X is a leaving group suitable of reacting with another monomer or acceptor, to form an interglycosidic linkage; R.1 is a non-participating amino protecting group so as to effect an a-linkage upon activation of X followed by coupling to an appropriate acceptor; R2 and R4 can be similarly protected to allow for eventual 0-sulphation, whilst R3 is required to be differentially protected so as to allow the formation of an acceptor hydroxyl group to couple this block to the next in the chain. The building blocks in Fig. 4 exemplify the kind of derivatised monosaccharides required to effect the synthesis of heparin AT-III binding pentasaccharides.
6 ORH X2 ORH X2 ORs y_ R -2 ORH
RHO E D rNat RLO RIP c RB RIP B
RLO A RA
Fig. 4 The protecting groups represented by 'Rs' in Fig. 4 are sites that will eventually require 0-sulphation, the protecting groups represented by 'RH' need to be orthogonal to 'Rs' and represents sites that will eventually become hydroxyl groups. The substituents `X1' and 'X2' represent leaving groups that are activated to react with another suitable protected building block to form a glycosidic linkage, and,in the case of Xi, may also be derivatised as alkyl glycosides or substituted with a group suitable to allow conjugation to a support for drug delivery. The 'Rt.' groups are protecting groups orthogonal to both 'Rs' and 'RH', and represent sites through which chain elongation via glycosylation occurs. 'R' is representative of either a protected or latent carboxylate function. The 'RA' groups are non-participating amino protecting groups that enable a-linkages to be formed while the `RB' groups may be either a participating or non-participating amino protecting group. There is another level of complexity to be added to the synthesis in as much as the protecting groups in blocks D and B that are indicated by the boxes, need to be such that they allow for the formation of a 13-glycosidic linkage. This may require a two stage protection at the indicated sites, ie. a protection followed by deprotection and subsequent reprotection with a different protecting group.
The initial protection is required to effect the correct stereochemistry in a glycosylation, and second stage protection to allow for the correct sulphation pattern.
As is evident, the pentasaccharide can be constructed in a variety of different ways; blocks B and A can be coupled, blocks E and D can be coupled, block C can be coupled to either, and the resulting dimer and trimer can finally be coupled to form the pentasaccharide. Alternatively, each block can be added sequentially and so on. There are a number of alternative
RHO E D rNat RLO RIP c RB RIP B
RLO A RA
Fig. 4 The protecting groups represented by 'Rs' in Fig. 4 are sites that will eventually require 0-sulphation, the protecting groups represented by 'RH' need to be orthogonal to 'Rs' and represents sites that will eventually become hydroxyl groups. The substituents `X1' and 'X2' represent leaving groups that are activated to react with another suitable protected building block to form a glycosidic linkage, and,in the case of Xi, may also be derivatised as alkyl glycosides or substituted with a group suitable to allow conjugation to a support for drug delivery. The 'Rt.' groups are protecting groups orthogonal to both 'Rs' and 'RH', and represent sites through which chain elongation via glycosylation occurs. 'R' is representative of either a protected or latent carboxylate function. The 'RA' groups are non-participating amino protecting groups that enable a-linkages to be formed while the `RB' groups may be either a participating or non-participating amino protecting group. There is another level of complexity to be added to the synthesis in as much as the protecting groups in blocks D and B that are indicated by the boxes, need to be such that they allow for the formation of a 13-glycosidic linkage. This may require a two stage protection at the indicated sites, ie. a protection followed by deprotection and subsequent reprotection with a different protecting group.
The initial protection is required to effect the correct stereochemistry in a glycosylation, and second stage protection to allow for the correct sulphation pattern.
As is evident, the pentasaccharide can be constructed in a variety of different ways; blocks B and A can be coupled, blocks E and D can be coupled, block C can be coupled to either, and the resulting dimer and trimer can finally be coupled to form the pentasaccharide. Alternatively, each block can be added sequentially and so on. There are a number of alternative
7 coupling sequences that can be easily conceived and the choice made in regard to this, in itself, has a marked effect on the synthetic methodologies that will finally be employed, and therefore impacts on the overall success of the synthesis.
In one aspect the invention provides for a monosaccharide building block in the D-glucopyrano configuration, for the preparation of synthetic heparinoids, said building block of General Formula I, ORs RLO-00µ..L...\,,.
RHO RA Xi General Formula I (Block A) Wherein X1 includes but is not limited to: hydroxy, alkoxy, aryloxy, benzyloxy, substituted benzyloxy; thioalkyl, thioaryl, halogen, trichloroacetimidoyl, phosphate and related phosphate ester type leaving groups, or other suitable leaving group; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group; a lipoaminoacid or other such group suitable for conjugation to delivery systems or solid supports; and the stereochemistry may be alpha or beta; other suitable groups will be known to those skilled in the art, RA includes but is not limited to: an azido function, an amine; an NH-Dde, NH-DTPM, NH-Fmoc, NH-Sac, NH-Cbz, NH-Troc, N-phthalimido; or, other such suitable protected amino functions known to those skilled in the art, RH is a benzyl or, substituted benzyl protecting group, allyl, allyloxycarbonyl, or RH1 and RA can combine together to form a cyclic carbamate;
RL includes but is not limited to: a H atom; a levulinoyl, chloroacetyl, 4-acetoxybenzoyl, 4-acetamidobenzoyl, 4-azidobenzoyl, or other substituted benzoyl type protecting group; a benzyl group, a 4-acetoxybenzyl, 4-acetamidobenzyl or other such suitable substituted benzyl type protecting group; y-aminobutyryl, 4-N-[1 -(4,4-dimethy1-2,6-dioxocyclohex-1-ylidene)ethylamino]-butyryl, 4-N-0 -(1,3-dimethy1-2,4,6(1H,3H,5H)-___
In one aspect the invention provides for a monosaccharide building block in the D-glucopyrano configuration, for the preparation of synthetic heparinoids, said building block of General Formula I, ORs RLO-00µ..L...\,,.
RHO RA Xi General Formula I (Block A) Wherein X1 includes but is not limited to: hydroxy, alkoxy, aryloxy, benzyloxy, substituted benzyloxy; thioalkyl, thioaryl, halogen, trichloroacetimidoyl, phosphate and related phosphate ester type leaving groups, or other suitable leaving group; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group; a lipoaminoacid or other such group suitable for conjugation to delivery systems or solid supports; and the stereochemistry may be alpha or beta; other suitable groups will be known to those skilled in the art, RA includes but is not limited to: an azido function, an amine; an NH-Dde, NH-DTPM, NH-Fmoc, NH-Sac, NH-Cbz, NH-Troc, N-phthalimido; or, other such suitable protected amino functions known to those skilled in the art, RH is a benzyl or, substituted benzyl protecting group, allyl, allyloxycarbonyl, or RH1 and RA can combine together to form a cyclic carbamate;
RL includes but is not limited to: a H atom; a levulinoyl, chloroacetyl, 4-acetoxybenzoyl, 4-acetamidobenzoyl, 4-azidobenzoyl, or other substituted benzoyl type protecting group; a benzyl group, a 4-acetoxybenzyl, 4-acetamidobenzyl or other such suitable substituted benzyl type protecting group; y-aminobutyryl, 4-N-[1 -(4,4-dimethy1-2,6-dioxocyclohex-1-ylidene)ethylamino]-butyryl, 4-N-0 -(1,3-dimethy1-2,4,6(1H,3H,5H)-___
8 trioxopyrimidin-5-ylidene)methylamino]-butyryl, 4-N-Alloc-butyryl, 4-N-Fmoc-butyryl, 4-N-Boc-butyryl type protecting groups allyloxycarbonyl, allyl ether, carbonate type protecting groups; or RL and Rsi can combine to form a benzylidene or substituted benzylidene ring.; or, other such suitable protecting groups as known to those skilled in the art, and Rs includes but is not limited to: 4-methoxyphenyl; substituted benzyl groups;
alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups; carbonate protecting groups, a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group allyl, methoxymethyl, methoxyethyl , benzyloxymethyl;; or, other suitable protecting groups as known to those skilled in the art.
Alternatively RL and Rs can combine to form a benzylidene or substituted benzylidene ring.
In a second aspect the invention provides for a monosaccharide building block in the L-idopyrano conformation, for the preparation of synthetic heparinoids, said building block of General Formula II, REO ORH
RLO ORs General Formula II (Block B) Wherein X2 includes but is not limited to: a hydroxyl group; thioalkyl, thioaryl, halogen, trichloroacetimidoyl, phosphate and related phosphate ester type leaving groups, or other suitable leaving group; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group; and the stereochemistry may be alpha or beta; other suitable groups will be known to those skilled in the art, Rs is defined as in General Formula I, RH is defined as in General Formula I, RL is defined as in General Formula I, and
alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups; carbonate protecting groups, a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group allyl, methoxymethyl, methoxyethyl , benzyloxymethyl;; or, other suitable protecting groups as known to those skilled in the art.
Alternatively RL and Rs can combine to form a benzylidene or substituted benzylidene ring.
In a second aspect the invention provides for a monosaccharide building block in the L-idopyrano conformation, for the preparation of synthetic heparinoids, said building block of General Formula II, REO ORH
RLO ORs General Formula II (Block B) Wherein X2 includes but is not limited to: a hydroxyl group; thioalkyl, thioaryl, halogen, trichloroacetimidoyl, phosphate and related phosphate ester type leaving groups, or other suitable leaving group; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group; and the stereochemistry may be alpha or beta; other suitable groups will be known to those skilled in the art, Rs is defined as in General Formula I, RH is defined as in General Formula I, RL is defined as in General Formula I, and
9 RE includes but is not limited to: methyl, C2-05 alkyl; substituted alkyl; or, benzyl and substituted benzyl groups; other suitable groups will be known to those skilled in the art. Or RH is selected from the group consisting of benzyl or substituted benzyl protecting group, allyl, allyloxycarbonyl;
RS is selected from the group consisting of 4-methoxyphenyl;
substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups; carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group ally!, methoxymethyl, methoxyethyl, benzyloxymethyl;
RE is selected from the group consisting of methyl, C2-05 alkyl;
substituted alkyl,C3-05 alkenyl; or, benzyl and substituted benzyl groups;
RL is selected from a H atom; a levulinoyl, chloroacetyl, 4-acetoxybenzoyl, 4-acetamidobenzoyl, 4-azidobenzoyl, or other substituted benzoyl type protecting group; a benzyl group, a 4-acetoxybenzyl, 4-acetamidobenzyl or other such suitable substituted benzyl type protecting group; y-aminobutyryl, 4-N-[1 -(4,4 -di methy1-2,6-d ioxocyclohex-1 -ylidene)ethylamino]-butyryl, 4-N-[1-(1,3-dimethy1-2,4,6(1 H,3H,5H)-trioxopyrimidin-5-ylidene)methylaminolbutyryl, 4-N-Alloc-butyryl, 4-N-Fmoc-butyryl, 4-N-Boc-butyryl type protecting groups;
allyloxycarbonyl, ally' ether, carbonate type protecting groups;
X2 is selected from a hydroxyl group; thioalkyl, thioaryl, halogen, imidoyl, phosphate and related phosphate ester type leaving groups, a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group;
and the stereochemistry may be alpha or beta.
In a third aspect the invention provides for a monosaccharide building block in the L-idopyrano configuration, for the preparation of synthetic heparinoids, said building block of General Formula III, Rm0 ORH X2 RLO ORs
RS is selected from the group consisting of 4-methoxyphenyl;
substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups; carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group ally!, methoxymethyl, methoxyethyl, benzyloxymethyl;
RE is selected from the group consisting of methyl, C2-05 alkyl;
substituted alkyl,C3-05 alkenyl; or, benzyl and substituted benzyl groups;
RL is selected from a H atom; a levulinoyl, chloroacetyl, 4-acetoxybenzoyl, 4-acetamidobenzoyl, 4-azidobenzoyl, or other substituted benzoyl type protecting group; a benzyl group, a 4-acetoxybenzyl, 4-acetamidobenzyl or other such suitable substituted benzyl type protecting group; y-aminobutyryl, 4-N-[1 -(4,4 -di methy1-2,6-d ioxocyclohex-1 -ylidene)ethylamino]-butyryl, 4-N-[1-(1,3-dimethy1-2,4,6(1 H,3H,5H)-trioxopyrimidin-5-ylidene)methylaminolbutyryl, 4-N-Alloc-butyryl, 4-N-Fmoc-butyryl, 4-N-Boc-butyryl type protecting groups;
allyloxycarbonyl, ally' ether, carbonate type protecting groups;
X2 is selected from a hydroxyl group; thioalkyl, thioaryl, halogen, imidoyl, phosphate and related phosphate ester type leaving groups, a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group;
and the stereochemistry may be alpha or beta.
In a third aspect the invention provides for a monosaccharide building block in the L-idopyrano configuration, for the preparation of synthetic heparinoids, said building block of General Formula III, Rm0 ORH X2 RLO ORs
10 General Formula III (Alternate Block B) Wherein X2 is defined as in General Formula II, Rs is defined as in General Formula II, RH is defined as in General Formula I, RL is defined as in General Formula I, and Rm includes but is not limited to a p-methoxyphenyl protecting group or other suitable oxidatively labile protecting group; a trityl group; or, other such suitable protecting groups as known to those skilled in the art.
In a fourth aspect the invention provides for a monosaccharide building block in the D-glucopyrano configuration for the preparation of synthetic heparinoids, said building block of General Formula IV, RLO ORs0 General Formula IV (Block C) Wherein X2 is defined as in General Formula II, Rs includes but is not limited to: an azido function, an amine; an NH-Dde or NH-DTPM group; or other suitably protected amino functions as known to those skilled in the art, or Rs (adjacent Rs )and Rs can combine together to form a cyclic carbamate;
RL is defined as in General Formula I, and Rs (adjacent Rs) is is selected from the group consisting of 4-methoxyphenyl;
substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups; carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group allyl, methoxymethyl, methoxyethyl, benzyloxymethyl, or R54 and Rs may be combined to form a cyclic carbamate;
In a fourth aspect the invention provides for a monosaccharide building block in the D-glucopyrano configuration for the preparation of synthetic heparinoids, said building block of General Formula IV, RLO ORs0 General Formula IV (Block C) Wherein X2 is defined as in General Formula II, Rs includes but is not limited to: an azido function, an amine; an NH-Dde or NH-DTPM group; or other suitably protected amino functions as known to those skilled in the art, or Rs (adjacent Rs )and Rs can combine together to form a cyclic carbamate;
RL is defined as in General Formula I, and Rs (adjacent Rs) is is selected from the group consisting of 4-methoxyphenyl;
substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups; carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group allyl, methoxymethyl, methoxyethyl, benzyloxymethyl, or R54 and Rs may be combined to form a cyclic carbamate;
11 Rs (adjacent the oxygen) is selected from the group consisting of 4-methoxyphenyl; substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups;
carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group allyl, methoxymethyl, methoxyethyl , benzyloxymethyl;
In a fifth aspect the invention provides for a monosaccharide building block in the D-glucuronate configuration for the preparation of synthetic heparinoids, said building block of General Formula V, 0 oRE
ORp X2 General Formula V (Block D) Wherein X2 is as defined in General Formula II, Rp includes but is not limited to: 4-methoxyphenyl; substituted benzyl groups;
alkylacyl, arylacyl and alkylarylacyl, or substituted alkylacyl, arylacyl and alkylarylacyl protecting groups; carbonate protecting groups; or, other suitable protecting groups as known to those skilled in the art.
RL is defined as in General Formula I, and RE is defined as in General Formula II.
In a sixth aspect the invention provides for a monosaccharide building block in the D-glucopyrano configuration for the preparation of synthetic heparinoids, said building block of General Formula VI, RHROH.......\µµ,. ORs ¨
carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group allyl, methoxymethyl, methoxyethyl , benzyloxymethyl;
In a fifth aspect the invention provides for a monosaccharide building block in the D-glucuronate configuration for the preparation of synthetic heparinoids, said building block of General Formula V, 0 oRE
ORp X2 General Formula V (Block D) Wherein X2 is as defined in General Formula II, Rp includes but is not limited to: 4-methoxyphenyl; substituted benzyl groups;
alkylacyl, arylacyl and alkylarylacyl, or substituted alkylacyl, arylacyl and alkylarylacyl protecting groups; carbonate protecting groups; or, other suitable protecting groups as known to those skilled in the art.
RL is defined as in General Formula I, and RE is defined as in General Formula II.
In a sixth aspect the invention provides for a monosaccharide building block in the D-glucopyrano configuration for the preparation of synthetic heparinoids, said building block of General Formula VI, RHROH.......\µµ,. ORs ¨
12 General Formula VI (Block E) Wherein X2 is as defined as in General Formula II, RB is defined as in General Formula IV, RH may be selected independently and are defined as in General Formula I, and Rs is defined as in General Formula I
or, wherein RH (adjacent the ORs moiety) is selected from the group consisting of benzyl or substituted benzyl protecting group, allyl, allyloxycarbonyl;
RH (adjacent the Rb moiety) is selected from the group consisting of benzyl or substituted benzyl protecting group, allyl, allyloxycarbonyl, or this RH
and RB independently can combine together to form a cyclic carbamate;
Rs is selected from the group consisting of 4-methoxyphenyl;
substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl; and substituted alkylacyl, arylacyl or alkylarylacy protecting groups; carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group allyl, methoxymethyl, methoxyethyl, benzyloxymethyl,or Rs5 and RH
can be combined to form a cyclic acetal or ketal moiety;
RB is selected from the group consisting of an azido function, an amine; an NH-Dde or NH-DTPM group, or RH ( adjacent the RB) and RB can combine together to form a cyclic carbamate;
X2 is selected from a hydroxyl group; thioalkyl, thioaryl, halogen, trichloroacetimidoyl, phosphate and related phosphate ester type leaving groups, a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group; and the stereochemistry may be alpha or beta.
or, wherein RH (adjacent the ORs moiety) is selected from the group consisting of benzyl or substituted benzyl protecting group, allyl, allyloxycarbonyl;
RH (adjacent the Rb moiety) is selected from the group consisting of benzyl or substituted benzyl protecting group, allyl, allyloxycarbonyl, or this RH
and RB independently can combine together to form a cyclic carbamate;
Rs is selected from the group consisting of 4-methoxyphenyl;
substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl; and substituted alkylacyl, arylacyl or alkylarylacy protecting groups; carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group allyl, methoxymethyl, methoxyethyl, benzyloxymethyl,or Rs5 and RH
can be combined to form a cyclic acetal or ketal moiety;
RB is selected from the group consisting of an azido function, an amine; an NH-Dde or NH-DTPM group, or RH ( adjacent the RB) and RB can combine together to form a cyclic carbamate;
X2 is selected from a hydroxyl group; thioalkyl, thioaryl, halogen, trichloroacetimidoyl, phosphate and related phosphate ester type leaving groups, a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group; and the stereochemistry may be alpha or beta.
13 In a seventh aspect the invention provides for a monosaccharide building block in the D-glucopyrano configuration for the preparation of synthetic heparinoids, said building block of General Formula VII, ORs RLO--......,;....\,,..
General Formula VII (Common Intermediate for Blocks A, C and E) Wherein X1 is defined as in General Formula I, RL is defined as in General Formula 1, and Rs is defined as in General Formula I.
RL and Rs may also together combine to form a benzylidene or substituted benzylidene ring or X1 is selected from the group consisting of hydroxy, alkoxy, aryloxy, benzyloxy, substituted benzyloxy; thioalkyl, thioaryl, halogen, trichloroacetimidoyl, phosphate and related phosphate ester type leaving groups, atbutyldiphenylsilyloxy or other such substituted silyloxy protecting group; a lipoaminoacid or other such group suitable for conjugation to delivery systems or solid supports; and the stereochemistry may be alpha or beta;
RL is selected from a H atom; a levulinoyl, chloroacetyl, 4-acetoxybenzoyl, 4-acetamidobenzoyl, 4-azidobenzoyl, or other substituted benzoyl type protecting group; a benzyl group, a 4-acetoxybenzyl, 4 -acetamidobenzyl or other such suitable substituted benzyl type protecting group; y-aminobutyryl, 4-N-[1 -(4,4 -di methy1-2,6-dioxocyclohex-1 -ylidene)ethyla mino]-butyryl, 4-N-[1 -(1 ,3-dimethy1-2,4,6(1 H,3H,5H)-trioxopyrimidin-5-ylidene)methylaminolbutyryl, 4-N-Alloc-butyryl, 4-N-Fmoc-butyryl, 4-N-Boc-butyryl type protecting groups;
allyloxycarbonyl, allyl ether, carbonate type protecting groups.
_
General Formula VII (Common Intermediate for Blocks A, C and E) Wherein X1 is defined as in General Formula I, RL is defined as in General Formula 1, and Rs is defined as in General Formula I.
RL and Rs may also together combine to form a benzylidene or substituted benzylidene ring or X1 is selected from the group consisting of hydroxy, alkoxy, aryloxy, benzyloxy, substituted benzyloxy; thioalkyl, thioaryl, halogen, trichloroacetimidoyl, phosphate and related phosphate ester type leaving groups, atbutyldiphenylsilyloxy or other such substituted silyloxy protecting group; a lipoaminoacid or other such group suitable for conjugation to delivery systems or solid supports; and the stereochemistry may be alpha or beta;
RL is selected from a H atom; a levulinoyl, chloroacetyl, 4-acetoxybenzoyl, 4-acetamidobenzoyl, 4-azidobenzoyl, or other substituted benzoyl type protecting group; a benzyl group, a 4-acetoxybenzyl, 4 -acetamidobenzyl or other such suitable substituted benzyl type protecting group; y-aminobutyryl, 4-N-[1 -(4,4 -di methy1-2,6-dioxocyclohex-1 -ylidene)ethyla mino]-butyryl, 4-N-[1 -(1 ,3-dimethy1-2,4,6(1 H,3H,5H)-trioxopyrimidin-5-ylidene)methylaminolbutyryl, 4-N-Alloc-butyryl, 4-N-Fmoc-butyryl, 4-N-Boc-butyryl type protecting groups;
allyloxycarbonyl, allyl ether, carbonate type protecting groups.
_
14 Rs is selected from the group consisting of 4-methoxyphenyl, 4 methoxybenzyl; substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups;
carbonate protecting groups; tert-Butyldiphenylsilyl;
RL and Rs may also together combine to form an alkylidene, isopropylidene, benzylidene or substituted benzylidene ring.
In an eighth aspect the invention provides for a disaccharide building block for the preparation of synthetic heparinoids, said building block of General Formula VIII, ORs 0 RH1 RA Xi RLO ORs General Formula VIII (Block B-A) Wherein X1 is defined as in General Formula I, RHi is defined as being selected from RH of General Formula I, with the addition that RHi and RA can combine together to form a cyclic carbamate, RA is defined as in General Formula I, with the addition that RH1 and RN can combine together to form a cyclic carbamate Rs is defined as in General Formula I, RH is defined as in General Formula I, RL is defined as in General Formula I, and RE is defined as in General Formula II or Xi is selected from the group consisting of hydroxy, alkenyloxy, alkoxy, aryloxy, benzyloxy, substituted benzyloxy; thioalkyl, thioaryl, halogen, imidoyl, phosphate and related phosphate ester type leaving groups, a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group; a
carbonate protecting groups; tert-Butyldiphenylsilyl;
RL and Rs may also together combine to form an alkylidene, isopropylidene, benzylidene or substituted benzylidene ring.
In an eighth aspect the invention provides for a disaccharide building block for the preparation of synthetic heparinoids, said building block of General Formula VIII, ORs 0 RH1 RA Xi RLO ORs General Formula VIII (Block B-A) Wherein X1 is defined as in General Formula I, RHi is defined as being selected from RH of General Formula I, with the addition that RHi and RA can combine together to form a cyclic carbamate, RA is defined as in General Formula I, with the addition that RH1 and RN can combine together to form a cyclic carbamate Rs is defined as in General Formula I, RH is defined as in General Formula I, RL is defined as in General Formula I, and RE is defined as in General Formula II or Xi is selected from the group consisting of hydroxy, alkenyloxy, alkoxy, aryloxy, benzyloxy, substituted benzyloxy; thioalkyl, thioaryl, halogen, imidoyl, phosphate and related phosphate ester type leaving groups, a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group; a
15 lipoaminoacid or other such group suitable for conjugation to delivery systems or solid supports; and the stereochemistry may be alpha or beta;
RH is selected from the group consisting of benzyl or substituted benzyl protecting group, allyl, allyloxycarbonyl;
RH1 is selected from the group consisting of benzyl or substituted benzyl protecting group, allyl, allyloxycarbonyl, or RH1 and RA can combine together to form a cyclic carbamate;
RA is selected from the group consisting of an azido function, an amine; an NH-Dde, NH-DTPM, NH-Fmoc, NH-Boc, NH-Troc, N-phthalimido, NH-Ac, NH-Allyloxycarbonyl; or RHi and RA can combine together to form a cyclic carbamate;
Rs (on block A) is selected from the group consisting of 4-methoxyphenyl; substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups;
carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group allyl, methoxymethyl, methoxyethyl, benzyloxymethyl or benzoyl, Rs (on block B) is selected from the group consisting of 4-methoxyphenyl; substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups;
carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group allyl, methoxymethyl, methoxyethyl, benzyloxymethyl;
RE is selected from the group consisting of methyl, C2-05 alkyl;
substituted alkyl,C3-05 alkenyl; or, benzyl and substituted benzyl groups;
RL is selected from a H atom; a levulinoyl, chloroacetyl, 4-acetoxybenzoyl, 4-acetamidobenzoyl, 4-azidobenzoyl, or other substituted benzoyl type
RH is selected from the group consisting of benzyl or substituted benzyl protecting group, allyl, allyloxycarbonyl;
RH1 is selected from the group consisting of benzyl or substituted benzyl protecting group, allyl, allyloxycarbonyl, or RH1 and RA can combine together to form a cyclic carbamate;
RA is selected from the group consisting of an azido function, an amine; an NH-Dde, NH-DTPM, NH-Fmoc, NH-Boc, NH-Troc, N-phthalimido, NH-Ac, NH-Allyloxycarbonyl; or RHi and RA can combine together to form a cyclic carbamate;
Rs (on block A) is selected from the group consisting of 4-methoxyphenyl; substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups;
carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group allyl, methoxymethyl, methoxyethyl, benzyloxymethyl or benzoyl, Rs (on block B) is selected from the group consisting of 4-methoxyphenyl; substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups;
carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group allyl, methoxymethyl, methoxyethyl, benzyloxymethyl;
RE is selected from the group consisting of methyl, C2-05 alkyl;
substituted alkyl,C3-05 alkenyl; or, benzyl and substituted benzyl groups;
RL is selected from a H atom; a levulinoyl, chloroacetyl, 4-acetoxybenzoyl, 4-acetamidobenzoyl, 4-azidobenzoyl, or other substituted benzoyl type
16 protecting group; a benzyl group, a 4-acetoxybenzyl, 4-acetamidobenzyl or other such suitable substituted benzyl type protecting group; y-aminobutyryl, 4-N-[1-(4,4-dimethy1-2,6-dioxocyclohex-1-ylidene)ethylamino1-butyryl, 4-N41 -(1,3-dimethy1-2,4,6(1H,3H,5H)-trioxopyrimidin-5-ylidene)methylaminolbutyryl, 4-N-Alloc-butyryl, 4-N-Fmoc-butyryl, 4-N-Boc-butyryl type protecting groups;
allyloxycarbonyl, allyl ether, carbonate type protecting groups.
In a ninth aspect the invention provides for a disaccharide building block for the preparation of synthetic heparinoids, said building block of General Formula IX, ORs Rm0 RH1 RA Xi RLO ORs General Formula IX (Alternate Block B-A) Wherein X1 is as defined as in General Formula I, RA is defined as in General Formula XIII, REll is defined as in General Formula XIII, Rs is defined as in General Formula I, RI_ is defined as in General Formula I, and Rm is defined as in General Formula III
Or alternatively, X1 is selected from the group consisting of hydroxy, alkenyloxy, alkoxy, aryloxy, benzyloxy, substituted benzyloxy; thioalkyl, thioaryl, halogen, imidoyl, phosphate and related phosphate ester type leaving groups, a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group; a lipoaminoacid or other such group suitable for conjugation to delivery systems or solid supports; and the stereochemistry may be alpha or beta;
allyloxycarbonyl, allyl ether, carbonate type protecting groups.
In a ninth aspect the invention provides for a disaccharide building block for the preparation of synthetic heparinoids, said building block of General Formula IX, ORs Rm0 RH1 RA Xi RLO ORs General Formula IX (Alternate Block B-A) Wherein X1 is as defined as in General Formula I, RA is defined as in General Formula XIII, REll is defined as in General Formula XIII, Rs is defined as in General Formula I, RI_ is defined as in General Formula I, and Rm is defined as in General Formula III
Or alternatively, X1 is selected from the group consisting of hydroxy, alkenyloxy, alkoxy, aryloxy, benzyloxy, substituted benzyloxy; thioalkyl, thioaryl, halogen, imidoyl, phosphate and related phosphate ester type leaving groups, a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group; a lipoaminoacid or other such group suitable for conjugation to delivery systems or solid supports; and the stereochemistry may be alpha or beta;
17 RA is lected from the group consisting of an azido function, an amine; an NH-Dde, NH-DTPM, NH-Fmoc, NH-Boc, NH-Troc, N-phthalimido, NH-Ac, NH-Allyloxycarbonyl; or RHI and RA can combine together to form a cyclic carbamate;
Rs (on block A) is selected from the group consisting of 4-methoxyphenyl; substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups;
carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group allyl, methoxynnethyl, methoxyethyl, benzyloxymethyl;
Rs (on block B) is selected from the group consisting of 4-methoxyphenyl; substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups;
carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group allyl, methoxymethyl, methoxyethyl, benzyloxymethyl;
RH is selected from the group consisting of benzyl or substituted benzyl protecting group, allyl, allyloxycarbonyl;
RH1 is selected from the group consisting of benzyl or substituted benzyl protecting group, allyl, allyloxycarbonyl, or RH1 and RA can combine together to form a cyclic carbamate;
Rm is selected from a p-methoxyphenyl or p-methoxybenzyl protecting group or other suitable oxidatively labile protecting group; a trityl group;
or Rm and RL are combined together to form an isopropylidene, benzylidene, substituted benzylidene, cyclohexylidene or other acetal or ketal protecting group;
Rs (on block A) is selected from the group consisting of 4-methoxyphenyl; substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups;
carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group allyl, methoxynnethyl, methoxyethyl, benzyloxymethyl;
Rs (on block B) is selected from the group consisting of 4-methoxyphenyl; substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups;
carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group allyl, methoxymethyl, methoxyethyl, benzyloxymethyl;
RH is selected from the group consisting of benzyl or substituted benzyl protecting group, allyl, allyloxycarbonyl;
RH1 is selected from the group consisting of benzyl or substituted benzyl protecting group, allyl, allyloxycarbonyl, or RH1 and RA can combine together to form a cyclic carbamate;
Rm is selected from a p-methoxyphenyl or p-methoxybenzyl protecting group or other suitable oxidatively labile protecting group; a trityl group;
or Rm and RL are combined together to form an isopropylidene, benzylidene, substituted benzylidene, cyclohexylidene or other acetal or ketal protecting group;
18 RL is selected from a H atom; a levulinoyl, chloroacetyl, 4-acetoxybenzoyl, 4-acetamidobenzoyl, 4-azidobenzoyl, or other substituted benzoyl type protecting group; a benzyl group, a 4-acetoxybenzyl, 4-acetamidobenzyl or other such suitable substituted benzyl type protecting group; y-aminobutyryl, 4-N-E1 -(4,4 -dimethy1-2,6-dioxocyclohex-1-ylidene)ethylaminol-butyryl, 4-N-E1 -(1,3-dimethy1-2,4,6(1H,3H,5H)-trioxopyrimidin-5-ylidene)methylaminol-butyryl, 4-N-Alloc-butyryl, 4-N-Fmoc-butyryl, 4-N-Boc-butyryl type protecting groups;
allyloxycarbonyl, allyl ether, carbonate type protecting groups.
In a tenth aspect the invention provides for a disaccharide building block for the preparation of synthetic heparinoids, said building block of General Formula X, oRE
Rp0 ORp RB X2 ORs General Formula X (Block D-C) Wherein X2 is as defined in General Formula II, Rsi is defined as being selected from Rs of General Formula I, with the addition that Rs, and RB can combine together to form a cyclic carbamate.
RB is defined as in General Formula IV, with the addition that Rs, and RB can combine together to form a cyclic carbamate.
Rs is defined as in General Formula I, Rp are defined as in General Formula V, RL is defined as in General Formula I, and X2 E is defined as in General Formula II oris selected from the group consisting of hydroxy, alkenyloxy, alkoxy, aryloxy, benzyloxy, substituted benzyloxy; thioalkyl, thioaryl, halogen, imidoyl, phosphate and related phosphate ester type leaving groups, a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group; a
allyloxycarbonyl, allyl ether, carbonate type protecting groups.
In a tenth aspect the invention provides for a disaccharide building block for the preparation of synthetic heparinoids, said building block of General Formula X, oRE
Rp0 ORp RB X2 ORs General Formula X (Block D-C) Wherein X2 is as defined in General Formula II, Rsi is defined as being selected from Rs of General Formula I, with the addition that Rs, and RB can combine together to form a cyclic carbamate.
RB is defined as in General Formula IV, with the addition that Rs, and RB can combine together to form a cyclic carbamate.
Rs is defined as in General Formula I, Rp are defined as in General Formula V, RL is defined as in General Formula I, and X2 E is defined as in General Formula II oris selected from the group consisting of hydroxy, alkenyloxy, alkoxy, aryloxy, benzyloxy, substituted benzyloxy; thioalkyl, thioaryl, halogen, imidoyl, phosphate and related phosphate ester type leaving groups, a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group; a
19 lipoaminoacid or other such group suitable for conjugation to delivery systems or solid supports; and the stereochemistry may be alpha or beta;
Rs is selected from the group consisting of 4-methoxyphenyl;
substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups; carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group allyl, methoxymethyl, methoxyethyl , benzyloxymethyl;
Rsi is selected from the group consisting of 4-methoxyphenyl;
substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups; carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group allyl, methoxymethyl, methoxyethyl, benzyloxymethyl, or Rsi and RB
may be combined to form a cyclic carbamate;
RE is selected from the group consisting of methyl, C2-05 alkyl;
substituted alkyl,C3-05 alkenyl; or, benzyl and substituted benzyl groups;
RB is selected from the group consisting of an azido function, an NH-Dde or NH-DTPM group, or Rs4 and RB can combine together to form a cyclic carbamate;
Rp (adjacent 0-RL) is selected from the group consisting of 4-methoxyphenyl; benzyl, substituted benzyl groups; alkylacyl, arylacyl and alkylarylacyl, or substituted alkylacyl, arylacyl and alkylarylacyl protecting groups;, carbonate protecting groups;
Rp (adjacent the link to block C) is selected from the group consisting of hydroxy, 4-methoxyphenyl;benzyl, substituted benzyl groups;
alkylacyl, arylacyl and alkylarylacyl, or substituted alkylacyl, arylacyl and ,
Rs is selected from the group consisting of 4-methoxyphenyl;
substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups; carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group allyl, methoxymethyl, methoxyethyl , benzyloxymethyl;
Rsi is selected from the group consisting of 4-methoxyphenyl;
substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups; carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group allyl, methoxymethyl, methoxyethyl, benzyloxymethyl, or Rsi and RB
may be combined to form a cyclic carbamate;
RE is selected from the group consisting of methyl, C2-05 alkyl;
substituted alkyl,C3-05 alkenyl; or, benzyl and substituted benzyl groups;
RB is selected from the group consisting of an azido function, an NH-Dde or NH-DTPM group, or Rs4 and RB can combine together to form a cyclic carbamate;
Rp (adjacent 0-RL) is selected from the group consisting of 4-methoxyphenyl; benzyl, substituted benzyl groups; alkylacyl, arylacyl and alkylarylacyl, or substituted alkylacyl, arylacyl and alkylarylacyl protecting groups;, carbonate protecting groups;
Rp (adjacent the link to block C) is selected from the group consisting of hydroxy, 4-methoxyphenyl;benzyl, substituted benzyl groups;
alkylacyl, arylacyl and alkylarylacyl, or substituted alkylacyl, arylacyl and ,
20 alkylarylacyl protecting groups;, carbonate protecting groups, silyl protecting groups, carbamate protecting groups, C3-05 alkenyl;
RL is selected from a H atom; a levulinoyl, chloroacetyl, 4-acetoxybenzoyl, 4-acetamidobenzoyl, 4-azidobenzoyl, or other substituted benzoyl type protecting group; a 4-acetoxybenzyl, 4-acetamidobenzyl or other such suitable substituted benzyl type protecting group; y-aminobutyryl, 4-N-[1-(4,4-dimethy1-2,6-dioxocyclohex-1 -ylidene)ethylamino]-butyryl, 4-N-[1-(1 ,3 -dimethyl-2,4,6(1 H,3H,5H)-trioxopyrimidin-5-ylidene)methylamino]-butyryl, 4-N-Alloc-butyryl, 4-N-Fmoc-butyryl, 4-N-Boc-butyryl type protecting groups;
allyloxycarbonyl, allyl ether, carbonate type protecting groups.
In an eleventh aspect the invention provides for a disaccharide building block for the preparation of synthetic heparinoids, said building block of General Formula XI, ORs RHO _t__0 0 ORE
RBRp0 ORp X2 General Formula XI (Block E-D) Wherein X2 is as defined in General Formula II, Rp are defined as in General Formula V, RE is defined as in General Formula 11, RB is defined as in General Formula IV, with the addition that RB and RH2 can combine to form a cyclic carbamate, R1-2 is defined as being selected from RH of General Formula 1, with the addition that RB and R1-i2 can combine to form a cyclic carbamate, RH is defined as in General Formula 1, and
RL is selected from a H atom; a levulinoyl, chloroacetyl, 4-acetoxybenzoyl, 4-acetamidobenzoyl, 4-azidobenzoyl, or other substituted benzoyl type protecting group; a 4-acetoxybenzyl, 4-acetamidobenzyl or other such suitable substituted benzyl type protecting group; y-aminobutyryl, 4-N-[1-(4,4-dimethy1-2,6-dioxocyclohex-1 -ylidene)ethylamino]-butyryl, 4-N-[1-(1 ,3 -dimethyl-2,4,6(1 H,3H,5H)-trioxopyrimidin-5-ylidene)methylamino]-butyryl, 4-N-Alloc-butyryl, 4-N-Fmoc-butyryl, 4-N-Boc-butyryl type protecting groups;
allyloxycarbonyl, allyl ether, carbonate type protecting groups.
In an eleventh aspect the invention provides for a disaccharide building block for the preparation of synthetic heparinoids, said building block of General Formula XI, ORs RHO _t__0 0 ORE
RBRp0 ORp X2 General Formula XI (Block E-D) Wherein X2 is as defined in General Formula II, Rp are defined as in General Formula V, RE is defined as in General Formula 11, RB is defined as in General Formula IV, with the addition that RB and RH2 can combine to form a cyclic carbamate, R1-2 is defined as being selected from RH of General Formula 1, with the addition that RB and R1-i2 can combine to form a cyclic carbamate, RH is defined as in General Formula 1, and
21 Rs is defined as in General Formula I or X2 is selected from a hydroxyl group; thioalkyl, thioaryl, halogen, trichloroacetimidoyl, phosphate and related phosphate ester type leaving groups, a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group; and the stereochemistry may be alpha or beta;
Rp ( adjacent the 0 link) is selected from the group consisting of 4-methoxyphenyl; benzyl, substituted benzyl groups; alkylacyl, arylacyl and alkylarylacyl, or substituted alkylacyl, arylacyl and alkylarylacyl protecting groups;, carbonate protecting groups;
Rp (adjacent X2) is selected from the group consisting of 4-methoxyphenyl; benzyl, substituted benzyl groups; alkylacyl, arylacyl and alkylarylacyl, or substituted alkylacyl, arylacyl and alkylarylacyl protecting groups;, carbonate protecting groups, silyl protecting groups, carbamate protecting groups, C3-05 alkenyl;
RE is selected from the group consisting of methyl, C2-05 alkyl;
substituted alkyl, C3-05 alkenyl; or, benzyl and substituted benzyl groups;
RB is selected from the group consisting of an azido function, an amine; an NH-Dde or NH-DTPM group, or RH2 and RBI can combine together to form a cyclic carbamate;
RH is selected from the group consisting of benzyl or substituted benzyl protecting group, allyl, allyloxycarbonyl;
RH2 is selected from the group consisting of benzyl or substituted benzyl protecting group, allyl, allyloxycarbonyl, or RH2 and Rat independently can combine together to form a cyclic carbamate;
Rs is selected from the group consisting of 4-methoxyphenyl; 4 methoxybenzyl, substituted benzyl groups; alkylacyl, benzoyl arylacyl or alkylarylacyl, and substituted alkylacyl, 4-chlorobenzoyl ,arylacyl or
Rp ( adjacent the 0 link) is selected from the group consisting of 4-methoxyphenyl; benzyl, substituted benzyl groups; alkylacyl, arylacyl and alkylarylacyl, or substituted alkylacyl, arylacyl and alkylarylacyl protecting groups;, carbonate protecting groups;
Rp (adjacent X2) is selected from the group consisting of 4-methoxyphenyl; benzyl, substituted benzyl groups; alkylacyl, arylacyl and alkylarylacyl, or substituted alkylacyl, arylacyl and alkylarylacyl protecting groups;, carbonate protecting groups, silyl protecting groups, carbamate protecting groups, C3-05 alkenyl;
RE is selected from the group consisting of methyl, C2-05 alkyl;
substituted alkyl, C3-05 alkenyl; or, benzyl and substituted benzyl groups;
RB is selected from the group consisting of an azido function, an amine; an NH-Dde or NH-DTPM group, or RH2 and RBI can combine together to form a cyclic carbamate;
RH is selected from the group consisting of benzyl or substituted benzyl protecting group, allyl, allyloxycarbonyl;
RH2 is selected from the group consisting of benzyl or substituted benzyl protecting group, allyl, allyloxycarbonyl, or RH2 and Rat independently can combine together to form a cyclic carbamate;
Rs is selected from the group consisting of 4-methoxyphenyl; 4 methoxybenzyl, substituted benzyl groups; alkylacyl, benzoyl arylacyl or alkylarylacyl, and substituted alkylacyl, 4-chlorobenzoyl ,arylacyl or
22 a lkylarylacy protecti ng groups; allyloxycarbonyl, ethoxycarbonyl, tertbutoxycarbonyl,carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group allyl, methoxymethyl, methoxyethyl, benzyloxymethyl;
or Rs and RH can be combined to form a cyclic acetal or ketal moiety;
In a twelfth aspect the invention provides for a disaccharide building block for the preparation of synthetic heparinoids, said building block of General Formula XII, ORs RHO
RB
ORp X2 General Formia XII (Alternate Block E-D) Wherein X2 is as defined in General Formula II, Rp are defined as in General Formula V, Rm is defined as in General Formula III, RB and RFQ are as defined in General Formula XI, RH isdefined as in General Formula I, and Rs is defined as in General Formula I or X2 is selected from a hydroxyl group; thioalkyl, thioaryl, halogen, trichloroacetimidoyl, phosphate and related phosphate ester type leaving groups, a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group; and the stereochemistry may be alpha or beta;
Rp (adjacent the 0 linking group) is selected from the group consisting of 4-methoxyphenyl; benzyl, substituted benzyl groups; alkylacyl,
or Rs and RH can be combined to form a cyclic acetal or ketal moiety;
In a twelfth aspect the invention provides for a disaccharide building block for the preparation of synthetic heparinoids, said building block of General Formula XII, ORs RHO
RB
ORp X2 General Formia XII (Alternate Block E-D) Wherein X2 is as defined in General Formula II, Rp are defined as in General Formula V, Rm is defined as in General Formula III, RB and RFQ are as defined in General Formula XI, RH isdefined as in General Formula I, and Rs is defined as in General Formula I or X2 is selected from a hydroxyl group; thioalkyl, thioaryl, halogen, trichloroacetimidoyl, phosphate and related phosphate ester type leaving groups, a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group; and the stereochemistry may be alpha or beta;
Rp (adjacent the 0 linking group) is selected from the group consisting of 4-methoxyphenyl; benzyl, substituted benzyl groups; alkylacyl,
23 arylacyl and alkylarylacyl, or substituted alkylacyl, arylacyl and alkylarylacyl protecting groups; carbonate protecting groups;
Rp (adjacent X) is selected from the group consisting of 4-methoxyphenyl; benzyl, substituted benzyl groups; alkylacyl, arylacyl and alkylarylacyl, or substituted alkylacyl, arylacyl and alkylarylacyl protecting groups;, carbonate protecting groups, silyl protecting groups, carbamate protecting groups, 03-05 alkenyl;
RB is selected from the group consisting of an azido function, an amine; an NH-Dde or NH-DTPM group, or RH2 and RBI can combine together to form a cyclic carbamate;
RH is selected from the group consisting of benzyl or substituted benzyl protecting group, allyl, allyloxycarbonyl;
RH2 is selected from the group consisting of benzyl or substituted benzyl protecting group, allyl, allyloxycarbonyl, or RH2 and RBI independently can combine together to form a cyclic carbamate;
RS is selected from the group consisting of 4-methoxyphenyl; 4 methoxybenzyl, substituted benzyl groups; alkylacyl, benzoyl, arylacyl or alkylarylacyl, and substituted alkylacyl, 4-chlorobenzoyl, arylacyl or alkylarylacy protecting groups; allyloxycarbonyl, ethoxycarbonyl, tertbutoxycarbonyl, carbonate protecting groups; is selected from the group consisting of 4-methoxyphenyl; substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups; carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group allyl, methoxymethyl, methoxyethyl, benzyloxymethyl;
Or Rs and RH can be combined to form a cyclic acetal or ketal moiety;
Rp (adjacent X) is selected from the group consisting of 4-methoxyphenyl; benzyl, substituted benzyl groups; alkylacyl, arylacyl and alkylarylacyl, or substituted alkylacyl, arylacyl and alkylarylacyl protecting groups;, carbonate protecting groups, silyl protecting groups, carbamate protecting groups, 03-05 alkenyl;
RB is selected from the group consisting of an azido function, an amine; an NH-Dde or NH-DTPM group, or RH2 and RBI can combine together to form a cyclic carbamate;
RH is selected from the group consisting of benzyl or substituted benzyl protecting group, allyl, allyloxycarbonyl;
RH2 is selected from the group consisting of benzyl or substituted benzyl protecting group, allyl, allyloxycarbonyl, or RH2 and RBI independently can combine together to form a cyclic carbamate;
RS is selected from the group consisting of 4-methoxyphenyl; 4 methoxybenzyl, substituted benzyl groups; alkylacyl, benzoyl, arylacyl or alkylarylacyl, and substituted alkylacyl, 4-chlorobenzoyl, arylacyl or alkylarylacy protecting groups; allyloxycarbonyl, ethoxycarbonyl, tertbutoxycarbonyl, carbonate protecting groups; is selected from the group consisting of 4-methoxyphenyl; substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups; carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group allyl, methoxymethyl, methoxyethyl, benzyloxymethyl;
Or Rs and RH can be combined to form a cyclic acetal or ketal moiety;
24 RM is selected from the group consisting of a p-methoxyphenyl protecting group or other suitable oxidatively labile protecting group; a trityl group.
In a thirteenth aspect the invention provides for a disaccharide building block for the preparation of synthetic heparinoids, said building block of General Formula XIII, A
*
0 Rg X2 0 ------- .....\__RS:1__Os.
Rp0 ORp 0 ORs0 General Formula XIII (Alternate Block D-C) Wherein X2 is defined as in General Formula II, Rg and Rsi are defined as in General Formula X, Rs is defined as in General Formula I, Rp is defined as in General Formula V, and A includes but is not limited to; H, Methoxy, Methyl; other suitable substituents will be known to those in the art,or X2 is selected from a hydroxyl group; thioalkyl, thioaryl, halogen, imidoyl, phosphate and related phosphate ester type leaving groups, a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group;
and the stereochemistry may be alpha or beta;
RB is selected from the group consisting of an azido function, an amine; an NH-Dde or NH-DTPM group, or Rg4 and R B can combine together to form a cyclic carbamate;
In a thirteenth aspect the invention provides for a disaccharide building block for the preparation of synthetic heparinoids, said building block of General Formula XIII, A
*
0 Rg X2 0 ------- .....\__RS:1__Os.
Rp0 ORp 0 ORs0 General Formula XIII (Alternate Block D-C) Wherein X2 is defined as in General Formula II, Rg and Rsi are defined as in General Formula X, Rs is defined as in General Formula I, Rp is defined as in General Formula V, and A includes but is not limited to; H, Methoxy, Methyl; other suitable substituents will be known to those in the art,or X2 is selected from a hydroxyl group; thioalkyl, thioaryl, halogen, imidoyl, phosphate and related phosphate ester type leaving groups, a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group;
and the stereochemistry may be alpha or beta;
RB is selected from the group consisting of an azido function, an amine; an NH-Dde or NH-DTPM group, or Rg4 and R B can combine together to form a cyclic carbamate;
25 Rs is selected from the group consisting of 4-methoxyphenyl;
substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups; carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group allyl, methoxymethyl, methoxyethyl , benzyloxymethyl;
Rsi is selected from the group consisting of 4-methoxyphenyl;
substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups; carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group allyl, methoxymethyl, methoxyethyl, benzyloxymethyl;
or R54 and R s may be combined to form a cyclic carbamate;
Rp (adjacent the 0 linking atom to the benzyl) is selected from the group consisting of 4-methoxyphenyl; benzyl, substituted benzyl groups;
alkylacyl, arylacyl and alkylarylacyl, or substituted alkylacyl, arylacyl and alkylarylacyl protecting groups;, carbonate protecting groups;
Rp (adjacent the 0 linking atom to C) is selected from the group consisting of 4-methoxyphenyl; benzyl, substituted benzyl groups; alkylacyl, arylacyl and alkylarylacyl, or substituted alkylacyl, arylacyl and alkylarylacyl protecting groups;, carbonate protecting groups, silyl protecting groups, carbamate protecting groups, C3-05 alkenyl;
A includes but is not limited to; H, Methoxy, Methyl; other suitable substituents will be known to those in the art.
In a fourteenth aspect the invention provides for a trisaccharide building block for the preparation of synthetic heparinoids, said building block of General Formula XIV,
substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups; carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group allyl, methoxymethyl, methoxyethyl , benzyloxymethyl;
Rsi is selected from the group consisting of 4-methoxyphenyl;
substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups; carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group allyl, methoxymethyl, methoxyethyl, benzyloxymethyl;
or R54 and R s may be combined to form a cyclic carbamate;
Rp (adjacent the 0 linking atom to the benzyl) is selected from the group consisting of 4-methoxyphenyl; benzyl, substituted benzyl groups;
alkylacyl, arylacyl and alkylarylacyl, or substituted alkylacyl, arylacyl and alkylarylacyl protecting groups;, carbonate protecting groups;
Rp (adjacent the 0 linking atom to C) is selected from the group consisting of 4-methoxyphenyl; benzyl, substituted benzyl groups; alkylacyl, arylacyl and alkylarylacyl, or substituted alkylacyl, arylacyl and alkylarylacyl protecting groups;, carbonate protecting groups, silyl protecting groups, carbamate protecting groups, C3-05 alkenyl;
A includes but is not limited to; H, Methoxy, Methyl; other suitable substituents will be known to those in the art.
In a fourteenth aspect the invention provides for a trisaccharide building block for the preparation of synthetic heparinoids, said building block of General Formula XIV,
26 ORs Rp0 ORp 0 ORs0 General Formula XIV (Block E-D-C) Wherein X2 is defined as in General Formula II, RB and R81 are defined as in General Formula X, Rs is defined as in General Formula I, Rp is defined as in General Formula V, RE is defined as in General Formula II, RBI is defined as being selected from R3 of General Formula IV, with the addition that RBI can combine together with RH2 to form a cyclic carbamate, RH2 is defined as being selected from RH of General Formula I, with the addition that RH2 can combine together with Rsito form a cyclic carbamate, and RH is defined as in General Formula I or X2 is selected from a hydroxyl group; thioalkyl, thioaryl, halogen, trichloroacetimidoyl, phosphate and related phosphate ester type leaving groups, a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group; and the stereochemistry may be alpha or beta;
Rp (adjacent block E) is selected from the group consisting of 4 methoxyphenyl; benzyl, substituted benzyl groups; alkylacyl, arylacyl and alkylarylacyl, or substituted alkylacyl, arylacyl and alkylarylacyl protecting groups;, carbonate protecting groups;
Rp (adjacent Block C) is selected from the group consisting of 4 methoxyphenyl; benzyl, substituted benzyl groups; alkylacyl, arylacyl and alkylarylacyl, or substituted alkylacyl, arylacyl and alkylarylacyl protecting groups;, carbonate protecting groups, silyl protecting groups, carbamate protecting groups, C3-05 alkenyl;
Rp (adjacent block E) is selected from the group consisting of 4 methoxyphenyl; benzyl, substituted benzyl groups; alkylacyl, arylacyl and alkylarylacyl, or substituted alkylacyl, arylacyl and alkylarylacyl protecting groups;, carbonate protecting groups;
Rp (adjacent Block C) is selected from the group consisting of 4 methoxyphenyl; benzyl, substituted benzyl groups; alkylacyl, arylacyl and alkylarylacyl, or substituted alkylacyl, arylacyl and alkylarylacyl protecting groups;, carbonate protecting groups, silyl protecting groups, carbamate protecting groups, C3-05 alkenyl;
27 RE is selected from the group consisting of methyl, C2-05 alkyl;
substituted alkyl, C3-05 alkenyl; or, benzyl and substituted benzyl groups;
RB1 is selected from the group consisting of an azido function, an amine; an NH-Dde or NH-DTPM group, or RH2 and Rai can combine together to form a cyclic carbamate;
RH is selected from the group consisting of benzyl or substituted benzyl protecting group, allyl, allyloxycarbonyl;
RH2 is selected from the group consisting of benzyl or substituted benzyl protecting group, allyl, allyloxycarbonyl, or RH2 and Rai independently can combine together to form a cyclic carbamate;
Rs (on block E) is selected from the group consisting of 4-methoxyphenyl; 4-methoxybenzyl, substituted benzyl groups; alkylacyl, benzoyl, arylacyl or alkylarylacyl, and substituted alkylacyl, 4-chlorobenzoyl, arylacyl or alkylarylacy protecting groups; allyloxycarbonyl, ethoxycarbonyl, tertbutoxycarbonyl, carbonate protecting groups; is selected from the group consisting of 4-methoxyphenyl; substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups; carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group ally!, methoxymethyl, methoxyethyl, benzyloxymethyl;
or Rs and RH can be combined to form a cyclic acetal or ketal moiety;
RS (on block C and adjacent the ring 0 ) is selected from the group consisting of 4methoxyphenyl; substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups; carbonate protecting groups; a tbutyldiphenylsilyloxy or other such
substituted alkyl, C3-05 alkenyl; or, benzyl and substituted benzyl groups;
RB1 is selected from the group consisting of an azido function, an amine; an NH-Dde or NH-DTPM group, or RH2 and Rai can combine together to form a cyclic carbamate;
RH is selected from the group consisting of benzyl or substituted benzyl protecting group, allyl, allyloxycarbonyl;
RH2 is selected from the group consisting of benzyl or substituted benzyl protecting group, allyl, allyloxycarbonyl, or RH2 and Rai independently can combine together to form a cyclic carbamate;
Rs (on block E) is selected from the group consisting of 4-methoxyphenyl; 4-methoxybenzyl, substituted benzyl groups; alkylacyl, benzoyl, arylacyl or alkylarylacyl, and substituted alkylacyl, 4-chlorobenzoyl, arylacyl or alkylarylacy protecting groups; allyloxycarbonyl, ethoxycarbonyl, tertbutoxycarbonyl, carbonate protecting groups; is selected from the group consisting of 4-methoxyphenyl; substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups; carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group ally!, methoxymethyl, methoxyethyl, benzyloxymethyl;
or Rs and RH can be combined to form a cyclic acetal or ketal moiety;
RS (on block C and adjacent the ring 0 ) is selected from the group consisting of 4methoxyphenyl; substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups; carbonate protecting groups; a tbutyldiphenylsilyloxy or other such
28 substituted silyloxy protecting group allyl, methoxymethyl, methoxyethyl , benzyloxymethyl;
Rs (on block C and adjacent the 0 linking atom) is selected from the group consisting of 4-methoxyphenyl; substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups; carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group allyl, methoxymethyl, methoxyethyl, benzyloxymethyl;
or Rs and RB may be combined to form a cyclic carbamate;
RB is selected from the group consisting of an azido function, an amine; an NH-Dde or NH-DTPM group, or RB4 and RB can combine together to form a cyclic carbamate;
In a fifteenth aspect the invention provides for a trisaccharide building block for the preparation of synthetic heparinoids, said building block of General Formula XV, ORs REO()RH Roo RLO 0 RA Xi RS10 RES 0 ORs General Formula XV (Block C-B-A) Wherein X1 is defined as in General Formula I
RA and RHi are defined as in General Formula VIII, Rs is defined as in General Formula I, RH is defined as in General Formula I,
Rs (on block C and adjacent the 0 linking atom) is selected from the group consisting of 4-methoxyphenyl; substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups; carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group allyl, methoxymethyl, methoxyethyl, benzyloxymethyl;
or Rs and RB may be combined to form a cyclic carbamate;
RB is selected from the group consisting of an azido function, an amine; an NH-Dde or NH-DTPM group, or RB4 and RB can combine together to form a cyclic carbamate;
In a fifteenth aspect the invention provides for a trisaccharide building block for the preparation of synthetic heparinoids, said building block of General Formula XV, ORs REO()RH Roo RLO 0 RA Xi RS10 RES 0 ORs General Formula XV (Block C-B-A) Wherein X1 is defined as in General Formula I
RA and RHi are defined as in General Formula VIII, Rs is defined as in General Formula I, RH is defined as in General Formula I,
29 RE is defined as in General Formula II, RB and Rsi are defined as in General Formula X, and RL is defined as in General Formula I or Xi is selected from the group consisting of hydroxy, akenyloxy, alkoxy, aryloxy, benzyloxy, substituted benzyloxy; thioalkyl, thioaryl, halogen, imidoyl, phosphate and related phosphate ester type leaving groups, a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group; a lipoaminoacid or other such group suitable for conjugation to delivery systems or solid supports; and the stereochemistry may be alpha or beta;
RH is selected from the group consisting of benzyl or substituted benzyl protecting group, allyl, allyloxycarbonyl;
RH1 is selected from the group consisting of benzyl or substituted benzyl protecting group, allyl, allyloxycarbonyl;
RA is selected from the group consisting of an azido function, an amine; an NH-Dde, NH-DTPM, NH-Fmoc, NH-Boc, NH-Cbz, NH-Troc, N-phthalimido, NH-Ac, NH-Allyloxycarbonyl; or RH and RA can combine together to form a cyclic carbamate;
Rs ( on block A ) is selected from the group consisting of 4-methoxyphenyl; substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups;
carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group allyl, methoxymethyl, methoxyethyl, benzyloxymethyl;
Rs ( on block B ) is selected from the group consisting of 4-methoxyphenyl; substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups;
carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group allyl, methoxymethyl, methoxyethyl, benzyloxymethyl;
RH is selected from the group consisting of benzyl or substituted benzyl protecting group, allyl, allyloxycarbonyl;
RH1 is selected from the group consisting of benzyl or substituted benzyl protecting group, allyl, allyloxycarbonyl;
RA is selected from the group consisting of an azido function, an amine; an NH-Dde, NH-DTPM, NH-Fmoc, NH-Boc, NH-Cbz, NH-Troc, N-phthalimido, NH-Ac, NH-Allyloxycarbonyl; or RH and RA can combine together to form a cyclic carbamate;
Rs ( on block A ) is selected from the group consisting of 4-methoxyphenyl; substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups;
carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group allyl, methoxymethyl, methoxyethyl, benzyloxymethyl;
Rs ( on block B ) is selected from the group consisting of 4-methoxyphenyl; substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups;
carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group allyl, methoxymethyl, methoxyethyl, benzyloxymethyl;
30 Rs ( on block C ) is selected from the group consisting of 4-- methoxyphenyl; substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups;
carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group allyl, methoxymethyl, methoxyethyl , benzyloxymethyl;
Rs4 is selected from the group consisting of 4-methoxyphenyl;
substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups; carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group allyl, methoxymethyl, methoxyethyl, benzyloxymethyl, or R54 and RB may be combined to form a cyclic carbamate;
RE is selected from the group consisting of methyl, C2-05 alkyl;
substituted alkyl,C3-05 alkenyl; or, benzyl and substituted benzyl groups;
RE is selected from the group consisting of an azido function, an amine; an NH-Dde or NH-DTPM group, or RE4 and RE can combine together to form a cyclic carbamate;
RL is selected from a H atom; a levulinoyl, chloroacetyl, 4-acetoxybenzoyl, 4-acetamidobenzoyl, 4-azidobenzoyl, or other substituted benzoyl type protecting group; a benzyl group, a 4-acetoxybenzyl, 4-acetamidobenzyl or other such suitable substituted benzyl type protecting group; y-aminobutyryl, 4-N-[1-(4,4-dimethy1-2,6-dioxocyclohex-1-ylidene)ethylamino]-butyryl, 4-N41-(1,3-climethy1-2,4,6(1H,3H,5H)-trioxopyrimidin-5-ylidene)methylaminoj-butyryl, 4-N-Alloc-butyryl, 4-N-Fmoc-butyryl, 4-N-Boc-butyryl type protecting groups;
allyloxycarbonyl, allyl ether, carbonate type protecting groups;
carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group allyl, methoxymethyl, methoxyethyl , benzyloxymethyl;
Rs4 is selected from the group consisting of 4-methoxyphenyl;
substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups; carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group allyl, methoxymethyl, methoxyethyl, benzyloxymethyl, or R54 and RB may be combined to form a cyclic carbamate;
RE is selected from the group consisting of methyl, C2-05 alkyl;
substituted alkyl,C3-05 alkenyl; or, benzyl and substituted benzyl groups;
RE is selected from the group consisting of an azido function, an amine; an NH-Dde or NH-DTPM group, or RE4 and RE can combine together to form a cyclic carbamate;
RL is selected from a H atom; a levulinoyl, chloroacetyl, 4-acetoxybenzoyl, 4-acetamidobenzoyl, 4-azidobenzoyl, or other substituted benzoyl type protecting group; a benzyl group, a 4-acetoxybenzyl, 4-acetamidobenzyl or other such suitable substituted benzyl type protecting group; y-aminobutyryl, 4-N-[1-(4,4-dimethy1-2,6-dioxocyclohex-1-ylidene)ethylamino]-butyryl, 4-N41-(1,3-climethy1-2,4,6(1H,3H,5H)-trioxopyrimidin-5-ylidene)methylaminoj-butyryl, 4-N-Alloc-butyryl, 4-N-Fmoc-butyryl, 4-N-Boc-butyryl type protecting groups;
allyloxycarbonyl, allyl ether, carbonate type protecting groups;
31 In a sixteenth aspect the invention provides for a tetrasaccharide building block for the preparation of synthetic heparinoids, said building block of General Formula XVI, ORs RLO Rp0 0 RA Xi 0 Rp RSi RB 0 ORs General Formula XVI (Block D-C-B-A) Wherein Xi is defined as in General Formula I
RA and RHi are defined as in General Formula VIII, Rs is defined as in General Formula I, RH is defined as in General Formula I, RE is defined as in General Formula II, RB and R51 are defined as in General Formula X, Rp is as defined in General Formula V, and RL is as defined in General Formula I or is selected from the group consisting of hydroxy, alkenyloxy, alkoxy, aryloxy, benzyloxy, substituted benzyloxy; thioalkyl, thioaryl, halogen, imidoyl, phosphate and related phosphate ester type leaving groups, a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group; a lipoaminoacid or other such group suitable for conjugation to delivery systems or solid supports; and the stereochemistry may be alpha or beta, RH is selected from the group consisting of benzyl or substituted benzyl protecting group, allyl, allyloxycarbonyl;
RHi is selected from the group consisting of benzyl or substituted benzyl protecting group, allyl, allyloxycarbonyl, or RH' and RA can combine together to form a cyclic carbamate;
RA and RHi are defined as in General Formula VIII, Rs is defined as in General Formula I, RH is defined as in General Formula I, RE is defined as in General Formula II, RB and R51 are defined as in General Formula X, Rp is as defined in General Formula V, and RL is as defined in General Formula I or is selected from the group consisting of hydroxy, alkenyloxy, alkoxy, aryloxy, benzyloxy, substituted benzyloxy; thioalkyl, thioaryl, halogen, imidoyl, phosphate and related phosphate ester type leaving groups, a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group; a lipoaminoacid or other such group suitable for conjugation to delivery systems or solid supports; and the stereochemistry may be alpha or beta, RH is selected from the group consisting of benzyl or substituted benzyl protecting group, allyl, allyloxycarbonyl;
RHi is selected from the group consisting of benzyl or substituted benzyl protecting group, allyl, allyloxycarbonyl, or RH' and RA can combine together to form a cyclic carbamate;
32 RA is selected from the group consisting of an azido function, an amine; an NH-Dde, NH-DTPM, NH-Fmoc, NH-Boc, NH-Cbz, NH-Troc, N-phthalimido, NH-Ac, NH-Allyloxycarbonyl; or RH,' and RA can combine together to form a cyclic carbamate, RS ( on block A) is selected from the group consisting of 4-methoxyphenyl; substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups;
carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group allyl, methoxymethyl, methoxyethyl, benzyloxymethyl, RS ( on block B) is selected from the group consisting of 4-methoxyphenyl; substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups;
carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group ally!, methoxymethyl, methoxyethyl, benzyloxymethyl, RS ( on block C and adjacent the ring oxygen) is selected from the group consisting of 4-methoxyphenyl; substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups; carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group allyl, methoxymethyl, methoxyethyl , benzyloxymethyl, Rs ( on block C and adjacent the linking 0 ) is selected from the group consisting of 4-methoxyphenyl; substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups; carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group allyl, methoxymethyl, methoxyethyl, benzyloxymethyl, or Rs4 and RB may be combined to form a cyclic carba mate, _
carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group allyl, methoxymethyl, methoxyethyl, benzyloxymethyl, RS ( on block B) is selected from the group consisting of 4-methoxyphenyl; substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups;
carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group ally!, methoxymethyl, methoxyethyl, benzyloxymethyl, RS ( on block C and adjacent the ring oxygen) is selected from the group consisting of 4-methoxyphenyl; substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups; carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group allyl, methoxymethyl, methoxyethyl , benzyloxymethyl, Rs ( on block C and adjacent the linking 0 ) is selected from the group consisting of 4-methoxyphenyl; substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups; carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group allyl, methoxymethyl, methoxyethyl, benzyloxymethyl, or Rs4 and RB may be combined to form a cyclic carba mate, _
33 RE ( on block D) is selected from the group consisting of methyl, C2' C5 alkyl; substituted alkyl, 03-05 alkenyl; or, benzyl and substituted benzyl groups;
RE ( on block B ) is selected from the group consisting of methyl, C2-05 alkyl; substituted alkyl,C3-05 alkenyl; or, benzyl and substituted benzyl groups, Rs is selected from the group consisting of an azido function, an amine; an NH-Dde or NH-DTPM group, or R54 and RB can combine together to form a cyclic carbamate, Rp ( adjacent RL) is selected from the group consisting of 4-methoxyphenyl; benzyl, substituted benzyl groups; alkylacyi, arylacyl and alkylarylacyl, or substituted alkylacyl, arylacyl and alkylarylacyl protecting groups;, carbonate protecting groups;
Rp ( on group D and adjacent group C ) is selected from the group consisting of 4-methoxyphenyl; benzyl, substituted benzyl groups; alkylacyl, arylacyl and alkylarylacyl, or substituted alkylacyl, arylacyl and alkylarylacyl protecting groups;, carbonate protecting groups, silyl protecting groups, carbamate protecting groups, C3-05 alkenyl;
RL is selected from a H atom; a levulinoyl, chloroacetyl, 4-acetoxybenzoyl, 4-acetamidobenzoyl, 4-azidobenzoyl, or other substituted benzoyl type protecting group; a benzyl group, a 4-acetoxybenzyl, 4-acetamidobenzyl or other such suitable substituted benzyl type protecting group; y-aminobutyryl, 4-N4144,4 -dimethy1-2,6-dioxocyclohex-1-ylidene)ethylamino]-butyryl, 4-N-[1-(1,3-dimethy1-2,4,6(1H,3H,5H)-trioxopyrimidin-5-ylidene)methylamino}-butyryl, 4-N-Alloc-butyryl, 4-N-Fmoc-butyryl, 4-N-Boc-butyryl type protecting groups;
allyloxycarbonyl, allyl ether, carbonate type protecting groups;
RE ( on block B ) is selected from the group consisting of methyl, C2-05 alkyl; substituted alkyl,C3-05 alkenyl; or, benzyl and substituted benzyl groups, Rs is selected from the group consisting of an azido function, an amine; an NH-Dde or NH-DTPM group, or R54 and RB can combine together to form a cyclic carbamate, Rp ( adjacent RL) is selected from the group consisting of 4-methoxyphenyl; benzyl, substituted benzyl groups; alkylacyi, arylacyl and alkylarylacyl, or substituted alkylacyl, arylacyl and alkylarylacyl protecting groups;, carbonate protecting groups;
Rp ( on group D and adjacent group C ) is selected from the group consisting of 4-methoxyphenyl; benzyl, substituted benzyl groups; alkylacyl, arylacyl and alkylarylacyl, or substituted alkylacyl, arylacyl and alkylarylacyl protecting groups;, carbonate protecting groups, silyl protecting groups, carbamate protecting groups, C3-05 alkenyl;
RL is selected from a H atom; a levulinoyl, chloroacetyl, 4-acetoxybenzoyl, 4-acetamidobenzoyl, 4-azidobenzoyl, or other substituted benzoyl type protecting group; a benzyl group, a 4-acetoxybenzyl, 4-acetamidobenzyl or other such suitable substituted benzyl type protecting group; y-aminobutyryl, 4-N4144,4 -dimethy1-2,6-dioxocyclohex-1-ylidene)ethylamino]-butyryl, 4-N-[1-(1,3-dimethy1-2,4,6(1H,3H,5H)-trioxopyrimidin-5-ylidene)methylamino}-butyryl, 4-N-Alloc-butyryl, 4-N-Fmoc-butyryl, 4-N-Boc-butyryl type protecting groups;
allyloxycarbonyl, allyl ether, carbonate type protecting groups;
34 In an seventeenth aspect the invention provides for a tetrasaccharide building block for the preparation of synthetic heparinoids, said building block of General Formula XVII, 0 Rs RHO
RH2-C->""C". 0 O RB1 RE ORs REO
Rp0 Rsi 0 ORp RB 0 ORs General Formula XVII (Block E-D-C-B) Wherein X2 is defined as in General Formula IV, RH is defined as in General Formula I, RE is defined as in General Formula II, RB and Rsi are defined as in General Formula X, Rs is defined as in General Formula I, Rp is defined as in General Formula V, RL is defined as in General Formula I, and RBI and RH2 are defined as in General Formula XIV, or RH is selected from the group consisting of benzyl or substituted benzyl protecting group, allyl, allyloxycarbonyl;
RH2 is selected from the group consisting of benzyl or substituted benzyl protecting group, allyl, allyloxycarbonyl, or RH2 and RB1 independently can combine together to form a cyclic carbamate;
Rs ( on block B ) is selected from the group consisting of 4-methoxyphenyl; substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups;
carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group allyl, methoxymethyl, methoxyethyl, benzyloxymethyl;
RH2-C->""C". 0 O RB1 RE ORs REO
Rp0 Rsi 0 ORp RB 0 ORs General Formula XVII (Block E-D-C-B) Wherein X2 is defined as in General Formula IV, RH is defined as in General Formula I, RE is defined as in General Formula II, RB and Rsi are defined as in General Formula X, Rs is defined as in General Formula I, Rp is defined as in General Formula V, RL is defined as in General Formula I, and RBI and RH2 are defined as in General Formula XIV, or RH is selected from the group consisting of benzyl or substituted benzyl protecting group, allyl, allyloxycarbonyl;
RH2 is selected from the group consisting of benzyl or substituted benzyl protecting group, allyl, allyloxycarbonyl, or RH2 and RB1 independently can combine together to form a cyclic carbamate;
Rs ( on block B ) is selected from the group consisting of 4-methoxyphenyl; substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups;
carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group allyl, methoxymethyl, methoxyethyl, benzyloxymethyl;
35 Rs ( on block C and adjacent the ring 0 )is selected from the group consisting of 4-methoxyphenyl; substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups; carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group allyl, methoxymethyl, methoxyethyl , benzyloxymethyl;
Rs ( on block C and adjacent the 0 linking atom) is selected from the group consisting of 4-methoxyphenyl; substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups; carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group allyl, methoxymethyl, methoxyethyl, benzyloxymethyl, or this Rs and RB may be combined to form a cyclic carbamate, Rs ( on block E) is selected from the group consisting of 4-methoxyphenyl; 4-methoxybenzyl, substituted benzyl groups; alkylacyl, benzoyl, arylacyl or alkylarylacyl, and substituted alkylacyl, 4-chlorobenzoyl, arylacyl or alkylarylacy protecting groups; allyloxycarbonyl, ethoxycarbonyl, tertbutoxycarbonyl, carbonate protecting groups; is selected from the group consisting of 4-methoxyphenyl; substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups; carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group allyl, methoxymethyl, methoxyethyl, benzyloxymethyl;or this Rs and RH can be combined to form a cyclic acetal or keta I moiety;
RE ( on block D ) is selected from the group consisting of methyl, C2-05 alkyl; substituted alkyl, C3-05 alkenyl; or, benzyl and substituted benzyl groups;
,
Rs ( on block C and adjacent the 0 linking atom) is selected from the group consisting of 4-methoxyphenyl; substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups; carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group allyl, methoxymethyl, methoxyethyl, benzyloxymethyl, or this Rs and RB may be combined to form a cyclic carbamate, Rs ( on block E) is selected from the group consisting of 4-methoxyphenyl; 4-methoxybenzyl, substituted benzyl groups; alkylacyl, benzoyl, arylacyl or alkylarylacyl, and substituted alkylacyl, 4-chlorobenzoyl, arylacyl or alkylarylacy protecting groups; allyloxycarbonyl, ethoxycarbonyl, tertbutoxycarbonyl, carbonate protecting groups; is selected from the group consisting of 4-methoxyphenyl; substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups; carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group allyl, methoxymethyl, methoxyethyl, benzyloxymethyl;or this Rs and RH can be combined to form a cyclic acetal or keta I moiety;
RE ( on block D ) is selected from the group consisting of methyl, C2-05 alkyl; substituted alkyl, C3-05 alkenyl; or, benzyl and substituted benzyl groups;
,
36 RE (on block B ) is selected from the group consisting of methyl, Cr C5 alkyl; substituted alkyl,C3-05 alkenyl; or, benzyl and substituted benzyl groups;
RB is selected from the group consisting of an azido function, an amine; an NH-Dde or NH-DTPM group, or Rs4 and RB can combine together to form a cyclic carbamate;
R81 is selected from the group consisting of an azido function, an amine; an NH-Dde or NH-DTPM group, or RH2 and RBI can combine together to form a cyclic carbamate;
Rp ( on block D adjacent block E ) is selected from the group consisting of 4-methoxyphenyl; benzyl, substituted benzyl groups; alkylacyl, arylacyl and alkylarylacyl, or substituted alkylacyl, arylacyl and alkylarylacyl protecting groups;, carbonate protecting groups;
Rp ( on block D adjacent block C ) is selected from the group consisting of 4-methoxyphenyl; benzyl, substituted benzyl groups; alkylacyl, arylacyl and alkylarylacyl, or substituted alkylacyl, arylacyl and alkylarylacyl protecting groups;, carbonate protecting groups, silyl protecting groups, carbamate protecting groups, C3-05 alkenyl;
X2 is selected from a hydroxyl group; thioalkyl, thioaryl, halogen, trichloroacetimidoyl, phosphate and related phosphate ester type leaving groups, a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group; and the stereochemistry may be alpha or beta In a eighteenth aspect the invention provides for a pentasaccharide building block for the preparation of synthetic heparinoids, said building block of General Formula XVIII,
RB is selected from the group consisting of an azido function, an amine; an NH-Dde or NH-DTPM group, or Rs4 and RB can combine together to form a cyclic carbamate;
R81 is selected from the group consisting of an azido function, an amine; an NH-Dde or NH-DTPM group, or RH2 and RBI can combine together to form a cyclic carbamate;
Rp ( on block D adjacent block E ) is selected from the group consisting of 4-methoxyphenyl; benzyl, substituted benzyl groups; alkylacyl, arylacyl and alkylarylacyl, or substituted alkylacyl, arylacyl and alkylarylacyl protecting groups;, carbonate protecting groups;
Rp ( on block D adjacent block C ) is selected from the group consisting of 4-methoxyphenyl; benzyl, substituted benzyl groups; alkylacyl, arylacyl and alkylarylacyl, or substituted alkylacyl, arylacyl and alkylarylacyl protecting groups;, carbonate protecting groups, silyl protecting groups, carbamate protecting groups, C3-05 alkenyl;
X2 is selected from a hydroxyl group; thioalkyl, thioaryl, halogen, trichloroacetimidoyl, phosphate and related phosphate ester type leaving groups, a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group; and the stereochemistry may be alpha or beta In a eighteenth aspect the invention provides for a pentasaccharide building block for the preparation of synthetic heparinoids, said building block of General Formula XVIII,
37 ORs ORs RH2 RBi RE ORs 0 0 o R----1-1 C---.)&.t.=====\RA Xi Rp0 ORp RS1 RB 0 ORs A
General Formula XVIII (Block E-D-C-B-A) Wherein Xi is defined as in General Formula I
RA and RH1 are defined as in General Formula VIII, and R1-11 can also be allyl and alloxycarbonyl or RA and can combine together to form a cyclic carbamate.
Rs is defined as in General Formula I, RH is defined as in General Formula I,or RH is selected from the group consisting of benzyl or substituted benzyl protecting group, allyl, allyloxycarbonyl, RE is defined as in General Formula II, RB and Rsi are defined as in General Formula X, Rp is defined as in General Formula V, and may be benzyl, Rp (adjacent the link from D to C) may also be silyl protecting groups, carbamate protecting groups, C3-05 alkenyl, and RBI and Rii2 are defined as in General Formula XIV or RH2 is selected from the group consisting of benzyl or substituted benzyl protecting group, ally!, allyloxycarbonyl, or RH2 and RBI independently can combine together to form a cyclic carbamate, Rsi on block C (Rs4 in the claims) is selected from the group consisting of 4-methoxyphenyl; substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups;
carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group; allyl, methoxymethyl, methoxyethyl, benzyloxymethyl, or R54 and RB may be combined to form a cycic carbamate;
General Formula XVIII (Block E-D-C-B-A) Wherein Xi is defined as in General Formula I
RA and RH1 are defined as in General Formula VIII, and R1-11 can also be allyl and alloxycarbonyl or RA and can combine together to form a cyclic carbamate.
Rs is defined as in General Formula I, RH is defined as in General Formula I,or RH is selected from the group consisting of benzyl or substituted benzyl protecting group, allyl, allyloxycarbonyl, RE is defined as in General Formula II, RB and Rsi are defined as in General Formula X, Rp is defined as in General Formula V, and may be benzyl, Rp (adjacent the link from D to C) may also be silyl protecting groups, carbamate protecting groups, C3-05 alkenyl, and RBI and Rii2 are defined as in General Formula XIV or RH2 is selected from the group consisting of benzyl or substituted benzyl protecting group, ally!, allyloxycarbonyl, or RH2 and RBI independently can combine together to form a cyclic carbamate, Rsi on block C (Rs4 in the claims) is selected from the group consisting of 4-methoxyphenyl; substituted benzyl groups; alkylacyl, arylacyl or alkylarylacyl, and substituted alkylacyl, arylacyl or alkylarylacy protecting groups;
carbonate protecting groups; a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group; allyl, methoxymethyl, methoxyethyl, benzyloxymethyl, or R54 and RB may be combined to form a cycic carbamate;
38 Rs on block E C B A, (Rsi,2,35 in the claims) can be a tbutyldiphenylsilyloxy or other such substituted silyloxy protecting group; allyl, methoxymethyl, methoxyethyl, benzyloxymethyl, In a nineteenth aspect, the invention provides a method for the preparation of compounds of the eighth aspect, involving the step of reacting a compound of the second or third aspect with a compound of the first or seventh aspect to form a new glycosidic bond.
In a twentieth aspect, the invention provides a method for the preparation of compounds of the eighth aspect, involving the step of selectively removing the protecting group Rm from compounds of the ninth aspect and oxidizing the product of said deprotection.
In a twenty first aspect, the invention provides a method for the preparation of compounds of the tenth aspect, involving the step of reacting a compound of the fifth aspect with a compound of the fourth or seventh aspect to form a new glycosidic bond.
In a twenty second aspect, the invention provides a method for the preparation of compounds of the eleventh aspect, involving the step of reacting a compound of the fifth aspect with a compound of the sixth or seventh aspect to form a new glycosidic bond.
In a twenty third aspect, the invention provides a method for preparation of compounds of the thirteenth aspect involving the reaction of a compound of the fourth or seventh aspect with a suitable donor molecule, to form a new glycosidic bond.
In a twenty fourth aspect, the invention provides a method for the preparation of compounds of the fourteenth aspect involving the step of using any one or
In a twentieth aspect, the invention provides a method for the preparation of compounds of the eighth aspect, involving the step of selectively removing the protecting group Rm from compounds of the ninth aspect and oxidizing the product of said deprotection.
In a twenty first aspect, the invention provides a method for the preparation of compounds of the tenth aspect, involving the step of reacting a compound of the fifth aspect with a compound of the fourth or seventh aspect to form a new glycosidic bond.
In a twenty second aspect, the invention provides a method for the preparation of compounds of the eleventh aspect, involving the step of reacting a compound of the fifth aspect with a compound of the sixth or seventh aspect to form a new glycosidic bond.
In a twenty third aspect, the invention provides a method for preparation of compounds of the thirteenth aspect involving the reaction of a compound of the fourth or seventh aspect with a suitable donor molecule, to form a new glycosidic bond.
In a twenty fourth aspect, the invention provides a method for the preparation of compounds of the fourteenth aspect involving the step of using any one or
39 more of the compounds of the fourth, fifth, sixth, seventh, tenth, eleventh, twelfth or thirteenth aspect in a glycosidic bond forming reaction.
In a twenty fifth aspect, the invention provides a method for the preparation of compounds of the fifteenth aspect involving the step of using any one or more compounds of the first, second, third, fourth, seventh, eighth and ninth aspects in a glycosidic bond forming reaction.
In a twenty sixth aspect, the invention provides a method for the preparation of compounds of the sixteenth aspect involving the step of using any one or more of the compounds of the first, second third, fourth, fifth, seventh, eighth, ninth, tenth, thirteenth or fifteenth aspect in a glycosidic bond forming reaction.
In a twenty seventh aspect, the invention provides a method for the preparation of compounds of the seventeenth aspect involving the step of using any one or more of the compounds of the second, third, fourth, fifth, seventh, tenth, eleventh, twelfth, thirteenth or fourteenth aspect in a glycosidic bond forming reaction.
In a twenty eighth aspect, the invention provides a method for the preparation of compounds of the eighteenth aspect involving the step of using any one or more of the compounds of the 1,2,3,4,5,7,8,9, 10, 11, 12, 13, 14, or 15, 16 or 17th aspect in a glycosidic bond forming reaction.
Brief Description of the Drawings Figure 1 is an NMR spectrograph of the bis-methyl ester of compound P-33 of the invention.
Figure 2 is an NMR spectrogram of compound P-40 of the invention.
39a Detailed Description of the Invention Embodiments of the invention representative of the best mode will be described with reference to the following examples. Standard operation protocols (SOPs) are provided for many of the examples.
List of Abbreviations:
AcO: Acetyl, All: Ally!, Alloc: Allyloxycarbonyl, Bn: Benzyl, Bz: Benzoyl, CAN: (NH4)2Celv(NO3)6, ceric ammonium (IV) nitrate,
In a twenty fifth aspect, the invention provides a method for the preparation of compounds of the fifteenth aspect involving the step of using any one or more compounds of the first, second, third, fourth, seventh, eighth and ninth aspects in a glycosidic bond forming reaction.
In a twenty sixth aspect, the invention provides a method for the preparation of compounds of the sixteenth aspect involving the step of using any one or more of the compounds of the first, second third, fourth, fifth, seventh, eighth, ninth, tenth, thirteenth or fifteenth aspect in a glycosidic bond forming reaction.
In a twenty seventh aspect, the invention provides a method for the preparation of compounds of the seventeenth aspect involving the step of using any one or more of the compounds of the second, third, fourth, fifth, seventh, tenth, eleventh, twelfth, thirteenth or fourteenth aspect in a glycosidic bond forming reaction.
In a twenty eighth aspect, the invention provides a method for the preparation of compounds of the eighteenth aspect involving the step of using any one or more of the compounds of the 1,2,3,4,5,7,8,9, 10, 11, 12, 13, 14, or 15, 16 or 17th aspect in a glycosidic bond forming reaction.
Brief Description of the Drawings Figure 1 is an NMR spectrograph of the bis-methyl ester of compound P-33 of the invention.
Figure 2 is an NMR spectrogram of compound P-40 of the invention.
39a Detailed Description of the Invention Embodiments of the invention representative of the best mode will be described with reference to the following examples. Standard operation protocols (SOPs) are provided for many of the examples.
List of Abbreviations:
AcO: Acetyl, All: Ally!, Alloc: Allyloxycarbonyl, Bn: Benzyl, Bz: Benzoyl, CAN: (NH4)2Celv(NO3)6, ceric ammonium (IV) nitrate,
40 ClAc: Monochloroacetyl, Cres: p-Tolyl, DCC: Dicyclohexylcarbodiimide, Dde: 1-(4,4-dimethy1-2,6-dioxocyclohex-ylidene)ethyl, DEAD: Diethyl azodicarboxylate, DIPEA Diisopropylethylamine, DNIAP:4-N,N-dimethylaminopyridine, DMF: N, N-Dimethylformamide, DMTST: Dimethyl (methylthio)sulfoniumtetrafluoromethansulfonate, DTPMB : 2,6-di-tert-butyl-4-methylpyridine DTPM: (1,3-dimethy1-2,4,6 (1H, 3H, 5H)-trioxopyrimidin-5-ylidene) methyl, Lev: 4-0xopentanoyl, MCPBA 3-chloroperbenzoic acid, Mes: Methanesulfonyl, Mp: 4-Methoxyphenyl, Mpm: 4-methoxybenzyl, NBS: N-Bromosuccinimide, NIS: N-lodosuccinimide, NMP: N-Methylpyrollidone NPht: N-Phthaloyl PDC: Pyridiniumdichromate, Pent: n-Pentenyl, Ph3P: Triphenylphosphine, Ply: Pivaloyl, TBAF: Tetrabutylammoniumfluoride, TBDMS: tert-Butyldimethylsilyl, TBDPS: tert-Butyldiphenylsilyl, TCA: Trichloroacetimidyl, TEMPO: 2,2,6,6-Tetramethy1-1-piperidinyloxyl, TFA: Trifluoroacetic acid, TFAA: Trifluoroacetic acid anhydride, Tf: Trifluoromethanesulfonyl, TfN3: Trifluoromethanesulfonyl azide, prepared from NaN3 and Tf20, TfOH: Trifluoromethanesulfonic acid,
41 THF: Terahydrofuran, TMS: Trimethylsilyl, Tos: p-Toluenesulfonyl, p-TosOH: p-Toluenesulfonic acid, Trit: Triphenylmethyl.
Standard Operating Procedures Standard Operating Procedure 1: Formation of Benzylidene acetals Standard Operating Procedure 2: Formation of p-Methoxybenzylidene acetals Standard Operating Procedure 3: Formation of isopropylidene acetals:
Standard Operating Procedure 4: Dealkylidenation (Removal of isopropylidene, benzylidene and p-methoxybenzylidene) Standard Operating Procedure 5: Regioselective opening of the p-methoxy-benzyliden acetal to a 6 -0-pMethoxybenzyl ether Standard Operating Procedure 6: Regioselective opening of a benzylidene ring to a 4-0-benzyl ether Standard Operating Procedure 7: Introduction of a benzyl or p-methoxybenzyl ether Standard Operating Procedure 8:Introdution of a tert-butyldiphenylsilyl ether Standard Operating Procedure 9: Cleavage of a tert-Butyl-diphenylsilyl ether Standard Operating Procedure 10:Introduction of a N-DTPM-group Standard Operating Procedure 11 :Cleavage of a N-DTPM-group Standard Operating Procedure 12: Introduction of an azide group via diazo transfer reaction Standard Operating Procedure 13: Hydrolysis of thioglycosides (NBS) Standard Operating Procedure 14: Hydrolysis of thioglycosides (NIS) Standard Operating Procedure 15:Chemoselective Oxidation to Uronic acids Standard Operating Procedure 16: Methyl ester formation on the Uronic acids Standard Operating Procedure 17: Regioselective 6-0-Benzoylation Standard Operating Procedure 18: Common procedure for O-Benzoylation Standard Operating Procedure 19:Common procedure for O-Acetylation Standard Operating Procedure 20: PDC-oxidation of alcohols to carboxylic acids Standard Operating Procedure 21 :Chemoselective 1-0-Benzoyl cleavage
Standard Operating Procedures Standard Operating Procedure 1: Formation of Benzylidene acetals Standard Operating Procedure 2: Formation of p-Methoxybenzylidene acetals Standard Operating Procedure 3: Formation of isopropylidene acetals:
Standard Operating Procedure 4: Dealkylidenation (Removal of isopropylidene, benzylidene and p-methoxybenzylidene) Standard Operating Procedure 5: Regioselective opening of the p-methoxy-benzyliden acetal to a 6 -0-pMethoxybenzyl ether Standard Operating Procedure 6: Regioselective opening of a benzylidene ring to a 4-0-benzyl ether Standard Operating Procedure 7: Introduction of a benzyl or p-methoxybenzyl ether Standard Operating Procedure 8:Introdution of a tert-butyldiphenylsilyl ether Standard Operating Procedure 9: Cleavage of a tert-Butyl-diphenylsilyl ether Standard Operating Procedure 10:Introduction of a N-DTPM-group Standard Operating Procedure 11 :Cleavage of a N-DTPM-group Standard Operating Procedure 12: Introduction of an azide group via diazo transfer reaction Standard Operating Procedure 13: Hydrolysis of thioglycosides (NBS) Standard Operating Procedure 14: Hydrolysis of thioglycosides (NIS) Standard Operating Procedure 15:Chemoselective Oxidation to Uronic acids Standard Operating Procedure 16: Methyl ester formation on the Uronic acids Standard Operating Procedure 17: Regioselective 6-0-Benzoylation Standard Operating Procedure 18: Common procedure for O-Benzoylation Standard Operating Procedure 19:Common procedure for O-Acetylation Standard Operating Procedure 20: PDC-oxidation of alcohols to carboxylic acids Standard Operating Procedure 21 :Chemoselective 1-0-Benzoyl cleavage
42 Standard Operating Procedure 22: Deacylation under Zemplen conditions Standard Operating Procedure 23: Introduction of the 4-0xopentanoyl (=Levulinoyl) group Standard Operating Procedure 24:Cleavage of the 4-0xopentanoyl (=
Levulinoyl) group Standard Operating Procedure 25: Formation of Trichloroacetimidates Standard Operating Procedure 26: Regioselective introduction of a 6-0-pMethoxyphenyl group under Mitsunobu conditions Standard Operating Procedure 27: Cleavage of the p-Methoxyphenyl ether Standard Operating Procedure 28: Cleavage of p-Methoxybenzyl ethers Standard Operating Procedure 29: Formation of a 2,3-cyclic carbamate Standard Operating Procedure 30: Cleavage of the N-phthaloyl group Standard Operating Procedure 31: Introduction of a thiocresyl ether at the reducing end Standard Operating Procedure 32: Glycosylation with thioglycosides a) NIS -promoted glycosylation b) DMTST promoted glycosylations:
Standard Operating Procedure 33: Glycosylations with trichloroacetimidates Standard Operating Procedure 34: Glycosylations using 2,3-cyclocarbamoyl protected p Thiocresyl glycosides as glycosyl donors Standard Operating Procedure 35: Introduction of an Alloc-group Standard Operating Procedure 36: Cleavage of an Alloc-group Standard Operating Procedure 37: Lewis acid mediated benzylation Standard Operating Procedure 38: benzylation under mild basic conditions Standard Operating Procedure 39: Ester cleavage under very mild conditions Standard Operating Procedure 1: Formation of Benzylidene acetals The starting material (47.5 mmol) was dissolved in acetonitrile (100 ¨ 200 ml) and reacted with benzaldehyde dimethyl acetal (1.2 equiv.) and a catalytic amount of p-toluenesulphonic acid monohydrate (0.01-0.1 equiv). The reaction was stirred at 50 C under reduced pressure (350 mbar) until the TLC
shows completion. Subsequently, the mixture was neutralized with triethylamine (pH 9) and concentrated in vacuo. The remaining residue was
Levulinoyl) group Standard Operating Procedure 25: Formation of Trichloroacetimidates Standard Operating Procedure 26: Regioselective introduction of a 6-0-pMethoxyphenyl group under Mitsunobu conditions Standard Operating Procedure 27: Cleavage of the p-Methoxyphenyl ether Standard Operating Procedure 28: Cleavage of p-Methoxybenzyl ethers Standard Operating Procedure 29: Formation of a 2,3-cyclic carbamate Standard Operating Procedure 30: Cleavage of the N-phthaloyl group Standard Operating Procedure 31: Introduction of a thiocresyl ether at the reducing end Standard Operating Procedure 32: Glycosylation with thioglycosides a) NIS -promoted glycosylation b) DMTST promoted glycosylations:
Standard Operating Procedure 33: Glycosylations with trichloroacetimidates Standard Operating Procedure 34: Glycosylations using 2,3-cyclocarbamoyl protected p Thiocresyl glycosides as glycosyl donors Standard Operating Procedure 35: Introduction of an Alloc-group Standard Operating Procedure 36: Cleavage of an Alloc-group Standard Operating Procedure 37: Lewis acid mediated benzylation Standard Operating Procedure 38: benzylation under mild basic conditions Standard Operating Procedure 39: Ester cleavage under very mild conditions Standard Operating Procedure 1: Formation of Benzylidene acetals The starting material (47.5 mmol) was dissolved in acetonitrile (100 ¨ 200 ml) and reacted with benzaldehyde dimethyl acetal (1.2 equiv.) and a catalytic amount of p-toluenesulphonic acid monohydrate (0.01-0.1 equiv). The reaction was stirred at 50 C under reduced pressure (350 mbar) until the TLC
shows completion. Subsequently, the mixture was neutralized with triethylamine (pH 9) and concentrated in vacuo. The remaining residue was
43 dissolved in an organic solvent (e.g. dichloromethane or ethyl acetate) and extracted with H20, saturated brine solution, dried over Na2SO4 and concentrated. Final purification was achieved either by crystallization or by silica gel chromatography. The typical yields for the product formation varied between 70 and 95 %.
Standard Operating Procedure 2: Formation of p-Methoxybenzylidene acetals The starting material (47.5 mmol) was dissolved in DMF/acetonitrile (1/1, 100 ¨ 200 ml) and reacted with p-methoxybenzaldehyde dimethyl acetal (1.2 equiv.) and a catalytic amount of p-toluenesulphonic acid monohydrate (0.01-0.1 equiv). The reaction was stirred between 50 - 60 C under reduced pressure (350 mbar) until the TLC shows completion. Subsequently, the mixture was neutralized with triethylamine (pH 9) and concentrated in vacuo. The remaining residue was dissolved in an organic solvent (e.g.
dichloromethane or ethyl acetate) and extracted with Ii0, saturated brine solution, dried over Na2SO4 and concentrated. Final purification was achieved either by crystallization or by silica gel chromatography. The typical yields for the product formation varied between 70 and 85 %.
Standard Operating Procedure 3: Formation of isopropylidene acetals:
A solution of starting material (10 mmol) and catalytic amounts of camphorsulfonic acid (0.01-0.1 equiv) in 2,2-dimethoxypropane (50 ml) was stirred at 25 C until completion, neutralized with triethylamine and concentrated. The remaining residue was dissolved in an organic solvent (e.g.
dichloromethane or ethyl acetate) and extracted with 1-120 and saturated brine solution. The organic layer was dried over Na2SO4 and concentrated. Final purification was achieved either by crystallization or by silica gel chromatography. The typical yields for the product formation varied between 75 and 93 %.
Standard Operating Procedure 4:
Standard Operating Procedure 2: Formation of p-Methoxybenzylidene acetals The starting material (47.5 mmol) was dissolved in DMF/acetonitrile (1/1, 100 ¨ 200 ml) and reacted with p-methoxybenzaldehyde dimethyl acetal (1.2 equiv.) and a catalytic amount of p-toluenesulphonic acid monohydrate (0.01-0.1 equiv). The reaction was stirred between 50 - 60 C under reduced pressure (350 mbar) until the TLC shows completion. Subsequently, the mixture was neutralized with triethylamine (pH 9) and concentrated in vacuo. The remaining residue was dissolved in an organic solvent (e.g.
dichloromethane or ethyl acetate) and extracted with Ii0, saturated brine solution, dried over Na2SO4 and concentrated. Final purification was achieved either by crystallization or by silica gel chromatography. The typical yields for the product formation varied between 70 and 85 %.
Standard Operating Procedure 3: Formation of isopropylidene acetals:
A solution of starting material (10 mmol) and catalytic amounts of camphorsulfonic acid (0.01-0.1 equiv) in 2,2-dimethoxypropane (50 ml) was stirred at 25 C until completion, neutralized with triethylamine and concentrated. The remaining residue was dissolved in an organic solvent (e.g.
dichloromethane or ethyl acetate) and extracted with 1-120 and saturated brine solution. The organic layer was dried over Na2SO4 and concentrated. Final purification was achieved either by crystallization or by silica gel chromatography. The typical yields for the product formation varied between 75 and 93 %.
Standard Operating Procedure 4:
44 Dealkylidenation (Removal of isopropylidene, benzylidene and p-methoxybenzylidene) A solution of the acetal (31 mmol) in 150 ml dichloromethane was cooled to 0 C and reacted with 80 % aqueous TFA (20.0 ml, cooled to 03C). After stirring at 0 C until completion, the reaction mixture was neutralized with 30 %
NaOH solution and extracted with water and saturated brine solution. The organic layer was dried over Na2SO4 and concentrated. Final purification was achieved either by crystallization or by silica gel chromatography. The typical yields for the product formation varied between 70 and 95 %.
Modification using p-Tos0Hx0H2 in Me0H/CH3CN for cleavage:
The acetal (16.6 mmol) was dissolved in 100mL of dry acetonitrile and 25 mL
Me0H and the solution was reacted with catalytic amounts of p-Tos0Hx0H2.
The reaction mixture was heated at elevated Temperature (between 40 and 60 C) until completion and then neutralized with Et3N, concentrated in vacuo and purified either by crystallization or by silica gel chromatography. The typical yields for the product formation varied between 70 and 95 %.
Standard Operating Procedure 5: Regioselective opening of the p-methoxybenzyliden acetal to a 6-0-pMethoxybenzyl ether A suspension of the starting sugar (10.2 mmol), molecular sieves 3A (6.5 g, freshly activated) and Na(CN)BH3 (3.85 g, 58.2 mmol) in dry DMF (90 ml) was stirred for 1 hr at r.t. and cooled down to 0 C. Subsequently, a solution of TFA (11.2 mL, 143.9 mmol in 51 mL dry DMF) was added dropwise and stirring continued at 50 to 60 C until completion of the reaction. The reaction mixture was cooled to 20 C, diluted with ethyl acetate and extracted with a saturated aqueous NaHCO3 solution and filtered through a celite pad. The combined organic layers were washed with saturated brine solution, dried over MgSO4 and concentrated. Final purification was achieved either by crystallization or by silica gel chromatography. The typical yields for the product formation varied between 70 and 90 %.
NaOH solution and extracted with water and saturated brine solution. The organic layer was dried over Na2SO4 and concentrated. Final purification was achieved either by crystallization or by silica gel chromatography. The typical yields for the product formation varied between 70 and 95 %.
Modification using p-Tos0Hx0H2 in Me0H/CH3CN for cleavage:
The acetal (16.6 mmol) was dissolved in 100mL of dry acetonitrile and 25 mL
Me0H and the solution was reacted with catalytic amounts of p-Tos0Hx0H2.
The reaction mixture was heated at elevated Temperature (between 40 and 60 C) until completion and then neutralized with Et3N, concentrated in vacuo and purified either by crystallization or by silica gel chromatography. The typical yields for the product formation varied between 70 and 95 %.
Standard Operating Procedure 5: Regioselective opening of the p-methoxybenzyliden acetal to a 6-0-pMethoxybenzyl ether A suspension of the starting sugar (10.2 mmol), molecular sieves 3A (6.5 g, freshly activated) and Na(CN)BH3 (3.85 g, 58.2 mmol) in dry DMF (90 ml) was stirred for 1 hr at r.t. and cooled down to 0 C. Subsequently, a solution of TFA (11.2 mL, 143.9 mmol in 51 mL dry DMF) was added dropwise and stirring continued at 50 to 60 C until completion of the reaction. The reaction mixture was cooled to 20 C, diluted with ethyl acetate and extracted with a saturated aqueous NaHCO3 solution and filtered through a celite pad. The combined organic layers were washed with saturated brine solution, dried over MgSO4 and concentrated. Final purification was achieved either by crystallization or by silica gel chromatography. The typical yields for the product formation varied between 70 and 90 %.
45 Standard Operating Procedure 6: Regioselective opening of a benzylidene ring to a 4-0-benzyl ether A solution of the starting material (3.4 mmol) in 25 mL dichloromethane is cooled to 0 C and to it is added of a solution of BH3 in THF (1 M, 34 ml) and a solution of Bu2BOTf in dichloromethane (1 M, 3.7 ml). The reaction is stirred at 0 C till completion and then quenched with 10 ml Et3N and 10 ml Me0H, concentrated and coevaporated three times with toluene. Final purification was achieved either by crystallization or by silica gel chromatography. The typical yield for the product formation varied between 75 and 90 %.
Standard Operating Procedure 7: Introduction of a benzyl or p-methoxybenzyl ether The starting material (40.2 mmol) was dissolved in dry N,A1-dimethylformamide (100 mL) at 0 C and reacted with NaH (48.24 mmol, 1.2 eq per OH to be benzylated). Then benzyl bromide (1.1 eq per OH to be benzylated) was added dropwise and stirring continued at 0 C until completion. The same conditions were applied for the introduction of an ally!
ether (Allylbromide served as allylating reagent).
The excess of NaH was neutralized by careful addition of acetic acid, followed by concentration of the reaction mixture in vacuo. The residue was dissolved in ethyl acetate and subsequently washed with water, 10 % aqueous HCI
solution, saturated aqueous NaHCO3 solution, saturated brine solution, dried over Na2SO4 and concentrated in vacuo. Final purification was achieved either by crystallization or by silica gel chromatography. The typical yield for the product formation varied between 70 and 92 %.
The same procedure was followed for the formation of the p-methoxybenzyl ether except that p-methoxybenzyl chloride was added to the reaction instead of benzyl bromide and the reaction was performed between 50 and 60 C.
Standard Operating Procedure 8:
Introdution of a tert-butyldiphenylsilyl ether
Standard Operating Procedure 7: Introduction of a benzyl or p-methoxybenzyl ether The starting material (40.2 mmol) was dissolved in dry N,A1-dimethylformamide (100 mL) at 0 C and reacted with NaH (48.24 mmol, 1.2 eq per OH to be benzylated). Then benzyl bromide (1.1 eq per OH to be benzylated) was added dropwise and stirring continued at 0 C until completion. The same conditions were applied for the introduction of an ally!
ether (Allylbromide served as allylating reagent).
The excess of NaH was neutralized by careful addition of acetic acid, followed by concentration of the reaction mixture in vacuo. The residue was dissolved in ethyl acetate and subsequently washed with water, 10 % aqueous HCI
solution, saturated aqueous NaHCO3 solution, saturated brine solution, dried over Na2SO4 and concentrated in vacuo. Final purification was achieved either by crystallization or by silica gel chromatography. The typical yield for the product formation varied between 70 and 92 %.
The same procedure was followed for the formation of the p-methoxybenzyl ether except that p-methoxybenzyl chloride was added to the reaction instead of benzyl bromide and the reaction was performed between 50 and 60 C.
Standard Operating Procedure 8:
Introdution of a tert-butyldiphenylsilyl ether
46 A mixture of the starting material (29.0 mmol) and imidazole (70.1 mmol) was dissolved in 80 mL anhydrous DMF and heated to 55 C. To the solution was added tert-butyldiphenylchlorosilane (8.30 mL, 31.9 mmol) and stirring continued at 55 C until completion. The reaction mixture was then cooled to 20 C and quenched with aqueous NaHCO3 solution. After concentration in vacuo, the residue was taken up in ethyl acetate and the organic phase washed successively with water, 10% aqueous citric acid, water, saturated brine solution, dried over Na2SO4 and evaporated. Final purification was achieved either by crystallization or by silica gel chromatography. The typical yields for the product formation varied between 85 and 95 %.
Standard Operating Procedure 9: Cleavage of a tert-Butyl-diphenylsilyl ether To a solution of the silyl ether (2.15 mmol) in 2.5 mL dry THF and acetic acid (3.44 mmol) was added 1M TBAF solution in THF (3.22 mL) and stirring continued till completion of the reaction. Subsequently, the reaction mixture was concentrated in vacuo. Final purification was achieved either by crystallization or by silica gel chromatography. The typical yields for the product formation varied between 85 and 97 cio Standard Operating Procedure 10:Introduction of a N-DTPM-group To a solution of the starting amine (24.5 mmol) in methanol (60 ml) is added a solution of the DTPM reagent (5.43 g, 25.7 mmol) in methanol (60 ml) at 60 C. After completion of the reaction, the reaction mixture was concentrated in vacuo, taken up in dichloromethane, extracted with water and saturated brine solution, dried over MgSO4 and evaporated. Final purification was achieved either by crystallization or by silica gel chromatography. The typical yields for the product formation varied between 85 and 97 %
Standard Operating Procedure II :Cleavage of a N-DTPM-group The starting material (40.94 mmol) was dissolved in dry DMF (50m1) and reacted with ethylene diamine (20 ml) at room temperature until completion.
The reaction mixture was concentrated in vacuo and coevaporated with toluene. The residue was suspended in CHCb and filtered through a Celite
Standard Operating Procedure 9: Cleavage of a tert-Butyl-diphenylsilyl ether To a solution of the silyl ether (2.15 mmol) in 2.5 mL dry THF and acetic acid (3.44 mmol) was added 1M TBAF solution in THF (3.22 mL) and stirring continued till completion of the reaction. Subsequently, the reaction mixture was concentrated in vacuo. Final purification was achieved either by crystallization or by silica gel chromatography. The typical yields for the product formation varied between 85 and 97 cio Standard Operating Procedure 10:Introduction of a N-DTPM-group To a solution of the starting amine (24.5 mmol) in methanol (60 ml) is added a solution of the DTPM reagent (5.43 g, 25.7 mmol) in methanol (60 ml) at 60 C. After completion of the reaction, the reaction mixture was concentrated in vacuo, taken up in dichloromethane, extracted with water and saturated brine solution, dried over MgSO4 and evaporated. Final purification was achieved either by crystallization or by silica gel chromatography. The typical yields for the product formation varied between 85 and 97 %
Standard Operating Procedure II :Cleavage of a N-DTPM-group The starting material (40.94 mmol) was dissolved in dry DMF (50m1) and reacted with ethylene diamine (20 ml) at room temperature until completion.
The reaction mixture was concentrated in vacuo and coevaporated with toluene. The residue was suspended in CHCb and filtered through a Celite
47 pad. The filtrate was evaporated and final purification of the residue was achieved either by crystallization or by silica gel chromatography. The typical yields for the product formation varied between 85 and 92 %.
48 Standard Operating Procedure 12: Introduction of an azide group via diazo transfer reaction a) Preparation of a trifluoromethansulfonvlazide solution:
A solution of sodium azide (492mmo1) in water (80mL) was prepared under N2-atmosphere. To this stirred solution was added dichloromethane (100mL) at 0 C, followed by the addition of triflic anhydride (16.5 ml) over 10 min.
The mixture was further stirred for 2 hours at 0 C, the organic layer was separated and the aqueous layer was extracted with dichloromethane (2x40 mL). The combined organic layers were washed with saturated, aqueous NaHCO3 solution (80 mL), water (80 mL) and dried over Na2SO4. After filtration, this solution was directly used for the diazotransfer reaction.
b) Diazotransfer reaction:
To a solution of the starting material (26.0 mmol) and 4-N,AP-(dimethylamino)pyridine (14.5g) in acetonitrile (100mL) was added dropwise TfN3-solution (85m1) at room temperature within 10 min. The reaction was stirred till complete conversion of the starting material into the product.
The reaction mixture was concentrated in vacuo to 30 ml and suspended in chloroform. After filtration through a Celite pad, the filtrate was concentrated and the residue was purified by filtration through a short silica gel pad. The typical yields for the product formation varied between 85 and 95 %.
Standard Operating Procedure 13: Hydrolysis of thioglycosides (NBS) The starting thioglycoside (33.4 mmol) was suspended in 240 ml Acetone and 18 ml of distilled water and stirred for 45 min at ¨20 C. After addition of NBS
(155 mmol) stirring was continued at ¨20 C. After completion, the reaction was stopped by addition of NaS203 /NaHCO3 (20 A) aqueous solution , 1/1) and the mixture diluted with ethyl acetate, subsequently washed with water and saturated brine solution. The organic layer was dried over Na2SO4 and concentrated in vacuo. Final purification was achieved either by crystallization or by silica gel chromatography. The typical yields for the product formation varied between 75 and 90 %.
Standard Operating Procedure 14: Hydrolysis of thioglycosides (NIS) The starting thioglycoside (33.4 mmol) was suspended in 240 ml Acetone and 18 ml of distilled water and stirred for 45 min at ¨20 C. After addition of NIS
(56.8 mmol) and TMSOTf (2.84 mmol) stirring was continued until completion.
The reaction was stopped by addition of NaS203 /NaHCO3 (20 % aqueous solution , 1/1), diluted with ethyl acetate and washed with water and saturated brine solution. The organic layer was dried over Na2SO4 and concentrated in vacuo. Final purification was achieved either by crystallization (e.g.
petroleum spirit/ ethylacetate) or by silica gel chromatography. The typical yields for the product formation varied between 79 and 92 %.
Standard Operating Procedure 15: Chemoselective Oxidation to Uronic acids A solution of the starting material (20.0 mmol) in dichloromethane (141 ml) was cooled to 0 C and subsequently mixed with TEMPO (0.205 mmol in 12.8 ml dichloromethane), Aliquat 336 (N-methyl-N,N-diocty1-1-octanaminium chloride) (12.8 ml of a 0.08 M solution in dichloromethane) and KBr (2.08 mmol in 4.17 ml 1420) and stirring continued at 0 C. After 5 mins, a suspen-sion of Ca(0C1)2 (43.6 mmol) and NaHCO3 (43.6 mmol) in 135 ml 1-K) was added within 15 mins to the reaction mixture and stirring at 0 C was continued till completion. The reaction was concentrated in vacuo and freeze dried. The crude residue was used as such for the next reactions.
Standard Operating Procedure 16: Methyl ester formation on the Uronic acids The crude residue of the oxidation to the uronic acid was dissolved in 50 ml Toluene and 50 ml Methanol and titurated with TMSCHN2-solution (2M in hexane) until completion. The reaction mixture was quenched with acetic acid to destroy excess of esterification reagent and evaporated in vacuo. Final purification was achieved by silica gel chromatography. The typical yields for the product formation varied between 65 and 80 % over the steps oxidation and esterification.
Standard Operating Procedure 17: Regioselective 6-0-Benzoylation The starting material (32.04 mmol) was dissolved in dry dichloromethane (50 mL) and dry pyridine (10 mL) and cooled down to - 45 C. Benzoyl chloride ( 32.04 mmol) was added dropwise and stirring continued at - 45 C till comple-tion. The reaction was concentrated in vacuo and coevaporated with toluene three times. The remaining residue was dissolved in dichloromethane and washed with 10% aqueous citric acid solution, saturated aqueous NaHCO3 solution and saturated brine solution, dried over Na2SO4 and evaporated in vacuo. Final purification was achieved either by crystallization or by silica gel chromatography. The typical yields for the product formation varied between 75 and 94 %.
Standard Operating Procedure 18: Common procedure for 0-Benzoylation To a solution of the starting material (11.9mmol) and DMAP (13.6mmol) in 1,2-dichloroethane was added dropwise benzoylchloride (1.7g, 12.1mmol). at 0 C. The mixture was then left b stir until completion (dependent on the substrate between 20 to 55 C). Subsequently, the reaction mixture was diluted with dichloromethane and washed with water, 5% NaHSO4 solution, saturated aqueous NaHCO3 solution and saturated brine solution. The organic layer was dried over MgSO4 followed by removal of the solvent in vacuo to give a crude residue. Final purification was achieved either by crystallization or by silica gel chromatography. The typical yields for the product formation varied between 80 and 96 %.
Standard Operating Procedure 19:Common procedure for O-Acetylation To a suspension of the starting material (235 mmol, 3 acetylation sites) in pyridine (350 ml) at CC was added dropwise acetic anhydride (175 ml). After completion of the addition, the reaction was allowed to return to room temperature and stirred until completion. The reaction mixture was evaporated to dryness and 3x coevaporated with toluene. The residue was taken up in dichloromethane and washed with 5 % aqueous NaHSO4-solution, saturated aqueous NaHCO3-solution, water and saturated brine solution. The organic layer was dried over MgSO4 and evaporated. Final purification of the residue _ was achieved either by crystallization or by silica gel chromatography. The typical yields for the product formation varied between 88 and 98 %.
Standard Operating Procedure 20: PDC-oxidation of alcohols to carboxylic acids The starting material (1.15 mol) was dissolved in anhydrous DMF (7.0 ml) and reacted with PDC (11.5 mmol) under stirring at room temperature until complete conversion into the uronic acid. The reaction mixture was subsequently poured into 50 ml water and the whole extracted with diethyl ether. The combined ether layers were washed with 10 % aqueous citric acid solution, filtered through a short silica gel pad, dried over MgSO4, evaporated and dried under high vacuum.
Standard Operating Procedure 21: Chemoselective 1-0-Benzoyl cleavage The starting material (36.8 mmol) was dissolved in dry DMF (80 ml) and cooled to 0 C. Subsequently, hydrazine acetate (44.06 mmol) was added and stirring continued until completion. After addition of acetone and acetic acid the reaction mixture was concentrated in vacuo. The residue was dissolved in dichloromethane and extracted with 10% aqueous citric acid solution, saturated NaHCO3 solution, water and saturated brine solution, dried over MgSO4, evaporated and dried under high vaccuum. Final purification was achieved either by crystallization or by silica gel chromatography. The typical yields for the product formation varied between 72 and 88 %.
Standard Operating Procedure 22: Deacylation under Zemplen conditions The starting material (23.7 mmol) was suspended in dry Me0H (70 ml) and stirred for 30 mins at 0 C. Subsequently, Na0Me (0.1 equiv. / 0-Acyl group) =
was added (positive flush of N2) and stirring was continued at 0' C until completion. Finally, the reaction was neutralized with 10 % aqueous HCI and the solvent evaporated. Final purification was achieved either by crystallization or by silica gel chromatography. The typical yield for the product formation varied between 90 and 98 %.
Standard Operating Procedure 23: Introduction of the 4-0xopentanoyi (=Levulinoyl) group a) Preparation of the Lev20 solution:
To a solution of DCC (31.2 mmol) in 100 mL dichloromethane was added levulinic acid (62.4 mmol) and DIPEA (62.42 mmol). The supernatant was used as such for the levulination reaction.
Reaction The above Lev20 solution was added to a solution of the starting sugar (15.6 mmol) dissolved in 25 mL of dry dichloromethane and stirring was continued until completion. Subsequently, the reaction mixture was filtered through a Celite pad and all combined organic layers were extracted with 10 %
aqueous citric acid solution, saturated aqueous brine solution, dried with Na2SO4 and concentrated. Final purification was achieved either by crystallization or by silica gel chromatography. The typical yields for the product formation varied between 85 and 96 %.
Standard Operating Procedure 24:Cleavage of the 4-0xopentanoyl (=
Levulinoyl) group A solution of the starting sugar (1.28 mmol) and acetic acid (1.35 mL) in pyridine (5.0 mL) was cooled to 0 C followed by addition of hydrazine hydrate (200 1.14 Stirring at 0 C was continued until completion and the reaction mixture diluted with dichloromethane, subsequently extracted with 10%
aqueous citric acid, 10 % aqueous NaHCO3 solution, saturated brine solution, dried over Na2SO4, filtered and concentrated. Final purification was achieved either by crystallization or silica gel chromatography. The typical yields for the product formation varied between 80 and 95 %.
Standard Operating Procedure 25: Formation of Trichloroacetimidates a) with DBU:
A solution of the starting sugar (1.99 mmol) and trichloroacetonitrile (601 1AL, 5.87 mmol) in 5 mL dry dichloromethane was stirred at room temperature for 30 min. The reaction mixture was then cooled to CPC and DBU (100 mop added. Stirring was continued until completion (dependent on the substrate, stirring was performed from 0 C to 20 C). The reaction mixture was concentrated to one half of its volume and directly loaded on a short plug of silica gel and purified via silica gel chromatography. The typical yields for the product formation varied between 78 and 95 %.
b) with K2CO3:
A solution of the starting sugar (1.99 mmol) and trichloroacetonitrile (601 pl, 5.87 mmol) in 5 mL dry dichloromethane is stirred at rt for 30 min. The reaction mixture was then cooled down to CPC and anhydrous K2CO3 (19.9 mmol) added. The reaction was stirred at 0 C till completion and then filtered through a celite pad. The filtrate was dried over Na2SO4 and evaporated. Final purification was achieved either by crystallization or by silica gel chromatography. The typical yield for the product formation varied between 78 and 95 %.
Standard Operating Procedure 26: Regioselective introduction of a 6-0-p-Methoxyphenyl group under Mitsunobu conditions A solution of the starting sugar (13.52 mmol), 4-methoxyphenol (20.3 mmol) and triphenylphosphine (20.3 mmol) in 85 ml dry dichloromethane was stirred at 0 C for 45 min. After addition of DEAD-reagent (22.9 mmol) at 0 C, the reaction mixture was further stirred at room temperature until completion, filtered through a celite pad, diluted with dichloromethane and extracted with 10 % aqueous NaHCO3/NaOH solution (1/1), 10 % aqueous citric acid solution and aqueous saturated brine solution. The organic layer was dried over Na2SO4 and concentrated. Final purification was achieved by silica gel chromatography. The typical yield for the product formation varied between 70 and 89 `)/0.
_ _ _ Standard Operating Procedure 27: Cleavage of the p-Methoxyphenyl ether The starting material (1.18 mmol) was dissolved in 30 ml acetonitrile and 7.5 ml water and cooled to 0 C. Subsequently, CAN (3.83 mmol) was added and stirring continued at CPC until completion. The reaction mixture was diluted with ethyl acetate and extracted with water. The aqueous layer was made alkaline by addition of solid NaHCO3 and back extracted with ethyl acetate.
The combined organic layers were extracted with saturated aqueous Na HCO3 solution and saturated brine solution, dried over MgSO4 and evaporated.
Final purification was achieved by silica gel chromatography. The typical yields for the product formation varied between 73 and 89 %.
Standard Operating Procedure 28: Cleavage of p-Methoxybenzyl ethers The starting material (0.60 mmol) was dissolved in 27 ml acetonitrile and 3.0 ml water and cooled to 0 C. Subsequently, CAN (4.5 equiv.) was added and stirring continued from 0 C to room temperature until completion. The reaction mixture was diluted with ethyl acetate and extracted with water. The aqueous layer was made alkaline by addition of solid NaHCO3 and back extracted with ethyl acetate. The combined organic layers were extracted with saturated aqueous NaHCO3 solution and saturated brine solution, dried over MgSO4 and evaporated. Final purification was achieved by silica gel chromatography.
The typical yields for the product formation varied between 73 and 85 %
Standard Operating Procedure 29: Formation of a 2,3-cyclic carbamate To a stirred solution of the starting material (3.56 mmol) in dichloromethane (100 ml) and 10% aqueous solution of NaHCO3 (75 ml) was added a solution of triphosgene (1.25 mmol) in 10 ml dry dichloromethane. The reaction was stirred at room temperature till completion. The organic phase was washed with water, dried over Na2SO4, filtered and concentrated. Final purification was achieved either by crystallization or silica gel chromatography. The typical yield for the product formation varied between 75 and 95 %.
Standard Operating Procedure 30: Cleavage of the N-phthaloyl group The N-phthaloylated starting material (45.9 mmol) was dissolved in n-butanol (200 ml) and treated with 1,2-diaminoethane (50 ml) at 100 C. After stirring at 100 C until completion, the reaction mixture was concentrated in vacuo, coevaporated with toluene three times and dried under high vacuum. Final purification was achieved by silica gel chromatography. The typical yield for the product formation varied between 78 and 92 A,.
Standard Operating Procedure 31: Introduction of a thiocresyl ether at the reducing end A solution of the 1-0-glycosyl acetate (10.48 mmol) and p-thiocresol (12.58 mmol) in dry dichloromethane (30m1) was stirred at CPC and subsequently activated by the addition of boron trifluoride diethylether complex (12.58mmol) over 5 min. Stirring was continued (0 C -4 20 C) until completion and the reaction stopped by the addition of triethyl amine (14.0 mmol). The reaction mixture was diluted with dichloromethane and extracted with saturated NaHCO3-solution, water and saturated brine solution, dried over MgSO4 and evaporated in vacuo. Final purification was achieved by crystallization or silica gel chromatography. The typical yield for the product formation varied between 81 and 92 %.
Standard Operating Procedure 32: Glycosylation with thioglycosides a) NIS-promoted glycosylation A mixture of glycosyl acceptor (1 mmol), thioglycoside (1 mmol) and 1.0 g of freshly activated molecular sieves in 20 ml of a dry solvent (e.g. CH3CN, CH2Cl2, Toluene, Ether) was stirred for 45 min at r.t and cooled down to the reaction temperature. Subsequently, N-lodosuccinimide (1.7 mmol) was added and stirring continued for 20 min at the reaction temperature. After the addition of a Lewis acid as promotor (e.g. TfOH, 85-170 pmol), stirring was continued at the reaction temperature until completion. The reaction mixture was quenched with triethyl amine, filtered through a celite pad and extracted with a 10 % aqueous KHCO3/Na2S203 solution, water and saturated brine solution, dried over MgSO4 and evaporated. Final purification was achieved by silica gel column chromatography. The typical yields for the product formation varied between 65 and 85 %.
b) DMTST promoted glycosylations:
A mixture of glycosyl acceptor (1 mmol), thioglycoside (1 mmol) and 1.0 g of freshly activated molecular sieves in 20 ml of a dry solvent (e.g. CH3CN, CH2Cl2, Toluene, Ether) was stirred for 45 min at r.t and cooled down to the reaction temperature. Stbsequently, DMTST (3-5 equiv.) was added and stirring continued at the reaction temperature until completion. The reaction mixture was quenched with triethyl amine, filtered through a celite pad and extracted with aqueous NaHCO3-solution, water and saturated brine solution, dried over Na2SO4, concentrated in vacuo and purified by silica gel column chromatography. The typical yields for the product formation varied between 50 and 85 %.
Standard Operating Procedure 33:
Glvcosvlations with trichloroacetimidates A suspension of the trichloroacetimidate (1.54 mmol), glycosyl acceptor (1.13 mmol) and freshly activated molecular sieves (1.0 g) in an anhydrous solvent (e.g. CH3CN, CH2Cl2, Toluene, Ether, 20 mL) was stirred at rt for 1 h and then cooled to reaction temperature. Subsequently, a catalytic amount of a promotor (e.g. TMSOTf, 0.01-0.1 equiv.) was added and stirring continued at reaction temperature until completion. The reaction was quenched with triethylamine) and filtered through a Celite pad. The combined organic layers were washed with aqueous NaHCO3-solution and saturated brine solution, dried over Na2SO4, concentrated in vacuo and purified by silica gel column chromatography. The typical yields for the product formation varied between 50 and 85 %.
Standard Operating Procedure 34:
Glycosylations using 2,3-cyclocarbamoyl protected pThiocresyl glycosides as glycosyl donors PhSCI (0.2 mmol, 2 equiv.) in dry dichloromethane (1 ml) was added dropwise to a mixture of Ag0Tf (0.2 mmol) in dry dichloromethane (2 ml) at ¨78 C
containing freshly activated molecular sieves 3 A. After stirring for 15 mins at ¨78 C, a solution of the thioglycoside (0.1 mmol, 1 equiv.) and DTBMP (0.2 mmol, 2 equiv.) in dry dichloromethane (2 ml) was slowly added. After further stirring for 15 mins at ¨78 C, the glycosyl acceptor (0.2 mmol, 2 equiv.) in dry dichloromethane (1 ml) was slowly added and stirring continued until completion. The reaction was quenched with saturated aqueous NaHCO3 solution (1 ml), warmed to rt and diluted with dichloromethane. The organic layer was dried over MgSO4, filtered and evaporated. Final purification was achieved by silica gel chromatography. The typical yields for the product formation varied between 60 and 90 %.
Standard Operating Procedure 35: Introduction of an Alloc-group A solution of starting material (2 mmol), dry pyridine (5 mmol) and dry THF (5 ml) was cooled to 0oC. Subsequently, Allylchloroformate (2.2 mmol) were added dropwise and stirring was continued until completion. The reaction mixture was diluted with dichloromethane and subsequently washed with 10 % aqueous citric acid solution, saturated NaHCO3 solution, water and saturated brine solution. The organic layer was dried over Na2SO4, filtered and evaporated. Final purification was achieved either by crystallization or by silica gel chromatography. The typical yields for the product formation varied between 80 and 95 %.
Standard Operating Procedure 36: Cleavage of an Alloc-group A mixture of the Allyloxycarbonate (1.17 mmol), dimedone (1.33 mmol) and Pd(Ph3P)4 (0.30 mmol) was dissolved in dry THF (60 ml) and stirred under Ar atmosphere until completion of the reaction. The reaction mixture was concentrated in vacuo and purified by silica gel chromatography. The typical yields for the product formation varied between 78 and 97 %.
Standard Operating Procedure 37: Lewis acid mediated benzylation To a stirred mixture of the starting material (1 mmol) and benzyl trichloroacetimidate in dry hexane/dichloromethane (10 ml, 2/1) was added Lewis acid (0.01-0.05 equiv., e.g. TMSOTf, Tf0H) and stirring was continued at rt until completion. The reaction was quenched with triethyl amine and concentrated. Final purification was achieved by silica gel chromatography.
The typical yields for the product formation varied between 50 and 92 %.
Standard Operating Procedure 38: benzylation under mild basic conditions The starting material (3.49 mmol) was dissolved in dry DMSO (20 ml) and cooled to 0 C. To the stirred solution were added successively benzyl bromide (3.5 equiv./OH-group), barium oxide (1.5 equiv/OH-group), catalytic amounts of TBAI ( 0.05 egiv./OH-group) and potassium hydroxide (3.5 equiv./ OH-group). Stirring was continued from O'C to rt until completion. The reaction was quenched with methanol, and further stirred for 30 min. After dilution with ether, the organic layer was washed with water and brine solution, dried over MgSO4 and concentrated in vacuo. Final purification was achieved by silica gel chromatography.
Standard Operating Procedure 39: Ester cleavage under aqueous conditions The starting material (0.3mmol ester groups) was dissolved in 11.8 ml of a mixture of water and THF (3:7), cooled to 0 C and reacted with 1M aqueous NaOH-solution (5.0 ml). Stirring was continued until completion and the reaction mixture titurated with 10 % aqueous HCI-solution to a pH of 9.5.
After evaporation of the THF, the mixture was freeze dried and the remaining residue purified by silica gel chromatography to yield the product. The typical yields for the product formation varied between 85 and 95 %.
Example 1: Synthesis of Building Blocks A-1 and A-2 from N-Acetyl Glucosamine H...Ø...\,........\,,,,,.
H2........\õ0,....\,,,,,,, a HO
b HO
HO
AcNH OH A-1-i AcNH OMe HO H.!...).HO
-0.- c HO H.St.....1...\.,,,,,,,, OMe d A-1-ii NH2 OMe DTPMHNA-1-iii R 110 (: -\,(==)El 0 ---).-e R *I HO
--s.-- f , R = H: A-1-iv-a DTPMHN OMe R = H: A-1-v-a H2N OMe R = Me0: A-1-iv-b R = Me0: A-1-v-b R HO
R
Bn0 R = H: A-1-vi-a N3OMe N3OMe R = Me0: A-1-vi-b h R = H: A-1-vi-a R = Me0: A-1-vii-b HC
i j 1 HBoz0 ,.....\4.... 0) HOEIn0 A-1-viii N3 OMe MHPO" 7 Bn0 Bn0 OMe OMe Example 1: Synthesis of building blocks A-1 and A-2 from N-Acetyl glucosamine, yields are reported for R=H, conditions; a) Amberlite IR 120 (ion exchange resin) (H+), Me0H, 60 C, (70 %); b) 1M NaOH, 120 C; c) 1.
SOP 10; 2. AP20, pyridine; 3. Na0Me, Me0H (70 %, 4 steps); d) SOP 1 (91 % for R=H) or SOP 2 for R = OMe; e) SOP 11, (95%); f) SOP 12, (85 %, 2 steps); g) SOP 7, (91%); h) SOP 4, (91 %); i) SOP 17, (82 %); j) SOP 5.
Preparation of A-14 N-Acetyl-2-deoxy-a/8-D-glucopyranoside (8.5 g, 38.4mmol) was suspended in 100 ml dry methanol. Subsequently, 12.0 g Amberlite IR 120 iron exchange resin (H-form) was added and the reaction mixture refluxed for 70 hrs at 65 C. After cooling to 25 C, the iron exchange resin was removed by filtration and several times extracted with methanol. The combined methanol layers were neitralized with triethyl amine and concentrated in vacuo. The crude residue was purified by crystallization to furnish the title compound in 70 %
yield (cdf3 -mixture).
Preparation of A-1-iii:
Methyl glycoside A-1-i (20.6 mmol) was suspended in 100 ml aqueous NaOH
solution (1 M) and stirred under reflux at 120 C until completion. After cooling and neutralization with 10 % aqueous HCI, the mixture was concentrated in vacuo and crude A-1-ii suspended in 200 ml methanol and reacted with N-[(1,3-dimethy1-2,4,6 (1H,3H,5H)-trioxopyrimidin-5-ylidene) methyl]-/V;N"-di me-thylamine (23.6 mmol) at 50 C (pH ¨ 9.0) until completion. After evaporation and drying, crude A-1-iii was reacted with 150 mL acetylation mixture (Pyridine/Ac20, 2/1, v/v) until completion, concentrated in vacuo, coeva-porated with toluene and dried. The residue was suspended in ethyl acetate and extracted with water, 10 % aqueous HCI, saturated, aqueous NaHCO3 solution and 1-h0, dried over Na2SO4 and concentrated. The crude residue was dissolved in dry methanol and reacted with a catalytic amount of Na0Me.
After completion, the reaction was neutralized with Amberlite IR 120 and filtered. The organic layer was evaporated and dried to furnish the title compound A-1-iii in 70 % yield (over 4 steps).
Preparation of A-1-iv-a:
Methyl-2-deoxy-2-441-(1,3-dimethy1-2,4,6(1H, 3H, 5H)-trioxopyrimidin-5-ylidene) methyl)-a-D-glucopyranoside A-1-iii (16.0 g, 44.5mmol) in acetonitrile (200m1) was reacted with benzaldehyde dimethyl acetal (14.0 ml, 92.3 mmol) and a catalytic amount of p-toluenesulphonic acid monohydrate. After 2 hours at 55 C, the mixture was neutralized and evaporated. The remaining residue was extracted, washed and evaporated. Yield: 18.3 g (92 %), Rf = 0.20 (1,2-dichloroethane/ ethylacetate = 7/3).
Preparation of A-i-v-a:
Methyl-4,6-0-benzylidene-2-deoxy-2-N41-(1,3-dimethyl-2,4,6(1H, 3H, 5H)-trioxopyrimidin-5-ylidene) methyl]-a-D-glucopyranoside A-1 -iv-a (18.30 g, 40.90 mmol) in DMF (50m1) was reacted with ethylenediamine (20m1) at room temperature. After stirring for 35 minutes, the mixture was concentrated.
Yield:
10.90 g (94.7 %), Rf = 0.18 (chloroform/methanol = 9/1).
Preparation of A-1-vi-a:
To a solution of methy1-2-amino-4,6-0-benzylidene-2-deoxy-a-D-glucopyra-noside (7.5 g, 26.7 mmol) and 4-N,NL(dimethylamino)pyridine (14.5g) in acetonitrile (100mL) was added TfN3-solution (85m1) at room temperature.
The reaction mixture was concentrated and the residue was purified by filtration through a short silica gel pad. Yield: 7100 g (85.3 %), Rf = 0.18 (chloroform/ methanol = 9/1).
Preparation of A-1-vii-a:
Methyl 2-azido-2-deoxy-4,6-benzylidene-a-D-glucopyranoside A-1 -vi-a (10.87g, 35.40 mmol) in N,Ar-dimethylformamide (50mL) was reacted with NaH (95 %, 0.92g, 36.4 mmol) and benzyl bromide (5.47 ml, 45.9 mmol). After completion, the excess of NaH was quenched, followed by concentration. The residue was extracted, washed and concentrated. Yield: 12.93 g (92.0 %), Rf = 0.37 (petroleum spirit/ethyl acetate = 3/1).
Preparation of A-1:
Methyl-2-azido-3-0-benzy1-2-deoxy-a-D-glucopyranoside (9.87g, 31.9 mmol) in dichloromethane (50 mL) and pyridine (10 mL) was treated with benzoyl chloride (3.72mL, 32.04 mmol) at - 45 C for 2 hours. The reaction was concentrated and the residue extracted, washed and evaporated. Yield: 10.78 g (81.7 cY0), Rf = 0.31 (petroleum spirit/ ethylacetate = 1/1).
Compound A-1:
1H-NMR (400 MHz, CDCI3): 5= 8.03 (d, 2 H, Aryl), 7.57 (m, 1H, Aryl), 7.45-7.29 (m, 7H, Aryl), 4.93 (d, 1H, em=J 10.8 Hz, OCH2), 4.82 (d, 1H, Jgem =
10.8 Hz, OCH2), 4.81 ( d, 1H, J1,2 = 3.6 Hz, H-1a), 4.73 (dd, 1H, J5,6a = 4.4 Hz, Jgem = 12.0 Hz, H-6a), 4.47 (dd, 1H, J5,6b = 2.0 Hz, H-6b), 3.85 ( dd, 1H, J3,4 = 8.8 Hz, H-3), 3.57 ( ddd, 1H, J. = 10.0 Hz, H-4), 3.45 (s, 3H, OMe), 3.37 ( dd, 1H, J2,3 = 10.0 Hz, H-2), 2.80 (bs, 1H, 4-0H).
_ _ Example 2: Synthesis of Buildinp Blocks A-3 and A-4 R* HO a wR = H: A-1-iv-a DTPMHN
OMe R R = H: A-1-ix-a Bn0 DTPMHN OMe R = Me0: A-1-iv-b y R = Me0: A-1-ix-b HoH Bn0 0 Mpm.C.20µ
7 DTPMHN OMe HO Bn0=
..........._ x 0 A-1-x A-4 OMe I
OMe Example 2: Synthesis of building block A-3 and A-4, conditions: a) SOP 7, (72 % for R = H); b) SOP 4, (82 %); c) SOP 17, (84 %); d) SOP 5.
Compound A-3:
1H-NMR (400 MHz, CDCb): 3 = 10.16 (dd, 1 H, JNH,2 = 9.4 Hz, J NH, =OH = 14.0 Hz, NH), 8.11 (d, 1H, =C-H), 7.68-7.22 (3m, 8H, Aryl), 4.84 ( d, 1H, J1,2 =
3.5 Hz, H-1a), 4.83 (dd, 1H, .la ¨da, 6b = 12.3 Hz, J5,6a = 3.5 Hz, I46a), 4.73 (d, 1H, Jgem = 11.7 Hz, OCH2), 4.46 (dd, 1H, J5,6b = 2.1 Hz, H-6b), 3.91 (m, 1H, H-5), 3.72 (dd, 1H, J3,4 7--- J2,3 = 8.8 Hz, H-3), 3.57 (ddd, 1H, J4,5 = 9.5 Hz, H-4), 3.48 (s, 3H, OMe), 3.38 (ddd, 1H, J2,3= 10.5 Hz, H-2), 3.32 (s, 3H, NMe), 3.31 (s, 3H, NMe), 3.05 (bs, 1H, 4-0H).
¨ ¨
Example 3: Synthesis of L-ido configured plycosyl donor B-1 ..-- HO ¨
(!)-1) H --0... 0 r 0138 HO¨ OBn ...-0.>
r 0 a 0 b r 1 c 0 --0- 0 .. .,.- --0C
oil.... --I-BA -i .." B-1-ii .., "
B-1-11 i Ac Mes0 HO-1 c:
OAc M es OBn OBn ..--0 d 0 e f 0 /....., --00"
B-1 -iv B-1 -v B-1-vi 0/
OBn Ac0 OBn HO OBn (...1-....TSCres -F...... ? -0 SCres .-0 SCres g h ----Ow-B-1-vii ---10- B-1 -vi ii ¨IP.- 0 B-1 -ix OH
Ac0 OAc OH OH Me2C
HO oBOBnmp0 Bn SC res ..,....4- ....
0 ' 0 SC res '0 SCres k I
0 (3-1-7( ¨11"- B-1 -xi 0 0 Bz OH OBz OH OBz Me2C
m p0 can /F1....7-- -0 SCres OLev OBz Example 3: Synthesis of Building Block B-1, conditions: a) SOP 7, (95%); b) 60% aqueous Acetic acid, 60 C (90%); c) Methanesulfonyl chloride, Pyridine, 0 C-RT (87 %); d) Cesium Acetate, Ac20, 120 C (95%); e) SOP 22, (92%); f) 1. 90% TFA, 0 C; 2. Ac20, Pyridine; 3. SOP 31, (73%, 3 steps); g) SOP 22, (98%); h) SOP 3, (92%); i) SOP 18, (98%); j) 80% acetic acid, 100 C (98%);
k) SOP 26, (89%); I) SOP 23, (98%).
_ Preparation of B-1-iii:
B-1-ii (15.60 mmol) was dissolved in 60 % aqueous acetic acid (50 ml) and stirred at 60 C until completion. After neutralization with solid NaHCO3, the mixture was evaporated and co evaporated with toluene. Crude B-1-iii was dissolved in CHCI3/H20, the organic layer separated, dried over Na2SO4 and evaporated. The remaining residue was purified by a short silica gel chroma-tography to yield B-1-iii in 90 % (4.36 g).
Preparation of B-1-iv:
17.72 mmol of B-1-iii was dissolved in 25 ml dry pyridine, to which mesyl chloride (methylsulfonyl chloride, 42.5 mmol) was added dropwise at 0 C. The mixture was stirred at 4 C until completion and was subsequently poured into warm water (50 C, 90 ml), cooled and the precipitate isolated by filtration.
B-1-iv was obtained after drying in 87 % yield (7.19 g).
Preparation of B-1-v:
B-1-iv (6.43 mmol) and cesium acetate (64.3 mmol) were suspended in 25 ml acetic anhydride and refluxed at 125 C until completion. The reaction mixture was concentrated in vacuo, co evaporated with toluene and the residue extracted from ethyl acetate/H20 (1/1). The organic layer was collected and washed with saturated aqueous NaHCO3 solution and saturated brine solution, dried over Na2SO4 and evaporated. Purification was achieved by silica gel chromatography. Yield: 2.68 g (95 %).
Preparation of B-1-vii:
B-1-vi (5.61 mmol) was dissolved in aqueous TFA (90 %, 15 ml) and further stirred at 0 C until completion. The reaction mixture was neutralized with aqueous NaOH solution at 0 C, concentrated in vacuo and dried. The residue was suspended in 90 ml acetylation mixture (pyridine/acetic anhydride = 2/1) and 50 ml dichloromethane at 0 C and further stirred until completion. After concentration in vacuo and co evaporation with toluene, the residue was dissolved in ethyl acetate/H20 (1/1), the organic layer collected and washed ¨ -with 10 13/0 aqueous citric acid solution, saturated aqueous NaHCO3 solution and brine solution, dried over Na2SO4 and evaporated. The crude residue and p-thiocresol (6.0 mmol) were dissolved in 40 ml anhydrous dichloromethane and cooled to 0 C, reacted with BF3x0Et2 (8.41 mmol) and further stirred at rt until completion. The reaction was stopped with saturated NaHCO3 solution and the organic layer was washed with water, dried over Na2SO4 and evaporated. Final purification was achieved by silica gel chromatography to yield B-1-vii in 73% over 3 steps.
Preparation of B-1-xi:
B-1-x (8.0 mmol) was dissolved in 80 % aqueous AcOH and heated at 100 C
until completion. The mixture was cooled to rt, neutralized with solid NaHCO3 and dissolved in ethyl acetate/water (1/1). After removal of the aqueous layer, the organic layer was dried over MgSO4 and evaporated to dryness furnishing B-1-xi in 98 A yield.
Compound B-1:
1H-NMR (400 MHz, CDCI3): 8 = 8.07 (d, 2H, Aryl), 7.57-7.30 (m, 10H, Aryl), 7.10 (d, 2 H, Aryl), 6.88-6.81 (m, 4H, Mp), 5.55 (d, 1H, 42 < 1.5 Hz,H-10), 5.45 (m, 1H, H-2), 5.26 (ddd, 1H, H-5), 5.13 (m, 111, H-4), 4.91 (d, 1H, Jgem =
12.1 Hz, OCH2), 4.78 (d, 1H, Jgem = 12.1 Hz, 0CH2), 4.16 (dd, 1H, Jgem = 9.6 Hz, J5,6. = 7.6 Hz, H-6a), 4.08 (dd, 1H, J5,6b = 5.2 Hz, H-6b), 3.93 (m, 11-I, H-3), 3.77 (s, 3H, OCH3), 2.58-2.36 (m, 4H, (CH)2 Lev), 2.32 (s, 3H, SCH3), 2.05 (s, 3H, CH3C=0).
Example 4: Synthesis of L-ido configured glvcosvl donor B-2.
HO OBn OBn OBn 1-.L1......1" -0 SCres SCres -=
SCres HO OH B-1-viii ¨v.- o 8-2-i ¨pm. a b 0 OBz c OMe OMe ompm QBn MPm OBn '0 SCres -- SCres 8-2-iii d OH OBz Lev OBz Example 4: Synthesis of L-ido configured glycosyl donor B-2; a) SOP 2; b) SOP 18; c) SOP 5; d) SOP 23.
Example 5: Synthesis of Building Block C-1, C-la and C-lb \,...0Mpm 0*".....µisf... g meo 01 Bz R ¨31il- 13.z."-C-3\-=""R
C-la-iii: R=SMe N3 f / C-lb-iii: R=SCres C-la: R=SMe C-1b: R=SCres lb 0---..\.f...\....
Me = HO
R
C-la-ii: R=SMe N3 C-lb-ii: R=SCres e4 OH
OAc HO a Ac 0 VI--=,. ...\---0 R ---)..-Ac0 R
1.2.-0...
C-1-1-a: R=SMe C-1-ii-a: R=SMe C-1-i-b: R=SCres C-1-ii-b: R=SCres ...4:1A .....\_,c .
OAc Ac0 Ac OH --Ow- Ac c Ac0 0 OTBDPS --O.- d C-1-iii N3 C-1-iv .....H.,\........\õ, HO 0 e ¨AP-f N3 Me0 HO4. OTBDPS --40"-C-1-v C-1-vi OM pm g Me * Bz0 OTBDPS-4.1" Bz0 OTBDPS
C-1-vii N3 _ -Example 5: Synthesis of Building Blocks C-I, C-la and C-1 b, conditions: a) SOP 19; b) SOP 13, (78 %, 2 steps); c) SOP 8, (91 A)); d) SOP 22; e) SOP 2, (85%, 2 steps for C-1 -vi); f) SOP 18; g) SOP 5, (75 %, 2 steps for C-1).
Preparation of C-1-iia:
To methyl 2-azido-2-deoxy-1-thio-13-o--glucopyranoside. (10g, 42.50 mmol) in pyridine (50m1) at ODC was added acetic anhydride (20g) and the reaction stirred for 1 hour. The reaction mixture was evaporated to dryness and the residue extracted to give the title triacetate (15.23g, quantitative,), Rf=0.7 (CHCI3/Petroleum ethers, 1 :1).
Preparation of C-1 -iii:
To a solution of methyl 3,4,6-tri-O-acety1-2-azido-2-deoxy-1-thio-O-D-glucopyranoside (14.1g, 39 mmol) in wet acetone (200m1) was added NBS (3 equiv.). The resulting mixture was allowed b stir for 2h. The mixture was then quenched, concentrated and the residue purified by silica gel chromatography to give the title hemiacetal as an oil (10.1g, 78%), f = 0.5 (Et0Ac/Petroleum ether, 1:1).
Preparation of C-1-vi:
A mixture of 2-azido-2-deoxy-13-o-glucopyranosyl tert-butyldiphenylsilane (5.5g,12.42 mmol), 4-methoxybenzaldehyde dimethylacetal (4.4g, 24mmol), and 4-toluenesulphonic acid (100mg ) in acetonitrile/DMF (200m1, 5:3) were heated at 60 C for 1 hour. The reaction mixture was then neutralized and evaporated to give the crude compound as an oil. The residue was purified by silica chromatography to give the product (6.7g, 96%, 85% from C-1-iv); Rf =
0.8 (dichloromethane/Petroleum ethers; 10:2).
Preparation of C-1 -vii:
A mixture of DMAP (1.63g, 13.2 mmol) and benzoyl chloride (1.7g, 12.1mmol) and 2-azido-2.deoxy-4,6-0-(4-methoxybenzylidene)-13-D-glucopyranosyl tett-butyldiphenylsilane (6.7g, 11.9 mmol) in 1,2 -dichloroethane (100mL) was stirred at 60 C for 1h. The reaction mixture was quenched, extracted, washed and concentrated to give a crude residue. The residue was passed through a plug of silica to give the product (5.5g, 69%); Rf = 0.7 (dichloromethane/Petroleum ethers; 4:1).
Preparation of C-1:
To a mixture of 2-azido-2-deoxy-3-0-benzoy1-4,6-0-(4-methoxybenzylidene)-p-o-glucopyranosyl tert-butyldiphenylsilane (10g, 15mmol), sodiumcyanoborohydride (5g, 75.6 mmol) and molecular sieves in DMF
(200mL) at 0 C was added trifluoroacetic acid (28g, 247mmo1) at 0 C and then left to run overnight at rt. The reaction mixture was quenched, filtered and concentrated and the residue purified by column chromatography to give the title compound (7.0g, 70%), Rf = 0.4 (ethylacetate/petroleum ethers, 3:7).
Compound C-1:
1H-NMR (400 MHz, CDC13):8 = 8.08 (d, 2 H, Aryl), 7.72 (m, 4 H, Aryl), 7.59 (m, 1 H, Aryl), 7.47 (m, 3 H, Aryl), 7.42 (m, 2 H, Aryl), 7.34 (m, 3 H, Aryl), 7.13 (d, 2 H, Mpm) 6.83 (d, 2H, Mpm), 4.96 (dd, 1 H, J2,3 J3,4 = 9.7 Hz, H-3), 4.53 (d, 1 H, J1,2 = 7.6 Hz, H-113), 4.37 (2d, 2 H, OCH2), 3.83 (ddd, 1 H, H-4), 3.79 (s, 3 H, OCH3), 3.65 (dd, 1 H, H-2), 3.53 (dd, 1 H, Jgem = 10.8 Hz, J5,6a = 4.1 Hz, 6a), 3,46 (dd, 1 H, J5,6b = 4.1 Hz, H-6b), 3.12 (m, 1 H, 11-5), 3.02 (d, 1 H, 11,0H
= 3.5 Hz, 4-0H), 1.12 (s, 9 H, C(CH3)3).
Example 6: Synthesis of Building Block C-2 e0H
HO a 0 C-1-1-a: R=SMe C-2-1-a: R=SMe C-1-i-b: R=SCres C-2-I-b: R=SCres OH
0 c Bz0 R
C-2-ii-a: R=SMe C-2-iii-a: R=SMe C-2-ii-b: R=SCres C-2-iii-b: R=SCres r0Bz r0Bz 4:1 HO e HO f HO Bz OTBDPS
N3 C-2- v N3 C-2 N3 C-2-iv-a: R=SMe C-2-iv-b: R=SCres Example 6: Synthesis of Building Block C-2, conditions: a) SOP 1, (90% for R=SMe); b) SOP 18, (87% for R=SMe); c) SOP 4, p-Tos0H, Me0H, CH3CN
(86% for R=SMe); d) SOP 17, (92% for R=SMe); e) SOP 13, (94%); f) SOP
8, (82%).
Compound C-2:
1H-NMR (400 MHz, CDCI3): 8=8.09 (d, 2 H, Aryl), 7.97 (d, 2 H, Aryl), 7.72 (m, 4 H, Aryl), 7.60 (m, 1 H, Aryl), 7.50-7.27 (m, 11 H, Aryl), 4.98 (dd, 1 H, J2,3 J3,4 = 9.7 Hz, H-3), 4.58 (d, 1 H, J1,2 = 7.8 Hz, H13), 4.51 (dd, 1 H, Jge, =
11.3 Hz, J5,6a = 4.7 Hz, H-6a), 4.36 (dd, 1 H, J5,6b = 2.2 Hz, H-6b), 3.72-3.68 (m, H, H-2, H-4), 3.31 (m, 1 H, H-5), 3.23 (d, 1 H, J4,01-1= 4.5 Hz, 4-0H), 1.13 (s, 9 H, C(CH3)3).
Example 7: Synthesis of several carbamoylated Building Blocks C-3a to C-3d and C-4a to C-4d, containing a 6-0 benzoyl or 6-0-p-methoxybenzyl protection HO HO 0 R1 a b Pht R R = H, Me0 C-3-ii NPht c HO R 1 0 110, R = H, Me0C-3-iii NH2 0 R1 R = H
C-3-iv R = Me0 HO 0 f OBz u C-3-v HO (0M:m HO
H
C-4a: R1=SCres C-3a: R1= SCres C-4b: R1 = SEt C-3b: R1= SEt C-4c: R1= OTBDPS
C-3c: R1= OTBDPS C-4d: R1 = SMe C-3d: R/ = SMe Example 7: Synthesis of several carbamoylated building blocks C-3a to C-3d and C-4a to C-4d, containing a 6-0-benzoyl or 6-0-p-methoxybenzyl protection, conditions: a) R = Me0: SOP 2; R = H: SOP 1, (82 %, R1 = SCres, R = H); b) SOP 30, (87 %, R1= SCres, R = H); c) SOP 29, (95 %, R1 = Scres, R = H); d) SOP 4, (72 %, R1 = SCres); e) SOP 17, (85 %); f) SOP 5.
Compound C-3a:
1H-NMR (400 MHz, CDCI3): 6 = 8.06 (d, 2 H, Aryl), 7.62 (m, 1 H, Aryl), 7.48 (t, 2 H, Aryl), 7.38 (d, 2 H, Aryl), 6.97 (d, 2 H, Aryl), 5.06 (bs, 1H, NH), 4.79 (dd, 1H, sigem = 12.0 Hz, J5,6a= 3.6 Hz, H-6a), 4.70 (d, 1H, J1,2 = 9.2 Hz, H-1f3), 4.63 (dd, 1H, J5,6b = 2.0 Hz, H-6b), 4.18 (dd, 1H, .32,3 ==1 J3,4 = 10.4 Hz, 143), 3.89 (dd, 1H, J4,5 = 9.2 Hz, H-4), 3.72 (m, 1H, H-5), 3.23 (ddd, 1H, H-2), 3.12 (bs, 1H, 4-0H), 2.29 (s, 3H, SCH3).
Example 8: Synthesis of several 6-0Mp and cyclic 2,3-carbamoyl protected building blocks C-5a to C-5c PVO a HO R1 --41" Bz0 R1 ¨Ow' C-3-ii NPht C-5-i Pht 1-1( MpO
HO Bz0 0 HO Bz0 R d PhtPht C-5-iii MpO
OMp NHz 0 C-5a: R1 = SMe C-5b: R1 = SEt C-5c: R1 = OTBDPS
Example 8: Synthesis of several 6-0Mp and cyclic 2,3-carbamoyl protected building blocks C-5a to C-5c, conditions: a) SOP 18, (92 % for R1 =
OTBDPS); b) SOP 4, (82 %); c) SOP 26, (75 % for R1 = OTBDPS); d) SOP
30, (87 %); e) SOP 29, (95 %).
Compound C-5c:
1H-NMR (400 MHz, CDCI3): c = 7.69 (m, 2 H, Aryl), 7.63 (m, 2H, Aryl), 7.46-7.31 (m, 6H, Aryl), 6.82 (bs, 4H, Mp), 5.04 ( bs, 1H, NH), 4.78 (d, 1H, J12 =
7.6 Hz, H-113), 4.15-4.10 (m, 3H, H's not assigned), 3.97 (dd, 1H, J =11.6 Hz, J = 9.6 Hz, H not assigned), 3.78 (s, 3H, OMe), 3.56 (m, 1H, H not assigned), 3.48 (m, 1H, H not assigned), 2.80 (bs, 1H, 4-0H), 1.08 (s, 9H, C-(CH3)3).
Example 9: Synthesis of Building Blocks C-6-a and C-6-b and C-7 Me0 H0 Me* * H0 R
C-3-iii-a: R=SCres C-6-i-a: R=SCres C-3-iii-f: R=SMe C-6-i-b: R=SMe Me c HO d Mpm0 R Mpm0 R
C-6-ii-a: R=SCres C-6-a: R=SCres C-6-ii-b: R=SMe C-6-b: R=SMe OM pm OMpm Mpr7;,¨,- OH Mp m0 OTB D PS
Example 9: Synthesis of building blocks C-6-a, C-6-b and C-7, conditions; a) SOP 12, (83 %); b) SOP 7; c) SOP 5, (75 %, 2steps); d) SOP 14 ( 82 %); e) SOP 8 (91 M.
Compound C-6-a:
1H-NMR (400 MHz, CDCI3): 8 = 7.43 (d, 2 H, Aryl), 7.25 (m, 4 H, Aryl), 7.08 (d, 2 H, Aryl), 6.88 (m, 4 H, Aryl), 4.81 (d, 1 H, Jgem = 10.8 Hz, OCH2), 4.74 (d, H, Jgem = 10.8 Hz, 0C142), 4.53 (d, 1 H, Jgem = 11.1 Hz, OCH2), 4.48 (d, 1 H, Jgem = 10.8 Hz, OCH2), 4.35 (d, 1 H, J1,2 ='= 10.0 Hz, H-1[3), 3.82 (s, 3 H, OCH3), 3.79 (s, 3 H, OCH3), 3.76 (dd, 1 H, Jgem = 10.5 Hz, J5,6a = 5.4 Hz, H-6a), 3.70 (dd, 1 H, J6,6b = 5.4 Hz, H-6b), 3.56 (ddd, 1 H, H-4), 3.42 (m, 1 H, H-5), 3.34 (dd, 1 H, J3,4 = 8.8 Hz, H-3), 3.24 (dd, 1 H, J2,3 = 9.4 Hz, H-2), 2.72 (d, 1 H, J4,01-1= 3.5 Hz, 4-0H), 2.38 (s, 3 H, SCH3).
Compound C-7:
1H-NMR (400 MHz, CDCI3): 7.63 (d, 4 H, Aryl), 7.35-7.21 (m, 8H, Aryl), 7.08 (m, 2 H, Aryl), 6.83-6.78 (m, 4 H, Aryl), 4.72 (d, 1H, Jgem = 11.0 Hz, OCH2), 4.59 (d, 1H, Jgem = 11.0 Hz, OCH2), 4.29 (d, 1 H, J1,2 = 7.8 Hz, H-1 i3), 4.27 (d, 1H, Jgem = 11.7 Hz, OCH2), 4.21 (d, 1H, Jgem = 11.7 Hz, OCH2), 3.72 (s, 3 H, OCH3), 3.71 (s, 3 H, OCH3), 3.51 (ddd, 1 H, J3,4 J4,6 = 8.6 Hz, H-4), 3.40-_ 3.32 (m, 3 H, H-6a, H-6b, 1-1-2), 3.05 (dd, 1 H, J2,3 = 9.8 Hz, 1-1-3), 2.90 (m, 1 H, H-5), 2.51 (d, 1 H, J4,01-1= 2.2 Hz, 4-0H), 1.12 (s, 9 H, C(CH3)3)=
Example 10: Synthesis of building block C-8a to C-8c HO R
a b C-3-ii-c Pht C-8-i NPht OH
c H
R
mmomillIMP.-d C-8-ii NPht c_g_iii NPht .... it..,4.M,,% ......3 .4....\...V1p --lb- A110 e C-8-iv H2 C-8a R = SMe C-8b R = SEt C-8c R = OTBDPS
Example 10: Synthesis of building blocks C-8a to C-8c, conditions: a) SOP 7, AllBr, DMF (65 %, R=OTBDPS); b) SOP 4, (86 %, R=OTBDPS); c) SOP 26, (70 %, R=OTBDPS); d) SOP-30; e) SOP 12, (70 %, 2 steps for R=OTBDPS).
Compound C-8c:
1H-NMR (400 MHz, CDCI3): 6 = 7.72 (m, 4 H, Aryl), 7.43-7.16 (m, 6 H, Aryl), 6.76 (m, 4H, Mp), 5.96 (m, 1 H, =CH Allyl), 5.31 (m, 1 H, =CH Allyl), 5.22 (m, 1 H, =CH Allyl), 4.42 (d, 1 H, J1,2 = 7.6 Hz, H-10), 4.39 (m, 1 H, OCH2 Allyl), 4.23 (m, 1 H, OCH2 Ally!), 3.97 (dd, 1 H, Jgem = 10.0 Hz, J5,6a = 3.6 Hz, I-1-6a), 3.92 (dd, 1 H, J5,6b = 5.2 Hz, H-6b), 3.77 (s, 3 H, OCH3), 3.66 (ddd, 1 H, J4,5 --J3,4 = 9.4 Hz, H-4), 3.42 ( dd, 1 H, J = 9.8 Hz and J = 7.8 Hz, H not assigned), 3.22 (m, 1 H, H-5), 3.09 (dd, 1 H, J = 8.4 Hz and J = 9.6 Hz, H not assigned), 2.48 (d, 1 H, J4,0H= 2.8 Hz, 4-0H), 1.12 (s, 9 H, C(CH3)3).
Example 11: Synthesis of Building Block D-1:
OH
OH SM a HO D-1-i OH be Bn SMe Bn0 OBn OH
Bn0 OBn OTBDPS e HO r Bn0 D-1-v OBn OTBDPS
HO Bn0 DA OBn0 OTBDPS
Example 11: Synthesis of building block D-1; a) SOP 1, (95 %); b) SOP 7, (85 %); c) SOP 13, (92 %); d) SOP 8; e) SOP 4, (70 %, 2 steps); f) 1. SOP 15; 2.
SOP 16, (75 %, 2 steps).
Compound D-1:
1H-NMR (400 MHz, CDCI3): 8 = 7.72 (m, 4 H, Aryl), 7.41 (m, 2 H, Aryl), 7.32 ¨
7.25 (m, 14 H, Aryl), 5.04 (d, 1 H, Jgern = 11.0 Hz, OCH2), 4.81 (m, 3 H, OCH2), 4.63 (d, 1 H, J1,2 = 7.4 Hz, H-10), 3.88 (ddd, 1 H, J3,4:=-= J4,5= 9.2 Hz, H-4), 3.70 (s, 3 H, OCH3), 3.53 (dd, 1H, J = 7.5 Hz, J = 9.0 Hz, H not assigned), 3.47 (d, 1 H, J4,5 = 9.8 Hz, H-5), 3.42 (dd, 1 H, J = 8.9 Hz and J = 8.9 Hz, H
not assigned), 2.87 (d, 1 H, 14,0H = 2.4 Hz, 4-0H), 1.11 (s, 91-1, C(CH3)3).
Example 12: Synthesis of Building Block 0-2, a 2-0-Allyloxycarbonyl protected thioethyl glycoside OAc Ac0.-; 0 a Ph.....4:20,.......\0 0 b AcC ¨IP' ---10.-HO ,..---0-2-i 0-2-ii OTrit PhC... j..............
0 0 c Lev0 0 d Bn0 ----- ¨V.--0.-Bn0 ----D-2-iii D-2-iv .... 0::...,%Vle ...._0...:\::.....
Lev 0 e Lev0 0 Bn0 ----- ¨III' Bn0 SEt D --2v D.2 0Alloc Example 12: Synthesis of Building Block 0-2, conditions: a) 1. SOP 22; 2.
SOP 1; b) SOP 7; c) 1. SOP 4; 2. TritCI, Pyridine, (CICH2)2; 3. SOP 23; d) 1.
Cr03, H2SO4, Acetone, 0 C, 2. SOP 16; e) 1. Dimethyl dioxirane , Acetone; 2.
EtSH, TFAA, CH2Cl2, 3. SOP 35.
Example 13: Synthesis of Bui'dim] Block D-3 _ c0Bz a Bz0 0 ¨ b --Ow- BnC-4.....\....-OBz 4111.' 0 OBz B41i CI -....,, 0-3-1 _. OH
_cOiliz 0 c Bz0 HO 0 d Bn-OOTBDPS
Bn0 OTBDPS --P.-OBz Bz0 3-iii .....11.1...
OMe HO 0 a Lev 0 f Bn0 OTBDPS ¨10-Bn0 OTBDPS --IN.
Bz0 0.3-v Bz0 D-3-iv 0 Me OMe Lev0-) .., OH ¨" Lev0-21 ---09 Bn0 ON
Bn0 D-3-vi Bz0 03 Bz0 Example 13: Synthesis of Building Block D-3, conditions: a) 1. SOP 4, Amberlite IR 120, H20, 80 C; 2. SOP 18, (85 %, 2 steps) b) 1. SOP 21; 2.
SOP 8, ( 70 %, 2 steps); c) SOP 22, (96 %); d) 1. SOP 15; 2. SOP 16, (80 %, 2 steps); e) SOP 23, (92 %); f) SOP 9, (95 /0); g) SOP 25a, (91 /0).
Preparation of D-3-i, step 1:
The starting material (57 mmol) and Amberlite IR 120 iron exchange resin (H+-form, 20 g) were suspended in water (180 ml) and stirred at 80 C until completion. The iron exchange resin Inas removed by filtration and extracted with water The combined aqueous layers were neutralized with triethyl amine and freeze dried.
Compound D-3-v:
¨ ---1H-NMR (400 MHz, CDCI3): 8 = 7.95 (m, 2 H, Aryl), 7.68 (m, 2 H, Aryl), 7.58 ¨
7.12 (m, 16 H, Aryl), 5.47 (dd, J1,2= 7.6 Hz, J2,3 = 9.6 Hz, H-2), 5.31 (dd, J3,4=
9.6 Hz, H-4), 4.64 (d, 1H, 7.6 Hz, H-1(3), 4.60 (d, 1H, Jgem = 12.0 Hz, OCH2), 4.55 (d, 1H, Jgem = 12.0 Hz, OCH2), 3.74 (dd, 1H, 1-1-3), 3.70 (s, 3H, OCH3), 3.63 (d, 1H, J4,5 = 9.6 Hz, H-5), 2.68¨ 2.16 (m, 4H, (CH2)2-Ley), 2.15 (s, 3H, CH3), 0.96 (s, 9H, C(CH3)3).
Example 14: Syntheses of a range of block D donor soars D-4 to D-7 from a common intermediate, a 4-0-leyulinoyl cilucal.
....
Lev 0 .....e...._ Bn0 R SAr Lev0 Bn0 D-6b: R=ClAc0 D-6a: R=Alloc0 D-4 Moo \ ... (.....mi/
OMe Lev 0 Lev Bn0 0 (S=0)Ar Bn0 ..---ClAc0 D-2-v D-7 \ b .........31N ....fie Lev0 0 Bn0 0(CH2)3CH=CH2 0Alloc Example 14: Syntheses of D-4 to D-7 as donor sugars, conditions: a) 1.
Dimethyl dioxirane, Acetone; 2. TBAF, THE; 3. SOP 35; b) 1. Dimethyl dioxirane, Acetone; 2. 4-penten-1-ol, ZnC12, CH2Cl2; 3. SOP 35; c) 1. Dimethyl dioxirane, Acetone; 2. ArSH, TFAA, CH2Cl2, (Ar = Ph, p-Tol); 3. SOP 35 or (ClAc)20, Pyridine, CH2Cl2 (for D-6b); d) MCPBA, CH2Cl2 (for D-6b as substrate).
_ INTENTIONALLY LEFT BLANK
Example 15: Synthesis of Building Block E-1 to E-4 OTBDPS
BO------q Bn0 E.4 N3 e OH
OTBDPS
OTBDPS
HOH
b Bneno 0 73&\,......\...R
R 2-41.1" 1-1 H0 R
C-1-i-a: R=SMe E-1-i-a: R=SMe E-1-ii-a: R=SMe C-1-i-b: R=SCres E-1-i-b: R=SCres E-1-ii-b: R=SCres .....,&µ: .7, ....\....4H
......&.t µ..)E .....\...3z C Bn0 d Bn0 0 ---11.--Bn0 R --1.- Bn0 R
E-1-iii-a: R=SMe N3 E-1-iv-a: R=SMe N3 E-1-iii-b: R=SCres E-1-iv-b: R=SCres ........:01 ....\,...V1p yOMpm B ni2;
OBz Bn0 R
Bn0 R
Bn0 N3 Br;C.1) E-1-v-a: R=SMe E-1-vi-a: R=SMe E-1-v-b: R=SCres E-1-vi-b: R=SCres OTCA
e 1 omp h OMpm Bn0 0 Bng&.,.\...,%
Bri¨C..) OTCA
OTCA
Example 15: Synthesis of Building Block E-1 to E-4, conditions: a) SOP 8; b) SOP 7; c) SOP 9, (84% over 3 steps, R=SMe); d) SOP 18, (82%, R=SMe); e) 1. SOP 13, (75%, for E-1-iv-a as starting material); 2. SOP 25b, (88%); f) 1.
TosCI, Pyridine; 2. p-Me0-C6F14-0Na, NMP, 60 C; g) SOP 7, (78 %, R=SMe);
h) 1. SOP 14; 2. SOP 25b, (79 %, 2 steps, R=SMe).
Preparation of E-1-i-a:
_ _ A mixture of methyl 2-azido-2-deoxy-thio-O-D-glucopyranoside (10g, 42.5mmol) and imidazole (4.9 g, 71.25 mmol) in 20 mL DMF was treated with tert-butyldiphenylchlorosilane (11.6mL, 44.63mmol) for 2h. The reaction mixture was concentrated, extracted, washed and dried. yield: 23g (crude light yellow syrup), Rf = 0.74 (CHCI3/methanol = 9/1).
Preparation of E-1-ii-a:
The silyl ether from the previous step in 50 mL DMF, was treated with 2.68g of 95% NaH (106.25 mmol) and 12.64 mL (106.25 mmol) of benzyl bromide at 0 C. After 1h the excess NaH was quenched and the reaction concentrated, extracted, washed and concentrated to afford a yellow syrup yield: 28.5g (crude yellow syrup), Rf = 0.80 (hexane/ethyl acetate =7/3).
Preparation of E-1-iii-a:
The crude yellow syrup from the above reaction was treated with 36.5 mL
AcOH and 106.3 mL (106.25 mmol) of 1M solution of TBAF in THF overnight.
The reaction was concentrated and purified by chromatography to afford the title compound. 14.9g (84%, 3 steps) Rf= 0.36 (petroleum spirit/ethyl acetate = 7/3) Preparation of E-1-iv-a:
Methyl 2-azido-2,3 di-O-benzy1-2-deoxy-thio-13-D-glucopyranoside (14.5 g, 34.9 mmol) in dichloromethane (200 ml) and anhydrous pyridine (8.6 ml, 106.2 mmol) was treated with benzoylchloride (4.93 ml, 42.5 mmol) at 0 C
for 1 hour. The reaction mixture was quenched, extracted, washed and evaporated. The residue was purified by silica gel column chromatography to afford the title compound as a white solid.
Yield: 14.9 g (82 %), Rf = 0.82 (Petroleum spirit/Ethyl acetate = 7/3).
Preparation of E-1:
Methyl 2-azido-6-0-benzoy1-2,3di-O-benzy1-2-deoxy-thio-? -D-glucopyranoside (8.68 g, 16.7 mmol) in acetone (50 ml) was treated with N-bromosuccinimide (8.92 g, 50.12 mmol) at 0 C for 1 hour. The reaction mixture was then quenched, extracted, washed and evaporated, furnishing a yellow syrup which was purified by chromatography. Yield: 6.13 g (75%), Rf =
0.57 (Petroleum spirit/Ethyl acetate = 7/3). A cooled mixture of 2-azido-6-0-____ benzoy1-2,3 di-O-benzyl- 2-deoxy-a/P-0-glucopyranose (5g, 10.2 mmol), K2CO3 (7.0 g , 51 mmol) and trichloroacetonitrile (5.1m1, 51 mmol) in 30 ml of dichloromethane was stirred for 2h. The mixture was then filtered through celite and the filtrate was concentrated and purified on a short column of silica gel to obtain the title compound as an amorphous white solid. Yield 5.69 g (88%), Rf = 0.85 (Petroleum spirit/Ethyl acetate = 7/3).
Compound E-1:
1H-NMR (400 MHz, CDC13): 5 = 8.73 (s, 1 H, C=NH), 8.00 (m, 2 H, Aryl), 7.56 (m, 1 H, Aryl), 7.43-7.25 (m, 12 H, Aryl), 5.66 (d, 1H, J = 8.4 Hz, HAN, 4.95 (d, 1H, Jgem = 10.8 Hz, 0CH2), 4.87 (d, 2H, J = 10.8 Hz , OCH2), 4.62 (d, 2H, Jgem = 10.8 Hz, OCH2), 4.58 (dd, 1H, Jgem = 12.4 Hz, J5,6. = 2.0 Hz, H-6a), 4.46 (dd, 1H, J5,6b = 3.6 Hz, 1-1-6b), 3.77-3.72 (m, 3H, H-5, 2H not assigned), 3.62 (dd, 1H, J = 8.3 Hz, J = 9.7 Hz, H not assigned).
Compound E-2:
1H-NMR (400 MHz, CDCI3): (5= 8.70 (s, 1 H, C=NH), 7.38-7.22 (m, 10H, Aryl), 7.13 (m, 2H, Aryl), 6.83 (d, 2H, Mpm), 6.44 (d, 1H, J1,2 = 3.5 Hz, H-1a), 4.93 (d, 1H, Jgem = 10.5 Hz, OCH2), 4.89 (d, 1H, Jgem = 10.5 Hz, OCH2), 4.78 (d, 1H, Jgem = 10.5 Hz, OCH2), 4.57 (d, 1H, Jgem = 11.7 Hz, OCH2), 4.51 (d, 1H, Jgem = 11.7 Hz, OCH2), 4.39 (d, 1H, Jgem = 11.7 Hz, OCH2), 4.02 (dd, 1H, J3,4 --' J2,3 = 9.5 Hz, H-3), 3.98 (m, 1H, H-5), 3.86 (dd, 1H, J4,5 = 9.6 Hz, H-4), 3.76 (dd, 1H, H-2), 3.75 (s, 3H, OCH3), 3.69 (dd, 1H, J5,6. = 3.5 Hz, Jgem = 10.5 Hz, H-6a), 3.63 (dd, 1H, J5,6b = 1.8 Hz, 11-6b).
Example 16: Synthesis of Building Blocks E-5 to E-8 ¨
TBDPSO
.
µ
Bn0 Bn0 SR
BnOunoll.) E-1-vii-a: R=Cres NPht E-1-vii-b: R=Me 1-15.42 eie Bn0 Bn0 SR
TBDPSO...........\....
NPht E-1-viii-a: R=Cres Bn0 E-1-viii-b: R=Me NMe2 Bn0 SR
i, b \ 0 DTPMNH
E-8-1-a: R=Cres HO.........\_.
N
/ E-8-I-b: R=Me i Bn0 Bn0 SR = DTPM-NMe2 HC.L......\õ.....
----1"" Bn0 C
Bn0 SR
E-1-ix-a: R=Cres E-1-ix-b: R=Me DTPMNH
E-5-i-a: R=Cres MprrC
e2/.
E-5-i-b: R=Me Bn0 ..0 Bn0 SR
h/ .4......
\ . d A
DTPMNH
Mp..Ø0140....\...
BnBz0C) E-6-1-a: R=Cres Bn0 SR
Bn0 SR
E-6-i-b: R=Me Bn0 DTPMNH
DTPMNH
E-5-ii-a: R=Cres g,i E-7-i-a: Rres E-5-ii-b: R=Me E-7-1-b: R=Me Mpn...i , e Bn0 e DTPMNH TCA
Bn0 Mp0.......
Bz0......., O
Bn0 Bn0 Bn0 DTPMNH
DTPMNH
OT CA
Example 16: Syntheses of Building Blocks E-5 to E-8, conditions: a) SOP 6, (85 %, R=SMe); b) SOP 30, (86 %, R=SMe); c) SOP 10, (88 %, R=SMe); d) SOP 18, (92%, R=SMe); e) 1. SOP 13; 2. SOP 25b, (85%, 2 steps, R=SMe);
f) SOP 7; g) 1. SOP 14; 2. SOP 25b; h) 1. TsCI, DMF; 2. p-Me0-C6H4-0Na, NMP, 60 C; i) SOP 8.
Compound E-5:
1H-NMR (400 MHz, CDCI3): (5= 10.20 (dd, 1 H, JNH,=C-H = 14.0 Hz, ,INH,1-1-2 =
9.9 Hz, NH), 8.80 (s, 1 H, C=NH), 8.16 (d, 1H, =C-H), 7.99 (m, 2H, Aryl) 7.58 (m, 1 H, Aryl), 7.45 (m, 2 H, Aryl), 7.30-7.17 (m, 10H, Aryl), 6.42 (d, 1H, 42 =
3.6 Hz, H-1a), 4.89 (d, 1H, em=Jg 8.4 Hz, OCH2), 4.68-4.60 (m, 3H, OCH2), 4.58 (dd, 1H, J5,6a = 2.0 Hz, Jgem = 12.4 Hz, H-6a), 4.51 (dd, 1 1-1, J6,6b =
4.0 Hz, H-6b), 4.22 (m, 1 H, H-5), 4.03 (dd, 1 H, J3,4 --- J2,3 = 9.6 Hz, 143), 3.80 (dd, 1 H, J4,5 = 9.4 Hz, H-4), 3.70 (ddd, 1 H, H-2), 3.32 (s, 3 H, NCH3), 3.25 (s, 3 H, NCH3).
Example 17: Preparation of L-iduronic acid containing disaccharides B-A-1 to OBn .........43z R20 .0 SCres HO 0 + Bn0 Lev0 OBz RiOMe B-1 / B-4 1a A-1:121 = N3 R 2 - _Mp / Mpm A-3: R1 = DTPMNH
...........*Bz B-A-1: R1= N3, R2= Mp OR OBn Bn0 0 B-A-2: R1= N3, R2= Mpm B-A-3: R1= DTPMNH, R2= Mp OMe B-A-4: R1= DTPMNH, R2= Mpm Lev0 OBz 11 b OBz HO OBn 0 B-A-5: R1= N3 B-A-6: R1= DTPMNH OMe Lev0 OBz 1 :i..:*313z Me0 OBn 0 Bno B-A-7: R1= N3 jpg R1 B-A-8: R1= DTPMNH 0 OMe Lev OBz dOBz Me0 OBn B-A-9: R1= N3'..Frol:44 Rh B-A-10: R1= DTPMNH 0 OMe HO OBz Example 17: Preparation L-iduronic acid containing disaccharides B-A-1 to B-A-10; a) SOP 32a, (76 %, for B-A-1); b) SOP 27, (88%, for B-A-5); c) 1.SOP
20; 2. SOP 16, (84% for B-A-7, 2 steps); d) SOP 24, (94%, for B-A-9).
Formation of disaccharide B-A-1 (step a) A suspension of A-1 (410 mg, 992 pmol), B-1 (680 mg, 992 pmol) and freshly activated molecular sieves 4 A (1.0 g) in dry CH2Cl2 (20 mL) was stirred for min at 0 C. N-lodosuccinimide (405 mg, 1.8 mmol) was added and stirring continued for 20 min. After addition of trifluoromethanesulfonic acid (10.6 pl, 119.7 pmol), the reaction mixture was further stirred until completion (from 0 C to 25 C) and quenched with aqueous NaHCO3-solution (10 %). The mixture was diluted with CH2Cl2 and filtered through a celite pad. The filtrate was washed with a 10 `)/0 KHCO3/Na2S203 solution, water and saturated brine solution, dried over MgSO4 and evaporated. Final purification was achieved by silica gel column chromatography. Yield: 730 mg (76 %).
Formation of disaccharide B-A-7(step c) Disaccharide B-A-5 (1.00 g, 1.15 mol) was dissolved in anhydrous DMF (7.0 ml) and reacted with pyridinium dichromate (4.33 g, 11.5 mmol) under stirring at room temperature until complete conversion into the uronic acid. The reaction mixture was subsequently poured into 50 ml water and the whole extracted with diethyl ether. The combined ether layers were washed with 10 % aqueous citric acid solution, filtered through a short silica gel pad, dried over MgSO4, evaporated and dried under high vacuum. The crude residue was dissolved in Toluene (3 ml) and methanol (3 ml) and titurated with TMSCHN2 solution (2M in hexane) until completion. The excess of TMSCHN2 was destroyed by addition of acetic acid and the mixture evaporated. Final purification was achieved via silica gel chromatography. Yield: 871 mg (84 %).
Compound B-A-9:
1H-NMR (400 MHz, CDCI3): 8= 8.03 (m, 2H, Aryl), 7.91 (m, 2H, Aryl), 7.53 (m, 2H, Aryl), 7.42-7.23 (m, 14H, Aryl), 5.37 (d, 1H, J1,2 < 1.5 Hz, H-1'a), 5.21 (m, 1H, H-2'), 4.97 (d, 1H, .14,5 = 2.3 Hz, 1-1-5'), 4.84 (d, 2H, Jg em = 10.8 Hz, OCH2), 4.81 (d, 1H, Jgem = 10.8 Hz, OCH2), 4.80 (d, 1H, Ji,2 = 3.6 Hz, H-1a), 4.77 (1H, J5,6a = 1.8 Hz, H-6a), 4.70 (m, 2H, OCH2), 4.47 (dd, 1H, J5,6b = 4.2 Hz, Joel/ = 12.3 Hz, H-6b), 4.05-3.97 (m, 3H, 11-4', 144, H-5), 3.91-3.87 (m, 2H, H-3', H-3), 3.49 (s, 3H, OCH3), 3.44 (m, 1H, H-2), 3.43 (s, 3H, OCH3).
Selected 13C-NMR (100 MHz, CDCI3): 5 = 98.73 C-1 (JcH = 172.5 Hz), 98.35 C-1' (JcH = 171.8 Hz).
Example 18: Syntheses of Building Blocks E-D-1 to E-D-12 OR1 Bn0 Bn0; 131&=\=....\,.....,-X 0 Bri-- ..) o OMe R ......4n......
R
E-1, E-2, E-3, E-5, E-6, E-7, Bn0 OTBDPS
E-1-v-a, E-1-v-b, E-1-vi-a, E-1-vi-b B
E-1-a, E-1-b, E-5-ii-a, E-5-ii-b E-D-1 : R = N3, RI = Bz E-6-i-a, E-6-i-b, E-7-1-a, E-7-1-b E-D-2 : R = N3,12.1 = Mpm +
E-D-3 : R = N3, R1 = Mp a E-D-4 : R = DTPMNH, 111 = Bz 0 all _e E-D-5 : R = DTPMNH, R1= Mpm HO --&\.:....\.õ1) E-D-6 : R = DTPMNH, Ri= Mpm Bn0 OTBDPS
OBn b/
Bngno 0 R ...........\0 OMe E-D-7: R = N3, Ri = Bz en0 ED-8 : R = N3, R1 = Mpm Bn0 OTCA
E-0-9: R= N3, R1= Mp E-D-10 : R = DTPMNH, R1 = Bz E-0-11 : R = DTPMNH, R1 = Mpm E-D-12 : R = DTPMNH, R1 = Mpm Example 18: Syntheses of disaccharides E-D-1 to E-D-12, conditions: a) SOP
32 a/b for X =SMe/ Scres or SOP 33 for X = OTCA, (88 % for E-D-1 via E-1, 84% for E-D-4 via E-5, as a/filnixtures), b) 1. SOP 9; 2. SOP 25a, (90 % for E-D-7 over 2 steps).
Preparation of E-D-1:Methyl (2-azido-6-0-benzoy1-3,4-di-O-benzy1-2-deoxy-a-D-glucopyranosyl)-(1-44)-tert-butyldiphenylsily12,3-di-O-benzyl-13¨D-glucopyranosid)uronate A mixture of 2-azido-6-0-benzoy1-2,3 di-O-benzyl- 2-deoxy-a/3-D-glucopyranosyl trichloroacetimidate (2.5 g, 3.94 mmol), and methyl (tert-butyldiphenylsilyl 2,3-di-O-benzy1-0-D-glucopyranoside) uronate (1.6 g, 255 -mmol) and molecular sieves 4A (2.5 g) in 50 ml diethyl ether was treated with TBDMSOTf (180 I, 788.76 mol) at -20 C for 1h. The reaction was quenched filtered, concentrated and the residue purified by silica gel column chromatography to obtain the desired disaccharide 2.48 g, 88%. Rf= 0.67 (toluene/ethyl acetate 9/1) Compound E-D-1:
E-D-1 was formed according to SOP 33 with ether as solvent at -30 C and TBDMSOTf as promotor in 86 % yield (a/(3-mixture).
1H-NMR (400 MHz, CDCI3): 8 = 8.00 (m, 2H, Aryl), 7.68 (m, 4H, Aryl), 7.56 (m, 1H, Aryl), 7.42 (m, 4H, Aryl), 7.36-7.17 (m, 2411, Aryl), 5.47 (d, 1H, J12 =
3.8 Hz, H-1 'a), 5.02 (d, 1H, Jgem = 11.4 Hz, OCH2), 4.97 (d, 1H, Jgem = 11.0 Hz, OCH2), 4.84 (m, 4H, OCH2), 4.75 (d, 1H, Jgem = 11.4 Hz, OCH2), 4.66 (d, 1H, J1,2 = 7.5 Hz, H-1I3), 4.57 (d, 1H, Jgem = 10.9 Hz, OCH2), 4.45 (m, 2H, H-6'a, H-6'b), 4.15 (dd, J = 8.8 Hz and J = 9.6 Hz), 3.86 (m, 1H), 3.65 (s, 3H, OCH3, 3.68-3.58 (m, 3H), 3.55 (d, 1H, J4,5 = 10.0 Hz, 1-1-5), 3.31 (dd, 1H, J2,3 =
10.2 Hz, H-2'), 1.12 (s, 9H, C(CH3)3).
Compound E-D-4:
E-D-4 was formed according to SOP 33 with ether as solvent at -30 C and TBDMSOTf as promotor in 84 % yield (a/(3-mixture).
Selected 1H-NMR (400 MHz, CDCI3): 8 = 10.02 (dd, 1 H, JNH,=GH = 14.4 Hz, JNH,I-1.2 = 9.6 Hz, N-H), 8.02 (m, 2 H, Aryl), 7.79 (d, 1H, =C-H), 7.72-6.93 (m, 33 H, Aryl), 5.60 (d, 1H, J1,2 = 3.6 Hz, H-ta.), 4.49 (d, 1H, J1,2 = 7.8 Hz, 1-1-113), 3.66 (s, 3 H, OCH3), 3.29 (s, 3 H, NCH3), 3.28 (s, 3 H, NCH3), 1.14 (s, 9 H, C(CH3)3).
Preparation of E-D-7: Methyl (2-azido-6-0-benzoyl-3,4-di-O-benzy1-2-deoxy-a-D-glucopyranosyl)-(1¨#4)-2,3-di-O-benzyl-P-D-glucopyranosyl trichloroacetimidyl)uronate A solution of methyl (2-azido-6-0-benzoy1-3,4-di-O-benzy1-2-deoxy-a-D-gluco-pyranosyl)-(1¨>4)-tert-butyldiphenylsily12,3-di-O-benzyl-(3-D-glucopyranoside) uronate (2.09 g, 1.90 mmol) in acetic acid (1.74 ml, 30.45 mmol) and 1 M
solution of tetrabutylammoniumfluoride (7.6 ml, 7.61 mmol) was stirred at room temperature overnight. The reaction mixture was then concentrated and the residual syrup was purified by silica gel column chromatography to obtain the desired hemiacetal. Yield: 1.57 g (95.8%), Rf= 0.21 (toluene/ethyl acetate 9/1).
A mixture of methyl (2-azido-6-0-benzoy1-3,4-di-O-benzy1-2-deoxy-a-o-glucopyranosyl)-(1--)4)-2,3-di-O-benzyl-p-D-glucopyranosyl)uronate (594 mg, 690.70 mot), trichloroacetonitrile (280 I , 2.74 mmol) and DBU (31 IA 209.3 g.trnol) in 8.0 ml dichloromethane was stirred at 0 C for 1 h. The mixture was then concentrated and purified on a short column of silica gel to obtain the title compound as an amorphous white solid. Yield: 662 mg (95.3 %), 13= 0.46 (toluene/ethyl acetate 9/1).
Compound E-D-7:
Selected 1H-NMR (400 MHz, CDCI3): 6 = 8.68 (s, 1H, C=NH), 8.00 (m, 2H, Aryl), 7.56 (m, 2H, Aryl), 7.43-7.23 (m, 22H, Aryl), 6.48 (d, 1H, 42 = 4.3 Hz, H-1ot), 5.59 (d, 1H, J2= 3.6 Hz, H-1 'a), 5.03 (1H, Jem = 10.8 Hz, OCH2), 4.93-4.83 (m, 4H, OCH2), 4.70 (d, 1H, Jgem= 12.0 Hz, OCH2), 4.64 (d, 1H, Jgern = 12.0 Hz, OCH2), 4.60 (d, 1H, Jgem= 11.2 Hz, OCH2), 4.47 (m, 2H, H-6'a, H-6'b), 4.42 (m, 1H, not assigned), 4.15 (m, 2H, not assigned), 3.97 (dd, 1H, J = 8.2 Hz and J = 10.2 Hz, not assigned), 3.80 (m, 1H, not assigned), 3.76 (m, 3H, OCH3), 3.72-3.64 (m, 2H, not assigned), 3.30 (dd, 1H, J2,3 = 10.4 Hz, H-2').
Example 19: Syntheses of disaccharides E-D-13 to E-D-44 ...c...)Y11.....
OW
Bn0 Bn0 OTBDPS
Bn---..1004)0.
R2 C....\_... Me R = Ac, Alloc, Bz, Piv 0... 0 Bn0 OTBDPS
+ ¨Po- a E-D-13 to E-D-OW
---&.....\......\sõN. 0 x b E-1, E-2, E-5, E-6, E-1-iv-a, E-1-iv-b, E-1-vi-a, E-1-vi-b, E-5-ii-a, E-5-ii-b, Bn00 E-6-i-a, E-6-i-b Br* R2 .......t.....\1 0 OM e Bn E-D-29 to E-D-44 R10 TCA
E-D-13 & E-D-29: R3= Bz, R2= N3, R1= Alloc E-D-21 & E-D47: R3= Bz, R2= N3, R1 = Bz E-D-14 & E-D-30: R3= Bz, R2= NHDTPM, R1r- Alloc E-D-22 & E-D-38: R3= Bz, R2= NHDTPM, R1= Bz E-D-15 & E-D-31 : R3 = Mom, R2= N3, Ri = Alloc E-D-23 & E-D-39: R3= Mpm, R2= N3, Ri = Bz E-D-16 & E-D-32 : R3 = Mpm, R2= NHDTPM, R1= AI oc E-D-24 & E-D-40: R3= Mpm, R2= NHDTPM, R1= Bz E-D-17 & E-D-33 : R3 = Bz, R2= N3, Ri= Piv E-D-25 & E-D-41: R3 = Bz, R2 = N3, Ri = Ac E-D-18 & E-D-34: R3 = Si, R2= NHDTPM, R1= Piv E-D-26 & E-D-42: R3= Bz, R2= NHDTPM, R1= Ac E-D-19 & E-D-35 : R3 = Mpm, R2= N3, Ri = Ply E-D-27 & E-D-43: R3= Mpm, R2= N3, Ri = Ac E-D-20 & E-D-36: R3 = Mpm, R2= NHDTPM, R1= Piv E-D-28 & E-D-44: R3= Mpm, R2= NHDTPM, R1= Ac Example 19: Syntheses of disaccharides E-D-13 to E-D-44, conditions: a) SOP 32 a/b for X = SMe/ Scres or SOP 33 for X = OTCA ( 70 % for E-D-23, a/13 mixture); b) 1. SOP 9; 2. SOP 25a.
Compound E-D-27:
E-D-27 was formed according to SOP 33 with ether as solvent at -20 C and TBDMSOTf as promotor in 70 % yield (a/(3 -mixture).
Selected 1H-NMR (400 MHz, CDCI3): 5 = 7.58 (m, 2H, Aryl), 7.54 (m, 2H, Aryl), 7.36 ¨ 7.00 (m, 23 H, Aryl), 6.73 (m, 2H, Aryl), 5.37 (d, 1H, J1,2 =
3.9 Hz, 1+1 'a), 5.12 (dd, 1H, J2,3 = 8.8 Hz, 1+2), 4.63 (d, 1H, Jgem = 11.2 Hz, OCH2), 4.58 (d, 1H, Jgem = 11.2 Hz, OCH2), 4.48 (d, 1H, J1,2 = 7.3 Hz, H-113), 3.66 (s, 3 H, OCH3), 3.55 (s, 3 H, OCH3), 3.34 (m, 1H), 3.22 (dd, 1H, J = 3.4 Hz, J =
10.7 Hz), 1.81 (s, 3 H, OAc), 0.98 (s, 9H, C(CH3)3).
Example 20 : Synthesis of alternative E-D-disaccharides E-D-45 to E-D-50 OBz ORI
Bn0 Bn0 X HBOno 0 OTBDPS
Bn0 E-1, E-5, E-1-iv-a, D-8a: RI = Mp E-1-iv-b, E-5-ii-a, E-5-ii-b D-8b: RI = Mpm D-8c: RI = All OBz )1 a Bn0 0 Bn0 R2 ORI
OTBDPS
Bn0 E-D-45: RI = Mp, R2= N3 E-D-46: RI = Mp, R2 = NHDTPM
E-D-47: RI = Mpm, R2 = N3 E-D-48: RI = Mpm, R2 = NHDTPM
E-D-49: RI = All, R2 = N3 E-D-50: RI = All, R2 = NHDTPM
Example 20: Synthesis of alternative E-D-disaccharides E-D-45 to E-D-50, conditions: a) SOP 32a/b for X = SMe/SCres or SOP 33 for X = OTCA, diethyl ether, TBDMS-0Tf, -20 deg. C (75 % for E-D-45 as a/(3-mixture).
--Example 21: Synthesis of trisaccharides E-D-C-1 to E-D-C-16 BnBn0 R4 0 Me 0 + H
E-0-9 E-D-10 Bn Bn 0 OTCA R20 N3 OTBDPS
Bnrill;&r) R40.4\1 0 0 Bn Bn R20 N3 OTBDPS
E-D-C-1 :121 = Mpm, R2 = Mpm, R3 = Mpm, R4 r- NHDTPM E-D-C-9 :
R1= Mpm, R2' Mpm, R3 = Mpm, R4= N3 E-D-C-2 : Rl = Mp, R2r- Mpm, Ra = Mpm, R4= NHDTPM E-D-C-10 R1 = Mp, R2 = Mpm, R3= Mpm, R4 = N3 E-D-C-3 : R1 = Mpm, R2 = Mpm, R3= Bz, R4= NHDTPM E-D-C-11:
R1 = Mpm, R2 = Mpm, R3 = Bz, R4= N3 : R = Mp, R2= Mpm, R3 = Bz, R4= NHDTPM E-D-C-12:121 = Mp, R2 = Mpm, R3 = Bz, R4 = N3 E-D-C-5 : R1 = Mpm, R2 43z, R3 = Mpm, R4= NHDTPM E-D-C-13:
Ri = Mpm, R2 =Bz, R3 = Mpm, R4= N3 E-0-C-6 : R1 = Mp, R2 =Bz, R3 4-- Mpm, R4= NHDTPM E-D-C-14:
R1= Mp, R2 =Bz, R3 = Mpm, R4= N3 E-D-C-7 : R1 = Mpm, R2 43z, R3 = Bz, R4= NHDTPM E-D-C-15:
R1 = Mpm, R2 =Bz, R3 =Bz, R4 =N3 E-D-C-8 : R1 = Mp, R2=Bz, R3 = Bz, R4= NHDTPM E-D-C-16:
R1 = Mp, R2 r:Bz, R3 = Bz, R4= N3 Example 21: Synthesis of trisaccharide E-D-C-1 to E-D-C-16, conditions: a) SOP 33, (70 % for E-D-C 15 as an a/(3 mixture).
Compound E-D-C-15:
E-D-C-15 was formed according to SOP 33 with dichloromethane as solvent at 0 to 20 C and TBDMSOTf as promotor in 70 % yield (a/13-mixture).
1H-NMR (400 MHz, CDCI3): 8 = 7.93 (m, 2H, Aryl), 7.87 (m, 2H, Aryl), 7.66 (m, 2H, Aryl), 7.61 (m, 2H, Aryl), 7.46 (m, 2H, Aryl), 7.38-6.99 (m, 32 H, Aryl), 6.79 (m, 2H, Aryl), 5.27 (d, 1 H, J1,2 = 3.8 Hz, 141"a), 4.99 (dd, 1 H, J3,4 J2,3 = 9.5 Hz, H-3), 4.80-4.69 (m, 6 H, OCH2), 4.52 (m, 3 H, OCH2), 4.40 (d, 1H, J-1,2 = 8.0 Hz, H-113), 4.38-4.32 (m, 2 H, not assigned), 4.29 (d, 1 H, J1,2 =
7.5 Hz, H-113), 4.15 (m, 1 H, Jgem = 12.0 Hz, OCH2), 4.02 (dd, 1 H, J4,5 = 9.6 Hz, H-4), 3.80 (2 dd, 2 H, H-3", 1+41 3.71, (s, 3 H, 0C113), 3.67 (m, 1 H, not assigned), 3.61-3.53 (m, 2 H, H-5', 11-2'), 3.46 (dd, 1 H, Jgem = 11.2 Hz, ..)5,6a =
2.4 Hz, H-6a), 3.41 (dd, 1H, J2,3 '-- J3,4 = 9.0 Hz, H-3'), 3.27 (s, 3 H, OCH3), 3.21 (dd, 1 H, J2,3 = 10.0 Hz, H-2"), 3.14 (dd, 1 H, 132'), 3.00 (dd, 1 H, J5,6b <2.0 Hz, H-6b), 2.75 (m, 1 H, H-5) 1.05 (s, 9H,C(CH3)3).
Example 22: Synthesis of trisaccharides E-D-C-17 to E-D-C-32 Bn BrCf. R4 %.1e nOR1 E-D-37 to E-D-40 Bn0 0 HO. 12`0.0TBDPS
13z0 OTCA N3 Bn Bn0 434 0 cOR1 0 Bn OTBDPS
Bz0 N3 E-0-C-17: = Mpm, Mpm, R3= Mpm, c= NHDTPM E-D-C-25: R1 = Mpm, t= Mpm, Mpm, Ft= N3 E-D-C-18 : = Mp, R2= Mpm, = Mpm, Ft = NHDTPM E-D-C-26: R1 = Mp, Mpm, R3= Mpm, 124= N3 E.0-C-19: Fe M pm , = Mpm, R3= Bz, R4= NHDTPM E-D-C-27: RMpm, = Mpm, Bz, Fe N3 E-D-C-20 : = Mp, RI = Mpm, = Bz, R4= NHDTPM E-D-C-28: Mp, Ft Mpm, R3= Bz, R4= N3 E-D-C-21: Ft = Mpm, R2 =Bz, R3= Mpm, = NHDTPM
ED-C.29: R1 Mpm, FBz, Fe = Mpm, R4= N3 E-D-C-22: I Mp, =Bz, R Mpm, R NHDTPM E-D-C-30: R1 = Mp, Fe =Bz, R3 = Mpm, Ft = N3 E-D-C-23: I Mpm, Fe =Elz, Fe = Bz, R4= NHDTPM E-D-C-31: R1 Mpm, Bz,F R3= Bz, R4= N3 E-D-C-24: Ft = Mp, Fe =Elz, R3= Bz, R4= NHDTPM E-D-C-32: R1= Mp, IBz, Fe = Bz, Ft = N3 Example 22: Synthesis of trisaccharide E-D-C-17 to E-D-C-32, conditions: a) SOP 33.
Example 23: Formation of trisaccharidic Trichloroacetimidates E-D-C-33 to E-oR3 Bn0 0 Bn0 R20 TBDPS
Bn0 N3 E-D-C-1 to E-D-C-16 OR3 la Bn0 Bn0 0 En R70.4\
E-D-C-33 : R1 = Mpm, R2= Mpm, It = Mpm, Ft = NHDTPM E-D-C-41 : Ft1 = Mpm, RI =
Mpm, R3= Mpm, Ft = N3 E-D-C-34 : R1= Mp, R2 = Mpm, Ft = Mpm, R4= NHDTPM E-D-C-42 : R1= Mp, R2=
Mpm, R3 = Mpm, R4= N3 E-D-C-35 :R1= Mpm, 122= Mpm, R3= Bz, R4= NHDTPM E-D-C-43 : RI = Mpm, R2=
Mpm, It = Bz, R4= N3 E-D-C-36 : R1 = Mp, R2 = Mpm, RI = Bz, R4= NHDTPM E-D-C-44 : R1 = Mp, Ft =
Mpm, Ft= Bz, R4= N3 E-D-C-37 : R1 = Mpm, F= Bz, R3 = Mpm, R4= NHDTPM E-D-C-45 : R1= Mpm, Ft2 =Bz, R3= Mpm, R4= N3 E-D-C-38 : R1 = Mp, R2 =Bz, R3= Mpm, R4= NHDTPM E-D-C-46 : 114= Mp,122=Bz, R3 = Mpm, R4= N3 E-D-C-39 :R1= Mpm, Fe =Bz, R3 = Bz, R4= NHDTPM E-D-C-47 : R1 = Mpm, Ft2 =Bz, R3= Bz, R4= N3 -fl-C-40 = R1 = Mn.R2 =Rz. R3 = Rz. R4 =NHDTPM ED-C.48 : R1 = Mp, R2 =Bz, R3 = Bz, R4=
Example 23: Formation of trisaccharidic Trichloroacetimidates E-D-C-33 to E-D-C-48, conditions: a) 1. SOP 9; 2. SOP 25, (82% over 2 steps for E-D-C-47 Example 24: Syntheses of trisaccharides E-D-C-9 to E-D-C-12 and E-D-C-49 to E-cr oz_...\...)Me 0 C-6a : R = SCres, R1= Mpm, R2= Mpm C-7: R = OTBDPS, R1 = Mpm, R2= Mpm Lev Bn0 + C-8c : R = OTBDPS, R1 = Mp, R2 = All " Bz OTCAR C-10 : R = SCres, Ri = Mp, R2= Mpm ' C-11 : R = SCres, R1= Mpm, W = All C-3 to C-9 C-12: R = OTBDPS, R1= Mpm, R2= All a C-13 : R = SCres, Ri = Mp, R2 =All C-14 : R = OTBDPS, R1 = Mp, R2 = Mpm D-C-1 : R = SCres, RI = Mpm, Fe = Mpm 0 OMe OR1 D-C-5 :R
= OTBDPS, R1= Mpm, R2= Mpm D-C-2 : R = SCres, R1= Mpm, Fe = AllHO 0 0 D-C-6 :
R = OTBDPS, R1 = Mpm, R2= All n D-C-3 : R = SCres, R1= Mp, R2= Mpm Bn0 R20 R D-C-7 :
R = OTBDPS, R1= Mp, R2= Mpm o n.) D-C-4 : R = SCres, Ri= Mp, R2= All Bz0 N3 D-C-8 :
R = OTBDPS, R1= Mp, R2 = All 11.
in li) in OR3 b OR3 oI\)Bn0 B
tI\)o Bn(-).&t., .")\ illin 0 0 OMe o N3 N3 ...........\,......
11.
oI
Bz0 R20 R
oI
E-D-C-49 : R = SCres, Ri = Mpm, R2= Mpm, Fe = Bz ED-C-11 : R = OTBDPS, R 1=
Mpm, Fe = Mpm, R3= Bz E-D-C-50 : R = SCres, Fe = Mpm, R2 =All, R3= Bz E-D-C-57 : R =OTBDPS, R 1=
Mpm, It = All, R3 =Bz E-D-C-51 : R = SCres, re = Mp, R2= Mpm, Fe =Bz E-D-C-12 : R = OTBDPS, R 1=
Mp, R2= Mpm, R3= Bz i E-D-C-52 : R = SCres, R1= Mp, R2= All, R3 = Bz E-D-C-58 : R = OTBDPS, R =
Mp, R2 = All, R3 = Bz E-D-C-53 : R = SCres, R1= Mpm, R2= Mpm, = Mpm E-D-C-9 : R = OTBDPS, R 1=
Mpm, Fe . Mpm, R3= Mpm E-D-C-54 : R = SCres, R1= Mpm, R2= All, R3= Mpm E-D-C-59 : R = OTBDPS, R 1=
Mpm, Fe = All, R3= Mpm E-D-C-55 : R= SCres, Ill = Mp, R2= Mpm, It = Mpm E-D-C-10 : R= OTBPS, R1= Mp, R2= Mpm, It = Mpm E-D-C-56 : R = SCres. Ri = Mn. 122 = All. R3= Mom E-D-C-60 : R = OTBPS, R 1=
Mp, R2= All, R3= Mom Example 24: Syntheses of trisaccharides E-D-C-9 to E-D-C-12 and E-D-C-49 to E-D-C-60, conditions: a) 1. SOP 33; 2. SOP 24; b) SOP 33.
(for D-C-5: 70 %, 2 steps); b) SOP 33, ( 78 % for E-D-C-9 as an oc/11 mixture).
Compound D-C-5:
D-C-5 was formed according to SOP 33 with ether as solvent at -20 C and TMSOTf as promotor, followed by SOP 24 in 70 % yield (over 2 steps as a/13-mixture).
Selected 1H-NMR (400 MHz in CDCI3): 6 = 7.88 (m, 2H, Ar), 7.67- 7.58 (m, 5H, Ar), 7.42 (m, 2H, Ar), 7.37-7.12 (m, 16H, Aryl), 6.84 (m, 3H, Ar), 5.14 (dd, 1H, J1,2 = 8.2 Hz, J2,3= 9.5Hz, H-2'), 4.90 (d, 1H, Jgem = 10.7 HZ, OCH2), 4.73 (d, 1H, Jgem= 11.5 Hz, OCH2), 4.65 (d, 1H, J1,2= 8.2 Hz, H-1'(3), 4.63 ¨
4.58 (m, 2H, OCH2), 4.51 (d, 1H, Jgem = 12.0 Hz, OCH2), 4.20 (d, 1H, J1,2=
7.9 Hz, H-1 3), 4.05 (d, 1H, Jgem = 11.9 Hz, OCH2), 4.02 ¨ 3.95 (m, 2H, not assigned), 3.81 (s, 3H, OCH3), 3.80 (s, 3H, OCH3), 3.71 (d, 1H, J4,5 = 9.9 Hz, 1-1-5), 3.67 (s, 3H, OCH3), 3.47 - 3.40 (m, 3H, not assigned), 3.21 (dd, 1 H, J
= 9.0 Hz, J = 9.8 Hz, not assigned), 3.00 (dd, 1 H, J5,6b = 1.4 Hz, Jgem =
10.5 Hz, H-6b), 2.63 (m, 1 H, H-5), 2.35 (bs, 1 H, 4-0H), 1.07 (s, 9H, C(CH3)3).
Compound E-D-C-9:
E-D-C-9 was formed according to SOP 33 with ether as solvent at -20 C and TBDMSOTf as promotor in 78 % yield (a43-mixture).
Selected 1H-NMR (400 MHz, CDCI3): 8 = 7.77 (m, 2H, Aryl), 7.59, 7.54 (2m, 2 x 2H, Aryl), 7.35 ¨ 7.00 (m, 30 H, Aryl), 6.88 (m, 2H, Aryl), 6.82 (m, 2H, Aryl), 6.73 (m, 2H, Aryl), 5.41 (d, 1 H, J1,2 = 3.5 Hz, H-1"a), 5.19 (dd, 1 H, J2,3 ===-: J1,2 = 9.6 Hz, H-2'), 4.85 - 4.78 (m, 4 H, OCH2), 4.67 (m, 2H, OCH2), 4.65 (d, 1H, J1,2 = 8.5 Hz, 14113, not assigned), 4.38 (d, 1 H, em=Jg 11.1 Hz, OCH2), 4.29 (d, 1 H, Jgem = 11.7 Hz, OCH2), 4.17 (dd, 1H, not assigned), 4.11 (d, 1H, J1,2 =
7.9 Hz, H-10 not assigned), 4.03 (d, 1 H, Jgem = 12.0 Hz, OCH2), 3.90 - 3.76 (m, 3H, not assigned), 3.730, 3.727 (2s, 2 x 3H, OCK), 3.65 (s, 3H, OCH3), 3.54 (s, 3H, OCH3), 2.89 (dd, 1 H, Jgem = 10.5 HZ, J5,6b <2.0 Hz, H-6b), 2.52 (m, 1H, H-5), 1.02 (s, 9 H, C(CH3)3).
Example 25: Synthesis of trisaccharides E-D-C-41, E-D-C-42 and E-D-C-61 to E-D-C-66 OMpm Bn0 Bn(7.:&=-=kft.)) N3 ..........\%.....\........_ Me E-D-C-53 : RI = Mpm, R2 = Mpm Bn0 0--..Ø..., E-D-C-54 : RI = Mpm, R2 = All E-D-C-55 : RI = Mp, R2= Mpm Bz0 R20 \SCres E-D-C-56 : RI = Mp, R2= All I, a OMpm Bn0 Bn0 ome 0--......\.1:::\........
E-D-C-61 : RI = Mpm, R2= Mpm E-D-C-62 : RI = Mpm, R2 = All Bn0 WO SCres E-D-C-63 : RI = Mp, R2= Mpm E-D-C-64 : RI = Mp, R2 = All it b OMpm Bn0 Bn0 (pie N ......"..:)...\....,0 ' E-D-C-41 : RI = Mpm, R2= Mpm E-D-C-42 : RI = Mp, R2= Mpm E-D-C-65 : RI = Mpm, R2 = All Bn0 R20 OTCA
E-D-C-66 : RI = Mp, R2= All N3 Example 25: Synthesis of trisaccharides E-D-C-41, E-D-C-42 and E-D-C-61 to E-D-C-66, conditions: a) 1. SOP 39; 2. SOP 38; 3. SOP 16; b) 1. SOP 14; 2.
SOP 25a.
Example 26: An alternative route to the trisaccharides E-D-C-61 and E-D-C-0 OMe ORI
D-C-9 : RI = MPm ADO 0 D-C-10 : RI =Mp Br-if..====='\,..---\P------1,(LMpm0& SCres Bz0 N3 a4 0 OMe ORI
0-C-11 : RI =Mpm,.,o D-C-12 : RI =Mp Bn ' Mpm0 SCres Bn0 N3 OMpm BnBn .4. ----b lr 0...........:0M1 ...3ni Bn 0 Bn N3 0 OrI..
E-D-C-61 : RI =Mpm 0 Bn 0--1.0:......\ .._ E-D-C-63 : RI = Mp Bn0 MPrn SCres Example 26: An alternative route to the trisaccharides E-D-C-61 and E-D-C-63, conditions: a) 1. SOP 39; 2. SOP 38; 3. SOP 16; 4. Pd(Ph3P)4, p-TolSO2Na, THF, Me0H; b) SOP 33.
Example 27: Syntheses of blocks E-D-C-67 to E-D-C-70 0 OMe OMp Lev0"..\. .....\ + HO-......\:f.%\,., Bn0 OTCA 0 SCres Alice() C-15 i 0 OMp Bn0 0 SCres Alloc0 D-C-13)7.---NH
b 0 OMe 'I' OMp Bn 0 SCres Alloc0 D-C-14--NH
Bn0 OR0 Bn0 +
c 1 BnBOn 0 0 OMe OMp Bn 0 SCres Mica) Nir---NH
E-D-C-67 : R = Mp E-D-C-68 : R = Bz 0 cr......DR.\.) d Bn Bn0 0 OMe OMp \iC.)..\ /0"--'=-=.....\:::1 Bn 0 SCres Bn0 4 NH
E-D-C-69 : R = Mp E-D-C-70 : R = Bz 0 Example 27 : Syntheses of trisaccharides E-D-C-67 to E-D-C-70, conditions:
a) SOP 33; b) SOP 24; c) SOP 33; d) 1. SOP 36; 2. SOP 37.
Example 28: Synthesis of trisaccharides E-D-C-70 and E-D-C-71 OBz Bnilen 0 --&.µ......) !kJ 0 OMe ..3 ......
OMp HO'''.._.\,......\_..
R
Bn0 0 C-16/C-5c Bn OTCA
la OBz BnB0 ---..&....141...) 4, v 1 OM
Bn R
E-D-C-70 : R = SCres o E-D-C-71 : R = OTBDPS
Example 28: Synthesis of trisaccharides E-D-C-70 and E-D-C-71, conditions:
a) SOP 33, (55% for E-D-C-71, a/13 mixture).
Compound E-D-C-71:
E-D-C-71 was formed according to SOP 33 with dichloromethane as solvent at 40 C and TBDMSOTf as promotor in 55 `)/0 yield (as a/13-mixture).
Selected 1H-NMR (400 MHz, CDCI3): 8 = 7.91 (m, 2H, Aryl), 7.61 (m, 2H, Aryl), 7.55 (m, 2H, Aryl), 7.50 ¨ 7.02 (m, 29 H, Aryl), 6.65 (m, 4H, Mp), 5.38 (d, 1 H, Ji,2 = 3.9 Hz, H-1"a), 5.22 (bs, 1 H, NH), 4.67 (d, 1H, J1,2 = 7.4 Hz, H-113, not assigned), 4.50 (d, 1H, J12 = 7.8 Hz, H-113, not assigned), 3.92 (d, 1 H, J4,5 = 9.8 Hz, H-5'), 3.698 (s, 3 H, OCH3), 3.693 (s, 3 H, OCH3), 1.03 (s, 9 H, C(CH3)3).
Mfound = 1408.52 (M+H20)+, m ¨calc = 1390.54 (MI.).
Example 29: Syntheses of trisaccharides E-D-C-61, E-D-C-72 and E-D-C-73 ::Ø....11/1e OMpm Lev0 0 Mpm HC .......4.\._ Bn0 TCA
+ 0 SCres Bn0 C-6-a 0 OMe i OMpm Lev00 Bn Mpm0 SCres Bn0 D-C-15 4Ae....\ lb,1 OMpm Bn Mpm0 SCres Bon D-C-11 ,OR
BOBnOn ---"\....
c I
E-1 to E-3 N1 3 TCA
OR
Bn0 0 Bn0 0 OMe ..\1N)i....\..o.....\
OMpm Bn 0 0 Mpm0 0 SCres E-D-C-61 : R = Mpm Bn0 E-D-C-72 : R = Mp E-D-C-73 : R = Bz Example 29: Syntheses of trisaccharides E-D-C-72 to E-D-C-73 and E-D-C-61, conditions: a) SOP 33; b) SOP 24; c) SOP 33.
Example 30: Syntheses of trisaccharides C-B-A-1 to C-B-A-4 _ OBz MpOLA)n..7.,,, Lev A110*
SCres C-17 N3OTCA 4 HO BA OBz ..4,,0 _\\3z pilif7 oBn.i OBz Lev '0 --SCres HO
+ Br:O&No....) N3 orc::::1 13z b A-1/A-3 R OMe 0c,=\mpcoiLvi 0OBz OBz Bp Lev R
OMe N3 0 OBz C-B-A-1: R= N3_ C-B-A-2: R= DTPMNH
4 OBz OBz meo B Bn0 HO'....\:\
ADO O7I--,...j4 OMe N3 0 OBz C-B-A-3: R=N3 C-B-A-4: R=DTPMNH
Example 30: Syntheses of trisaccharides C-6-A-1 to C-6-A-4, conditions: a) SOP 33; b) SOP 32a; c) 1. SOP 27; 2. SOP 20; 3. SOP 16; 4. SOP 24.
-Example 31: Synthesis of trisaccharides C-B-A-5 to C-B-A-8 OBz RO 4, N3 TCA OMe C-18 : R = Bz, R1 = AcB-A-9 1 OBz OH
C-19 : R = Mpm, R1 =Ac C-20: R = Bz, R1 = Lev C-21 : R = Mpm, Ri = Lev OBz I4m Me OBn Bn0 $0, 0 R 07....1.... ..i N3OMe OBz C-B-A-5 : R = Bz, R1 = Ac C-B-A-6 : R = Mpm, R1 = Ac C-B-A-7 : R = Bz, R1 = Lev C-B-A-8 : R = Mom. R1 = Lev Example 31: Synthesis of trisaccharides C-B-A-5 and C-B-A-8, conditions: a) SOP 33, (50% for C-B-A-5, a/f3 mixture).
Compound C-B-A-5:
C-B-A-5 was formed according to SOP 33 with ether as solvent at - 20 C and TBDMSOTf as promotor in 50 % yield (as a./13-mixture).
Mfound = 1269.65 (M+H+H20)4", M¨calc = 1250.43 (M+).
Example 32: Syntheses of D-C-B trisaccharides D-C-B-1 to D-C-B-3.
0 OMe OR1 Me Lev 0 HO
OBn BrZ7).......\õõõ,OTCA Alloc0 + 0 N.)----NH 0 OBz SCres C-B-2, R1 =Bz a 1 C-B-3, R1 =Mp C-B-4, R1 =Mpm OR/
Lev0 (3OMe OBn BnO-X.00=1....\/ 0 0 SCres OBn OBz D-C-B-1, R1= Bz D-C-B-2, R1= Mp D-C-B-3, R1= Mpm Example 32: Syntheses of D-C-B-trisaccharides D-C-B-1 to D-C-B-3, conditions: a) 1. SOP 33; 2. SOP 36; 3. SOP 37.
Example 33: Syntheses of D-C-B trisaccharides D-C-B-4 to D-C-B-7.
0R1 Rhin ........Ø..\-1 HO
... cOM.e....\___ SCres Lev0 0 + N3 0 Bz Bn0 Alloc0 OTCA
C-B-5 : R1 = Mpm, R2= Mpm, 0 C-B-6 : R1 = Mpm, R2 = All, a C-B-7 : R1 = Mp, R2= Mpm, C-B-8 : R1 = Mp, R2= All, .4....\le z OR1 Me0 OBn Lev OR20 op.rz.
Bn0 SCres OBn N3 OBz D-C-B-4 : R1 = Mpm, R2 = Mpm, D-C-B-5 : R1 = Mpm, R2 = All, D-C-B-6 : R1 = Mp, R2 = Mpm, D-C-B-7 : R1 = Mp, R2 = All, Example 33: Syntheses of D-C-B-trisaccharides D-C-B-4 to D-C-B-7, conditions: a) 1. SOP 33; 2. SOP 36; 3. SOP 37.
=
Example 34: Syntheses of tetrasaccharides D-C-B-A-1 to D-C-B-A-2 OBz MP Me0 0"-----.
OBn Bn0 HP 0 s C-8-A-9 N3 :.:::Ae....\ OMe +
0 OBz Lev0 SCres 0 o Bn0 Allop a D-6a OBz ...../le....\" 47..\\3 Lev 0 0 0 Me OBn Bn0 Bn0 0 Allac D-C-B-A-1 N30Me o OBz OBz _ c..\1:)Me....\, OMp Me0 p0 nBn Bn0 0 D-C-B-A-2 OMe Bn0 \)7.--NH
OBz 0 o Example 34: Syntheses of tetrasaccharides D-C-B-A-1 and D-C-B-A-2, conditions: a) SOP 32a; b)1. SOP 36; 2. SOP 37; 3. SOP 24.
Example 35: Alternative syntheses of tetrasaccharides D-C-B-A-2 _ ¨
........... i:oBzµ
.:::0,..k .7...\"......_47...\__p ON
0 0 Me0 0 Lev0 ".....00Br4 Bn0 Bn0 SCres 4. 0 1 OMe OBn Cli---NH
D-C-16 0 1 HO OBz a .. OBz......
0 OMe OMp oBn Bn0 0 00 OMe Bn0 %),---NH
OBz Example 35: Alternative synthesis of tetrasaccharide D-C-B-A-2, conditions:
a) 1. SOP 34; 2. SOP 24.
Example 36: Syntheses of tetrasaccharides D-C-B-A-3 to D-C-B-A-8 .................0Bz ..:-_ OMe,...........
OR2 Me 0 OBn Bn0 Lev0 0 Bn0 Rio SCres 01-P 4.
OMe OBn N3 HO OBz D-C-15 : R1 = Mpm, li = Mpm D-C-17 : R1 = Mpm, li = Mp 1131:U:RI;1TPMNH
D-C-18 : R1= Mpm, Ff = Bz all, OBz Iloe 0 Me OBn .......q R
OMe Bn0 N3 FIr07n0--.A110 Bz D-C-B-A-3 : R= DTPMNH, R1= Mpm, Fi = Mpm, D-C-B-A-4 : R= DTPMNH, R1= Mpm, if = Bz D-C-B-A-5 : R= DTPMNH, W = Mpm, Fe = Mp D-C-B-A-6 : R= N3, R1 = Mpm, Fe = Mpm, D-C-B-A-7 : R= N3, R1 = Mpm, Ff = Bz D-C-B-A-8 :R= NA, R1 = Mpm, li = Mp Example 36: Syntheses of tetrasaccharides D-C-B-A-3 to D-C-B-A-8, conditions: a) 1 SOP 32b; 2. SOP 24.
Example 37: Syntheses of tetrasaccharides E-D-C-B-1 to E-D-C-B-4 ¨
.......7....\IR
Bn0 0 OMpm Me0 Bn0 0 OBn ...........\õ OMe HO --4.....\0 -0 SCres + MPm Bn0 OTCA
N
3 OBz 0Alloc a E-D-29 :
E-D-31 : R = Mpm ....1 ..\10 1 Bn0 Bn0 OMe MPm Me OBn 0 --0 SCres Bri;3".....\/...
Mpm E-D-C-B-1 : R = Bz 0Alloc E-D-C-B-2 : R = Mpm 0 OBz 11 b OR
B nen--0...4 o OMe E-D-C-B-3 : R = Bz "Pm Me OBn0 E-D-C-B-4 : R = Mpm SCres Mpm OBn N3 0 OBz Example 37: Syntheses of tetrasaccharides E-D-C-B-1 to E-D-C-B-4, conditions: a) SOP 33; b) 1. SOP 36; 2. SOP 37.
Example 38: Syntheses of blocks E-D-C-B-5 to E-D-C-B-8 _ /OR
BnO ) OBn B 0 0 OMe HO 0 071.....7",-0 SCres 0 + 7NH
E-D-29 : R = Bz N3 nA........\...
ED-51 : R = Mp Bn0 TCA C-B-3 OBz Alloc0 a 0 .....311 ...)0 Bn0 Bn0 0 OMe OMp N3 ........4)...\"_.........o.e..4\
Me$Bn,...1.,.....r.
E-D-C-B-5 : R = Bz 0 0 SCres E-D-C-B-6 : R = Mp Bn0 0Alloc OBz OR
Bn0 1 b Bn¨C--,=0.)) 0 OMe OMp u.n N3 ............v .......Ø.\--1 E-D-C-B-7: R = Bz E-D-C-B-8: R = Mp 0 "0 SCres Bn0 0 OBn d-----NH
OBz Example 38: Syntheses of tetrasaccharides E-D-C-B-5 to E-D-C-B-8, conditions: a) SOP 33; b) 1. SOP 36; 2. SOP 37.
Example 39: Syntheses of E-D-C-B-A pentasaccharides P-1 and P-2 OR E-D-C-69 : R = Mp OBz E-D-C-70 : R = Bz Bn0 f.T...#01:4311 ..........&\...)0 0 0........0Moe0 OMp Me0 0 Bn0 Bn 0¨...\,...--\+-\/ 0 SCres +
OMe OBn \)----NH HO
OBz OR
0 0 a OBz Bn0 BnO&Ice..) N3 :_\.....\/0MG0 C"IIP MW Bn0 Bn0 0 OMe OBn 7--- IVNI
0 OBz P-1 :R=Mp P-2: R= Bz Example 39: Syntheses of E-D-C-B-A pentasaccharides P-1 and P-2, conditions: a) SOP 34.
Example 40: Synthesis of E-D-C-B-A pentasaccharides P-3 to P-26 =
.
E-D-C-41 to E-D-C-48=
R2 E-D-C-65 to E-D-C-66 E-D-C-74 to E-D-C-87 en ...............\13z Bn0 3 0 Me =
Me0 13'10 04_413:ii Bn0 +
s Me nO 13-"Cill 3 - Finlz TCA i, a A
.............)5z ) 8n0 8n0 0 = Me I
3 = - Me .
13n0 .
3 Me , a . =13z P.3: R = All, le =Mom, R2 =13z P-11 : R = lApm,R1= Mpm, R2= Bz P-19: R = Bz., R1 = Mpm, R2= Bz P.4: R = A11,1:11 .. Mp, R2 = Bz P-12: R= Mpm, R' = Mp, R2=
13z P-20: R= Bz, R1= Mp, R2= Bz P-5 : R = All, R1= Mpm, R2= Mpm P-13 : R = Mpm, 111 = Mpm, R2= Mpm P-21 : R = Bz, R1= Mpm, R2= Mpm P-6 : R = All, R1= Mp, R2= Mom P-14 : R = Mpm, R1= Mp, R2=
Mpm P-22 : R =13z, R1= Mp, R2= Mpm P-i: R = All, R1= Mp, R2= Mp P-16 : R = Mpm, R1= Mp, R2=
Mp P-23 : R = Bz, R1= Mom, R2= Mp P-8 : R = All, R1= Mpen, R2= Mp P-16: R = Mpm, R1 = Mom, Ft2= Mp P-24 : R = Bz, R1 = Mp, R2 = Mp P-9 :1,1= All, RI = Mpm, R2 a TEMPS P-17 : R = Mimi, R1= Mpm, Ra= MOPS P-25 : R = Eft, Ri . Mpm, R2= MOPS
P-10 : R = All, RI = Mp, R2 = TEMPS P-18 : R = Mpm, R1= Mp, R2=
TBDPS P-26 : R =13Z, Ri = Mp, R2 TEMPS
, Example 40: Synthesis of E-D-C-B-A pentasaccharide P-3 to P-26, conditions:
a) SOP 33 (75 % for P-19 as an a/( mixture).
5 Compound P-19:
P-19 was formed according to SOP 33 with dichloromethane as solvent at . - 20 C and TMSOTf as promotor;
Mfound = 2068.76 (M+H+H20)+, Meek = 2049.74 (Mt).
Example 41: Alternative syntheses of E-D-C-B-A pentasaccharides P-11, P-12, P-19, P-20 and P-27 ..4z....) Bn0 0 Bn0 0 OMe OR1 Me0 .OBz Bn Bn0 071Ø7.-SCres + HO RO Bn0 OBn N3 OBz A-1 N3 E-D-C-B-3 : R = Mpm, R1 = Mpm 0 OMe E-D-C-B-9 : R = Mpm, R1 = Bz, E-D-C-B-10 : R = Mpm, R1 = Mp a 1 E-D-C-B-11 : R= Bz, R1 = Mp E-D-C-B-12 : R = Bz, R' = Mpm OBz Bn OBz nO 0 OMe wo 0 N30 -----.0B. t.:i Bn0 Bn0 RO OMe OBn N3 Bz P-11 : R = Mpm, R1 = Mpm 0 P-12 : R = Mpm, R1 = Mp P.19: R = Bz, R1 = Mpm P-20 : R= Bz, R1 = Mp P.27: R = Mpm, R1 = Bz Example 41: Alternative syntheses of E-D-C-B-A pentasaccharides P-11, P-12, P-19, P-20 and P-27, conditions: a) SOP 32a.
Example 42: Alternative syntheses of some E-D-C-B-A pentasaccharides OBz Bn 0 R 0 OMe OR1 0 ce........\.Ø..\/.........1.4MaCelin Bn0 N3 E-1 to E-3, N3 + H
E-1-iv-b, E-1-v-b, Bn0 Mpm 0 -0 D-C-B-A-6 to OMe E-1-vi-b OBn N3 BzD-C-B-A-8 0*2 Bn a i ........ µ
Bn0 0 N3 Me 0Bn Bn OMe P-11 : RI = Mpm, R2= Bz OBn N3 OBz P.12: RI = Mp, R2= Bz P-16 : RI= Mpm, R2= Mp P.13: RI = Mpm, R2= Mpm P.27: RI = Bz, R2= Bz P.14: R1 = Mp, R2= Mpm P-28: R1= Bz, R2= Mp P.15: R1 = Mp, R2= Mp P-29: RI = Bz, R2= Mpm Example 42: Alternative syntheses of some E-D-C-B-A pentasaccharides, conditions: a) SOP 32a (for R = SCres) or SOP 33 ( for R = OTCA).
_ _ _ Example 43:Svnthesis of pentasaccharide P-13 and P-30 0......&%...)V1pm ......HEtzok Bn 0 Bn0 N3 0 C...14:...\,..... Me Bn Bn0 0 MP ni -0 0 OMe Bn0 + B-Bn0 MPm SCres 0 Bz all ,...:)M1,..)rri OBz B nO
Bn N3 .. Cs.0111,......, 0 MPM Me Bn ---.'-'&\:2)1311 P-13 : R = N3 0 **0 P-30 : R = DTPMN H Bn o R 0OMe Bn0 MPrn N3 Bz Example 43: Formation of pentasaccharides P-13 and P-30, conditions: a) SOP 32a.
Example 44: Formation of pentasaccharide P-19 and P-31 OBz OEtz Bn0 "Pm Me0 0 Bno Bn=-="&t,f) 0 OMe OBn 0.--,...i..;\..,,10 0 Bz0 0 . oBz C-B-A-9 N30Me +
E-D-7 / E-D-10 Bn0 N3 OBz Bn0 Bn...0 nif...\
R .__ \ft:sMe....\ "Pm Me0 osn 0 Bn0 0 ogz N3 Bn0 0 OMe Bn0 N3 OBz P-19: R=N 3 0 P-31: R=NHDTPM
Example 44: Formation of pentasaccharide P-19 and P-31 conditions: a) SOP 33 Example preparation of P19:
_ A mixture of 0-(2-azido-6-0-benzoy1-3,4-di-O-benzy1-2-deoxy¨a-D-glucopyra-nosyl)-(1-->4)-(methyl 2,3 -di-O-benzy1-0-o-glucopyranosyluronate)-(1-->4)-2-azido-3-0-benzoy1-2-deoxy-6-0-p-methoxybenzyl¨a-D-glucopyranosyltrichloroacetimidate (30.0 mg, 21.2 mop and methyl (methyl 2-0-benzoy1-3-0-benzyl-a-L-idupyranosyluronate)-(1-4)-2-azido-3-0-benzyl-6-0-benzoy1-2-deoxy-a-D-glucopyranoside (15.4 mg 19.3 lamol) and 100 mg of molecular sieves 4A in 1.5 ml dry dichloromethane was treated with TBDMSOTf (0.97 pi, 4.24 Imo!) at -20 C for 20 hours. The reaction was quenched, filtered and concentrated. Further purification of the title compound was achieved by silica gel chromatography Yield: 15.83 mg (40%), Rf= 0.30 (toluene/ethyl acetate = 9/1).
Example 45: Partial deprotection of pentasaccharide P-19 OBz BnO*3.)...E...\...4 0 OBz Bn0 OMpm Me0 ogn Bn0 0 0 P-19 N3OMe OBz Bn0 \ -N3 OBz Bn0 1 a OH
0 OBz Bn-....(2.) 0 OMe 0 N3 .........113,..\.....0 0 M: 0.13on B n OP -Bn0 N30Me Bn0 z0 N3 OBz b 0 OH
Bn0 N3 o ONao < _ OH Na0 Bn 1 n N 3OMe Bn0 HO
Example 45: Partial deprotection of pentasaccharide P-19, conditions: a) SOP 28, 84%; b) SOP 39, 86%.
Compound P-33:
Mfound = 1503.5 (M-N2+2H)+, Moalc = 1529.51 (M+).
To ease the structural proof, a small part of P-33 was transformed into the bis methyl uronurate derivative and characterized via NMR-spectroscopy.
Characteristic 1H-NMR-spectral regions are shown in figure 1.
Mfound = 1514.62 (M+H)+, Mca1c = 1513.58 (M ).
Example 46: Partial deprotection of pentasaccharide P-30, containing a DTPM-group as amino protection OMpm OBz Bn0 OMe OMpm Me OBn 0---........;...\._ Bn DTPMNH
Bn0 0 OMe Bn0 MPin N3 OBz OH
4, a OH
Bn0 Bn 0 ONa ,13 ..............\õ, OH Nat) ogn Bn0 DTPMNH
Bn0 0 OMe Bn0 HO
OH
b Bn0 0 OH
Bn0 Bn0 0 ..õ......\.(2_\.....0ONa ..._.&,N3 ....\ .N a0 4 0 OBn Bn0 0 P-33 OMe Bn0 HO
Example 46: Partial deprotection of pentasaccharide P-30, containing a DTPM-group as amino protection, conditions: a) 1. SOP 28; 2. SOP 39; b) 1.
SOP 11 with MeNH2as primary amine and Me0H as solvent; 2. SOP 12.
Example 47: Partial deprotection of _pentasaccharide P-I, containing a cyclic carbamate as amino protection ....,&\7....\.3 Bn0 0 OBz c........\......v0Me ..........X4pµ Nieci...(4 ....---..N.) ug Bn . Bn0 30Me OH OBn 0 OBz Bn0 0 Il a 0 OBz Bn--; OM
OH me j........i 3 ___ C. :......\,/ _..........\
OBn ------)Bn0 Bn0 0 N3e OMe OH OBn )7----NH
0 OBz Bn0 0 OH
Bn;;;&\=-=-,\ 0 ONa OH
N3 ......\.......\/ ......Ø...\ NW 1E--...\in0 N
Bn0 HO
3OMe OH OBn c OH
Bn00 N3 ..._.......\/_....._.\...\ ONa OH Na0 -Ii:1::271r1Bil o Bn0 O
Bn0 HO
N30Me OBn N3 o OH
Example 47: Partial deprotection of pentasaccharide P-1, containing a cyclic carba mate as amino protection, conditions: a) SOP 27; b) SOP 39; c) SOP
12.
Example 48: Deprotection protocol for pentasaccharides P-37 of claim 4 ....: \,.: ..))Rs5 OR, Rip 0 RH20ORE2 = RB A (:).........0Ei ORs3 0 ORH Ri.H 0 X
0= 0 0 õ RA
Rpi C,======\*=..\/R540 0 oRpz Rs ORsz RH = RIM = RH2 = Rpi = Rp2= Bn;
Rsi = Rsz = Rs3 = Rs4 = Rs5 = Mpm, Mp, Bz;
RA= RB =RBI= NHDde, NHDTPM, N3;
or R54 a Ind RB = cyclic Carbamate; a REi = RE2 = Me, All, Bn; X = a-OMe OH
OH
Bne;;;C!) ..............&i 0 ONa OH ONaoBn Bno N30....Ø....vo HO 0 .1) 3 Bn0 OMe OBn N3 OH P-33 Example 48: Deprotection protocol for pentasaccharides P-37 of claim 4, conditions: a) 1. SOP 27 and 28; 2. SOP 39; 3. SOP 11 with MeNH2 as primary amine and Me0H as solvent; 4. SOP 12.
Example 49: Transformation of pentasaccharide P-33 into the 0-and N-sulfated pentasaccharide P-35 OH
OH
Bn Bn0 0 ONa N3 ..........\........\,...
OH Bn0 0 "0 N
Bn0 0 3E1:1;1---41) P-33 OMe OSO3Na Bn0 HO
a N3 OH
OSO3Na Bn0 -;&T.-)) ONa OSO3Na Na OBn 0...¨ =#\=-.\Bn0 Bn0 0 o 0 0 P-39 OMe OSO3Na Bn0 Na03S0 O3Na .
OSO3Na OSO3Na&\:..) 1.........
0 ONa b H
H)2 HO 0="_..1.4:.\ 0 OSO3Na Na0 0 OH S O;
P-39 OMe OS03Na HO Na03S
OSO3Na HO
0 ONa NaOSO2NH
OSO3Na Na0 0H
HO
0 0 '0 NaOSO2NH
OMe HO Na03S0 NaOSO2NH
OSO3Na P-40 Example 49: Transformation of pentasaccharide P43 into the 0-and N-sulfated pentasaccharide P-40, conditions: a) SO3xNMe3, DMF, 50 C; b) l-12 (70 psi), Pd/C, H20; c) SO3xPyridine, H20, pH = 9.5. The transformation of P-33 into P-40 has been performed according to literature: Petitou et al., Carbohydr. Res. 1987, 167, 67-75.
The 1H-NMR (400 MHz, D20) of P-40 is shown in figure 6.
REFERENCES
1 Lindahl, U., Backdtrom, G., Thunberg, L., Leder, I.G., Proc. Natl.
Acad. Sci. USA, 1980, Vol. 77, No. 11, 6551-6555; Reisenfeld, J., Thunberg, L., Hook, M., & Lindahl, U., J. Biol. Chem., 1981, Vol.
256, No. 5, 2389-2394.
2 Choay, J., Lormeau, J-C., Petitou, M., Sinay, P., and Fareed, J., Annals New York Academy of Sciences, 1981, 370, 644-649.
3 Pierre Sinay, Jean-Claude Jacquinet, Carbohydrate Research, 132, (1984), C5-C9.
4 C.A.A. van Boeckel, T. Beetz, J.N. Vos, A.J.M. de Jong, S.F. van Aelst, R.H. van den Bosch, J.M.R. Mertens and F.A. van der Vlugt., J.
Carbohydrate Chemistry, 4(3), 1985, 293-321.
5 .
J. Choay, M. Petitou, J.C. Lormeau, P. Sinay, J. Fareed, Ann.
NY Acad. Sci., 1981, 370, 644-649.
6 .
J. Choay et. a/., Biochem. Biophys. Res. Commun., 1983, 116, 492-499.
_
A solution of sodium azide (492mmo1) in water (80mL) was prepared under N2-atmosphere. To this stirred solution was added dichloromethane (100mL) at 0 C, followed by the addition of triflic anhydride (16.5 ml) over 10 min.
The mixture was further stirred for 2 hours at 0 C, the organic layer was separated and the aqueous layer was extracted with dichloromethane (2x40 mL). The combined organic layers were washed with saturated, aqueous NaHCO3 solution (80 mL), water (80 mL) and dried over Na2SO4. After filtration, this solution was directly used for the diazotransfer reaction.
b) Diazotransfer reaction:
To a solution of the starting material (26.0 mmol) and 4-N,AP-(dimethylamino)pyridine (14.5g) in acetonitrile (100mL) was added dropwise TfN3-solution (85m1) at room temperature within 10 min. The reaction was stirred till complete conversion of the starting material into the product.
The reaction mixture was concentrated in vacuo to 30 ml and suspended in chloroform. After filtration through a Celite pad, the filtrate was concentrated and the residue was purified by filtration through a short silica gel pad. The typical yields for the product formation varied between 85 and 95 %.
Standard Operating Procedure 13: Hydrolysis of thioglycosides (NBS) The starting thioglycoside (33.4 mmol) was suspended in 240 ml Acetone and 18 ml of distilled water and stirred for 45 min at ¨20 C. After addition of NBS
(155 mmol) stirring was continued at ¨20 C. After completion, the reaction was stopped by addition of NaS203 /NaHCO3 (20 A) aqueous solution , 1/1) and the mixture diluted with ethyl acetate, subsequently washed with water and saturated brine solution. The organic layer was dried over Na2SO4 and concentrated in vacuo. Final purification was achieved either by crystallization or by silica gel chromatography. The typical yields for the product formation varied between 75 and 90 %.
Standard Operating Procedure 14: Hydrolysis of thioglycosides (NIS) The starting thioglycoside (33.4 mmol) was suspended in 240 ml Acetone and 18 ml of distilled water and stirred for 45 min at ¨20 C. After addition of NIS
(56.8 mmol) and TMSOTf (2.84 mmol) stirring was continued until completion.
The reaction was stopped by addition of NaS203 /NaHCO3 (20 % aqueous solution , 1/1), diluted with ethyl acetate and washed with water and saturated brine solution. The organic layer was dried over Na2SO4 and concentrated in vacuo. Final purification was achieved either by crystallization (e.g.
petroleum spirit/ ethylacetate) or by silica gel chromatography. The typical yields for the product formation varied between 79 and 92 %.
Standard Operating Procedure 15: Chemoselective Oxidation to Uronic acids A solution of the starting material (20.0 mmol) in dichloromethane (141 ml) was cooled to 0 C and subsequently mixed with TEMPO (0.205 mmol in 12.8 ml dichloromethane), Aliquat 336 (N-methyl-N,N-diocty1-1-octanaminium chloride) (12.8 ml of a 0.08 M solution in dichloromethane) and KBr (2.08 mmol in 4.17 ml 1420) and stirring continued at 0 C. After 5 mins, a suspen-sion of Ca(0C1)2 (43.6 mmol) and NaHCO3 (43.6 mmol) in 135 ml 1-K) was added within 15 mins to the reaction mixture and stirring at 0 C was continued till completion. The reaction was concentrated in vacuo and freeze dried. The crude residue was used as such for the next reactions.
Standard Operating Procedure 16: Methyl ester formation on the Uronic acids The crude residue of the oxidation to the uronic acid was dissolved in 50 ml Toluene and 50 ml Methanol and titurated with TMSCHN2-solution (2M in hexane) until completion. The reaction mixture was quenched with acetic acid to destroy excess of esterification reagent and evaporated in vacuo. Final purification was achieved by silica gel chromatography. The typical yields for the product formation varied between 65 and 80 % over the steps oxidation and esterification.
Standard Operating Procedure 17: Regioselective 6-0-Benzoylation The starting material (32.04 mmol) was dissolved in dry dichloromethane (50 mL) and dry pyridine (10 mL) and cooled down to - 45 C. Benzoyl chloride ( 32.04 mmol) was added dropwise and stirring continued at - 45 C till comple-tion. The reaction was concentrated in vacuo and coevaporated with toluene three times. The remaining residue was dissolved in dichloromethane and washed with 10% aqueous citric acid solution, saturated aqueous NaHCO3 solution and saturated brine solution, dried over Na2SO4 and evaporated in vacuo. Final purification was achieved either by crystallization or by silica gel chromatography. The typical yields for the product formation varied between 75 and 94 %.
Standard Operating Procedure 18: Common procedure for 0-Benzoylation To a solution of the starting material (11.9mmol) and DMAP (13.6mmol) in 1,2-dichloroethane was added dropwise benzoylchloride (1.7g, 12.1mmol). at 0 C. The mixture was then left b stir until completion (dependent on the substrate between 20 to 55 C). Subsequently, the reaction mixture was diluted with dichloromethane and washed with water, 5% NaHSO4 solution, saturated aqueous NaHCO3 solution and saturated brine solution. The organic layer was dried over MgSO4 followed by removal of the solvent in vacuo to give a crude residue. Final purification was achieved either by crystallization or by silica gel chromatography. The typical yields for the product formation varied between 80 and 96 %.
Standard Operating Procedure 19:Common procedure for O-Acetylation To a suspension of the starting material (235 mmol, 3 acetylation sites) in pyridine (350 ml) at CC was added dropwise acetic anhydride (175 ml). After completion of the addition, the reaction was allowed to return to room temperature and stirred until completion. The reaction mixture was evaporated to dryness and 3x coevaporated with toluene. The residue was taken up in dichloromethane and washed with 5 % aqueous NaHSO4-solution, saturated aqueous NaHCO3-solution, water and saturated brine solution. The organic layer was dried over MgSO4 and evaporated. Final purification of the residue _ was achieved either by crystallization or by silica gel chromatography. The typical yields for the product formation varied between 88 and 98 %.
Standard Operating Procedure 20: PDC-oxidation of alcohols to carboxylic acids The starting material (1.15 mol) was dissolved in anhydrous DMF (7.0 ml) and reacted with PDC (11.5 mmol) under stirring at room temperature until complete conversion into the uronic acid. The reaction mixture was subsequently poured into 50 ml water and the whole extracted with diethyl ether. The combined ether layers were washed with 10 % aqueous citric acid solution, filtered through a short silica gel pad, dried over MgSO4, evaporated and dried under high vacuum.
Standard Operating Procedure 21: Chemoselective 1-0-Benzoyl cleavage The starting material (36.8 mmol) was dissolved in dry DMF (80 ml) and cooled to 0 C. Subsequently, hydrazine acetate (44.06 mmol) was added and stirring continued until completion. After addition of acetone and acetic acid the reaction mixture was concentrated in vacuo. The residue was dissolved in dichloromethane and extracted with 10% aqueous citric acid solution, saturated NaHCO3 solution, water and saturated brine solution, dried over MgSO4, evaporated and dried under high vaccuum. Final purification was achieved either by crystallization or by silica gel chromatography. The typical yields for the product formation varied between 72 and 88 %.
Standard Operating Procedure 22: Deacylation under Zemplen conditions The starting material (23.7 mmol) was suspended in dry Me0H (70 ml) and stirred for 30 mins at 0 C. Subsequently, Na0Me (0.1 equiv. / 0-Acyl group) =
was added (positive flush of N2) and stirring was continued at 0' C until completion. Finally, the reaction was neutralized with 10 % aqueous HCI and the solvent evaporated. Final purification was achieved either by crystallization or by silica gel chromatography. The typical yield for the product formation varied between 90 and 98 %.
Standard Operating Procedure 23: Introduction of the 4-0xopentanoyi (=Levulinoyl) group a) Preparation of the Lev20 solution:
To a solution of DCC (31.2 mmol) in 100 mL dichloromethane was added levulinic acid (62.4 mmol) and DIPEA (62.42 mmol). The supernatant was used as such for the levulination reaction.
Reaction The above Lev20 solution was added to a solution of the starting sugar (15.6 mmol) dissolved in 25 mL of dry dichloromethane and stirring was continued until completion. Subsequently, the reaction mixture was filtered through a Celite pad and all combined organic layers were extracted with 10 %
aqueous citric acid solution, saturated aqueous brine solution, dried with Na2SO4 and concentrated. Final purification was achieved either by crystallization or by silica gel chromatography. The typical yields for the product formation varied between 85 and 96 %.
Standard Operating Procedure 24:Cleavage of the 4-0xopentanoyl (=
Levulinoyl) group A solution of the starting sugar (1.28 mmol) and acetic acid (1.35 mL) in pyridine (5.0 mL) was cooled to 0 C followed by addition of hydrazine hydrate (200 1.14 Stirring at 0 C was continued until completion and the reaction mixture diluted with dichloromethane, subsequently extracted with 10%
aqueous citric acid, 10 % aqueous NaHCO3 solution, saturated brine solution, dried over Na2SO4, filtered and concentrated. Final purification was achieved either by crystallization or silica gel chromatography. The typical yields for the product formation varied between 80 and 95 %.
Standard Operating Procedure 25: Formation of Trichloroacetimidates a) with DBU:
A solution of the starting sugar (1.99 mmol) and trichloroacetonitrile (601 1AL, 5.87 mmol) in 5 mL dry dichloromethane was stirred at room temperature for 30 min. The reaction mixture was then cooled to CPC and DBU (100 mop added. Stirring was continued until completion (dependent on the substrate, stirring was performed from 0 C to 20 C). The reaction mixture was concentrated to one half of its volume and directly loaded on a short plug of silica gel and purified via silica gel chromatography. The typical yields for the product formation varied between 78 and 95 %.
b) with K2CO3:
A solution of the starting sugar (1.99 mmol) and trichloroacetonitrile (601 pl, 5.87 mmol) in 5 mL dry dichloromethane is stirred at rt for 30 min. The reaction mixture was then cooled down to CPC and anhydrous K2CO3 (19.9 mmol) added. The reaction was stirred at 0 C till completion and then filtered through a celite pad. The filtrate was dried over Na2SO4 and evaporated. Final purification was achieved either by crystallization or by silica gel chromatography. The typical yield for the product formation varied between 78 and 95 %.
Standard Operating Procedure 26: Regioselective introduction of a 6-0-p-Methoxyphenyl group under Mitsunobu conditions A solution of the starting sugar (13.52 mmol), 4-methoxyphenol (20.3 mmol) and triphenylphosphine (20.3 mmol) in 85 ml dry dichloromethane was stirred at 0 C for 45 min. After addition of DEAD-reagent (22.9 mmol) at 0 C, the reaction mixture was further stirred at room temperature until completion, filtered through a celite pad, diluted with dichloromethane and extracted with 10 % aqueous NaHCO3/NaOH solution (1/1), 10 % aqueous citric acid solution and aqueous saturated brine solution. The organic layer was dried over Na2SO4 and concentrated. Final purification was achieved by silica gel chromatography. The typical yield for the product formation varied between 70 and 89 `)/0.
_ _ _ Standard Operating Procedure 27: Cleavage of the p-Methoxyphenyl ether The starting material (1.18 mmol) was dissolved in 30 ml acetonitrile and 7.5 ml water and cooled to 0 C. Subsequently, CAN (3.83 mmol) was added and stirring continued at CPC until completion. The reaction mixture was diluted with ethyl acetate and extracted with water. The aqueous layer was made alkaline by addition of solid NaHCO3 and back extracted with ethyl acetate.
The combined organic layers were extracted with saturated aqueous Na HCO3 solution and saturated brine solution, dried over MgSO4 and evaporated.
Final purification was achieved by silica gel chromatography. The typical yields for the product formation varied between 73 and 89 %.
Standard Operating Procedure 28: Cleavage of p-Methoxybenzyl ethers The starting material (0.60 mmol) was dissolved in 27 ml acetonitrile and 3.0 ml water and cooled to 0 C. Subsequently, CAN (4.5 equiv.) was added and stirring continued from 0 C to room temperature until completion. The reaction mixture was diluted with ethyl acetate and extracted with water. The aqueous layer was made alkaline by addition of solid NaHCO3 and back extracted with ethyl acetate. The combined organic layers were extracted with saturated aqueous NaHCO3 solution and saturated brine solution, dried over MgSO4 and evaporated. Final purification was achieved by silica gel chromatography.
The typical yields for the product formation varied between 73 and 85 %
Standard Operating Procedure 29: Formation of a 2,3-cyclic carbamate To a stirred solution of the starting material (3.56 mmol) in dichloromethane (100 ml) and 10% aqueous solution of NaHCO3 (75 ml) was added a solution of triphosgene (1.25 mmol) in 10 ml dry dichloromethane. The reaction was stirred at room temperature till completion. The organic phase was washed with water, dried over Na2SO4, filtered and concentrated. Final purification was achieved either by crystallization or silica gel chromatography. The typical yield for the product formation varied between 75 and 95 %.
Standard Operating Procedure 30: Cleavage of the N-phthaloyl group The N-phthaloylated starting material (45.9 mmol) was dissolved in n-butanol (200 ml) and treated with 1,2-diaminoethane (50 ml) at 100 C. After stirring at 100 C until completion, the reaction mixture was concentrated in vacuo, coevaporated with toluene three times and dried under high vacuum. Final purification was achieved by silica gel chromatography. The typical yield for the product formation varied between 78 and 92 A,.
Standard Operating Procedure 31: Introduction of a thiocresyl ether at the reducing end A solution of the 1-0-glycosyl acetate (10.48 mmol) and p-thiocresol (12.58 mmol) in dry dichloromethane (30m1) was stirred at CPC and subsequently activated by the addition of boron trifluoride diethylether complex (12.58mmol) over 5 min. Stirring was continued (0 C -4 20 C) until completion and the reaction stopped by the addition of triethyl amine (14.0 mmol). The reaction mixture was diluted with dichloromethane and extracted with saturated NaHCO3-solution, water and saturated brine solution, dried over MgSO4 and evaporated in vacuo. Final purification was achieved by crystallization or silica gel chromatography. The typical yield for the product formation varied between 81 and 92 %.
Standard Operating Procedure 32: Glycosylation with thioglycosides a) NIS-promoted glycosylation A mixture of glycosyl acceptor (1 mmol), thioglycoside (1 mmol) and 1.0 g of freshly activated molecular sieves in 20 ml of a dry solvent (e.g. CH3CN, CH2Cl2, Toluene, Ether) was stirred for 45 min at r.t and cooled down to the reaction temperature. Subsequently, N-lodosuccinimide (1.7 mmol) was added and stirring continued for 20 min at the reaction temperature. After the addition of a Lewis acid as promotor (e.g. TfOH, 85-170 pmol), stirring was continued at the reaction temperature until completion. The reaction mixture was quenched with triethyl amine, filtered through a celite pad and extracted with a 10 % aqueous KHCO3/Na2S203 solution, water and saturated brine solution, dried over MgSO4 and evaporated. Final purification was achieved by silica gel column chromatography. The typical yields for the product formation varied between 65 and 85 %.
b) DMTST promoted glycosylations:
A mixture of glycosyl acceptor (1 mmol), thioglycoside (1 mmol) and 1.0 g of freshly activated molecular sieves in 20 ml of a dry solvent (e.g. CH3CN, CH2Cl2, Toluene, Ether) was stirred for 45 min at r.t and cooled down to the reaction temperature. Stbsequently, DMTST (3-5 equiv.) was added and stirring continued at the reaction temperature until completion. The reaction mixture was quenched with triethyl amine, filtered through a celite pad and extracted with aqueous NaHCO3-solution, water and saturated brine solution, dried over Na2SO4, concentrated in vacuo and purified by silica gel column chromatography. The typical yields for the product formation varied between 50 and 85 %.
Standard Operating Procedure 33:
Glvcosvlations with trichloroacetimidates A suspension of the trichloroacetimidate (1.54 mmol), glycosyl acceptor (1.13 mmol) and freshly activated molecular sieves (1.0 g) in an anhydrous solvent (e.g. CH3CN, CH2Cl2, Toluene, Ether, 20 mL) was stirred at rt for 1 h and then cooled to reaction temperature. Subsequently, a catalytic amount of a promotor (e.g. TMSOTf, 0.01-0.1 equiv.) was added and stirring continued at reaction temperature until completion. The reaction was quenched with triethylamine) and filtered through a Celite pad. The combined organic layers were washed with aqueous NaHCO3-solution and saturated brine solution, dried over Na2SO4, concentrated in vacuo and purified by silica gel column chromatography. The typical yields for the product formation varied between 50 and 85 %.
Standard Operating Procedure 34:
Glycosylations using 2,3-cyclocarbamoyl protected pThiocresyl glycosides as glycosyl donors PhSCI (0.2 mmol, 2 equiv.) in dry dichloromethane (1 ml) was added dropwise to a mixture of Ag0Tf (0.2 mmol) in dry dichloromethane (2 ml) at ¨78 C
containing freshly activated molecular sieves 3 A. After stirring for 15 mins at ¨78 C, a solution of the thioglycoside (0.1 mmol, 1 equiv.) and DTBMP (0.2 mmol, 2 equiv.) in dry dichloromethane (2 ml) was slowly added. After further stirring for 15 mins at ¨78 C, the glycosyl acceptor (0.2 mmol, 2 equiv.) in dry dichloromethane (1 ml) was slowly added and stirring continued until completion. The reaction was quenched with saturated aqueous NaHCO3 solution (1 ml), warmed to rt and diluted with dichloromethane. The organic layer was dried over MgSO4, filtered and evaporated. Final purification was achieved by silica gel chromatography. The typical yields for the product formation varied between 60 and 90 %.
Standard Operating Procedure 35: Introduction of an Alloc-group A solution of starting material (2 mmol), dry pyridine (5 mmol) and dry THF (5 ml) was cooled to 0oC. Subsequently, Allylchloroformate (2.2 mmol) were added dropwise and stirring was continued until completion. The reaction mixture was diluted with dichloromethane and subsequently washed with 10 % aqueous citric acid solution, saturated NaHCO3 solution, water and saturated brine solution. The organic layer was dried over Na2SO4, filtered and evaporated. Final purification was achieved either by crystallization or by silica gel chromatography. The typical yields for the product formation varied between 80 and 95 %.
Standard Operating Procedure 36: Cleavage of an Alloc-group A mixture of the Allyloxycarbonate (1.17 mmol), dimedone (1.33 mmol) and Pd(Ph3P)4 (0.30 mmol) was dissolved in dry THF (60 ml) and stirred under Ar atmosphere until completion of the reaction. The reaction mixture was concentrated in vacuo and purified by silica gel chromatography. The typical yields for the product formation varied between 78 and 97 %.
Standard Operating Procedure 37: Lewis acid mediated benzylation To a stirred mixture of the starting material (1 mmol) and benzyl trichloroacetimidate in dry hexane/dichloromethane (10 ml, 2/1) was added Lewis acid (0.01-0.05 equiv., e.g. TMSOTf, Tf0H) and stirring was continued at rt until completion. The reaction was quenched with triethyl amine and concentrated. Final purification was achieved by silica gel chromatography.
The typical yields for the product formation varied between 50 and 92 %.
Standard Operating Procedure 38: benzylation under mild basic conditions The starting material (3.49 mmol) was dissolved in dry DMSO (20 ml) and cooled to 0 C. To the stirred solution were added successively benzyl bromide (3.5 equiv./OH-group), barium oxide (1.5 equiv/OH-group), catalytic amounts of TBAI ( 0.05 egiv./OH-group) and potassium hydroxide (3.5 equiv./ OH-group). Stirring was continued from O'C to rt until completion. The reaction was quenched with methanol, and further stirred for 30 min. After dilution with ether, the organic layer was washed with water and brine solution, dried over MgSO4 and concentrated in vacuo. Final purification was achieved by silica gel chromatography.
Standard Operating Procedure 39: Ester cleavage under aqueous conditions The starting material (0.3mmol ester groups) was dissolved in 11.8 ml of a mixture of water and THF (3:7), cooled to 0 C and reacted with 1M aqueous NaOH-solution (5.0 ml). Stirring was continued until completion and the reaction mixture titurated with 10 % aqueous HCI-solution to a pH of 9.5.
After evaporation of the THF, the mixture was freeze dried and the remaining residue purified by silica gel chromatography to yield the product. The typical yields for the product formation varied between 85 and 95 %.
Example 1: Synthesis of Building Blocks A-1 and A-2 from N-Acetyl Glucosamine H...Ø...\,........\,,,,,.
H2........\õ0,....\,,,,,,, a HO
b HO
HO
AcNH OH A-1-i AcNH OMe HO H.!...).HO
-0.- c HO H.St.....1...\.,,,,,,,, OMe d A-1-ii NH2 OMe DTPMHNA-1-iii R 110 (: -\,(==)El 0 ---).-e R *I HO
--s.-- f , R = H: A-1-iv-a DTPMHN OMe R = H: A-1-v-a H2N OMe R = Me0: A-1-iv-b R = Me0: A-1-v-b R HO
R
Bn0 R = H: A-1-vi-a N3OMe N3OMe R = Me0: A-1-vi-b h R = H: A-1-vi-a R = Me0: A-1-vii-b HC
i j 1 HBoz0 ,.....\4.... 0) HOEIn0 A-1-viii N3 OMe MHPO" 7 Bn0 Bn0 OMe OMe Example 1: Synthesis of building blocks A-1 and A-2 from N-Acetyl glucosamine, yields are reported for R=H, conditions; a) Amberlite IR 120 (ion exchange resin) (H+), Me0H, 60 C, (70 %); b) 1M NaOH, 120 C; c) 1.
SOP 10; 2. AP20, pyridine; 3. Na0Me, Me0H (70 %, 4 steps); d) SOP 1 (91 % for R=H) or SOP 2 for R = OMe; e) SOP 11, (95%); f) SOP 12, (85 %, 2 steps); g) SOP 7, (91%); h) SOP 4, (91 %); i) SOP 17, (82 %); j) SOP 5.
Preparation of A-14 N-Acetyl-2-deoxy-a/8-D-glucopyranoside (8.5 g, 38.4mmol) was suspended in 100 ml dry methanol. Subsequently, 12.0 g Amberlite IR 120 iron exchange resin (H-form) was added and the reaction mixture refluxed for 70 hrs at 65 C. After cooling to 25 C, the iron exchange resin was removed by filtration and several times extracted with methanol. The combined methanol layers were neitralized with triethyl amine and concentrated in vacuo. The crude residue was purified by crystallization to furnish the title compound in 70 %
yield (cdf3 -mixture).
Preparation of A-1-iii:
Methyl glycoside A-1-i (20.6 mmol) was suspended in 100 ml aqueous NaOH
solution (1 M) and stirred under reflux at 120 C until completion. After cooling and neutralization with 10 % aqueous HCI, the mixture was concentrated in vacuo and crude A-1-ii suspended in 200 ml methanol and reacted with N-[(1,3-dimethy1-2,4,6 (1H,3H,5H)-trioxopyrimidin-5-ylidene) methyl]-/V;N"-di me-thylamine (23.6 mmol) at 50 C (pH ¨ 9.0) until completion. After evaporation and drying, crude A-1-iii was reacted with 150 mL acetylation mixture (Pyridine/Ac20, 2/1, v/v) until completion, concentrated in vacuo, coeva-porated with toluene and dried. The residue was suspended in ethyl acetate and extracted with water, 10 % aqueous HCI, saturated, aqueous NaHCO3 solution and 1-h0, dried over Na2SO4 and concentrated. The crude residue was dissolved in dry methanol and reacted with a catalytic amount of Na0Me.
After completion, the reaction was neutralized with Amberlite IR 120 and filtered. The organic layer was evaporated and dried to furnish the title compound A-1-iii in 70 % yield (over 4 steps).
Preparation of A-1-iv-a:
Methyl-2-deoxy-2-441-(1,3-dimethy1-2,4,6(1H, 3H, 5H)-trioxopyrimidin-5-ylidene) methyl)-a-D-glucopyranoside A-1-iii (16.0 g, 44.5mmol) in acetonitrile (200m1) was reacted with benzaldehyde dimethyl acetal (14.0 ml, 92.3 mmol) and a catalytic amount of p-toluenesulphonic acid monohydrate. After 2 hours at 55 C, the mixture was neutralized and evaporated. The remaining residue was extracted, washed and evaporated. Yield: 18.3 g (92 %), Rf = 0.20 (1,2-dichloroethane/ ethylacetate = 7/3).
Preparation of A-i-v-a:
Methyl-4,6-0-benzylidene-2-deoxy-2-N41-(1,3-dimethyl-2,4,6(1H, 3H, 5H)-trioxopyrimidin-5-ylidene) methyl]-a-D-glucopyranoside A-1 -iv-a (18.30 g, 40.90 mmol) in DMF (50m1) was reacted with ethylenediamine (20m1) at room temperature. After stirring for 35 minutes, the mixture was concentrated.
Yield:
10.90 g (94.7 %), Rf = 0.18 (chloroform/methanol = 9/1).
Preparation of A-1-vi-a:
To a solution of methy1-2-amino-4,6-0-benzylidene-2-deoxy-a-D-glucopyra-noside (7.5 g, 26.7 mmol) and 4-N,NL(dimethylamino)pyridine (14.5g) in acetonitrile (100mL) was added TfN3-solution (85m1) at room temperature.
The reaction mixture was concentrated and the residue was purified by filtration through a short silica gel pad. Yield: 7100 g (85.3 %), Rf = 0.18 (chloroform/ methanol = 9/1).
Preparation of A-1-vii-a:
Methyl 2-azido-2-deoxy-4,6-benzylidene-a-D-glucopyranoside A-1 -vi-a (10.87g, 35.40 mmol) in N,Ar-dimethylformamide (50mL) was reacted with NaH (95 %, 0.92g, 36.4 mmol) and benzyl bromide (5.47 ml, 45.9 mmol). After completion, the excess of NaH was quenched, followed by concentration. The residue was extracted, washed and concentrated. Yield: 12.93 g (92.0 %), Rf = 0.37 (petroleum spirit/ethyl acetate = 3/1).
Preparation of A-1:
Methyl-2-azido-3-0-benzy1-2-deoxy-a-D-glucopyranoside (9.87g, 31.9 mmol) in dichloromethane (50 mL) and pyridine (10 mL) was treated with benzoyl chloride (3.72mL, 32.04 mmol) at - 45 C for 2 hours. The reaction was concentrated and the residue extracted, washed and evaporated. Yield: 10.78 g (81.7 cY0), Rf = 0.31 (petroleum spirit/ ethylacetate = 1/1).
Compound A-1:
1H-NMR (400 MHz, CDCI3): 5= 8.03 (d, 2 H, Aryl), 7.57 (m, 1H, Aryl), 7.45-7.29 (m, 7H, Aryl), 4.93 (d, 1H, em=J 10.8 Hz, OCH2), 4.82 (d, 1H, Jgem =
10.8 Hz, OCH2), 4.81 ( d, 1H, J1,2 = 3.6 Hz, H-1a), 4.73 (dd, 1H, J5,6a = 4.4 Hz, Jgem = 12.0 Hz, H-6a), 4.47 (dd, 1H, J5,6b = 2.0 Hz, H-6b), 3.85 ( dd, 1H, J3,4 = 8.8 Hz, H-3), 3.57 ( ddd, 1H, J. = 10.0 Hz, H-4), 3.45 (s, 3H, OMe), 3.37 ( dd, 1H, J2,3 = 10.0 Hz, H-2), 2.80 (bs, 1H, 4-0H).
_ _ Example 2: Synthesis of Buildinp Blocks A-3 and A-4 R* HO a wR = H: A-1-iv-a DTPMHN
OMe R R = H: A-1-ix-a Bn0 DTPMHN OMe R = Me0: A-1-iv-b y R = Me0: A-1-ix-b HoH Bn0 0 Mpm.C.20µ
7 DTPMHN OMe HO Bn0=
..........._ x 0 A-1-x A-4 OMe I
OMe Example 2: Synthesis of building block A-3 and A-4, conditions: a) SOP 7, (72 % for R = H); b) SOP 4, (82 %); c) SOP 17, (84 %); d) SOP 5.
Compound A-3:
1H-NMR (400 MHz, CDCb): 3 = 10.16 (dd, 1 H, JNH,2 = 9.4 Hz, J NH, =OH = 14.0 Hz, NH), 8.11 (d, 1H, =C-H), 7.68-7.22 (3m, 8H, Aryl), 4.84 ( d, 1H, J1,2 =
3.5 Hz, H-1a), 4.83 (dd, 1H, .la ¨da, 6b = 12.3 Hz, J5,6a = 3.5 Hz, I46a), 4.73 (d, 1H, Jgem = 11.7 Hz, OCH2), 4.46 (dd, 1H, J5,6b = 2.1 Hz, H-6b), 3.91 (m, 1H, H-5), 3.72 (dd, 1H, J3,4 7--- J2,3 = 8.8 Hz, H-3), 3.57 (ddd, 1H, J4,5 = 9.5 Hz, H-4), 3.48 (s, 3H, OMe), 3.38 (ddd, 1H, J2,3= 10.5 Hz, H-2), 3.32 (s, 3H, NMe), 3.31 (s, 3H, NMe), 3.05 (bs, 1H, 4-0H).
¨ ¨
Example 3: Synthesis of L-ido configured plycosyl donor B-1 ..-- HO ¨
(!)-1) H --0... 0 r 0138 HO¨ OBn ...-0.>
r 0 a 0 b r 1 c 0 --0- 0 .. .,.- --0C
oil.... --I-BA -i .." B-1-ii .., "
B-1-11 i Ac Mes0 HO-1 c:
OAc M es OBn OBn ..--0 d 0 e f 0 /....., --00"
B-1 -iv B-1 -v B-1-vi 0/
OBn Ac0 OBn HO OBn (...1-....TSCres -F...... ? -0 SCres .-0 SCres g h ----Ow-B-1-vii ---10- B-1 -vi ii ¨IP.- 0 B-1 -ix OH
Ac0 OAc OH OH Me2C
HO oBOBnmp0 Bn SC res ..,....4- ....
0 ' 0 SC res '0 SCres k I
0 (3-1-7( ¨11"- B-1 -xi 0 0 Bz OH OBz OH OBz Me2C
m p0 can /F1....7-- -0 SCres OLev OBz Example 3: Synthesis of Building Block B-1, conditions: a) SOP 7, (95%); b) 60% aqueous Acetic acid, 60 C (90%); c) Methanesulfonyl chloride, Pyridine, 0 C-RT (87 %); d) Cesium Acetate, Ac20, 120 C (95%); e) SOP 22, (92%); f) 1. 90% TFA, 0 C; 2. Ac20, Pyridine; 3. SOP 31, (73%, 3 steps); g) SOP 22, (98%); h) SOP 3, (92%); i) SOP 18, (98%); j) 80% acetic acid, 100 C (98%);
k) SOP 26, (89%); I) SOP 23, (98%).
_ Preparation of B-1-iii:
B-1-ii (15.60 mmol) was dissolved in 60 % aqueous acetic acid (50 ml) and stirred at 60 C until completion. After neutralization with solid NaHCO3, the mixture was evaporated and co evaporated with toluene. Crude B-1-iii was dissolved in CHCI3/H20, the organic layer separated, dried over Na2SO4 and evaporated. The remaining residue was purified by a short silica gel chroma-tography to yield B-1-iii in 90 % (4.36 g).
Preparation of B-1-iv:
17.72 mmol of B-1-iii was dissolved in 25 ml dry pyridine, to which mesyl chloride (methylsulfonyl chloride, 42.5 mmol) was added dropwise at 0 C. The mixture was stirred at 4 C until completion and was subsequently poured into warm water (50 C, 90 ml), cooled and the precipitate isolated by filtration.
B-1-iv was obtained after drying in 87 % yield (7.19 g).
Preparation of B-1-v:
B-1-iv (6.43 mmol) and cesium acetate (64.3 mmol) were suspended in 25 ml acetic anhydride and refluxed at 125 C until completion. The reaction mixture was concentrated in vacuo, co evaporated with toluene and the residue extracted from ethyl acetate/H20 (1/1). The organic layer was collected and washed with saturated aqueous NaHCO3 solution and saturated brine solution, dried over Na2SO4 and evaporated. Purification was achieved by silica gel chromatography. Yield: 2.68 g (95 %).
Preparation of B-1-vii:
B-1-vi (5.61 mmol) was dissolved in aqueous TFA (90 %, 15 ml) and further stirred at 0 C until completion. The reaction mixture was neutralized with aqueous NaOH solution at 0 C, concentrated in vacuo and dried. The residue was suspended in 90 ml acetylation mixture (pyridine/acetic anhydride = 2/1) and 50 ml dichloromethane at 0 C and further stirred until completion. After concentration in vacuo and co evaporation with toluene, the residue was dissolved in ethyl acetate/H20 (1/1), the organic layer collected and washed ¨ -with 10 13/0 aqueous citric acid solution, saturated aqueous NaHCO3 solution and brine solution, dried over Na2SO4 and evaporated. The crude residue and p-thiocresol (6.0 mmol) were dissolved in 40 ml anhydrous dichloromethane and cooled to 0 C, reacted with BF3x0Et2 (8.41 mmol) and further stirred at rt until completion. The reaction was stopped with saturated NaHCO3 solution and the organic layer was washed with water, dried over Na2SO4 and evaporated. Final purification was achieved by silica gel chromatography to yield B-1-vii in 73% over 3 steps.
Preparation of B-1-xi:
B-1-x (8.0 mmol) was dissolved in 80 % aqueous AcOH and heated at 100 C
until completion. The mixture was cooled to rt, neutralized with solid NaHCO3 and dissolved in ethyl acetate/water (1/1). After removal of the aqueous layer, the organic layer was dried over MgSO4 and evaporated to dryness furnishing B-1-xi in 98 A yield.
Compound B-1:
1H-NMR (400 MHz, CDCI3): 8 = 8.07 (d, 2H, Aryl), 7.57-7.30 (m, 10H, Aryl), 7.10 (d, 2 H, Aryl), 6.88-6.81 (m, 4H, Mp), 5.55 (d, 1H, 42 < 1.5 Hz,H-10), 5.45 (m, 1H, H-2), 5.26 (ddd, 1H, H-5), 5.13 (m, 111, H-4), 4.91 (d, 1H, Jgem =
12.1 Hz, OCH2), 4.78 (d, 1H, Jgem = 12.1 Hz, 0CH2), 4.16 (dd, 1H, Jgem = 9.6 Hz, J5,6. = 7.6 Hz, H-6a), 4.08 (dd, 1H, J5,6b = 5.2 Hz, H-6b), 3.93 (m, 11-I, H-3), 3.77 (s, 3H, OCH3), 2.58-2.36 (m, 4H, (CH)2 Lev), 2.32 (s, 3H, SCH3), 2.05 (s, 3H, CH3C=0).
Example 4: Synthesis of L-ido configured glvcosvl donor B-2.
HO OBn OBn OBn 1-.L1......1" -0 SCres SCres -=
SCres HO OH B-1-viii ¨v.- o 8-2-i ¨pm. a b 0 OBz c OMe OMe ompm QBn MPm OBn '0 SCres -- SCres 8-2-iii d OH OBz Lev OBz Example 4: Synthesis of L-ido configured glycosyl donor B-2; a) SOP 2; b) SOP 18; c) SOP 5; d) SOP 23.
Example 5: Synthesis of Building Block C-1, C-la and C-lb \,...0Mpm 0*".....µisf... g meo 01 Bz R ¨31il- 13.z."-C-3\-=""R
C-la-iii: R=SMe N3 f / C-lb-iii: R=SCres C-la: R=SMe C-1b: R=SCres lb 0---..\.f...\....
Me = HO
R
C-la-ii: R=SMe N3 C-lb-ii: R=SCres e4 OH
OAc HO a Ac 0 VI--=,. ...\---0 R ---)..-Ac0 R
1.2.-0...
C-1-1-a: R=SMe C-1-ii-a: R=SMe C-1-i-b: R=SCres C-1-ii-b: R=SCres ...4:1A .....\_,c .
OAc Ac0 Ac OH --Ow- Ac c Ac0 0 OTBDPS --O.- d C-1-iii N3 C-1-iv .....H.,\........\õ, HO 0 e ¨AP-f N3 Me0 HO4. OTBDPS --40"-C-1-v C-1-vi OM pm g Me * Bz0 OTBDPS-4.1" Bz0 OTBDPS
C-1-vii N3 _ -Example 5: Synthesis of Building Blocks C-I, C-la and C-1 b, conditions: a) SOP 19; b) SOP 13, (78 %, 2 steps); c) SOP 8, (91 A)); d) SOP 22; e) SOP 2, (85%, 2 steps for C-1 -vi); f) SOP 18; g) SOP 5, (75 %, 2 steps for C-1).
Preparation of C-1-iia:
To methyl 2-azido-2-deoxy-1-thio-13-o--glucopyranoside. (10g, 42.50 mmol) in pyridine (50m1) at ODC was added acetic anhydride (20g) and the reaction stirred for 1 hour. The reaction mixture was evaporated to dryness and the residue extracted to give the title triacetate (15.23g, quantitative,), Rf=0.7 (CHCI3/Petroleum ethers, 1 :1).
Preparation of C-1 -iii:
To a solution of methyl 3,4,6-tri-O-acety1-2-azido-2-deoxy-1-thio-O-D-glucopyranoside (14.1g, 39 mmol) in wet acetone (200m1) was added NBS (3 equiv.). The resulting mixture was allowed b stir for 2h. The mixture was then quenched, concentrated and the residue purified by silica gel chromatography to give the title hemiacetal as an oil (10.1g, 78%), f = 0.5 (Et0Ac/Petroleum ether, 1:1).
Preparation of C-1-vi:
A mixture of 2-azido-2-deoxy-13-o-glucopyranosyl tert-butyldiphenylsilane (5.5g,12.42 mmol), 4-methoxybenzaldehyde dimethylacetal (4.4g, 24mmol), and 4-toluenesulphonic acid (100mg ) in acetonitrile/DMF (200m1, 5:3) were heated at 60 C for 1 hour. The reaction mixture was then neutralized and evaporated to give the crude compound as an oil. The residue was purified by silica chromatography to give the product (6.7g, 96%, 85% from C-1-iv); Rf =
0.8 (dichloromethane/Petroleum ethers; 10:2).
Preparation of C-1 -vii:
A mixture of DMAP (1.63g, 13.2 mmol) and benzoyl chloride (1.7g, 12.1mmol) and 2-azido-2.deoxy-4,6-0-(4-methoxybenzylidene)-13-D-glucopyranosyl tett-butyldiphenylsilane (6.7g, 11.9 mmol) in 1,2 -dichloroethane (100mL) was stirred at 60 C for 1h. The reaction mixture was quenched, extracted, washed and concentrated to give a crude residue. The residue was passed through a plug of silica to give the product (5.5g, 69%); Rf = 0.7 (dichloromethane/Petroleum ethers; 4:1).
Preparation of C-1:
To a mixture of 2-azido-2-deoxy-3-0-benzoy1-4,6-0-(4-methoxybenzylidene)-p-o-glucopyranosyl tert-butyldiphenylsilane (10g, 15mmol), sodiumcyanoborohydride (5g, 75.6 mmol) and molecular sieves in DMF
(200mL) at 0 C was added trifluoroacetic acid (28g, 247mmo1) at 0 C and then left to run overnight at rt. The reaction mixture was quenched, filtered and concentrated and the residue purified by column chromatography to give the title compound (7.0g, 70%), Rf = 0.4 (ethylacetate/petroleum ethers, 3:7).
Compound C-1:
1H-NMR (400 MHz, CDC13):8 = 8.08 (d, 2 H, Aryl), 7.72 (m, 4 H, Aryl), 7.59 (m, 1 H, Aryl), 7.47 (m, 3 H, Aryl), 7.42 (m, 2 H, Aryl), 7.34 (m, 3 H, Aryl), 7.13 (d, 2 H, Mpm) 6.83 (d, 2H, Mpm), 4.96 (dd, 1 H, J2,3 J3,4 = 9.7 Hz, H-3), 4.53 (d, 1 H, J1,2 = 7.6 Hz, H-113), 4.37 (2d, 2 H, OCH2), 3.83 (ddd, 1 H, H-4), 3.79 (s, 3 H, OCH3), 3.65 (dd, 1 H, H-2), 3.53 (dd, 1 H, Jgem = 10.8 Hz, J5,6a = 4.1 Hz, 6a), 3,46 (dd, 1 H, J5,6b = 4.1 Hz, H-6b), 3.12 (m, 1 H, 11-5), 3.02 (d, 1 H, 11,0H
= 3.5 Hz, 4-0H), 1.12 (s, 9 H, C(CH3)3).
Example 6: Synthesis of Building Block C-2 e0H
HO a 0 C-1-1-a: R=SMe C-2-1-a: R=SMe C-1-i-b: R=SCres C-2-I-b: R=SCres OH
0 c Bz0 R
C-2-ii-a: R=SMe C-2-iii-a: R=SMe C-2-ii-b: R=SCres C-2-iii-b: R=SCres r0Bz r0Bz 4:1 HO e HO f HO Bz OTBDPS
N3 C-2- v N3 C-2 N3 C-2-iv-a: R=SMe C-2-iv-b: R=SCres Example 6: Synthesis of Building Block C-2, conditions: a) SOP 1, (90% for R=SMe); b) SOP 18, (87% for R=SMe); c) SOP 4, p-Tos0H, Me0H, CH3CN
(86% for R=SMe); d) SOP 17, (92% for R=SMe); e) SOP 13, (94%); f) SOP
8, (82%).
Compound C-2:
1H-NMR (400 MHz, CDCI3): 8=8.09 (d, 2 H, Aryl), 7.97 (d, 2 H, Aryl), 7.72 (m, 4 H, Aryl), 7.60 (m, 1 H, Aryl), 7.50-7.27 (m, 11 H, Aryl), 4.98 (dd, 1 H, J2,3 J3,4 = 9.7 Hz, H-3), 4.58 (d, 1 H, J1,2 = 7.8 Hz, H13), 4.51 (dd, 1 H, Jge, =
11.3 Hz, J5,6a = 4.7 Hz, H-6a), 4.36 (dd, 1 H, J5,6b = 2.2 Hz, H-6b), 3.72-3.68 (m, H, H-2, H-4), 3.31 (m, 1 H, H-5), 3.23 (d, 1 H, J4,01-1= 4.5 Hz, 4-0H), 1.13 (s, 9 H, C(CH3)3).
Example 7: Synthesis of several carbamoylated Building Blocks C-3a to C-3d and C-4a to C-4d, containing a 6-0 benzoyl or 6-0-p-methoxybenzyl protection HO HO 0 R1 a b Pht R R = H, Me0 C-3-ii NPht c HO R 1 0 110, R = H, Me0C-3-iii NH2 0 R1 R = H
C-3-iv R = Me0 HO 0 f OBz u C-3-v HO (0M:m HO
H
C-4a: R1=SCres C-3a: R1= SCres C-4b: R1 = SEt C-3b: R1= SEt C-4c: R1= OTBDPS
C-3c: R1= OTBDPS C-4d: R1 = SMe C-3d: R/ = SMe Example 7: Synthesis of several carbamoylated building blocks C-3a to C-3d and C-4a to C-4d, containing a 6-0-benzoyl or 6-0-p-methoxybenzyl protection, conditions: a) R = Me0: SOP 2; R = H: SOP 1, (82 %, R1 = SCres, R = H); b) SOP 30, (87 %, R1= SCres, R = H); c) SOP 29, (95 %, R1 = Scres, R = H); d) SOP 4, (72 %, R1 = SCres); e) SOP 17, (85 %); f) SOP 5.
Compound C-3a:
1H-NMR (400 MHz, CDCI3): 6 = 8.06 (d, 2 H, Aryl), 7.62 (m, 1 H, Aryl), 7.48 (t, 2 H, Aryl), 7.38 (d, 2 H, Aryl), 6.97 (d, 2 H, Aryl), 5.06 (bs, 1H, NH), 4.79 (dd, 1H, sigem = 12.0 Hz, J5,6a= 3.6 Hz, H-6a), 4.70 (d, 1H, J1,2 = 9.2 Hz, H-1f3), 4.63 (dd, 1H, J5,6b = 2.0 Hz, H-6b), 4.18 (dd, 1H, .32,3 ==1 J3,4 = 10.4 Hz, 143), 3.89 (dd, 1H, J4,5 = 9.2 Hz, H-4), 3.72 (m, 1H, H-5), 3.23 (ddd, 1H, H-2), 3.12 (bs, 1H, 4-0H), 2.29 (s, 3H, SCH3).
Example 8: Synthesis of several 6-0Mp and cyclic 2,3-carbamoyl protected building blocks C-5a to C-5c PVO a HO R1 --41" Bz0 R1 ¨Ow' C-3-ii NPht C-5-i Pht 1-1( MpO
HO Bz0 0 HO Bz0 R d PhtPht C-5-iii MpO
OMp NHz 0 C-5a: R1 = SMe C-5b: R1 = SEt C-5c: R1 = OTBDPS
Example 8: Synthesis of several 6-0Mp and cyclic 2,3-carbamoyl protected building blocks C-5a to C-5c, conditions: a) SOP 18, (92 % for R1 =
OTBDPS); b) SOP 4, (82 %); c) SOP 26, (75 % for R1 = OTBDPS); d) SOP
30, (87 %); e) SOP 29, (95 %).
Compound C-5c:
1H-NMR (400 MHz, CDCI3): c = 7.69 (m, 2 H, Aryl), 7.63 (m, 2H, Aryl), 7.46-7.31 (m, 6H, Aryl), 6.82 (bs, 4H, Mp), 5.04 ( bs, 1H, NH), 4.78 (d, 1H, J12 =
7.6 Hz, H-113), 4.15-4.10 (m, 3H, H's not assigned), 3.97 (dd, 1H, J =11.6 Hz, J = 9.6 Hz, H not assigned), 3.78 (s, 3H, OMe), 3.56 (m, 1H, H not assigned), 3.48 (m, 1H, H not assigned), 2.80 (bs, 1H, 4-0H), 1.08 (s, 9H, C-(CH3)3).
Example 9: Synthesis of Building Blocks C-6-a and C-6-b and C-7 Me0 H0 Me* * H0 R
C-3-iii-a: R=SCres C-6-i-a: R=SCres C-3-iii-f: R=SMe C-6-i-b: R=SMe Me c HO d Mpm0 R Mpm0 R
C-6-ii-a: R=SCres C-6-a: R=SCres C-6-ii-b: R=SMe C-6-b: R=SMe OM pm OMpm Mpr7;,¨,- OH Mp m0 OTB D PS
Example 9: Synthesis of building blocks C-6-a, C-6-b and C-7, conditions; a) SOP 12, (83 %); b) SOP 7; c) SOP 5, (75 %, 2steps); d) SOP 14 ( 82 %); e) SOP 8 (91 M.
Compound C-6-a:
1H-NMR (400 MHz, CDCI3): 8 = 7.43 (d, 2 H, Aryl), 7.25 (m, 4 H, Aryl), 7.08 (d, 2 H, Aryl), 6.88 (m, 4 H, Aryl), 4.81 (d, 1 H, Jgem = 10.8 Hz, OCH2), 4.74 (d, H, Jgem = 10.8 Hz, 0C142), 4.53 (d, 1 H, Jgem = 11.1 Hz, OCH2), 4.48 (d, 1 H, Jgem = 10.8 Hz, OCH2), 4.35 (d, 1 H, J1,2 ='= 10.0 Hz, H-1[3), 3.82 (s, 3 H, OCH3), 3.79 (s, 3 H, OCH3), 3.76 (dd, 1 H, Jgem = 10.5 Hz, J5,6a = 5.4 Hz, H-6a), 3.70 (dd, 1 H, J6,6b = 5.4 Hz, H-6b), 3.56 (ddd, 1 H, H-4), 3.42 (m, 1 H, H-5), 3.34 (dd, 1 H, J3,4 = 8.8 Hz, H-3), 3.24 (dd, 1 H, J2,3 = 9.4 Hz, H-2), 2.72 (d, 1 H, J4,01-1= 3.5 Hz, 4-0H), 2.38 (s, 3 H, SCH3).
Compound C-7:
1H-NMR (400 MHz, CDCI3): 7.63 (d, 4 H, Aryl), 7.35-7.21 (m, 8H, Aryl), 7.08 (m, 2 H, Aryl), 6.83-6.78 (m, 4 H, Aryl), 4.72 (d, 1H, Jgem = 11.0 Hz, OCH2), 4.59 (d, 1H, Jgem = 11.0 Hz, OCH2), 4.29 (d, 1 H, J1,2 = 7.8 Hz, H-1 i3), 4.27 (d, 1H, Jgem = 11.7 Hz, OCH2), 4.21 (d, 1H, Jgem = 11.7 Hz, OCH2), 3.72 (s, 3 H, OCH3), 3.71 (s, 3 H, OCH3), 3.51 (ddd, 1 H, J3,4 J4,6 = 8.6 Hz, H-4), 3.40-_ 3.32 (m, 3 H, H-6a, H-6b, 1-1-2), 3.05 (dd, 1 H, J2,3 = 9.8 Hz, 1-1-3), 2.90 (m, 1 H, H-5), 2.51 (d, 1 H, J4,01-1= 2.2 Hz, 4-0H), 1.12 (s, 9 H, C(CH3)3)=
Example 10: Synthesis of building block C-8a to C-8c HO R
a b C-3-ii-c Pht C-8-i NPht OH
c H
R
mmomillIMP.-d C-8-ii NPht c_g_iii NPht .... it..,4.M,,% ......3 .4....\...V1p --lb- A110 e C-8-iv H2 C-8a R = SMe C-8b R = SEt C-8c R = OTBDPS
Example 10: Synthesis of building blocks C-8a to C-8c, conditions: a) SOP 7, AllBr, DMF (65 %, R=OTBDPS); b) SOP 4, (86 %, R=OTBDPS); c) SOP 26, (70 %, R=OTBDPS); d) SOP-30; e) SOP 12, (70 %, 2 steps for R=OTBDPS).
Compound C-8c:
1H-NMR (400 MHz, CDCI3): 6 = 7.72 (m, 4 H, Aryl), 7.43-7.16 (m, 6 H, Aryl), 6.76 (m, 4H, Mp), 5.96 (m, 1 H, =CH Allyl), 5.31 (m, 1 H, =CH Allyl), 5.22 (m, 1 H, =CH Allyl), 4.42 (d, 1 H, J1,2 = 7.6 Hz, H-10), 4.39 (m, 1 H, OCH2 Allyl), 4.23 (m, 1 H, OCH2 Ally!), 3.97 (dd, 1 H, Jgem = 10.0 Hz, J5,6a = 3.6 Hz, I-1-6a), 3.92 (dd, 1 H, J5,6b = 5.2 Hz, H-6b), 3.77 (s, 3 H, OCH3), 3.66 (ddd, 1 H, J4,5 --J3,4 = 9.4 Hz, H-4), 3.42 ( dd, 1 H, J = 9.8 Hz and J = 7.8 Hz, H not assigned), 3.22 (m, 1 H, H-5), 3.09 (dd, 1 H, J = 8.4 Hz and J = 9.6 Hz, H not assigned), 2.48 (d, 1 H, J4,0H= 2.8 Hz, 4-0H), 1.12 (s, 9 H, C(CH3)3).
Example 11: Synthesis of Building Block D-1:
OH
OH SM a HO D-1-i OH be Bn SMe Bn0 OBn OH
Bn0 OBn OTBDPS e HO r Bn0 D-1-v OBn OTBDPS
HO Bn0 DA OBn0 OTBDPS
Example 11: Synthesis of building block D-1; a) SOP 1, (95 %); b) SOP 7, (85 %); c) SOP 13, (92 %); d) SOP 8; e) SOP 4, (70 %, 2 steps); f) 1. SOP 15; 2.
SOP 16, (75 %, 2 steps).
Compound D-1:
1H-NMR (400 MHz, CDCI3): 8 = 7.72 (m, 4 H, Aryl), 7.41 (m, 2 H, Aryl), 7.32 ¨
7.25 (m, 14 H, Aryl), 5.04 (d, 1 H, Jgern = 11.0 Hz, OCH2), 4.81 (m, 3 H, OCH2), 4.63 (d, 1 H, J1,2 = 7.4 Hz, H-10), 3.88 (ddd, 1 H, J3,4:=-= J4,5= 9.2 Hz, H-4), 3.70 (s, 3 H, OCH3), 3.53 (dd, 1H, J = 7.5 Hz, J = 9.0 Hz, H not assigned), 3.47 (d, 1 H, J4,5 = 9.8 Hz, H-5), 3.42 (dd, 1 H, J = 8.9 Hz and J = 8.9 Hz, H
not assigned), 2.87 (d, 1 H, 14,0H = 2.4 Hz, 4-0H), 1.11 (s, 91-1, C(CH3)3).
Example 12: Synthesis of Building Block 0-2, a 2-0-Allyloxycarbonyl protected thioethyl glycoside OAc Ac0.-; 0 a Ph.....4:20,.......\0 0 b AcC ¨IP' ---10.-HO ,..---0-2-i 0-2-ii OTrit PhC... j..............
0 0 c Lev0 0 d Bn0 ----- ¨V.--0.-Bn0 ----D-2-iii D-2-iv .... 0::...,%Vle ...._0...:\::.....
Lev 0 e Lev0 0 Bn0 ----- ¨III' Bn0 SEt D --2v D.2 0Alloc Example 12: Synthesis of Building Block 0-2, conditions: a) 1. SOP 22; 2.
SOP 1; b) SOP 7; c) 1. SOP 4; 2. TritCI, Pyridine, (CICH2)2; 3. SOP 23; d) 1.
Cr03, H2SO4, Acetone, 0 C, 2. SOP 16; e) 1. Dimethyl dioxirane , Acetone; 2.
EtSH, TFAA, CH2Cl2, 3. SOP 35.
Example 13: Synthesis of Bui'dim] Block D-3 _ c0Bz a Bz0 0 ¨ b --Ow- BnC-4.....\....-OBz 4111.' 0 OBz B41i CI -....,, 0-3-1 _. OH
_cOiliz 0 c Bz0 HO 0 d Bn-OOTBDPS
Bn0 OTBDPS --P.-OBz Bz0 3-iii .....11.1...
OMe HO 0 a Lev 0 f Bn0 OTBDPS ¨10-Bn0 OTBDPS --IN.
Bz0 0.3-v Bz0 D-3-iv 0 Me OMe Lev0-) .., OH ¨" Lev0-21 ---09 Bn0 ON
Bn0 D-3-vi Bz0 03 Bz0 Example 13: Synthesis of Building Block D-3, conditions: a) 1. SOP 4, Amberlite IR 120, H20, 80 C; 2. SOP 18, (85 %, 2 steps) b) 1. SOP 21; 2.
SOP 8, ( 70 %, 2 steps); c) SOP 22, (96 %); d) 1. SOP 15; 2. SOP 16, (80 %, 2 steps); e) SOP 23, (92 %); f) SOP 9, (95 /0); g) SOP 25a, (91 /0).
Preparation of D-3-i, step 1:
The starting material (57 mmol) and Amberlite IR 120 iron exchange resin (H+-form, 20 g) were suspended in water (180 ml) and stirred at 80 C until completion. The iron exchange resin Inas removed by filtration and extracted with water The combined aqueous layers were neutralized with triethyl amine and freeze dried.
Compound D-3-v:
¨ ---1H-NMR (400 MHz, CDCI3): 8 = 7.95 (m, 2 H, Aryl), 7.68 (m, 2 H, Aryl), 7.58 ¨
7.12 (m, 16 H, Aryl), 5.47 (dd, J1,2= 7.6 Hz, J2,3 = 9.6 Hz, H-2), 5.31 (dd, J3,4=
9.6 Hz, H-4), 4.64 (d, 1H, 7.6 Hz, H-1(3), 4.60 (d, 1H, Jgem = 12.0 Hz, OCH2), 4.55 (d, 1H, Jgem = 12.0 Hz, OCH2), 3.74 (dd, 1H, 1-1-3), 3.70 (s, 3H, OCH3), 3.63 (d, 1H, J4,5 = 9.6 Hz, H-5), 2.68¨ 2.16 (m, 4H, (CH2)2-Ley), 2.15 (s, 3H, CH3), 0.96 (s, 9H, C(CH3)3).
Example 14: Syntheses of a range of block D donor soars D-4 to D-7 from a common intermediate, a 4-0-leyulinoyl cilucal.
....
Lev 0 .....e...._ Bn0 R SAr Lev0 Bn0 D-6b: R=ClAc0 D-6a: R=Alloc0 D-4 Moo \ ... (.....mi/
OMe Lev 0 Lev Bn0 0 (S=0)Ar Bn0 ..---ClAc0 D-2-v D-7 \ b .........31N ....fie Lev0 0 Bn0 0(CH2)3CH=CH2 0Alloc Example 14: Syntheses of D-4 to D-7 as donor sugars, conditions: a) 1.
Dimethyl dioxirane, Acetone; 2. TBAF, THE; 3. SOP 35; b) 1. Dimethyl dioxirane, Acetone; 2. 4-penten-1-ol, ZnC12, CH2Cl2; 3. SOP 35; c) 1. Dimethyl dioxirane, Acetone; 2. ArSH, TFAA, CH2Cl2, (Ar = Ph, p-Tol); 3. SOP 35 or (ClAc)20, Pyridine, CH2Cl2 (for D-6b); d) MCPBA, CH2Cl2 (for D-6b as substrate).
_ INTENTIONALLY LEFT BLANK
Example 15: Synthesis of Building Block E-1 to E-4 OTBDPS
BO------q Bn0 E.4 N3 e OH
OTBDPS
OTBDPS
HOH
b Bneno 0 73&\,......\...R
R 2-41.1" 1-1 H0 R
C-1-i-a: R=SMe E-1-i-a: R=SMe E-1-ii-a: R=SMe C-1-i-b: R=SCres E-1-i-b: R=SCres E-1-ii-b: R=SCres .....,&µ: .7, ....\....4H
......&.t µ..)E .....\...3z C Bn0 d Bn0 0 ---11.--Bn0 R --1.- Bn0 R
E-1-iii-a: R=SMe N3 E-1-iv-a: R=SMe N3 E-1-iii-b: R=SCres E-1-iv-b: R=SCres ........:01 ....\,...V1p yOMpm B ni2;
OBz Bn0 R
Bn0 R
Bn0 N3 Br;C.1) E-1-v-a: R=SMe E-1-vi-a: R=SMe E-1-v-b: R=SCres E-1-vi-b: R=SCres OTCA
e 1 omp h OMpm Bn0 0 Bng&.,.\...,%
Bri¨C..) OTCA
OTCA
Example 15: Synthesis of Building Block E-1 to E-4, conditions: a) SOP 8; b) SOP 7; c) SOP 9, (84% over 3 steps, R=SMe); d) SOP 18, (82%, R=SMe); e) 1. SOP 13, (75%, for E-1-iv-a as starting material); 2. SOP 25b, (88%); f) 1.
TosCI, Pyridine; 2. p-Me0-C6F14-0Na, NMP, 60 C; g) SOP 7, (78 %, R=SMe);
h) 1. SOP 14; 2. SOP 25b, (79 %, 2 steps, R=SMe).
Preparation of E-1-i-a:
_ _ A mixture of methyl 2-azido-2-deoxy-thio-O-D-glucopyranoside (10g, 42.5mmol) and imidazole (4.9 g, 71.25 mmol) in 20 mL DMF was treated with tert-butyldiphenylchlorosilane (11.6mL, 44.63mmol) for 2h. The reaction mixture was concentrated, extracted, washed and dried. yield: 23g (crude light yellow syrup), Rf = 0.74 (CHCI3/methanol = 9/1).
Preparation of E-1-ii-a:
The silyl ether from the previous step in 50 mL DMF, was treated with 2.68g of 95% NaH (106.25 mmol) and 12.64 mL (106.25 mmol) of benzyl bromide at 0 C. After 1h the excess NaH was quenched and the reaction concentrated, extracted, washed and concentrated to afford a yellow syrup yield: 28.5g (crude yellow syrup), Rf = 0.80 (hexane/ethyl acetate =7/3).
Preparation of E-1-iii-a:
The crude yellow syrup from the above reaction was treated with 36.5 mL
AcOH and 106.3 mL (106.25 mmol) of 1M solution of TBAF in THF overnight.
The reaction was concentrated and purified by chromatography to afford the title compound. 14.9g (84%, 3 steps) Rf= 0.36 (petroleum spirit/ethyl acetate = 7/3) Preparation of E-1-iv-a:
Methyl 2-azido-2,3 di-O-benzy1-2-deoxy-thio-13-D-glucopyranoside (14.5 g, 34.9 mmol) in dichloromethane (200 ml) and anhydrous pyridine (8.6 ml, 106.2 mmol) was treated with benzoylchloride (4.93 ml, 42.5 mmol) at 0 C
for 1 hour. The reaction mixture was quenched, extracted, washed and evaporated. The residue was purified by silica gel column chromatography to afford the title compound as a white solid.
Yield: 14.9 g (82 %), Rf = 0.82 (Petroleum spirit/Ethyl acetate = 7/3).
Preparation of E-1:
Methyl 2-azido-6-0-benzoy1-2,3di-O-benzy1-2-deoxy-thio-? -D-glucopyranoside (8.68 g, 16.7 mmol) in acetone (50 ml) was treated with N-bromosuccinimide (8.92 g, 50.12 mmol) at 0 C for 1 hour. The reaction mixture was then quenched, extracted, washed and evaporated, furnishing a yellow syrup which was purified by chromatography. Yield: 6.13 g (75%), Rf =
0.57 (Petroleum spirit/Ethyl acetate = 7/3). A cooled mixture of 2-azido-6-0-____ benzoy1-2,3 di-O-benzyl- 2-deoxy-a/P-0-glucopyranose (5g, 10.2 mmol), K2CO3 (7.0 g , 51 mmol) and trichloroacetonitrile (5.1m1, 51 mmol) in 30 ml of dichloromethane was stirred for 2h. The mixture was then filtered through celite and the filtrate was concentrated and purified on a short column of silica gel to obtain the title compound as an amorphous white solid. Yield 5.69 g (88%), Rf = 0.85 (Petroleum spirit/Ethyl acetate = 7/3).
Compound E-1:
1H-NMR (400 MHz, CDC13): 5 = 8.73 (s, 1 H, C=NH), 8.00 (m, 2 H, Aryl), 7.56 (m, 1 H, Aryl), 7.43-7.25 (m, 12 H, Aryl), 5.66 (d, 1H, J = 8.4 Hz, HAN, 4.95 (d, 1H, Jgem = 10.8 Hz, 0CH2), 4.87 (d, 2H, J = 10.8 Hz , OCH2), 4.62 (d, 2H, Jgem = 10.8 Hz, OCH2), 4.58 (dd, 1H, Jgem = 12.4 Hz, J5,6. = 2.0 Hz, H-6a), 4.46 (dd, 1H, J5,6b = 3.6 Hz, 1-1-6b), 3.77-3.72 (m, 3H, H-5, 2H not assigned), 3.62 (dd, 1H, J = 8.3 Hz, J = 9.7 Hz, H not assigned).
Compound E-2:
1H-NMR (400 MHz, CDCI3): (5= 8.70 (s, 1 H, C=NH), 7.38-7.22 (m, 10H, Aryl), 7.13 (m, 2H, Aryl), 6.83 (d, 2H, Mpm), 6.44 (d, 1H, J1,2 = 3.5 Hz, H-1a), 4.93 (d, 1H, Jgem = 10.5 Hz, OCH2), 4.89 (d, 1H, Jgem = 10.5 Hz, OCH2), 4.78 (d, 1H, Jgem = 10.5 Hz, OCH2), 4.57 (d, 1H, Jgem = 11.7 Hz, OCH2), 4.51 (d, 1H, Jgem = 11.7 Hz, OCH2), 4.39 (d, 1H, Jgem = 11.7 Hz, OCH2), 4.02 (dd, 1H, J3,4 --' J2,3 = 9.5 Hz, H-3), 3.98 (m, 1H, H-5), 3.86 (dd, 1H, J4,5 = 9.6 Hz, H-4), 3.76 (dd, 1H, H-2), 3.75 (s, 3H, OCH3), 3.69 (dd, 1H, J5,6. = 3.5 Hz, Jgem = 10.5 Hz, H-6a), 3.63 (dd, 1H, J5,6b = 1.8 Hz, 11-6b).
Example 16: Synthesis of Building Blocks E-5 to E-8 ¨
TBDPSO
.
µ
Bn0 Bn0 SR
BnOunoll.) E-1-vii-a: R=Cres NPht E-1-vii-b: R=Me 1-15.42 eie Bn0 Bn0 SR
TBDPSO...........\....
NPht E-1-viii-a: R=Cres Bn0 E-1-viii-b: R=Me NMe2 Bn0 SR
i, b \ 0 DTPMNH
E-8-1-a: R=Cres HO.........\_.
N
/ E-8-I-b: R=Me i Bn0 Bn0 SR = DTPM-NMe2 HC.L......\õ.....
----1"" Bn0 C
Bn0 SR
E-1-ix-a: R=Cres E-1-ix-b: R=Me DTPMNH
E-5-i-a: R=Cres MprrC
e2/.
E-5-i-b: R=Me Bn0 ..0 Bn0 SR
h/ .4......
\ . d A
DTPMNH
Mp..Ø0140....\...
BnBz0C) E-6-1-a: R=Cres Bn0 SR
Bn0 SR
E-6-i-b: R=Me Bn0 DTPMNH
DTPMNH
E-5-ii-a: R=Cres g,i E-7-i-a: Rres E-5-ii-b: R=Me E-7-1-b: R=Me Mpn...i , e Bn0 e DTPMNH TCA
Bn0 Mp0.......
Bz0......., O
Bn0 Bn0 Bn0 DTPMNH
DTPMNH
OT CA
Example 16: Syntheses of Building Blocks E-5 to E-8, conditions: a) SOP 6, (85 %, R=SMe); b) SOP 30, (86 %, R=SMe); c) SOP 10, (88 %, R=SMe); d) SOP 18, (92%, R=SMe); e) 1. SOP 13; 2. SOP 25b, (85%, 2 steps, R=SMe);
f) SOP 7; g) 1. SOP 14; 2. SOP 25b; h) 1. TsCI, DMF; 2. p-Me0-C6H4-0Na, NMP, 60 C; i) SOP 8.
Compound E-5:
1H-NMR (400 MHz, CDCI3): (5= 10.20 (dd, 1 H, JNH,=C-H = 14.0 Hz, ,INH,1-1-2 =
9.9 Hz, NH), 8.80 (s, 1 H, C=NH), 8.16 (d, 1H, =C-H), 7.99 (m, 2H, Aryl) 7.58 (m, 1 H, Aryl), 7.45 (m, 2 H, Aryl), 7.30-7.17 (m, 10H, Aryl), 6.42 (d, 1H, 42 =
3.6 Hz, H-1a), 4.89 (d, 1H, em=Jg 8.4 Hz, OCH2), 4.68-4.60 (m, 3H, OCH2), 4.58 (dd, 1H, J5,6a = 2.0 Hz, Jgem = 12.4 Hz, H-6a), 4.51 (dd, 1 1-1, J6,6b =
4.0 Hz, H-6b), 4.22 (m, 1 H, H-5), 4.03 (dd, 1 H, J3,4 --- J2,3 = 9.6 Hz, 143), 3.80 (dd, 1 H, J4,5 = 9.4 Hz, H-4), 3.70 (ddd, 1 H, H-2), 3.32 (s, 3 H, NCH3), 3.25 (s, 3 H, NCH3).
Example 17: Preparation of L-iduronic acid containing disaccharides B-A-1 to OBn .........43z R20 .0 SCres HO 0 + Bn0 Lev0 OBz RiOMe B-1 / B-4 1a A-1:121 = N3 R 2 - _Mp / Mpm A-3: R1 = DTPMNH
...........*Bz B-A-1: R1= N3, R2= Mp OR OBn Bn0 0 B-A-2: R1= N3, R2= Mpm B-A-3: R1= DTPMNH, R2= Mp OMe B-A-4: R1= DTPMNH, R2= Mpm Lev0 OBz 11 b OBz HO OBn 0 B-A-5: R1= N3 B-A-6: R1= DTPMNH OMe Lev0 OBz 1 :i..:*313z Me0 OBn 0 Bno B-A-7: R1= N3 jpg R1 B-A-8: R1= DTPMNH 0 OMe Lev OBz dOBz Me0 OBn B-A-9: R1= N3'..Frol:44 Rh B-A-10: R1= DTPMNH 0 OMe HO OBz Example 17: Preparation L-iduronic acid containing disaccharides B-A-1 to B-A-10; a) SOP 32a, (76 %, for B-A-1); b) SOP 27, (88%, for B-A-5); c) 1.SOP
20; 2. SOP 16, (84% for B-A-7, 2 steps); d) SOP 24, (94%, for B-A-9).
Formation of disaccharide B-A-1 (step a) A suspension of A-1 (410 mg, 992 pmol), B-1 (680 mg, 992 pmol) and freshly activated molecular sieves 4 A (1.0 g) in dry CH2Cl2 (20 mL) was stirred for min at 0 C. N-lodosuccinimide (405 mg, 1.8 mmol) was added and stirring continued for 20 min. After addition of trifluoromethanesulfonic acid (10.6 pl, 119.7 pmol), the reaction mixture was further stirred until completion (from 0 C to 25 C) and quenched with aqueous NaHCO3-solution (10 %). The mixture was diluted with CH2Cl2 and filtered through a celite pad. The filtrate was washed with a 10 `)/0 KHCO3/Na2S203 solution, water and saturated brine solution, dried over MgSO4 and evaporated. Final purification was achieved by silica gel column chromatography. Yield: 730 mg (76 %).
Formation of disaccharide B-A-7(step c) Disaccharide B-A-5 (1.00 g, 1.15 mol) was dissolved in anhydrous DMF (7.0 ml) and reacted with pyridinium dichromate (4.33 g, 11.5 mmol) under stirring at room temperature until complete conversion into the uronic acid. The reaction mixture was subsequently poured into 50 ml water and the whole extracted with diethyl ether. The combined ether layers were washed with 10 % aqueous citric acid solution, filtered through a short silica gel pad, dried over MgSO4, evaporated and dried under high vacuum. The crude residue was dissolved in Toluene (3 ml) and methanol (3 ml) and titurated with TMSCHN2 solution (2M in hexane) until completion. The excess of TMSCHN2 was destroyed by addition of acetic acid and the mixture evaporated. Final purification was achieved via silica gel chromatography. Yield: 871 mg (84 %).
Compound B-A-9:
1H-NMR (400 MHz, CDCI3): 8= 8.03 (m, 2H, Aryl), 7.91 (m, 2H, Aryl), 7.53 (m, 2H, Aryl), 7.42-7.23 (m, 14H, Aryl), 5.37 (d, 1H, J1,2 < 1.5 Hz, H-1'a), 5.21 (m, 1H, H-2'), 4.97 (d, 1H, .14,5 = 2.3 Hz, 1-1-5'), 4.84 (d, 2H, Jg em = 10.8 Hz, OCH2), 4.81 (d, 1H, Jgem = 10.8 Hz, OCH2), 4.80 (d, 1H, Ji,2 = 3.6 Hz, H-1a), 4.77 (1H, J5,6a = 1.8 Hz, H-6a), 4.70 (m, 2H, OCH2), 4.47 (dd, 1H, J5,6b = 4.2 Hz, Joel/ = 12.3 Hz, H-6b), 4.05-3.97 (m, 3H, 11-4', 144, H-5), 3.91-3.87 (m, 2H, H-3', H-3), 3.49 (s, 3H, OCH3), 3.44 (m, 1H, H-2), 3.43 (s, 3H, OCH3).
Selected 13C-NMR (100 MHz, CDCI3): 5 = 98.73 C-1 (JcH = 172.5 Hz), 98.35 C-1' (JcH = 171.8 Hz).
Example 18: Syntheses of Building Blocks E-D-1 to E-D-12 OR1 Bn0 Bn0; 131&=\=....\,.....,-X 0 Bri-- ..) o OMe R ......4n......
R
E-1, E-2, E-3, E-5, E-6, E-7, Bn0 OTBDPS
E-1-v-a, E-1-v-b, E-1-vi-a, E-1-vi-b B
E-1-a, E-1-b, E-5-ii-a, E-5-ii-b E-D-1 : R = N3, RI = Bz E-6-i-a, E-6-i-b, E-7-1-a, E-7-1-b E-D-2 : R = N3,12.1 = Mpm +
E-D-3 : R = N3, R1 = Mp a E-D-4 : R = DTPMNH, 111 = Bz 0 all _e E-D-5 : R = DTPMNH, R1= Mpm HO --&\.:....\.õ1) E-D-6 : R = DTPMNH, Ri= Mpm Bn0 OTBDPS
OBn b/
Bngno 0 R ...........\0 OMe E-D-7: R = N3, Ri = Bz en0 ED-8 : R = N3, R1 = Mpm Bn0 OTCA
E-0-9: R= N3, R1= Mp E-D-10 : R = DTPMNH, R1 = Bz E-0-11 : R = DTPMNH, R1 = Mpm E-D-12 : R = DTPMNH, R1 = Mpm Example 18: Syntheses of disaccharides E-D-1 to E-D-12, conditions: a) SOP
32 a/b for X =SMe/ Scres or SOP 33 for X = OTCA, (88 % for E-D-1 via E-1, 84% for E-D-4 via E-5, as a/filnixtures), b) 1. SOP 9; 2. SOP 25a, (90 % for E-D-7 over 2 steps).
Preparation of E-D-1:Methyl (2-azido-6-0-benzoy1-3,4-di-O-benzy1-2-deoxy-a-D-glucopyranosyl)-(1-44)-tert-butyldiphenylsily12,3-di-O-benzyl-13¨D-glucopyranosid)uronate A mixture of 2-azido-6-0-benzoy1-2,3 di-O-benzyl- 2-deoxy-a/3-D-glucopyranosyl trichloroacetimidate (2.5 g, 3.94 mmol), and methyl (tert-butyldiphenylsilyl 2,3-di-O-benzy1-0-D-glucopyranoside) uronate (1.6 g, 255 -mmol) and molecular sieves 4A (2.5 g) in 50 ml diethyl ether was treated with TBDMSOTf (180 I, 788.76 mol) at -20 C for 1h. The reaction was quenched filtered, concentrated and the residue purified by silica gel column chromatography to obtain the desired disaccharide 2.48 g, 88%. Rf= 0.67 (toluene/ethyl acetate 9/1) Compound E-D-1:
E-D-1 was formed according to SOP 33 with ether as solvent at -30 C and TBDMSOTf as promotor in 86 % yield (a/(3-mixture).
1H-NMR (400 MHz, CDCI3): 8 = 8.00 (m, 2H, Aryl), 7.68 (m, 4H, Aryl), 7.56 (m, 1H, Aryl), 7.42 (m, 4H, Aryl), 7.36-7.17 (m, 2411, Aryl), 5.47 (d, 1H, J12 =
3.8 Hz, H-1 'a), 5.02 (d, 1H, Jgem = 11.4 Hz, OCH2), 4.97 (d, 1H, Jgem = 11.0 Hz, OCH2), 4.84 (m, 4H, OCH2), 4.75 (d, 1H, Jgem = 11.4 Hz, OCH2), 4.66 (d, 1H, J1,2 = 7.5 Hz, H-1I3), 4.57 (d, 1H, Jgem = 10.9 Hz, OCH2), 4.45 (m, 2H, H-6'a, H-6'b), 4.15 (dd, J = 8.8 Hz and J = 9.6 Hz), 3.86 (m, 1H), 3.65 (s, 3H, OCH3, 3.68-3.58 (m, 3H), 3.55 (d, 1H, J4,5 = 10.0 Hz, 1-1-5), 3.31 (dd, 1H, J2,3 =
10.2 Hz, H-2'), 1.12 (s, 9H, C(CH3)3).
Compound E-D-4:
E-D-4 was formed according to SOP 33 with ether as solvent at -30 C and TBDMSOTf as promotor in 84 % yield (a/(3-mixture).
Selected 1H-NMR (400 MHz, CDCI3): 8 = 10.02 (dd, 1 H, JNH,=GH = 14.4 Hz, JNH,I-1.2 = 9.6 Hz, N-H), 8.02 (m, 2 H, Aryl), 7.79 (d, 1H, =C-H), 7.72-6.93 (m, 33 H, Aryl), 5.60 (d, 1H, J1,2 = 3.6 Hz, H-ta.), 4.49 (d, 1H, J1,2 = 7.8 Hz, 1-1-113), 3.66 (s, 3 H, OCH3), 3.29 (s, 3 H, NCH3), 3.28 (s, 3 H, NCH3), 1.14 (s, 9 H, C(CH3)3).
Preparation of E-D-7: Methyl (2-azido-6-0-benzoyl-3,4-di-O-benzy1-2-deoxy-a-D-glucopyranosyl)-(1¨#4)-2,3-di-O-benzyl-P-D-glucopyranosyl trichloroacetimidyl)uronate A solution of methyl (2-azido-6-0-benzoy1-3,4-di-O-benzy1-2-deoxy-a-D-gluco-pyranosyl)-(1¨>4)-tert-butyldiphenylsily12,3-di-O-benzyl-(3-D-glucopyranoside) uronate (2.09 g, 1.90 mmol) in acetic acid (1.74 ml, 30.45 mmol) and 1 M
solution of tetrabutylammoniumfluoride (7.6 ml, 7.61 mmol) was stirred at room temperature overnight. The reaction mixture was then concentrated and the residual syrup was purified by silica gel column chromatography to obtain the desired hemiacetal. Yield: 1.57 g (95.8%), Rf= 0.21 (toluene/ethyl acetate 9/1).
A mixture of methyl (2-azido-6-0-benzoy1-3,4-di-O-benzy1-2-deoxy-a-o-glucopyranosyl)-(1--)4)-2,3-di-O-benzyl-p-D-glucopyranosyl)uronate (594 mg, 690.70 mot), trichloroacetonitrile (280 I , 2.74 mmol) and DBU (31 IA 209.3 g.trnol) in 8.0 ml dichloromethane was stirred at 0 C for 1 h. The mixture was then concentrated and purified on a short column of silica gel to obtain the title compound as an amorphous white solid. Yield: 662 mg (95.3 %), 13= 0.46 (toluene/ethyl acetate 9/1).
Compound E-D-7:
Selected 1H-NMR (400 MHz, CDCI3): 6 = 8.68 (s, 1H, C=NH), 8.00 (m, 2H, Aryl), 7.56 (m, 2H, Aryl), 7.43-7.23 (m, 22H, Aryl), 6.48 (d, 1H, 42 = 4.3 Hz, H-1ot), 5.59 (d, 1H, J2= 3.6 Hz, H-1 'a), 5.03 (1H, Jem = 10.8 Hz, OCH2), 4.93-4.83 (m, 4H, OCH2), 4.70 (d, 1H, Jgem= 12.0 Hz, OCH2), 4.64 (d, 1H, Jgern = 12.0 Hz, OCH2), 4.60 (d, 1H, Jgem= 11.2 Hz, OCH2), 4.47 (m, 2H, H-6'a, H-6'b), 4.42 (m, 1H, not assigned), 4.15 (m, 2H, not assigned), 3.97 (dd, 1H, J = 8.2 Hz and J = 10.2 Hz, not assigned), 3.80 (m, 1H, not assigned), 3.76 (m, 3H, OCH3), 3.72-3.64 (m, 2H, not assigned), 3.30 (dd, 1H, J2,3 = 10.4 Hz, H-2').
Example 19: Syntheses of disaccharides E-D-13 to E-D-44 ...c...)Y11.....
OW
Bn0 Bn0 OTBDPS
Bn---..1004)0.
R2 C....\_... Me R = Ac, Alloc, Bz, Piv 0... 0 Bn0 OTBDPS
+ ¨Po- a E-D-13 to E-D-OW
---&.....\......\sõN. 0 x b E-1, E-2, E-5, E-6, E-1-iv-a, E-1-iv-b, E-1-vi-a, E-1-vi-b, E-5-ii-a, E-5-ii-b, Bn00 E-6-i-a, E-6-i-b Br* R2 .......t.....\1 0 OM e Bn E-D-29 to E-D-44 R10 TCA
E-D-13 & E-D-29: R3= Bz, R2= N3, R1= Alloc E-D-21 & E-D47: R3= Bz, R2= N3, R1 = Bz E-D-14 & E-D-30: R3= Bz, R2= NHDTPM, R1r- Alloc E-D-22 & E-D-38: R3= Bz, R2= NHDTPM, R1= Bz E-D-15 & E-D-31 : R3 = Mom, R2= N3, Ri = Alloc E-D-23 & E-D-39: R3= Mpm, R2= N3, Ri = Bz E-D-16 & E-D-32 : R3 = Mpm, R2= NHDTPM, R1= AI oc E-D-24 & E-D-40: R3= Mpm, R2= NHDTPM, R1= Bz E-D-17 & E-D-33 : R3 = Bz, R2= N3, Ri= Piv E-D-25 & E-D-41: R3 = Bz, R2 = N3, Ri = Ac E-D-18 & E-D-34: R3 = Si, R2= NHDTPM, R1= Piv E-D-26 & E-D-42: R3= Bz, R2= NHDTPM, R1= Ac E-D-19 & E-D-35 : R3 = Mpm, R2= N3, Ri = Ply E-D-27 & E-D-43: R3= Mpm, R2= N3, Ri = Ac E-D-20 & E-D-36: R3 = Mpm, R2= NHDTPM, R1= Piv E-D-28 & E-D-44: R3= Mpm, R2= NHDTPM, R1= Ac Example 19: Syntheses of disaccharides E-D-13 to E-D-44, conditions: a) SOP 32 a/b for X = SMe/ Scres or SOP 33 for X = OTCA ( 70 % for E-D-23, a/13 mixture); b) 1. SOP 9; 2. SOP 25a.
Compound E-D-27:
E-D-27 was formed according to SOP 33 with ether as solvent at -20 C and TBDMSOTf as promotor in 70 % yield (a/(3 -mixture).
Selected 1H-NMR (400 MHz, CDCI3): 5 = 7.58 (m, 2H, Aryl), 7.54 (m, 2H, Aryl), 7.36 ¨ 7.00 (m, 23 H, Aryl), 6.73 (m, 2H, Aryl), 5.37 (d, 1H, J1,2 =
3.9 Hz, 1+1 'a), 5.12 (dd, 1H, J2,3 = 8.8 Hz, 1+2), 4.63 (d, 1H, Jgem = 11.2 Hz, OCH2), 4.58 (d, 1H, Jgem = 11.2 Hz, OCH2), 4.48 (d, 1H, J1,2 = 7.3 Hz, H-113), 3.66 (s, 3 H, OCH3), 3.55 (s, 3 H, OCH3), 3.34 (m, 1H), 3.22 (dd, 1H, J = 3.4 Hz, J =
10.7 Hz), 1.81 (s, 3 H, OAc), 0.98 (s, 9H, C(CH3)3).
Example 20 : Synthesis of alternative E-D-disaccharides E-D-45 to E-D-50 OBz ORI
Bn0 Bn0 X HBOno 0 OTBDPS
Bn0 E-1, E-5, E-1-iv-a, D-8a: RI = Mp E-1-iv-b, E-5-ii-a, E-5-ii-b D-8b: RI = Mpm D-8c: RI = All OBz )1 a Bn0 0 Bn0 R2 ORI
OTBDPS
Bn0 E-D-45: RI = Mp, R2= N3 E-D-46: RI = Mp, R2 = NHDTPM
E-D-47: RI = Mpm, R2 = N3 E-D-48: RI = Mpm, R2 = NHDTPM
E-D-49: RI = All, R2 = N3 E-D-50: RI = All, R2 = NHDTPM
Example 20: Synthesis of alternative E-D-disaccharides E-D-45 to E-D-50, conditions: a) SOP 32a/b for X = SMe/SCres or SOP 33 for X = OTCA, diethyl ether, TBDMS-0Tf, -20 deg. C (75 % for E-D-45 as a/(3-mixture).
--Example 21: Synthesis of trisaccharides E-D-C-1 to E-D-C-16 BnBn0 R4 0 Me 0 + H
E-0-9 E-D-10 Bn Bn 0 OTCA R20 N3 OTBDPS
Bnrill;&r) R40.4\1 0 0 Bn Bn R20 N3 OTBDPS
E-D-C-1 :121 = Mpm, R2 = Mpm, R3 = Mpm, R4 r- NHDTPM E-D-C-9 :
R1= Mpm, R2' Mpm, R3 = Mpm, R4= N3 E-D-C-2 : Rl = Mp, R2r- Mpm, Ra = Mpm, R4= NHDTPM E-D-C-10 R1 = Mp, R2 = Mpm, R3= Mpm, R4 = N3 E-D-C-3 : R1 = Mpm, R2 = Mpm, R3= Bz, R4= NHDTPM E-D-C-11:
R1 = Mpm, R2 = Mpm, R3 = Bz, R4= N3 : R = Mp, R2= Mpm, R3 = Bz, R4= NHDTPM E-D-C-12:121 = Mp, R2 = Mpm, R3 = Bz, R4 = N3 E-D-C-5 : R1 = Mpm, R2 43z, R3 = Mpm, R4= NHDTPM E-D-C-13:
Ri = Mpm, R2 =Bz, R3 = Mpm, R4= N3 E-0-C-6 : R1 = Mp, R2 =Bz, R3 4-- Mpm, R4= NHDTPM E-D-C-14:
R1= Mp, R2 =Bz, R3 = Mpm, R4= N3 E-D-C-7 : R1 = Mpm, R2 43z, R3 = Bz, R4= NHDTPM E-D-C-15:
R1 = Mpm, R2 =Bz, R3 =Bz, R4 =N3 E-D-C-8 : R1 = Mp, R2=Bz, R3 = Bz, R4= NHDTPM E-D-C-16:
R1 = Mp, R2 r:Bz, R3 = Bz, R4= N3 Example 21: Synthesis of trisaccharide E-D-C-1 to E-D-C-16, conditions: a) SOP 33, (70 % for E-D-C 15 as an a/(3 mixture).
Compound E-D-C-15:
E-D-C-15 was formed according to SOP 33 with dichloromethane as solvent at 0 to 20 C and TBDMSOTf as promotor in 70 % yield (a/13-mixture).
1H-NMR (400 MHz, CDCI3): 8 = 7.93 (m, 2H, Aryl), 7.87 (m, 2H, Aryl), 7.66 (m, 2H, Aryl), 7.61 (m, 2H, Aryl), 7.46 (m, 2H, Aryl), 7.38-6.99 (m, 32 H, Aryl), 6.79 (m, 2H, Aryl), 5.27 (d, 1 H, J1,2 = 3.8 Hz, 141"a), 4.99 (dd, 1 H, J3,4 J2,3 = 9.5 Hz, H-3), 4.80-4.69 (m, 6 H, OCH2), 4.52 (m, 3 H, OCH2), 4.40 (d, 1H, J-1,2 = 8.0 Hz, H-113), 4.38-4.32 (m, 2 H, not assigned), 4.29 (d, 1 H, J1,2 =
7.5 Hz, H-113), 4.15 (m, 1 H, Jgem = 12.0 Hz, OCH2), 4.02 (dd, 1 H, J4,5 = 9.6 Hz, H-4), 3.80 (2 dd, 2 H, H-3", 1+41 3.71, (s, 3 H, 0C113), 3.67 (m, 1 H, not assigned), 3.61-3.53 (m, 2 H, H-5', 11-2'), 3.46 (dd, 1 H, Jgem = 11.2 Hz, ..)5,6a =
2.4 Hz, H-6a), 3.41 (dd, 1H, J2,3 '-- J3,4 = 9.0 Hz, H-3'), 3.27 (s, 3 H, OCH3), 3.21 (dd, 1 H, J2,3 = 10.0 Hz, H-2"), 3.14 (dd, 1 H, 132'), 3.00 (dd, 1 H, J5,6b <2.0 Hz, H-6b), 2.75 (m, 1 H, H-5) 1.05 (s, 9H,C(CH3)3).
Example 22: Synthesis of trisaccharides E-D-C-17 to E-D-C-32 Bn BrCf. R4 %.1e nOR1 E-D-37 to E-D-40 Bn0 0 HO. 12`0.0TBDPS
13z0 OTCA N3 Bn Bn0 434 0 cOR1 0 Bn OTBDPS
Bz0 N3 E-0-C-17: = Mpm, Mpm, R3= Mpm, c= NHDTPM E-D-C-25: R1 = Mpm, t= Mpm, Mpm, Ft= N3 E-D-C-18 : = Mp, R2= Mpm, = Mpm, Ft = NHDTPM E-D-C-26: R1 = Mp, Mpm, R3= Mpm, 124= N3 E.0-C-19: Fe M pm , = Mpm, R3= Bz, R4= NHDTPM E-D-C-27: RMpm, = Mpm, Bz, Fe N3 E-D-C-20 : = Mp, RI = Mpm, = Bz, R4= NHDTPM E-D-C-28: Mp, Ft Mpm, R3= Bz, R4= N3 E-D-C-21: Ft = Mpm, R2 =Bz, R3= Mpm, = NHDTPM
ED-C.29: R1 Mpm, FBz, Fe = Mpm, R4= N3 E-D-C-22: I Mp, =Bz, R Mpm, R NHDTPM E-D-C-30: R1 = Mp, Fe =Bz, R3 = Mpm, Ft = N3 E-D-C-23: I Mpm, Fe =Elz, Fe = Bz, R4= NHDTPM E-D-C-31: R1 Mpm, Bz,F R3= Bz, R4= N3 E-D-C-24: Ft = Mp, Fe =Elz, R3= Bz, R4= NHDTPM E-D-C-32: R1= Mp, IBz, Fe = Bz, Ft = N3 Example 22: Synthesis of trisaccharide E-D-C-17 to E-D-C-32, conditions: a) SOP 33.
Example 23: Formation of trisaccharidic Trichloroacetimidates E-D-C-33 to E-oR3 Bn0 0 Bn0 R20 TBDPS
Bn0 N3 E-D-C-1 to E-D-C-16 OR3 la Bn0 Bn0 0 En R70.4\
E-D-C-33 : R1 = Mpm, R2= Mpm, It = Mpm, Ft = NHDTPM E-D-C-41 : Ft1 = Mpm, RI =
Mpm, R3= Mpm, Ft = N3 E-D-C-34 : R1= Mp, R2 = Mpm, Ft = Mpm, R4= NHDTPM E-D-C-42 : R1= Mp, R2=
Mpm, R3 = Mpm, R4= N3 E-D-C-35 :R1= Mpm, 122= Mpm, R3= Bz, R4= NHDTPM E-D-C-43 : RI = Mpm, R2=
Mpm, It = Bz, R4= N3 E-D-C-36 : R1 = Mp, R2 = Mpm, RI = Bz, R4= NHDTPM E-D-C-44 : R1 = Mp, Ft =
Mpm, Ft= Bz, R4= N3 E-D-C-37 : R1 = Mpm, F= Bz, R3 = Mpm, R4= NHDTPM E-D-C-45 : R1= Mpm, Ft2 =Bz, R3= Mpm, R4= N3 E-D-C-38 : R1 = Mp, R2 =Bz, R3= Mpm, R4= NHDTPM E-D-C-46 : 114= Mp,122=Bz, R3 = Mpm, R4= N3 E-D-C-39 :R1= Mpm, Fe =Bz, R3 = Bz, R4= NHDTPM E-D-C-47 : R1 = Mpm, Ft2 =Bz, R3= Bz, R4= N3 -fl-C-40 = R1 = Mn.R2 =Rz. R3 = Rz. R4 =NHDTPM ED-C.48 : R1 = Mp, R2 =Bz, R3 = Bz, R4=
Example 23: Formation of trisaccharidic Trichloroacetimidates E-D-C-33 to E-D-C-48, conditions: a) 1. SOP 9; 2. SOP 25, (82% over 2 steps for E-D-C-47 Example 24: Syntheses of trisaccharides E-D-C-9 to E-D-C-12 and E-D-C-49 to E-cr oz_...\...)Me 0 C-6a : R = SCres, R1= Mpm, R2= Mpm C-7: R = OTBDPS, R1 = Mpm, R2= Mpm Lev Bn0 + C-8c : R = OTBDPS, R1 = Mp, R2 = All " Bz OTCAR C-10 : R = SCres, Ri = Mp, R2= Mpm ' C-11 : R = SCres, R1= Mpm, W = All C-3 to C-9 C-12: R = OTBDPS, R1= Mpm, R2= All a C-13 : R = SCres, Ri = Mp, R2 =All C-14 : R = OTBDPS, R1 = Mp, R2 = Mpm D-C-1 : R = SCres, RI = Mpm, Fe = Mpm 0 OMe OR1 D-C-5 :R
= OTBDPS, R1= Mpm, R2= Mpm D-C-2 : R = SCres, R1= Mpm, Fe = AllHO 0 0 D-C-6 :
R = OTBDPS, R1 = Mpm, R2= All n D-C-3 : R = SCres, R1= Mp, R2= Mpm Bn0 R20 R D-C-7 :
R = OTBDPS, R1= Mp, R2= Mpm o n.) D-C-4 : R = SCres, Ri= Mp, R2= All Bz0 N3 D-C-8 :
R = OTBDPS, R1= Mp, R2 = All 11.
in li) in OR3 b OR3 oI\)Bn0 B
tI\)o Bn(-).&t., .")\ illin 0 0 OMe o N3 N3 ...........\,......
11.
oI
Bz0 R20 R
oI
E-D-C-49 : R = SCres, Ri = Mpm, R2= Mpm, Fe = Bz ED-C-11 : R = OTBDPS, R 1=
Mpm, Fe = Mpm, R3= Bz E-D-C-50 : R = SCres, Fe = Mpm, R2 =All, R3= Bz E-D-C-57 : R =OTBDPS, R 1=
Mpm, It = All, R3 =Bz E-D-C-51 : R = SCres, re = Mp, R2= Mpm, Fe =Bz E-D-C-12 : R = OTBDPS, R 1=
Mp, R2= Mpm, R3= Bz i E-D-C-52 : R = SCres, R1= Mp, R2= All, R3 = Bz E-D-C-58 : R = OTBDPS, R =
Mp, R2 = All, R3 = Bz E-D-C-53 : R = SCres, R1= Mpm, R2= Mpm, = Mpm E-D-C-9 : R = OTBDPS, R 1=
Mpm, Fe . Mpm, R3= Mpm E-D-C-54 : R = SCres, R1= Mpm, R2= All, R3= Mpm E-D-C-59 : R = OTBDPS, R 1=
Mpm, Fe = All, R3= Mpm E-D-C-55 : R= SCres, Ill = Mp, R2= Mpm, It = Mpm E-D-C-10 : R= OTBPS, R1= Mp, R2= Mpm, It = Mpm E-D-C-56 : R = SCres. Ri = Mn. 122 = All. R3= Mom E-D-C-60 : R = OTBPS, R 1=
Mp, R2= All, R3= Mom Example 24: Syntheses of trisaccharides E-D-C-9 to E-D-C-12 and E-D-C-49 to E-D-C-60, conditions: a) 1. SOP 33; 2. SOP 24; b) SOP 33.
(for D-C-5: 70 %, 2 steps); b) SOP 33, ( 78 % for E-D-C-9 as an oc/11 mixture).
Compound D-C-5:
D-C-5 was formed according to SOP 33 with ether as solvent at -20 C and TMSOTf as promotor, followed by SOP 24 in 70 % yield (over 2 steps as a/13-mixture).
Selected 1H-NMR (400 MHz in CDCI3): 6 = 7.88 (m, 2H, Ar), 7.67- 7.58 (m, 5H, Ar), 7.42 (m, 2H, Ar), 7.37-7.12 (m, 16H, Aryl), 6.84 (m, 3H, Ar), 5.14 (dd, 1H, J1,2 = 8.2 Hz, J2,3= 9.5Hz, H-2'), 4.90 (d, 1H, Jgem = 10.7 HZ, OCH2), 4.73 (d, 1H, Jgem= 11.5 Hz, OCH2), 4.65 (d, 1H, J1,2= 8.2 Hz, H-1'(3), 4.63 ¨
4.58 (m, 2H, OCH2), 4.51 (d, 1H, Jgem = 12.0 Hz, OCH2), 4.20 (d, 1H, J1,2=
7.9 Hz, H-1 3), 4.05 (d, 1H, Jgem = 11.9 Hz, OCH2), 4.02 ¨ 3.95 (m, 2H, not assigned), 3.81 (s, 3H, OCH3), 3.80 (s, 3H, OCH3), 3.71 (d, 1H, J4,5 = 9.9 Hz, 1-1-5), 3.67 (s, 3H, OCH3), 3.47 - 3.40 (m, 3H, not assigned), 3.21 (dd, 1 H, J
= 9.0 Hz, J = 9.8 Hz, not assigned), 3.00 (dd, 1 H, J5,6b = 1.4 Hz, Jgem =
10.5 Hz, H-6b), 2.63 (m, 1 H, H-5), 2.35 (bs, 1 H, 4-0H), 1.07 (s, 9H, C(CH3)3).
Compound E-D-C-9:
E-D-C-9 was formed according to SOP 33 with ether as solvent at -20 C and TBDMSOTf as promotor in 78 % yield (a43-mixture).
Selected 1H-NMR (400 MHz, CDCI3): 8 = 7.77 (m, 2H, Aryl), 7.59, 7.54 (2m, 2 x 2H, Aryl), 7.35 ¨ 7.00 (m, 30 H, Aryl), 6.88 (m, 2H, Aryl), 6.82 (m, 2H, Aryl), 6.73 (m, 2H, Aryl), 5.41 (d, 1 H, J1,2 = 3.5 Hz, H-1"a), 5.19 (dd, 1 H, J2,3 ===-: J1,2 = 9.6 Hz, H-2'), 4.85 - 4.78 (m, 4 H, OCH2), 4.67 (m, 2H, OCH2), 4.65 (d, 1H, J1,2 = 8.5 Hz, 14113, not assigned), 4.38 (d, 1 H, em=Jg 11.1 Hz, OCH2), 4.29 (d, 1 H, Jgem = 11.7 Hz, OCH2), 4.17 (dd, 1H, not assigned), 4.11 (d, 1H, J1,2 =
7.9 Hz, H-10 not assigned), 4.03 (d, 1 H, Jgem = 12.0 Hz, OCH2), 3.90 - 3.76 (m, 3H, not assigned), 3.730, 3.727 (2s, 2 x 3H, OCK), 3.65 (s, 3H, OCH3), 3.54 (s, 3H, OCH3), 2.89 (dd, 1 H, Jgem = 10.5 HZ, J5,6b <2.0 Hz, H-6b), 2.52 (m, 1H, H-5), 1.02 (s, 9 H, C(CH3)3).
Example 25: Synthesis of trisaccharides E-D-C-41, E-D-C-42 and E-D-C-61 to E-D-C-66 OMpm Bn0 Bn(7.:&=-=kft.)) N3 ..........\%.....\........_ Me E-D-C-53 : RI = Mpm, R2 = Mpm Bn0 0--..Ø..., E-D-C-54 : RI = Mpm, R2 = All E-D-C-55 : RI = Mp, R2= Mpm Bz0 R20 \SCres E-D-C-56 : RI = Mp, R2= All I, a OMpm Bn0 Bn0 ome 0--......\.1:::\........
E-D-C-61 : RI = Mpm, R2= Mpm E-D-C-62 : RI = Mpm, R2 = All Bn0 WO SCres E-D-C-63 : RI = Mp, R2= Mpm E-D-C-64 : RI = Mp, R2 = All it b OMpm Bn0 Bn0 (pie N ......"..:)...\....,0 ' E-D-C-41 : RI = Mpm, R2= Mpm E-D-C-42 : RI = Mp, R2= Mpm E-D-C-65 : RI = Mpm, R2 = All Bn0 R20 OTCA
E-D-C-66 : RI = Mp, R2= All N3 Example 25: Synthesis of trisaccharides E-D-C-41, E-D-C-42 and E-D-C-61 to E-D-C-66, conditions: a) 1. SOP 39; 2. SOP 38; 3. SOP 16; b) 1. SOP 14; 2.
SOP 25a.
Example 26: An alternative route to the trisaccharides E-D-C-61 and E-D-C-0 OMe ORI
D-C-9 : RI = MPm ADO 0 D-C-10 : RI =Mp Br-if..====='\,..---\P------1,(LMpm0& SCres Bz0 N3 a4 0 OMe ORI
0-C-11 : RI =Mpm,.,o D-C-12 : RI =Mp Bn ' Mpm0 SCres Bn0 N3 OMpm BnBn .4. ----b lr 0...........:0M1 ...3ni Bn 0 Bn N3 0 OrI..
E-D-C-61 : RI =Mpm 0 Bn 0--1.0:......\ .._ E-D-C-63 : RI = Mp Bn0 MPrn SCres Example 26: An alternative route to the trisaccharides E-D-C-61 and E-D-C-63, conditions: a) 1. SOP 39; 2. SOP 38; 3. SOP 16; 4. Pd(Ph3P)4, p-TolSO2Na, THF, Me0H; b) SOP 33.
Example 27: Syntheses of blocks E-D-C-67 to E-D-C-70 0 OMe OMp Lev0"..\. .....\ + HO-......\:f.%\,., Bn0 OTCA 0 SCres Alice() C-15 i 0 OMp Bn0 0 SCres Alloc0 D-C-13)7.---NH
b 0 OMe 'I' OMp Bn 0 SCres Alloc0 D-C-14--NH
Bn0 OR0 Bn0 +
c 1 BnBOn 0 0 OMe OMp Bn 0 SCres Mica) Nir---NH
E-D-C-67 : R = Mp E-D-C-68 : R = Bz 0 cr......DR.\.) d Bn Bn0 0 OMe OMp \iC.)..\ /0"--'=-=.....\:::1 Bn 0 SCres Bn0 4 NH
E-D-C-69 : R = Mp E-D-C-70 : R = Bz 0 Example 27 : Syntheses of trisaccharides E-D-C-67 to E-D-C-70, conditions:
a) SOP 33; b) SOP 24; c) SOP 33; d) 1. SOP 36; 2. SOP 37.
Example 28: Synthesis of trisaccharides E-D-C-70 and E-D-C-71 OBz Bnilen 0 --&.µ......) !kJ 0 OMe ..3 ......
OMp HO'''.._.\,......\_..
R
Bn0 0 C-16/C-5c Bn OTCA
la OBz BnB0 ---..&....141...) 4, v 1 OM
Bn R
E-D-C-70 : R = SCres o E-D-C-71 : R = OTBDPS
Example 28: Synthesis of trisaccharides E-D-C-70 and E-D-C-71, conditions:
a) SOP 33, (55% for E-D-C-71, a/13 mixture).
Compound E-D-C-71:
E-D-C-71 was formed according to SOP 33 with dichloromethane as solvent at 40 C and TBDMSOTf as promotor in 55 `)/0 yield (as a/13-mixture).
Selected 1H-NMR (400 MHz, CDCI3): 8 = 7.91 (m, 2H, Aryl), 7.61 (m, 2H, Aryl), 7.55 (m, 2H, Aryl), 7.50 ¨ 7.02 (m, 29 H, Aryl), 6.65 (m, 4H, Mp), 5.38 (d, 1 H, Ji,2 = 3.9 Hz, H-1"a), 5.22 (bs, 1 H, NH), 4.67 (d, 1H, J1,2 = 7.4 Hz, H-113, not assigned), 4.50 (d, 1H, J12 = 7.8 Hz, H-113, not assigned), 3.92 (d, 1 H, J4,5 = 9.8 Hz, H-5'), 3.698 (s, 3 H, OCH3), 3.693 (s, 3 H, OCH3), 1.03 (s, 9 H, C(CH3)3).
Mfound = 1408.52 (M+H20)+, m ¨calc = 1390.54 (MI.).
Example 29: Syntheses of trisaccharides E-D-C-61, E-D-C-72 and E-D-C-73 ::Ø....11/1e OMpm Lev0 0 Mpm HC .......4.\._ Bn0 TCA
+ 0 SCres Bn0 C-6-a 0 OMe i OMpm Lev00 Bn Mpm0 SCres Bn0 D-C-15 4Ae....\ lb,1 OMpm Bn Mpm0 SCres Bon D-C-11 ,OR
BOBnOn ---"\....
c I
E-1 to E-3 N1 3 TCA
OR
Bn0 0 Bn0 0 OMe ..\1N)i....\..o.....\
OMpm Bn 0 0 Mpm0 0 SCres E-D-C-61 : R = Mpm Bn0 E-D-C-72 : R = Mp E-D-C-73 : R = Bz Example 29: Syntheses of trisaccharides E-D-C-72 to E-D-C-73 and E-D-C-61, conditions: a) SOP 33; b) SOP 24; c) SOP 33.
Example 30: Syntheses of trisaccharides C-B-A-1 to C-B-A-4 _ OBz MpOLA)n..7.,,, Lev A110*
SCres C-17 N3OTCA 4 HO BA OBz ..4,,0 _\\3z pilif7 oBn.i OBz Lev '0 --SCres HO
+ Br:O&No....) N3 orc::::1 13z b A-1/A-3 R OMe 0c,=\mpcoiLvi 0OBz OBz Bp Lev R
OMe N3 0 OBz C-B-A-1: R= N3_ C-B-A-2: R= DTPMNH
4 OBz OBz meo B Bn0 HO'....\:\
ADO O7I--,...j4 OMe N3 0 OBz C-B-A-3: R=N3 C-B-A-4: R=DTPMNH
Example 30: Syntheses of trisaccharides C-6-A-1 to C-6-A-4, conditions: a) SOP 33; b) SOP 32a; c) 1. SOP 27; 2. SOP 20; 3. SOP 16; 4. SOP 24.
-Example 31: Synthesis of trisaccharides C-B-A-5 to C-B-A-8 OBz RO 4, N3 TCA OMe C-18 : R = Bz, R1 = AcB-A-9 1 OBz OH
C-19 : R = Mpm, R1 =Ac C-20: R = Bz, R1 = Lev C-21 : R = Mpm, Ri = Lev OBz I4m Me OBn Bn0 $0, 0 R 07....1.... ..i N3OMe OBz C-B-A-5 : R = Bz, R1 = Ac C-B-A-6 : R = Mpm, R1 = Ac C-B-A-7 : R = Bz, R1 = Lev C-B-A-8 : R = Mom. R1 = Lev Example 31: Synthesis of trisaccharides C-B-A-5 and C-B-A-8, conditions: a) SOP 33, (50% for C-B-A-5, a/f3 mixture).
Compound C-B-A-5:
C-B-A-5 was formed according to SOP 33 with ether as solvent at - 20 C and TBDMSOTf as promotor in 50 % yield (as a./13-mixture).
Mfound = 1269.65 (M+H+H20)4", M¨calc = 1250.43 (M+).
Example 32: Syntheses of D-C-B trisaccharides D-C-B-1 to D-C-B-3.
0 OMe OR1 Me Lev 0 HO
OBn BrZ7).......\õõõ,OTCA Alloc0 + 0 N.)----NH 0 OBz SCres C-B-2, R1 =Bz a 1 C-B-3, R1 =Mp C-B-4, R1 =Mpm OR/
Lev0 (3OMe OBn BnO-X.00=1....\/ 0 0 SCres OBn OBz D-C-B-1, R1= Bz D-C-B-2, R1= Mp D-C-B-3, R1= Mpm Example 32: Syntheses of D-C-B-trisaccharides D-C-B-1 to D-C-B-3, conditions: a) 1. SOP 33; 2. SOP 36; 3. SOP 37.
Example 33: Syntheses of D-C-B trisaccharides D-C-B-4 to D-C-B-7.
0R1 Rhin ........Ø..\-1 HO
... cOM.e....\___ SCres Lev0 0 + N3 0 Bz Bn0 Alloc0 OTCA
C-B-5 : R1 = Mpm, R2= Mpm, 0 C-B-6 : R1 = Mpm, R2 = All, a C-B-7 : R1 = Mp, R2= Mpm, C-B-8 : R1 = Mp, R2= All, .4....\le z OR1 Me0 OBn Lev OR20 op.rz.
Bn0 SCres OBn N3 OBz D-C-B-4 : R1 = Mpm, R2 = Mpm, D-C-B-5 : R1 = Mpm, R2 = All, D-C-B-6 : R1 = Mp, R2 = Mpm, D-C-B-7 : R1 = Mp, R2 = All, Example 33: Syntheses of D-C-B-trisaccharides D-C-B-4 to D-C-B-7, conditions: a) 1. SOP 33; 2. SOP 36; 3. SOP 37.
=
Example 34: Syntheses of tetrasaccharides D-C-B-A-1 to D-C-B-A-2 OBz MP Me0 0"-----.
OBn Bn0 HP 0 s C-8-A-9 N3 :.:::Ae....\ OMe +
0 OBz Lev0 SCres 0 o Bn0 Allop a D-6a OBz ...../le....\" 47..\\3 Lev 0 0 0 Me OBn Bn0 Bn0 0 Allac D-C-B-A-1 N30Me o OBz OBz _ c..\1:)Me....\, OMp Me0 p0 nBn Bn0 0 D-C-B-A-2 OMe Bn0 \)7.--NH
OBz 0 o Example 34: Syntheses of tetrasaccharides D-C-B-A-1 and D-C-B-A-2, conditions: a) SOP 32a; b)1. SOP 36; 2. SOP 37; 3. SOP 24.
Example 35: Alternative syntheses of tetrasaccharides D-C-B-A-2 _ ¨
........... i:oBzµ
.:::0,..k .7...\"......_47...\__p ON
0 0 Me0 0 Lev0 ".....00Br4 Bn0 Bn0 SCres 4. 0 1 OMe OBn Cli---NH
D-C-16 0 1 HO OBz a .. OBz......
0 OMe OMp oBn Bn0 0 00 OMe Bn0 %),---NH
OBz Example 35: Alternative synthesis of tetrasaccharide D-C-B-A-2, conditions:
a) 1. SOP 34; 2. SOP 24.
Example 36: Syntheses of tetrasaccharides D-C-B-A-3 to D-C-B-A-8 .................0Bz ..:-_ OMe,...........
OR2 Me 0 OBn Bn0 Lev0 0 Bn0 Rio SCres 01-P 4.
OMe OBn N3 HO OBz D-C-15 : R1 = Mpm, li = Mpm D-C-17 : R1 = Mpm, li = Mp 1131:U:RI;1TPMNH
D-C-18 : R1= Mpm, Ff = Bz all, OBz Iloe 0 Me OBn .......q R
OMe Bn0 N3 FIr07n0--.A110 Bz D-C-B-A-3 : R= DTPMNH, R1= Mpm, Fi = Mpm, D-C-B-A-4 : R= DTPMNH, R1= Mpm, if = Bz D-C-B-A-5 : R= DTPMNH, W = Mpm, Fe = Mp D-C-B-A-6 : R= N3, R1 = Mpm, Fe = Mpm, D-C-B-A-7 : R= N3, R1 = Mpm, Ff = Bz D-C-B-A-8 :R= NA, R1 = Mpm, li = Mp Example 36: Syntheses of tetrasaccharides D-C-B-A-3 to D-C-B-A-8, conditions: a) 1 SOP 32b; 2. SOP 24.
Example 37: Syntheses of tetrasaccharides E-D-C-B-1 to E-D-C-B-4 ¨
.......7....\IR
Bn0 0 OMpm Me0 Bn0 0 OBn ...........\õ OMe HO --4.....\0 -0 SCres + MPm Bn0 OTCA
N
3 OBz 0Alloc a E-D-29 :
E-D-31 : R = Mpm ....1 ..\10 1 Bn0 Bn0 OMe MPm Me OBn 0 --0 SCres Bri;3".....\/...
Mpm E-D-C-B-1 : R = Bz 0Alloc E-D-C-B-2 : R = Mpm 0 OBz 11 b OR
B nen--0...4 o OMe E-D-C-B-3 : R = Bz "Pm Me OBn0 E-D-C-B-4 : R = Mpm SCres Mpm OBn N3 0 OBz Example 37: Syntheses of tetrasaccharides E-D-C-B-1 to E-D-C-B-4, conditions: a) SOP 33; b) 1. SOP 36; 2. SOP 37.
Example 38: Syntheses of blocks E-D-C-B-5 to E-D-C-B-8 _ /OR
BnO ) OBn B 0 0 OMe HO 0 071.....7",-0 SCres 0 + 7NH
E-D-29 : R = Bz N3 nA........\...
ED-51 : R = Mp Bn0 TCA C-B-3 OBz Alloc0 a 0 .....311 ...)0 Bn0 Bn0 0 OMe OMp N3 ........4)...\"_.........o.e..4\
Me$Bn,...1.,.....r.
E-D-C-B-5 : R = Bz 0 0 SCres E-D-C-B-6 : R = Mp Bn0 0Alloc OBz OR
Bn0 1 b Bn¨C--,=0.)) 0 OMe OMp u.n N3 ............v .......Ø.\--1 E-D-C-B-7: R = Bz E-D-C-B-8: R = Mp 0 "0 SCres Bn0 0 OBn d-----NH
OBz Example 38: Syntheses of tetrasaccharides E-D-C-B-5 to E-D-C-B-8, conditions: a) SOP 33; b) 1. SOP 36; 2. SOP 37.
Example 39: Syntheses of E-D-C-B-A pentasaccharides P-1 and P-2 OR E-D-C-69 : R = Mp OBz E-D-C-70 : R = Bz Bn0 f.T...#01:4311 ..........&\...)0 0 0........0Moe0 OMp Me0 0 Bn0 Bn 0¨...\,...--\+-\/ 0 SCres +
OMe OBn \)----NH HO
OBz OR
0 0 a OBz Bn0 BnO&Ice..) N3 :_\.....\/0MG0 C"IIP MW Bn0 Bn0 0 OMe OBn 7--- IVNI
0 OBz P-1 :R=Mp P-2: R= Bz Example 39: Syntheses of E-D-C-B-A pentasaccharides P-1 and P-2, conditions: a) SOP 34.
Example 40: Synthesis of E-D-C-B-A pentasaccharides P-3 to P-26 =
.
E-D-C-41 to E-D-C-48=
R2 E-D-C-65 to E-D-C-66 E-D-C-74 to E-D-C-87 en ...............\13z Bn0 3 0 Me =
Me0 13'10 04_413:ii Bn0 +
s Me nO 13-"Cill 3 - Finlz TCA i, a A
.............)5z ) 8n0 8n0 0 = Me I
3 = - Me .
13n0 .
3 Me , a . =13z P.3: R = All, le =Mom, R2 =13z P-11 : R = lApm,R1= Mpm, R2= Bz P-19: R = Bz., R1 = Mpm, R2= Bz P.4: R = A11,1:11 .. Mp, R2 = Bz P-12: R= Mpm, R' = Mp, R2=
13z P-20: R= Bz, R1= Mp, R2= Bz P-5 : R = All, R1= Mpm, R2= Mpm P-13 : R = Mpm, 111 = Mpm, R2= Mpm P-21 : R = Bz, R1= Mpm, R2= Mpm P-6 : R = All, R1= Mp, R2= Mom P-14 : R = Mpm, R1= Mp, R2=
Mpm P-22 : R =13z, R1= Mp, R2= Mpm P-i: R = All, R1= Mp, R2= Mp P-16 : R = Mpm, R1= Mp, R2=
Mp P-23 : R = Bz, R1= Mom, R2= Mp P-8 : R = All, R1= Mpen, R2= Mp P-16: R = Mpm, R1 = Mom, Ft2= Mp P-24 : R = Bz, R1 = Mp, R2 = Mp P-9 :1,1= All, RI = Mpm, R2 a TEMPS P-17 : R = Mimi, R1= Mpm, Ra= MOPS P-25 : R = Eft, Ri . Mpm, R2= MOPS
P-10 : R = All, RI = Mp, R2 = TEMPS P-18 : R = Mpm, R1= Mp, R2=
TBDPS P-26 : R =13Z, Ri = Mp, R2 TEMPS
, Example 40: Synthesis of E-D-C-B-A pentasaccharide P-3 to P-26, conditions:
a) SOP 33 (75 % for P-19 as an a/( mixture).
5 Compound P-19:
P-19 was formed according to SOP 33 with dichloromethane as solvent at . - 20 C and TMSOTf as promotor;
Mfound = 2068.76 (M+H+H20)+, Meek = 2049.74 (Mt).
Example 41: Alternative syntheses of E-D-C-B-A pentasaccharides P-11, P-12, P-19, P-20 and P-27 ..4z....) Bn0 0 Bn0 0 OMe OR1 Me0 .OBz Bn Bn0 071Ø7.-SCres + HO RO Bn0 OBn N3 OBz A-1 N3 E-D-C-B-3 : R = Mpm, R1 = Mpm 0 OMe E-D-C-B-9 : R = Mpm, R1 = Bz, E-D-C-B-10 : R = Mpm, R1 = Mp a 1 E-D-C-B-11 : R= Bz, R1 = Mp E-D-C-B-12 : R = Bz, R' = Mpm OBz Bn OBz nO 0 OMe wo 0 N30 -----.0B. t.:i Bn0 Bn0 RO OMe OBn N3 Bz P-11 : R = Mpm, R1 = Mpm 0 P-12 : R = Mpm, R1 = Mp P.19: R = Bz, R1 = Mpm P-20 : R= Bz, R1 = Mp P.27: R = Mpm, R1 = Bz Example 41: Alternative syntheses of E-D-C-B-A pentasaccharides P-11, P-12, P-19, P-20 and P-27, conditions: a) SOP 32a.
Example 42: Alternative syntheses of some E-D-C-B-A pentasaccharides OBz Bn 0 R 0 OMe OR1 0 ce........\.Ø..\/.........1.4MaCelin Bn0 N3 E-1 to E-3, N3 + H
E-1-iv-b, E-1-v-b, Bn0 Mpm 0 -0 D-C-B-A-6 to OMe E-1-vi-b OBn N3 BzD-C-B-A-8 0*2 Bn a i ........ µ
Bn0 0 N3 Me 0Bn Bn OMe P-11 : RI = Mpm, R2= Bz OBn N3 OBz P.12: RI = Mp, R2= Bz P-16 : RI= Mpm, R2= Mp P.13: RI = Mpm, R2= Mpm P.27: RI = Bz, R2= Bz P.14: R1 = Mp, R2= Mpm P-28: R1= Bz, R2= Mp P.15: R1 = Mp, R2= Mp P-29: RI = Bz, R2= Mpm Example 42: Alternative syntheses of some E-D-C-B-A pentasaccharides, conditions: a) SOP 32a (for R = SCres) or SOP 33 ( for R = OTCA).
_ _ _ Example 43:Svnthesis of pentasaccharide P-13 and P-30 0......&%...)V1pm ......HEtzok Bn 0 Bn0 N3 0 C...14:...\,..... Me Bn Bn0 0 MP ni -0 0 OMe Bn0 + B-Bn0 MPm SCres 0 Bz all ,...:)M1,..)rri OBz B nO
Bn N3 .. Cs.0111,......, 0 MPM Me Bn ---.'-'&\:2)1311 P-13 : R = N3 0 **0 P-30 : R = DTPMN H Bn o R 0OMe Bn0 MPrn N3 Bz Example 43: Formation of pentasaccharides P-13 and P-30, conditions: a) SOP 32a.
Example 44: Formation of pentasaccharide P-19 and P-31 OBz OEtz Bn0 "Pm Me0 0 Bno Bn=-="&t,f) 0 OMe OBn 0.--,...i..;\..,,10 0 Bz0 0 . oBz C-B-A-9 N30Me +
E-D-7 / E-D-10 Bn0 N3 OBz Bn0 Bn...0 nif...\
R .__ \ft:sMe....\ "Pm Me0 osn 0 Bn0 0 ogz N3 Bn0 0 OMe Bn0 N3 OBz P-19: R=N 3 0 P-31: R=NHDTPM
Example 44: Formation of pentasaccharide P-19 and P-31 conditions: a) SOP 33 Example preparation of P19:
_ A mixture of 0-(2-azido-6-0-benzoy1-3,4-di-O-benzy1-2-deoxy¨a-D-glucopyra-nosyl)-(1-->4)-(methyl 2,3 -di-O-benzy1-0-o-glucopyranosyluronate)-(1-->4)-2-azido-3-0-benzoy1-2-deoxy-6-0-p-methoxybenzyl¨a-D-glucopyranosyltrichloroacetimidate (30.0 mg, 21.2 mop and methyl (methyl 2-0-benzoy1-3-0-benzyl-a-L-idupyranosyluronate)-(1-4)-2-azido-3-0-benzyl-6-0-benzoy1-2-deoxy-a-D-glucopyranoside (15.4 mg 19.3 lamol) and 100 mg of molecular sieves 4A in 1.5 ml dry dichloromethane was treated with TBDMSOTf (0.97 pi, 4.24 Imo!) at -20 C for 20 hours. The reaction was quenched, filtered and concentrated. Further purification of the title compound was achieved by silica gel chromatography Yield: 15.83 mg (40%), Rf= 0.30 (toluene/ethyl acetate = 9/1).
Example 45: Partial deprotection of pentasaccharide P-19 OBz BnO*3.)...E...\...4 0 OBz Bn0 OMpm Me0 ogn Bn0 0 0 P-19 N3OMe OBz Bn0 \ -N3 OBz Bn0 1 a OH
0 OBz Bn-....(2.) 0 OMe 0 N3 .........113,..\.....0 0 M: 0.13on B n OP -Bn0 N30Me Bn0 z0 N3 OBz b 0 OH
Bn0 N3 o ONao < _ OH Na0 Bn 1 n N 3OMe Bn0 HO
Example 45: Partial deprotection of pentasaccharide P-19, conditions: a) SOP 28, 84%; b) SOP 39, 86%.
Compound P-33:
Mfound = 1503.5 (M-N2+2H)+, Moalc = 1529.51 (M+).
To ease the structural proof, a small part of P-33 was transformed into the bis methyl uronurate derivative and characterized via NMR-spectroscopy.
Characteristic 1H-NMR-spectral regions are shown in figure 1.
Mfound = 1514.62 (M+H)+, Mca1c = 1513.58 (M ).
Example 46: Partial deprotection of pentasaccharide P-30, containing a DTPM-group as amino protection OMpm OBz Bn0 OMe OMpm Me OBn 0---........;...\._ Bn DTPMNH
Bn0 0 OMe Bn0 MPin N3 OBz OH
4, a OH
Bn0 Bn 0 ONa ,13 ..............\õ, OH Nat) ogn Bn0 DTPMNH
Bn0 0 OMe Bn0 HO
OH
b Bn0 0 OH
Bn0 Bn0 0 ..õ......\.(2_\.....0ONa ..._.&,N3 ....\ .N a0 4 0 OBn Bn0 0 P-33 OMe Bn0 HO
Example 46: Partial deprotection of pentasaccharide P-30, containing a DTPM-group as amino protection, conditions: a) 1. SOP 28; 2. SOP 39; b) 1.
SOP 11 with MeNH2as primary amine and Me0H as solvent; 2. SOP 12.
Example 47: Partial deprotection of _pentasaccharide P-I, containing a cyclic carbamate as amino protection ....,&\7....\.3 Bn0 0 OBz c........\......v0Me ..........X4pµ Nieci...(4 ....---..N.) ug Bn . Bn0 30Me OH OBn 0 OBz Bn0 0 Il a 0 OBz Bn--; OM
OH me j........i 3 ___ C. :......\,/ _..........\
OBn ------)Bn0 Bn0 0 N3e OMe OH OBn )7----NH
0 OBz Bn0 0 OH
Bn;;;&\=-=-,\ 0 ONa OH
N3 ......\.......\/ ......Ø...\ NW 1E--...\in0 N
Bn0 HO
3OMe OH OBn c OH
Bn00 N3 ..._.......\/_....._.\...\ ONa OH Na0 -Ii:1::271r1Bil o Bn0 O
Bn0 HO
N30Me OBn N3 o OH
Example 47: Partial deprotection of pentasaccharide P-1, containing a cyclic carba mate as amino protection, conditions: a) SOP 27; b) SOP 39; c) SOP
12.
Example 48: Deprotection protocol for pentasaccharides P-37 of claim 4 ....: \,.: ..))Rs5 OR, Rip 0 RH20ORE2 = RB A (:).........0Ei ORs3 0 ORH Ri.H 0 X
0= 0 0 õ RA
Rpi C,======\*=..\/R540 0 oRpz Rs ORsz RH = RIM = RH2 = Rpi = Rp2= Bn;
Rsi = Rsz = Rs3 = Rs4 = Rs5 = Mpm, Mp, Bz;
RA= RB =RBI= NHDde, NHDTPM, N3;
or R54 a Ind RB = cyclic Carbamate; a REi = RE2 = Me, All, Bn; X = a-OMe OH
OH
Bne;;;C!) ..............&i 0 ONa OH ONaoBn Bno N30....Ø....vo HO 0 .1) 3 Bn0 OMe OBn N3 OH P-33 Example 48: Deprotection protocol for pentasaccharides P-37 of claim 4, conditions: a) 1. SOP 27 and 28; 2. SOP 39; 3. SOP 11 with MeNH2 as primary amine and Me0H as solvent; 4. SOP 12.
Example 49: Transformation of pentasaccharide P-33 into the 0-and N-sulfated pentasaccharide P-35 OH
OH
Bn Bn0 0 ONa N3 ..........\........\,...
OH Bn0 0 "0 N
Bn0 0 3E1:1;1---41) P-33 OMe OSO3Na Bn0 HO
a N3 OH
OSO3Na Bn0 -;&T.-)) ONa OSO3Na Na OBn 0...¨ =#\=-.\Bn0 Bn0 0 o 0 0 P-39 OMe OSO3Na Bn0 Na03S0 O3Na .
OSO3Na OSO3Na&\:..) 1.........
0 ONa b H
H)2 HO 0="_..1.4:.\ 0 OSO3Na Na0 0 OH S O;
P-39 OMe OS03Na HO Na03S
OSO3Na HO
0 ONa NaOSO2NH
OSO3Na Na0 0H
HO
0 0 '0 NaOSO2NH
OMe HO Na03S0 NaOSO2NH
OSO3Na P-40 Example 49: Transformation of pentasaccharide P43 into the 0-and N-sulfated pentasaccharide P-40, conditions: a) SO3xNMe3, DMF, 50 C; b) l-12 (70 psi), Pd/C, H20; c) SO3xPyridine, H20, pH = 9.5. The transformation of P-33 into P-40 has been performed according to literature: Petitou et al., Carbohydr. Res. 1987, 167, 67-75.
The 1H-NMR (400 MHz, D20) of P-40 is shown in figure 6.
REFERENCES
1 Lindahl, U., Backdtrom, G., Thunberg, L., Leder, I.G., Proc. Natl.
Acad. Sci. USA, 1980, Vol. 77, No. 11, 6551-6555; Reisenfeld, J., Thunberg, L., Hook, M., & Lindahl, U., J. Biol. Chem., 1981, Vol.
256, No. 5, 2389-2394.
2 Choay, J., Lormeau, J-C., Petitou, M., Sinay, P., and Fareed, J., Annals New York Academy of Sciences, 1981, 370, 644-649.
3 Pierre Sinay, Jean-Claude Jacquinet, Carbohydrate Research, 132, (1984), C5-C9.
4 C.A.A. van Boeckel, T. Beetz, J.N. Vos, A.J.M. de Jong, S.F. van Aelst, R.H. van den Bosch, J.M.R. Mertens and F.A. van der Vlugt., J.
Carbohydrate Chemistry, 4(3), 1985, 293-321.
5 .
J. Choay, M. Petitou, J.C. Lormeau, P. Sinay, J. Fareed, Ann.
NY Acad. Sci., 1981, 370, 644-649.
6 .
J. Choay et. a/., Biochem. Biophys. Res. Commun., 1983, 116, 492-499.
_
Claims (21)
1. A pentasaccharide building block for the preparation of synthetic heparinoids, said building block being of General Formula la, General Formula la (Block E-D-C-B-A) wherein the configuration of the monosaccharidic units and the stereochemistry of the internal linkages is defined as D-gluco-alpha-1,4-D-glucurono-beta-1,4-D-Gluco-alpha-1,4-L-idurono-alpha1,4-D-gluco, and the substituents are defined as;
X1 is hydroxy, C2 to C10 alkoxy, aryloxy; thioalkyl, thioaryl, imidoyl, or tert-butyldiphenylsilyloxy; and the stereochemistry may be alpha or beta;
or an alpha methoxy group;
R H, R H and R H2 is benzyl;
R A, R B and R B1 is independently an azido function, an NH-Dde, or NH-DTPM, R E1 and R E2 are methyl;
R P1 and R P2 are benzyl;
R S1, R S2 and R S5 are independently benzoyl or acetyl groups;
RS3 and R S4 are independently 4-methoxyphenyl; substituted benzyl groups;
substituted alkylacyl groups; a tert-butyldiphenylsilyl, tert-butyldimethylsilyl or trimethylsiloxyethyl group; or allyl.
X1 is hydroxy, C2 to C10 alkoxy, aryloxy; thioalkyl, thioaryl, imidoyl, or tert-butyldiphenylsilyloxy; and the stereochemistry may be alpha or beta;
or an alpha methoxy group;
R H, R H and R H2 is benzyl;
R A, R B and R B1 is independently an azido function, an NH-Dde, or NH-DTPM, R E1 and R E2 are methyl;
R P1 and R P2 are benzyl;
R S1, R S2 and R S5 are independently benzoyl or acetyl groups;
RS3 and R S4 are independently 4-methoxyphenyl; substituted benzyl groups;
substituted alkylacyl groups; a tert-butyldiphenylsilyl, tert-butyldimethylsilyl or trimethylsiloxyethyl group; or allyl.
2. The pentasaccharide building block of claim 1, wherein:
R S1, R S2 and RS5 are benzoyl groups.
R S1, R S2 and RS5 are benzoyl groups.
3. The pentasaccharide building block of claim 1, wherein:
R S3 and R S4 are independently 4-methoxyphenyl; or substituted benzyl groups.
R S1, R S2 and R S5 are acetyl groups and
R S3 and R S4 are independently 4-methoxyphenyl; or substituted benzyl groups.
R S1, R S2 and R S5 are acetyl groups and
4. The pentasaccharide building block of claim 1, wherein:
X1 is alpha methoxy and;
X1 is alpha methoxy and;
5. The pentasaccharide building block of claim 1, wherein X1 is C2 R A, R B and R B1 are azido groups.
to C5 alkoxy.
to C5 alkoxy.
6. The pentasaccharide building block of claim 1, wherein R A is azido.
7. The pentasaccharide building block of claim 4, wherein R S3 is 4-methoxybenzyl.
8. The pentasaccharide building block of claim 4, wherein R S3, and R S4 are 4-methoxybenzyl.
9. The pentasaccharide building block of claim 1, wherein R B1 is azido.
10. A method of synthesizing the pentasaccharide of claim 1 comprising the steps of forming a trisaccharide EDC of formula IIa, wherein:
X2 is thioalkyl, thioaryl, halogen, trichloroacetimidoyl, or n-pentenyl and the stereochemistry may be alpha or beta;
R H and R H2 are benzyl;
R S3 and R S4 are independently 4-methoxyphenyl, substituted benzyl groups; substituted alkylacyl, tert-butyldiphenylsilyl, tert-butyldimethylsilyl or trimethylsiloxyethyl group, or allyl;
R S5 is benzoyl or acetyl;
R E1 is methyl;
R B and R B1 are independently an azido function, NH-Dde or NH-DTPM
group;
R P1 is benzyl;
R P2 is benzyl;
and forming a disaccharide BA of formula IIIa wherein:
X1 is alkoxy, alkenyloxy, aryloxy, substituted benzyloxy; thioalkyl, thioaryl, or a tert-butyldiphenylsilyloxy group; and the stereochemistry may be alpha or beta;
R H1 is benzyl;
R A is an azido function, NH-Dde, or NH-DTPM;
R S1 and R S2 are independantly benzoyl or acetyl;
R Q is either a) -(C=O)-OR E2 wherein R E2 is methyl;
group, allyl, or levulinoyl;
or b) -(CH2)-OR M wherein R M is p-methoxyphenyl, p-methoxybenzyl, a trityl R L is H;
and linking the trisaccharide to the disaccharide to form the pentasaccharide.
X2 is thioalkyl, thioaryl, halogen, trichloroacetimidoyl, or n-pentenyl and the stereochemistry may be alpha or beta;
R H and R H2 are benzyl;
R S3 and R S4 are independently 4-methoxyphenyl, substituted benzyl groups; substituted alkylacyl, tert-butyldiphenylsilyl, tert-butyldimethylsilyl or trimethylsiloxyethyl group, or allyl;
R S5 is benzoyl or acetyl;
R E1 is methyl;
R B and R B1 are independently an azido function, NH-Dde or NH-DTPM
group;
R P1 is benzyl;
R P2 is benzyl;
and forming a disaccharide BA of formula IIIa wherein:
X1 is alkoxy, alkenyloxy, aryloxy, substituted benzyloxy; thioalkyl, thioaryl, or a tert-butyldiphenylsilyloxy group; and the stereochemistry may be alpha or beta;
R H1 is benzyl;
R A is an azido function, NH-Dde, or NH-DTPM;
R S1 and R S2 are independantly benzoyl or acetyl;
R Q is either a) -(C=O)-OR E2 wherein R E2 is methyl;
group, allyl, or levulinoyl;
or b) -(CH2)-OR M wherein R M is p-methoxyphenyl, p-methoxybenzyl, a trityl R L is H;
and linking the trisaccharide to the disaccharide to form the pentasaccharide.
11. A method of claim 10, wherein:
X2 is thiomethyl, thiocresyl or trichloroacetimidoyl, and the stereochemistry may be alpha or beta, R Q is -(C=CO)OR E2 wherein R E2 is methyl.
X2 is thiomethyl, thiocresyl or trichloroacetimidoyl, and the stereochemistry may be alpha or beta, R Q is -(C=CO)OR E2 wherein R E2 is methyl.
12. A method of synthesizing the pentasaccharide as defined in claim 1, comprising the step of synthesizing a tetrasaccharide EDCB
(formula IV), wherein:
X2 is selected from a thioalkyl, thioaryl, halogen, trichloroacetimidoyl, phosphate and related phosphate ester type leaving groups, and the stereochemistry may be alpha or beta;
and linking the tetrasaccharide to a monosaccharide of formula V
wherein, X1, R H, R H1, R H2, R A, R B, R B1, R E1, R E2, R P1, R P2, R S1, R
S2, R S3, R S4 and R S5 are as defined in claim 1.
(formula IV), wherein:
X2 is selected from a thioalkyl, thioaryl, halogen, trichloroacetimidoyl, phosphate and related phosphate ester type leaving groups, and the stereochemistry may be alpha or beta;
and linking the tetrasaccharide to a monosaccharide of formula V
wherein, X1, R H, R H1, R H2, R A, R B, R B1, R E1, R E2, R P1, R P2, R S1, R
S2, R S3, R S4 and R S5 are as defined in claim 1.
13. A method of synthesizing the pentasaccharide as defined in claim 1 comprising synthesizing a tetrasaccharide DCBA of formula VI
and linking the tetrasaccharide to a monosaccharide of formula VII
wherein X2 is selected from a thioalkyl, thioaryl, trichloroacetimidoyl; and the stereochemistry may be alpha or beta; and wherein, X1, R H, R H1, R H2, R A, R B, R B1, R E1, R E2, R P1, R P2, R S1, R
S2, R S3, R S4 and RS5 are as defined in claim 1.
and linking the tetrasaccharide to a monosaccharide of formula VII
wherein X2 is selected from a thioalkyl, thioaryl, trichloroacetimidoyl; and the stereochemistry may be alpha or beta; and wherein, X1, R H, R H1, R H2, R A, R B, R B1, R E1, R E2, R P1, R P2, R S1, R
S2, R S3, R S4 and RS5 are as defined in claim 1.
14. A method of synthesizing the pentasaccharide as defined in claim 1 comprising the steps of forming a disaccharide ED of formula VIII, wherein:
X2 is selected from thioalkyl, thioaryl, halogen, trichloroacetimidoyl, phosphate and related phosphate ester type leaving groups, and the stereochemistry may be alpha or beta;
and forming a trisaccharide CBA of formula IX
Formula IX
wherein, X1, R H, R H1, R H2, R A, R B, R B1, R E1, R E2, R P1, R P2, R S1, R
S2, R S3, R S4 and RS5 are as defined in claim 1, and linking the disaccharide to the trisacharide.
X2 is selected from thioalkyl, thioaryl, halogen, trichloroacetimidoyl, phosphate and related phosphate ester type leaving groups, and the stereochemistry may be alpha or beta;
and forming a trisaccharide CBA of formula IX
Formula IX
wherein, X1, R H, R H1, R H2, R A, R B, R B1, R E1, R E2, R P1, R P2, R S1, R
S2, R S3, R S4 and RS5 are as defined in claim 1, and linking the disaccharide to the trisacharide.
15. The method as defined in any one of claims 12 to 14 wherein:
R S1, R S2 and R S5 are benzoyl groups.
R S1, R S2 and R S5 are benzoyl groups.
16. The method as defined in any one of claims 12 to 14 wherein:
wherein:
R S1, R S2 and R S5 are acetyl groups and R S3 and R S4 are independently 4-methoxyphenyl; or substitutd benzyl groups.
wherein:
R S1, R S2 and R S5 are acetyl groups and R S3 and R S4 are independently 4-methoxyphenyl; or substitutd benzyl groups.
17. The method as defined in any one of claims 12 to 14 wherein:
wherein:
X1 is alpha methoxy and;
R A, R B and R B1 are azido groups.
wherein:
X1 is alpha methoxy and;
R A, R B and R B1 are azido groups.
18. The method as defined in any one of claims 12 to 14 wherein X1 is C2 to C5 alkoxy.
19. The method as defined in any one of claims 12 to 14 whererin R A is azido.
20. The method as defined in any one of claims 12 to 14 wherein R S3 is 4-methoxybenzyl.
21. The method as defined in any one of claims 12 to 14 wherein R S3, and R S4 are 4-methoxybenzyl.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2806604A CA2806604C (en) | 2001-09-07 | 2002-09-06 | Synthetic heparin pentasaccharides |
| CA2806561A CA2806561C (en) | 2001-09-07 | 2002-09-06 | Synthetic heparin pentasaccharides |
| CA2806723A CA2806723C (en) | 2001-09-07 | 2002-09-06 | Synthetic heparin pentasaccharides |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPR758701 | 2001-09-07 | ||
| AUPR7587 | 2001-09-07 | ||
| PCT/AU2002/001228 WO2003022860A1 (en) | 2001-09-07 | 2002-09-06 | Synthetic heparin pentasaccharides |
Related Child Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2806604A Division CA2806604C (en) | 2001-09-07 | 2002-09-06 | Synthetic heparin pentasaccharides |
| CA2806723A Division CA2806723C (en) | 2001-09-07 | 2002-09-06 | Synthetic heparin pentasaccharides |
| CA2806561A Division CA2806561C (en) | 2001-09-07 | 2002-09-06 | Synthetic heparin pentasaccharides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2459562A1 CA2459562A1 (en) | 2003-03-20 |
| CA2459562C true CA2459562C (en) | 2013-05-07 |
Family
ID=34437858
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2459562A Expired - Fee Related CA2459562C (en) | 2001-09-07 | 2002-09-06 | Synthetic heparin pentasaccharides |
| CA2806604A Expired - Fee Related CA2806604C (en) | 2001-09-07 | 2002-09-06 | Synthetic heparin pentasaccharides |
| CA2806561A Expired - Fee Related CA2806561C (en) | 2001-09-07 | 2002-09-06 | Synthetic heparin pentasaccharides |
| CA2806723A Expired - Fee Related CA2806723C (en) | 2001-09-07 | 2002-09-06 | Synthetic heparin pentasaccharides |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2806604A Expired - Fee Related CA2806604C (en) | 2001-09-07 | 2002-09-06 | Synthetic heparin pentasaccharides |
| CA2806561A Expired - Fee Related CA2806561C (en) | 2001-09-07 | 2002-09-06 | Synthetic heparin pentasaccharides |
| CA2806723A Expired - Fee Related CA2806723C (en) | 2001-09-07 | 2002-09-06 | Synthetic heparin pentasaccharides |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US7541445B2 (en) |
| EP (2) | EP1440077B1 (en) |
| JP (1) | JP4688414B2 (en) |
| CN (1) | CN1558911B (en) |
| AU (1) | AU2002331426B2 (en) |
| CA (4) | CA2459562C (en) |
| DK (1) | DK1440077T3 (en) |
| ES (1) | ES2423888T3 (en) |
| PT (1) | PT1440077E (en) |
| WO (1) | WO2003022860A1 (en) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002331426B2 (en) | 2001-09-07 | 2008-01-10 | Dr. Reddy's Laboratories Sa | Synthetic heparin pentasaccharides |
| AU2002950657A0 (en) * | 2002-08-08 | 2002-09-12 | Alchemia Limited | Derivatives of monosaccharides for drug discovery |
| JP2006143694A (en) * | 2004-11-16 | 2006-06-08 | Tokyo Kasei Kogyo Kk | NEW p-METHOXYPHENYL SUGAR DERIVATIVE |
| ES2336297B1 (en) * | 2008-10-08 | 2011-01-24 | Laboratorios Farmaceuticos Rovi, S.A. | PENTASACARIDOS SYNTHESIS PROCEDURE DEPROTECTED FROM A PENTASACARIDO PRECURSOS PROTECTED. |
| EP2414371A4 (en) * | 2009-03-30 | 2014-06-25 | Univ Georgia | Heparan sulfate synthesis |
| EP2464668B1 (en) | 2009-07-31 | 2022-12-07 | Reliable Biopharmaceutical Corporation | Process for preparing fondaparinux sodium and intermediates useful in the synthesis thereof |
| US8420790B2 (en) | 2009-10-30 | 2013-04-16 | Reliable Biopharmaceutical Corporation | Efficient and scalable process for the manufacture of Fondaparinux sodium |
| US9259389B2 (en) * | 2009-12-18 | 2016-02-16 | Endotis Pharma | Pharmaceutical oral dosage form containing a synthetic oligosaccharide |
| EP2683746A4 (en) * | 2011-03-10 | 2014-09-03 | Callaghan Innovation Res Ltd | Oligosaccharide compounds |
| US20130005954A1 (en) * | 2011-06-28 | 2013-01-03 | Apicore, Llc | Process for preparing heparinoids and intermediates useful in the synthesis thereof |
| CN103360439B (en) | 2012-04-02 | 2017-12-15 | 浙江海正药业股份有限公司 | Prepare new intermediate of heparin pentasaccharides and preparation method thereof |
| IN2014MN02197A (en) * | 2012-05-25 | 2015-09-11 | Zhejiang Hisun Pharm Co Ltd | |
| CN102690302B (en) * | 2012-05-30 | 2015-07-01 | 济南圣泉唐和唐生物科技有限公司 | Preparation method of 1,2-O-isopropylidene-3-O-benzyl-alpha-D-glucofuranose |
| CN102718808A (en) * | 2012-06-04 | 2012-10-10 | 浙江星月药物科技股份有限公司 | Methods for preparing class-one polysaccharide derivative and intermediate of class-one polysaccharide derivative |
| WO2013184564A1 (en) * | 2012-06-05 | 2013-12-12 | Academia Sinica | Methods and intermediates for the preparation of fondaparinux |
| CN102775450B (en) * | 2012-07-03 | 2015-04-08 | 华东师范大学 | Method for preparing 1,6-Anhydro-2-azido-2-deoxy-beta-D-glucopyranose |
| CN102898487B (en) * | 2012-11-13 | 2016-03-09 | 麦科罗夫（南通）生物制药有限公司 | A kind of sulphur reaches liver certain herbaceous plants with big flowers sodium disaccharides intermediate fragments BA and synthetic method thereof |
| CN102942601B (en) * | 2012-11-30 | 2015-09-30 | 江苏华泰晨光药业有限公司 | A kind of preparation method of intermediate of Fondaparinux sodium |
| WO2014205115A2 (en) | 2013-06-19 | 2014-12-24 | The Regents Of The University Of California | Regioselective silyl exchange of per-silylated oligosaccharides |
| US9346844B2 (en) | 2013-07-25 | 2016-05-24 | Scinopharm Taiwan, Ltd. | Process for the production of fondaparinux sodium |
| KR20160036606A (en) * | 2013-07-25 | 2016-04-04 | 시노팜 타이완 리미티드 | Process for the production of fondaparinux sodium |
| AU2013395144B2 (en) * | 2013-07-25 | 2017-12-14 | Scinopharm Taiwan, Ltd. | Process for the production of Fondaparinux sodium |
| US10072039B2 (en) * | 2013-07-25 | 2018-09-11 | Scinopharm Taiwan, Ltd. | Process for the production of Fondaparinux sodium |
| CN103601765B (en) * | 2013-09-02 | 2017-01-04 | 上海艾康睿医药科技有限公司 | Fondaparinux sodium and intermediate thereof and preparation method |
| US10287309B2 (en) | 2013-11-14 | 2019-05-14 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Disaccharide intermediate and synthesis method thereof |
| CN104098618A (en) * | 2014-07-25 | 2014-10-15 | 河北常山生化药业股份有限公司 | Intermediate of fondaparinux sodium and preparation method for intermediate and fondaparinux sodium |
| WO2016040779A1 (en) * | 2014-09-12 | 2016-03-17 | The Board Of Trustees Of The University Of Illinois | Urea derivatives of polyene macrolide antibiotics |
| US9909534B2 (en) | 2014-09-22 | 2018-03-06 | Ini Power Systems, Inc. | Carbureted engine having an adjustable fuel to air ratio |
| CN105985388A (en) * | 2015-02-04 | 2016-10-05 | 苏州朗科生物技术有限公司 | Fondaparinux sodium impurity compound, preparation method therefor and application of Fondaparinux sodium impurity compound |
| CN105985387A (en) * | 2015-02-04 | 2016-10-05 | 苏州朗科生物技术有限公司 | Fondaparinux sodium impurity compound, preparation method therefor and use of Fondaparinux sodium impurity compound |
| CN104876979B (en) * | 2015-06-19 | 2018-10-09 | 天津红日药业股份有限公司 | One kind having active sulfonated five sugar compounds of Anti-Xa factor |
| CN104910217B (en) * | 2015-06-19 | 2018-04-17 | 天津红日药业股份有限公司 | Reference compound for Fondaparinux sodium quality control |
| US10023603B2 (en) * | 2015-07-16 | 2018-07-17 | Formosa Laboratories, Inc. | Preparation of monosaccharides, disaccharides, trisaccharides, and pentasaccharides of heparinoids |
| CN106518935B (en) * | 2016-10-26 | 2019-05-21 | 陕西国防工业职业技术学院 | A kind of synthetic method of bis- deoxidation -3- amino-L- idose of 3,6- and its derivative |
| CN107501359B (en) * | 2017-08-24 | 2020-07-31 | 深圳市海滨制药有限公司 | Fondaparinux sodium impurity compound and preparation method and application thereof |
| US11306157B2 (en) | 2018-12-21 | 2022-04-19 | California Institute Of Technology | Expedient synthesis of core disaccharide building blocks from natural polysaccharides for heparan sulfate oligosaccharide assembly |
| CN109734757B (en) * | 2019-03-11 | 2020-09-11 | 淮北师范大学 | Preparation method of related substance B of fondaparinux sodium injection |
| WO2021043631A1 (en) | 2019-09-02 | 2021-03-11 | Hepoligo Solutions Aps | Intermediates useful for preparing iduronic acid containing di- and polysaccharides |
| WO2021083735A1 (en) | 2019-10-29 | 2021-05-06 | Hepoligo Solutions Aps | Process for the production of 1,6-anhydro sugars |
| CN110746471B (en) * | 2019-11-04 | 2021-06-25 | 江苏美迪克化学品有限公司 | Preparation method of fondaparinux sodium disaccharide intermediate |
| WO2022107013A1 (en) * | 2020-11-19 | 2022-05-27 | Indian Institute Of Science Education And Research | Silver assisted gold catalysis for the preparation of fondaparinux pentasaccharide and intermediates |
| CN112552359B (en) * | 2020-12-21 | 2022-11-25 | 北京大学 | Automatic preparation method of fondaparinux sodium pentasaccharide intermediate |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US187381A (en) * | 1877-02-13 | Improvement in air and steasvj blowers for furnaces | ||
| US13862A (en) * | 1855-12-04 | Cutting pile fabrics | ||
| US684691A (en) | 1901-03-23 | 1901-10-15 | Donald E Webster | Micrometer-gage. |
| IL61201A (en) | 1979-10-05 | 1984-09-30 | Choay Sa | Oligosaccharides having no more than 8 saccharide moieties,their obtention from heparin and pharmaceutical compositions containing them |
| CA1171375A (en) | 1980-09-15 | 1984-07-24 | Ulf P.F. Lindahl | Oligosaccharides having selective anticoagulation activity |
| US4818816A (en) | 1981-04-28 | 1989-04-04 | Choay, S.A. | Process for the organic synthesis of oligosaccharides and derivatives thereof |
| FR2504535B1 (en) | 1981-04-28 | 1987-08-14 | Choay Sa | DISACCHARIDES DERIVED FROM URONIC ACID AND GLUCOSAMINE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FOR THE CONTROL OF BLOOD COAGULATION |
| FR2519987A1 (en) * | 1982-01-15 | 1983-07-22 | Choay Sa | Uronic acid derivs. - useful as glycoside intermediates or hapten(s) |
| FR2531436A1 (en) * | 1982-08-06 | 1984-02-10 | Choay Sa | Substituted pentasaccharides possessing biological properties, their preparation and their uses as medicaments |
| CA1247608A (en) | 1981-12-23 | 1988-12-28 | Jean Choay | Derivatives having uronic acid structure; process for preparing the same and their biological uses |
| FR2518550A1 (en) * | 1981-12-23 | 1983-06-24 | Choay Sa | Uronic acid derivs. - useful as glycoside intermediates or hapten(s) |
| AU563351C (en) | 1982-01-15 | 2003-06-19 | Glaxo Group Limited | Synthesis of oligosaccharides |
| US4801583A (en) * | 1982-01-15 | 1989-01-31 | Choay S.A. | Oligosaccharides and their biological applications |
| FR2564468B1 (en) * | 1984-05-16 | 1994-12-23 | Choay Sa | NOVEL OLIGOSACCHARIDES, THEIR SYNTHESIS PREPARATION AND THEIR BIOLOGICAL APPLICATIONS |
| JPS63218691A (en) * | 1987-03-09 | 1988-09-12 | Rikagaku Kenkyusho | Novel pentasaccharide compound, production thereof, anticoagulant and antithrombotic agent |
| EP0333243A3 (en) | 1988-03-10 | 1989-09-27 | Akzo N.V. | Sulphated k5 antigen and sulphated k5 antigen fragments |
| JPH03237101A (en) | 1989-12-18 | 1991-10-23 | Rikagaku Kenkyusho | Intermediate for synthesis of glycosylphosphatidylinositol anchor and intermediate for synthesis of glycosylphosphatidylinositol anchor-related compounds |
| JPH0616692A (en) * | 1992-07-03 | 1994-01-25 | Nisshin Oil Mills Ltd:The | New sugar derivative |
| CA2100821C (en) | 1993-07-19 | 2001-01-16 | Stephen Hanessian | Stereocontrolled glycosidation |
| JP3837876B2 (en) | 1996-11-05 | 2006-10-25 | 和光純薬工業株式会社 | Azidohalogenobenzyl derivatives and methods for protecting hydroxyl groups |
| JP3005669B2 (en) | 1996-12-19 | 2000-01-31 | 工業技術院長 | Method for producing asymmetric fluorinated primary amines |
| US6538117B1 (en) * | 1999-08-10 | 2003-03-25 | The Scripps Research Institute | Programmable one-pot oligosaccharide synthesis |
| TWI289566B (en) * | 1999-12-07 | 2007-11-11 | N.V.Organon | Antithrombotic compound |
| US6846917B2 (en) | 2001-01-23 | 2005-01-25 | Massachusetts Institute Of Technology | Solid- and solution-phase synthesis of heparin and other glycosaminoglycans |
| AU2002331426B2 (en) | 2001-09-07 | 2008-01-10 | Dr. Reddy's Laboratories Sa | Synthetic heparin pentasaccharides |
-
2002
- 2002-09-06 AU AU2002331426A patent/AU2002331426B2/en not_active Ceased
- 2002-09-06 CA CA2459562A patent/CA2459562C/en not_active Expired - Fee Related
- 2002-09-06 JP JP2003526933A patent/JP4688414B2/en not_active Expired - Fee Related
- 2002-09-06 CA CA2806604A patent/CA2806604C/en not_active Expired - Fee Related
- 2002-09-06 CA CA2806561A patent/CA2806561C/en not_active Expired - Fee Related
- 2002-09-06 ES ES02766941T patent/ES2423888T3/en not_active Expired - Lifetime
- 2002-09-06 EP EP02766941.5A patent/EP1440077B1/en not_active Expired - Lifetime
- 2002-09-06 PT PT2766941T patent/PT1440077E/en unknown
- 2002-09-06 CN CN028218558A patent/CN1558911B/en not_active Expired - Fee Related
- 2002-09-06 US US10/488,677 patent/US7541445B2/en not_active Expired - Fee Related
- 2002-09-06 DK DK02766941.5T patent/DK1440077T3/en active
- 2002-09-06 CA CA2806723A patent/CA2806723C/en not_active Expired - Fee Related
- 2002-09-06 WO PCT/AU2002/001228 patent/WO2003022860A1/en active Application Filing
- 2002-09-06 EP EP12188642.8A patent/EP2557086A3/en not_active Withdrawn
-
2009
- 2009-01-15 US US12/354,643 patent/US8114970B2/en not_active Expired - Fee Related
-
2011
- 2011-12-14 US US13/326,147 patent/US8404833B2/en not_active Expired - Fee Related
- 2011-12-14 US US13/326,060 patent/US8686131B2/en not_active Expired - Fee Related
-
2014
- 2014-01-29 US US14/167,822 patent/US9243018B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US9243018B2 (en) | 2016-01-26 |
| EP1440077B1 (en) | 2013-05-01 |
| CA2806604C (en) | 2014-04-08 |
| US20120220759A1 (en) | 2012-08-30 |
| CA2806723C (en) | 2015-12-29 |
| CA2806561C (en) | 2015-12-22 |
| CA2806723A1 (en) | 2003-03-20 |
| DK1440077T3 (en) | 2013-07-08 |
| EP1440077A4 (en) | 2010-06-02 |
| JP4688414B2 (en) | 2011-05-25 |
| US8114970B2 (en) | 2012-02-14 |
| US7541445B2 (en) | 2009-06-02 |
| AU2002331426A1 (en) | 2003-03-24 |
| US20050080042A1 (en) | 2005-04-14 |
| CA2806561A1 (en) | 2003-03-20 |
| EP2557086A3 (en) | 2014-11-05 |
| CN1558911B (en) | 2010-05-12 |
| CN1558911A (en) | 2004-12-29 |
| AU2002331426B2 (en) | 2008-01-10 |
| US8404833B2 (en) | 2013-03-26 |
| ES2423888T3 (en) | 2013-09-25 |
| EP2557086A2 (en) | 2013-02-13 |
| US20090187013A1 (en) | 2009-07-23 |
| JP2005505565A (en) | 2005-02-24 |
| US20120208993A1 (en) | 2012-08-16 |
| CA2459562A1 (en) | 2003-03-20 |
| EP1440077A1 (en) | 2004-07-28 |
| US20150005485A1 (en) | 2015-01-01 |
| PT1440077E (en) | 2013-06-04 |
| WO2003022860A1 (en) | 2003-03-20 |
| US8686131B2 (en) | 2014-04-01 |
| CA2806604A1 (en) | 2003-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2459562C (en) | Synthetic heparin pentasaccharides | |
| Van Boeckel et al. | Synthesis of a pentasaccharide corresponding to the antithrombin III binding fragment of heparin | |
| FI90242C (en) | A process for preparing a therapeutically useful pentasaccharide | |
| US8987430B2 (en) | Efficient and scalable process for the manufacture of fondaparinux sodium | |
| RU2167163C2 (en) | Synthetic polysaccharides, method of their synthesis and pharmaceutical composition containing thereof | |
| Slaghek et al. | Synthesis of hyaluronic acid-related di-, tri-, and tetra-saccharides having an N-acetylglucosamine residue at the reducing end | |
| Ito et al. | Studies Directed toward the Synthesis of Polysialogangliosides: The Regio-and Stereocontrolled Synthesis of Rationally Designed Fragments of the Tetrasialoganglioside GQ1b+. | |
| CA2253113C (en) | Carbohydrate derivatives | |
| JP3594990B2 (en) | 3-deoxyoligosaccharide, method for producing the same, and pharmaceutical composition containing the same | |
| US5220008A (en) | Oligosaccharide inhibitors for influenza virus | |
| AU2008200567B2 (en) | Synthetic Heparin Pentasaccharides | |
| AU2007203325B2 (en) | Synthetic Heparin Pentasaccharides | |
| Westman et al. | Synthesis of Non-glucosamino Glucan Oligosaccharides Related to Heparin and Heparan Sulphate | |
| Choudhury et al. | Synthesis of the Trisaccharide Repeating Unit of the K-Antigen from Klebsiella Type-63 | |
| JP5429734B2 (en) | Glycosphingolipid synthesis method | |
| Reichardt et al. | An exploratory study on the synthesis of heparin-like oligosaccharides by polycondensation | |
| Martín-Lomas et al. | An exploratory study on the synthesis of heparin-like oligosaccharides by polycondensation | |
| Park | Chiral auxiliaries for 1, 2-cis stereoselective glycosylations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20200908 |